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Abstract 
This thesis investigates the atomic structures and cell surface glycan receptor specificities of 
six human polyomaviruses. In healthy individuals, polyomaviruses establish usually 
asymptomatic chronic infections, but they may cause severe disease in immunocompromised 
patients. High-resolution X-ray structures of the major capsid protein VP1 alone and in 
complex with its specific glycan receptors allowed to analyze the molecular basis for 
underlying recognition events during early steps of the infection. The findings from 
crystallographic studies were corroborated with cell-based binding experiments using flow 
cytometry, interaction studies in solution by NMR spectroscopy, and infection studies in cell 
culture. The presented results highlight the enormous complexity of virus-glycan interactions 
and demonstrate that subtle differences in both the viral attachment protein and the cell-
surface glycan receptor modulate binding specificities and affinities and thus, are key 
determinants for tissue and host tropism, viral infectivity, and pathogenesis.  
JC Polyomavirus (JCPyV) causes the fatal demyelinating disease Progressive Multifocal 
Leukoencephalopathy (PML) in immunocompromised individuals. A brain isolate of JCPyV, a 
genotype 1 strain, requires α2,6-linked sialic acids on the LSTc glycan for attachment to host 
cells, whereas a kidney isolate, a genotype 3 strain, was reported to interact with gangliosides 
featuring α2,3- and α2,8-linked sialic acids. Comprehensive structural and functional analyses 
of these two representative strains and their glycan receptor specificities show that 
engagement of LSTc is a prerequisite for functional receptor engagement for all seven JCPyV 
genotypes while the weaker-binding gangliosides are not required for infection. Interestingly, 
the majority of JCPyV isolates from PML patients contain distinct mutations within or in 
proximity to the LSTc binding site on VP1. The presented results reveal that binding of these 
mutant viruses to glycans is abolished or severely compromised rendering them not infectious. 
Thus, these viruses likely utilize a so far unknown receptor for the infectious entry and/or play 
alternative roles in PML pathogenesis.  
In order to explore potential strategies for the development of antiviral compounds against 
PML a fragment-based screening approach was carried out and subsequent X-ray structure 
analysis identified a novel compound binding site inside the hydrophobic cavity of the JCPyV 
VP1 pentamer. Further studies show that modifications to the five-fold pore of the VP1 
pentamer result in a severe reduction of infectivity, suggesting that the pore is an important 
structural feature of polyomaviruses. Thus, targeting this pore may be proven to be an effective 
antiviral therapy.  
Crystal structures of VP1 from Trichodysplasia spinulosa-associated Polyomavirus (TSPyV) in 
complex with three different glycans reveal a sialic acid binding site that is shifted by about 
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18 Å from the ‘classical’ sialic acid binding sites of JCPyV and other polyomaviruses. 
Functional and cell-based studies confirm the importance of these novel interactions with sialic 
acids and suggest that glycolipids play an important role during TSPyV infection. Surprisingly, 
this new sialic acid binding site is also conserved in VP1 of Human Polyomavirus 12 
(HPyV12), whereas the human New Jersey Polyomavirus (NJPyV) employs a third location for 
the recognition of an Neu5Ac-α2,3-Gal-containing receptor. A structure-based phylogenetic 
analysis suggests that TSPyV, HPyV12, and NJPyV share their sialic acid binding site with 
closely related non-human polyomaviruses providing initial clues about determinants of host 
specificity and evolution of these viruses. In contrast, Human Polyomavirus 6 and 7 (HPyV6 
and HPyV7, respectively) carry uniquely elongated loops that cover the bulk of the outer virion 
surfaces, and moreover, obstruct the groove that binds sialylated glycan receptors in related 
viruses. Consistently, cell attachment and NMR studies further suggest that sialylated glycans 
are not required for cell attachment of both, HPyV6 and HPyV7.  
In conclusion, with its relatively high sequence homology and a conserved overall architecture, 
the growing Polyomaviridae family forms an excellent platform to analyze principles and 
molecular determinants of receptor specificity and antigenicity as well as critical factors for viral 
pathogenesis. A detailed understanding of the underlying molecular principles is important to 
establish a comprehensive toolbox, which can be used for new approaches for antiviral 
therapies and for the design of therapeutic gene vectors. 
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Zusammenfassung 
Diese Dissertation untersucht die atomaren Strukturen von sechs menschlichen Polyomaviren 
und das spezifische Andocken dieser Viren an Zuckerstrukturen auf Zelloberflächen der 
Wirtszellen. Bei gesunden Menschen verursachen Polyomaviren meist chronische 
asymptomatische Infektionen, jedoch können einige dieser Viren bei immungeschwächten 
Patienten schwere Erkrankung auslösen. Mit Hilfe von Röntgenstrukturen der Kapsidproteine 
in Komplexen mit Zuckerverbindungen konnten die molekularen Grundlagen für das 
spezifische Andocken dieser Viren an Zellen identifiziert werden. Anschließend wurden die 
Erkenntnisse aus den kristallographischen Studien mit zellbasierten Bindungsexperimenten 
mittels Durchflusszytometrie, Interaktionsstudien mittels NMR-Spektroskopie in Lösung und 
Infektionsstudien in Zellkultur überprüft und weiter analysiert. Die erhaltenen Ergebnisse 
unterstreichen die enorme Komplexität von Interaktionen zwischen Viren und Zuckerstrukturen 
auf der Zelloberfläche und zeigen, dass feine Unterschiede in den viralen Proteine oder den 
gebundenen Zuckermolekülen eine wichtige Rolle für die Erkennungsprozess und die 
Bindungsaffinität spielen. Diese spezifischen und gut regulierten Wechselwirkungen zwischen 
Virus und Rezeptoren auf der Wirtszelle sind nicht nur für die initiale Erkennung wichtig 
sondern auch die viralen Infektiosität und Pathogenese. 
JC Polyomavirus (JCPyV) kann bei immungeschwächten Personen die tödliche 
Gehirnerkrankung Progressive Multifokale Leukoenzephalopathie (PML) auslösen. Ein JCPyV 
Stamm aus dem Gehirn bindet an α2,6-verknüpfte Sialinsäure der linearen Zuckerstruktur 
LSTc auf der Wirtszelle, während Untersuchungen für einen anderen JCPyV Stamm, der aus 
der Niere isoliert wurde, zeigten, dass auch Gangliosiden mit α2,3- oder α2,8- verknüpfter 
Sialinsäure gebunden werden. Eine umfassende strukturelle und funktionelle Analyse der zwei 
repräsentative Virusstämme zeigt hier jedoch deutlich, dass die Bindung an LSTc eine 
Voraussetzung für die Infektion für alle sieben JCPyV Genotypen ist, während die schwächer 
gebundenen Ganglioside nicht für die Infektion erforderlich sind. Interessanterweise besitzen 
JCPyV Isolate von PML-Patienten oft eine kleine Anzahl von konservierten Mutationen 
innerhalb oder in unmittelbarer Nähe der LSTc-Bindungsstelle auf dem Kapsidprotein. Die hier 
vorgestellten Ergebnisse zeigen, dass die Bindung an Zuckerstrukturen durch die 
Veränderungen in VP1 verhindert oder stark beeinträchtigt ist und daher diesen Viren nicht 
mehr infektiös sind. Somit verwenden diese PML-assoziierten Viren wahrscheinlich ein bisher 
unbekanntes Molekül auf der Zelloberfläche für den infektiösen Eintritt und/oder sie tragen in 
einer anderen Weise zur PML-Pathogenese bei. 
Ein Fragment-basiertes Screening wurde durchgeführt um mögliche Strategien für die 
Entwicklung von antiviralen Verbindungen gegen PML zu testen. Die Bindung von einem 
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Fragment im Innenraum des hydrophoben VP1 Pentamers wurde mittels Strukturanalyse 
bestätigt. Zusätzlich konnte in einer Untersuchung gezeigt werden, dass Änderungen der 
fünffachen Pore der VP1-Pentamere die Virusinfektion verringern. Diese Erkenntnisse deuten 
darauf hin, dass die Poren ein wichtiger struktureller Bestandteil des Viruskapsids ist. Somit 
stellt auch die Pore oder gar der hydrophobe Innenraum des VP1 Pentamers einen möglichen 
Angriffsort für die Entwicklung von wirksamen antiviralen Therapien dar.  
Kristallstrukturen von VP1 des Trichodysplasia spinulosa-assoziierten Polyomavirus (TSPyV) 
im Komplex mit drei verschiedenen Zuckermolekülem zeigen eine Sialinsäure-Bindungsstelle, 
die um etwa 18 Å von der "klassischen" Sialinsäure-Bindungsstellen von JCPyV und anderer 
Polyomaviren entfernt ist. Funktionelle Untersuchungen bestätigen die Wichtigkeit dieser 
neuartigen Sialinsäure-Interaktion für die TSPyV Infektion und lassen zudem vermuten, dass 
besonders Glycolipide hierbei eine wichtige Rolle einnehmen. Diese neue Bindungsstelle ist 
auch im Kapsid des menschlichen Polyomavirus 12 (HPyV12) strukturell konserviert, während 
der menschliche New Jersey Polyomavirus (NJPyV) in einem dritten Bereich von VP1 mit 
einer spezifischer Zuckerstruktur wechselwirkt. Strukturbasierte phylogenetische Analysen 
zeigen, dass die Sialinsäure-Bindungsstellen von TSPyV, HPyV12 und NJPyV vermutlich auch 
in verwandten aber nicht-menschlichen Polyomaviren vorhanden sind und geben Hinweise 
über Determinanten der Wirtsspezifität und Evolution dieser Viren. Die humanen Polyomaviren 
6 und 7 (HPyV6 und HPyV7) besitzen im Gegensatz dazu verlängerte VP1-
Schleifenstrukturen, die den Großteil der Kapsidoberflächen abdecken und das Erkennen von 
Zuckermolekülen verhindert. Zusätzlich zeigen NMR-spektroskopische Untersuchungen, dass 
sialylierte Zucker nicht für das initiale Andocken von HPyV6 und HPyV7 an Zellen erforderlich 
sind. 
Zusammenfassend lässt sich sagen, das die wachsende Familie der Polyomaviren mit einer 
hohen Sequenzhomologie und konservierten Gesamtarchitektur eine hervorragende Plattform 
bildet, um Einblicke in grundlegende Prinzipien und molekularen Determinanten für 
Rezeptorspezifität, viraler Antigenität und Pathogenese zu erhalten. Ein detailliertes 
Verständnis der molekularen Grundlagen ist wichtig für neue Ansätze in der Entwicklung von 
antiviralen Therapien und auch therapeutische Genvektoren. 
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1.  Introduction 
Viruses have been known as distinct biological entities since the end of the 19th century. They 
are the most abundant entities on our planet and infect all life forms, from bacteria and 
archaea to animals and plants. Although viruses themselves have no fossil records in the 
conventional sense, it seems that they have left their traces throughout the history of life. The 
global effort to understand and control these small agents responsible for many human 
diseases is rising and constantly being fostered by epidemic outbreaks through history until 
today, for example the outbreak of Severe Acute Respiratory Syndrome (SARS) in 2002/03 in 
China, influenza pandemics such as the “swine flu” in 2009, and the Ebola virus outbreak in 
2014. The development of new technologies, such as nucleic acid sequencing, but also 
discoveries and advances in closely related fields including molecular and cell biology, 
immunology, structural biology, and high-throughput methods such as fragment-based drug 
discovery (FBDD) for potentially active antiviral molecules have led towards a better 
understanding of viruses and the development of vaccines and antiviral therapies.  
Prior to infection, viruses attach to specific receptors on the surface of their host cells in order 
to initiate cellular entry. Not only cellular attachment but also viral release and spread depend 
on precisely regulated interactions between viral proteins and their cognate receptors on the 
host cell surface. A detailed understanding of these interactions, which ultimately determine 
viral spread and tissue tropism, viral pathogenesis and host tropism, therefore provides a 
powerful platform for the development of antiviral strategies. 
1.1  Polyomaviruses 
Polyomaviruses are small non-enveloped viruses with a circular double stranded (ds) DNA 
genome. They were initially described in 1953 in mice by Ludwig Gross (Gross, 1953) but have 
been found in birds and several mammals, including humans, since then (DeCaprio and 
Garcea, 2013; Feltkamp et al., 2013). In addition, a fish-associated polyomavirus has been 
reported recently (Peretti et al., 2015). Their name is derived from Greek roots poly-, which 
means “many”, and -oma, which means “tumors”, due to the fact that the murine polyomavirus 
(MPyV) causes tumor formation when inoculated into mice. Between 1955 and 1963 lots of 
inactivated oral poliovirus vaccine that were contaminated with infectious amounts of another 
well-known member of the polyomavirus family, Simian Virus 40 (SV40), were administered to 
residents of the United States of America (Shah and Nathanson, 1976). SV40 infections are 
usually asymptomatic in rhesus macaques, but the virus has oncogenic potential in small 
animal models such as hamsters and transforming ability in cell culture. Thus, concerns about 
SV40-induced tumors in humans were raised but could not be proven (Shah, 2007). However, 
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more than 60 years of research focusing on molecular biology of the two model tumor viruses 
MPyV and SV40 resulted in fundamental discoveries about eukaryotic gene expression 
(Banerji et al., 1981; Benoist and Chambon, 1981; Fromm and Berg, 1983), DNA replication (Li 
and Kelly, 1984; Waga and Stillman, 1994) and oncogenic transfection (Lane and Crawford, 
1979; Linzer and Levine, 1979).  
The first two human polyomaviruses, JC polyomavirus (JCPyV) and BK polyomavirus 
(BKPyV), were identified in 1971 and are named after the initials of case patients (Gardner et 
al., 1971; Padgett et al., 1971). JCPyV is the causative agent of Progressive Multifocal 
Leukoencephalopathy (PML), which is a fatal brain disease in patients with Human 
Immunodeficiency Virus/ Acquired Immune Deficiency Syndrome (HIV/ AIDS) and more 
recently, in patients with multiple sclerosis (MS) who have been treated with 
immunomodulating drugs (Tan and Koralnik, 2010; Bellizzi et al., 2013; Diotti et al., 2013). 
Uncontrolled BKPyV infections contribute to polyomavirus-associated nephropathy (PVAN) 
and hemorrhagic cystitis in renal transplant recipients (Bennett et al., 2012; Rinaldo et al., 
2013). JCPyV and BKPyV were the only known human polyomaviruses for almost 40 years, 
but in the last decade improved genetic screening and high-throughput sequencing techniques 
led to the identification of several previously unknown polyomaviruses including species 
frequently circulating within the human population (Figure 1 and Table 1). One of them, the 
Merkel Cell Polyomavirus (MCPyV), is associated with Merkel Cell Carcinoma (MCC), a rare 
but very aggressive skin tumor in immunosuppressed and elderly individuals. MCPyV was the 
first known polyomavirus causing cancer in humans (Feng et al., 2008).  
The expansion of the Polyomaviridae family, including many human and non-human members, 
provoked its division into three genera, the Ortho-, Wuki-, and Avipolyomaviruses (Johne et al., 
2011). Polyomavirus species must have less than 81% nucleotide sequence similarities to 
another according to the current guidelines of the Committee on Taxonomy of Viruses (ICTV) 
(Johne et al., 2011).  
Seroprevalence studies have shown that polyomaviruses infect a large proportion of the 
human population worldwide (Table 1). The seroprevalence increases typically during 
childhood, suggesting that primary exposures occur early in life (Kean et al., 2009). Serological 
cross-reactivity appears between very closely related polyomaviruses such as SV40 and 
BKPyV (81% amino acid sequence identity of their major capsid protein VP1) but has been 
observed only to a minor extent between JCPyV and SV40 or BKPyV (≤ 79% VP1 amino acid 
sequence identity) (Viscidi and Clayman, 2006; Kean et al., 2009). However, the common 
human seroreactivity to African Green Monkey-derived Lymphotropic Polyomavirus (LPyV) 
found its explanation in the discovery of the Human Polyomavirus 9 (HPyV9) many years later 
(Sauvage et al., 2011; Scuda et al., 2011). In addition, serological studies could already predict 
the presence of a human polyomavirus species that is very similar to Chimpanzee 
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Polyomavirus (ChPyV) prior to the identification of New Jersey Polyomavirus (NJPyV) (Scuda 
et al., 2013; Mishra et al., 2014).  
 
 
Figure 1: The Polyomavirus family. A neighboring-joining phylogenetic tree based on the amino acid sequence of 
the major viral capsid protein VP1 was calculated by Clustal Omega (Sievers et al., 2011) and visualized in a polar 
tree layout using Tree Figure Drawing ToolVersion 1.4.2, Andrew Rambaut, Institute of Evolutionary Biology, 
University of Edinburgh. Full virus names and NCBI Genbank accession codes of sequences used for the analysis 
are given in the Appendix. Human polyomaviruses are highlighted in bold with Orthopolyomaviruses depicted in red 
and Wukipolyomaviruses in green. The origin of the Human Polyomavirus 12 (HPyV12) has not been confirmed yet.  
The recent burst in discovery of new members has reinvigorated the interest in polyomaviruses 
and their potential contributions to human disease and cancer (Dalianis and Hirsch, 2013; De 
Gascun and Carr, 2013; Moens et al., 2014). Moreover, the coexistence of at least 13 different 
polyomavirus species in humans or even in the same organ raises questions about potential 
immunological interactions and feeds also speculations about synergetic oncogenic 
transformation mechanisms due to co-infections with polyoma- or even other oncoviruses 
(Rinaldo and Hirsch, 2013; Moens et al., 2014). 
The work presented in this thesis focuses on JCPyV and the more recently discovered 
polyomaviruses, Trichodysplasia spinulosa-associated Polyomavirus (TSPyV), Human 
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Polyomaviruses 6 and 7 (HPyV6 and HPyV7, respectively), Human Polyomavirus 12 
(HPyV12), and NJPyV. However, our knowledge gained from studies with the two model 
viruses SV40 and MPyV, BKPyV, and other human and non-human polyomaviruses over the 
last decades is critical for studies focusing on the newly discovered polyomaviruses. 
Consistently, general characteristics of polyomaviruses highlighted in the following chapters of 
the introduction are explained and supported by findings from other members of this virus 
family.  
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The Polyomavirus Genome 
The organization of the circular dsDNA genome is highly conserved among polyomaviruses 
and is divided into three genetic regions: (a) the early coding region, (b) the late coding region, 
and (c) the non-coding control region (NCCR). In Figure 2 the genome of JCPyV is shown as 
an example. With about 5.0 to 5.5 kilo base pairs in length, the genome of polyomaviruses is 
forming a chromatin-like structure called minichromosome (Griffith, 1975) and encodes at least 
five viral proteins - the two regulatory proteins large T antigen (LT) and small T antigen (sT) in 
the early region and three viral capsid proteins VP1, VP2, and VP3 in the late region 
(DeCaprio and Garcea, 2013). Additionally, alternatively spliced variants of T antigens have 
been characterized in the early genome region of SV40 (Zerrahn et al., 1993), MPyV, JCPyV 
(Trowbridge and Frisque, 1995; Frisque et al., 2003), BKPyV (Abend et al., 2009), MCPyV 
(Shuda et al., 2008), and Saint Louis Polyomavirus (STLPyV) (Lim et al., 2013). For MPyV, 
middle T antigen (MT) is the primary transforming protein and cooperates with sT (Asselin et 
al., 1984), but the role of a tiny T (tT) remains unknown (Riley et al., 1997). Three splicing 
derivatives of JCPyV T antigen, T’135, T’136 and T’165 seem to fine-tune the transformation 
potential of the virus (Bollag et al., 2006).  
More recently, the overprinting gene ALTO (Alternate frame of the large T antigen) was 
identified for MCPyV (Carter et al., 2013). This novel protein with a potential role in cellular 
signaling processes is 248 amino acids long and is expressed during, but is not required for, 
MCPyV genome replication. The phylogenetic analysis reveals a single monophylogenic clade 
within the Polyomaviridae family named Almipolyomaviruses (ALTO or middle T containing 
polyomaviruses), which includes also TSPyV (Carter et al., 2013). 
Some members of the family feature additional proteins in the late translated region. SV40 
expresses VP4 about 24 hours after VP1, VP2, and VP3. VP4 acts as a viroporin and is not 
incorporated into the virion (Daniels et al., 2007; Raghava et al., 2011, 2013). The expression 
of agnoproteins has been detected for JCPyV, BKPyV, and SV40 (Jay et al., 1981; Rinaldo et 
al., 1998; Okada et al., 2002). These small proteins appear to be multifunctional with impact on 
various aspects of the viral life cycle from regulation of viral transcription and replication to 
inhibition of host DNA repair and to viroporin function (Suzuki et al., 2010; Unterstab et al., 
2010; Sariyer et al., 2011; Saribas et al., 2012; Coric et al., 2014). Putative agnoproteins have 
been found in a few primate polyomavirus genomes but not in more recently described human 
polyomaviruses (Ehlers and Moens, 2014). 
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The NCCR encloses the origin of replication (ORI), TATA- and TATA-like sequences, binding 
sites for LT, and cellular transcription factors as well as other promoter and transcription 
enhancer elements. Replication proceeds in a bidirectional, temporally defined manner from 
the ORI. Genetic rearrangements can occur in the NCCR and seem to be important for JCPyV 
tropism and pathogenicity (Reid et al., 2011; Delbue et al., 2012; Ferenczy et al., 2012). 
 
 
Figure 2: Organization of the circular dsDNA genome of JCPyV. The non-coding control region (NCCR) 
contains the early and late promoters, their transcription start sites and the origin of replication. The early region 
encodes LT and sT and alternatively spliced T’ forms. The viral capsid proteins VP1, VP2, and VP3 are encoded in 
the late region. Agnoproteins have been confirmed for BKPyV and JCPyV, and a VP4 has been identified for SV40 
but not for the recently discovered human polyomaviruses. Three alternative splicing forms of JCPyV T antigen, 
T’135, T’136 and T’165 are known. The position of a small non-coding regulatory microRNA (miRNA) is indicated. 
Small non-coding regulatory microRNAs (miRNAs) have been reported for a subset of human 
and non-human members of the polyomavirus family, each of which expresses a single miRNA 
in the late region targeting early region mRNA in varying locations (Sullivan et al., 2005; Chen 
et al., 2008; Seo et al., 2008; Sullivan et al., 2009; Chen et al., 2014). The major role of the 
miRNA is likely the regulation of early gene expression in order to control viral replication in the 
host (Broekema and Imperiale, 2013). However, some evidence suggests that polyomavirus 
miRNAs may have also cellular targets, influence cellular miRNA expression, or help to evade 
the immune system (Bauman et al., 2011; Lee et al., 2011; Xie et al., 2014).  
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Epidemiology and Pathogenicity 
JC Polyomavirus  
JCPyV infects approximately 50 to 80% of the human population (Knowles et al., 2003; Kean 
et al., 2009). The mode of viral transmission is not yet definitely defined, but initial infections 
seems to be linked to stromal cells of the tonsils, followed by a lifelong persistent infection in 
the kidney, bone marrow and B-lymphocytes (Monaco et al., 1996; Monaco et al., 1998). 
JCPyV might enter the upper respiratory tract by close interpersonal contact and presumably 
spread by the hematogenous route (Ferenczy et al., 2012). Alternatively, transmission by 
semen and organ transplantation, or urine-to-oral and transplancental routes have been 
suggested (Bofill-Mas et al., 2001; Bellizzi et al., 2013). JCPyV sheds in the urine of healthy 
individuals (Yogo et al., 1990) and the detection of JCPyV in stool samples and in sewage and 
rivers worldwide raises also the possibility of transmission through ingestion of non-sterile 
water and by a fecal-oral route (Hamza et al., 2009; McQuaig et al., 2009; Ahmed et al., 2010).  
The infection is mostly asymptomatic in healthy individuals, but in immunosuppressed hosts 
JCPyV can spread to the central nervous system (CNS), where the virus infects astrocytes, 
oligodendroctyes, and occasionally neurons (Du Pasquier et al., 2003; Koralnik et al., 2005; 
Wuthrich et al., 2009b). B-lymphocytes have been proposed to be a major carrier for the virus, 
enabling JCPyV to disseminate from and/or towards the brain via the blood-brain barrier (BBB) 
(Tornatore et al., 1992; Chapagain and Nerurkar, 2010; Van Loy et al., 2015). In the CNS, glial 
cells and in particular oligodendrocytes are critical to the process of myelination. JCPyV 
infection of oligodendrocytes leads to their cytolytic destruction and causes the brain disease 
Progressive Multifocal Leukoencephalopathy (PML) (more recently reviewed in Tan and 
Koralnik, 2010; Bellizzi et al., 2013; Diotti et al., 2013). Symptoms for PML are muscle 
weakness, sensory deficit, cognitive dysfunction, aphasia, and loss of coordination. The 
diagnosis for PML includes detection of viral DNA and proteins in the cerebrospinal fluid (CSF) 
or by brain biopsy. Characteristic lesions in the PML-affected brain are usually visible by 
Magnetic Resonance Imaging (MRI) in the cortical white matter, cerebellum, peduncles, or the 
brain stem (Wattjes et al., 2013). HIV-positive patients represented 80% of PML cases 
corresponding to approximately 3-5% of HIV-1-positive individuals (Major, 2010). Therefore, 
PML was considered mostly as an AIDS-defining illness until more recently, when PML 
became a growing concern in other types of patients. These new PML cases are associated 
with immunomodulatory therapies using monoclonal antibodies for diseases such as MS, 
Crohn's disease, non-Hodgkin's lymphoma, systemic lupus erythematosus, rheumatoid 
arthritis, and psoriasis (Diotti et al., 2013). In particular, individuals with MS who are receiving a 
therapy with Tysabri™ (natalizumab) have a 1:500 chance of developing PML with the 
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incidence increasing to 1:100 in individuals that were seropositive for JCPyV prior to the 
immunosuppressive therapy and after treatment with natalizumab for 25 to 28 months 
(Bloomgren et al., 2012). MS is an autoimmune disease that is characterized by inflammations 
in the brain and spinal cord and worsens during relapses. Natalizumab is an humanized anti-
VLA-4 (α4β1 integrin) antibody that blocks migration of VLA-4+ T- and B-lymphocytes across 
the BBB to the brain (Kawamoto et al., 2012). The treatment protects the brain of an MS 
patient from attacks by lymphocytes that bind to endothelial cells, but the lack of immune 
surveillance can result in increased spread of JCPyV to the brain (Diotti et al., 2013). As of 
December 2014, there had been 517 cases of natalizumab-induced PML and 119 deaths since 
Biogen Idec introduced the drug in 2004 (Biogen Idec, 2014). Moreover, also newly marketed 
therapies for MS and for the immune-mediated skin disease psoriasis have led to PML, 
including Novartis’ drug Gilenya™ (fingolimod) and dimethyl fumarate-containing drugs 
Fumaderm™ and Tecfidera™ (Ermis et al., 2013,van Oosten, 2013 #209; Sweetser et al., 
2013). However, a direct correlation between Gilenya™ and PML is disputed so far according 
to the company information (Novartis statement: Gilenya (fingolimod) safety information 
update; available online at www.novartis.com). 
PML causes a rapid destruction of the white and grey matter in the CNS and usually results in 
death within one year. There is no specific antiviral therapy against JCPyV available indicating 
the immediate need to better understand the pathogenesis of the virus (Brew et al., 2010; 
Diotti et al., 2013). In some cases, restoration of the immune system can support viral 
clearance and resolution of PML, but the return of function leads frequently to an immune 
reconstitution inflammatory syndrome (IRIS) (Gray et al., 2005). Until an effective PML therapy 
is identified, an early diagnosis via clinical surveillance and restoration of the immune system, 
while monitoring for and managing IRIS, is currently the best attempt to maximize patient 
chance of survival (PML consortium, available online: pmlconsortium.org; Brew et al., 2010).  
Genetic rearrangements of JCPyV, including duplication of enhancer elements in the NCCR 
that convert the virus to its neuropathogenic form, seem to be necessary for growth of JCPyV 
in the CNS (Ferenczy et al., 2012). The archetype strain (Cy) resides in the kidney and is 
usually detected in the urine of healthy individuals (Yogo et al., 1990). PML-type viruses are 
found in the CSF, brain tissue, and blood but not in the urine (Martin et al., 1985; Jensen and 
Major, 2001; Pietropaolo et al., 2003; Van Loy et al., 2015). The laboratory PML-prototype 
strain is the Mad-1 strain, which was originally isolated from the brain of a PML patient and 
contains a canonical 98-base pair tandem repeat in the NCCR (Frisque, 1983; Frisque et al., 
1984). However, the high seropositivity rates for JCPyV within the human population and the 
low rate of incidences for PML suggest that viral, cellular, and individual host factors play 
important roles in PML pathogenesis.  
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In 2005 and 2009 two other distinct CNS diseases were linked to the pathogenicity of JCPyV, 
JCPyV granule cell neuronopathy (GCN) and JCPyV encephalopathy (JCVE) (Koralnik et al., 
2005; Wuthrich et al., 2009b). Both clinical conditions have been observed in PML patients and 
independently (Wuthrich et al., 2009a; Schippling et al., 2013). In infected granule cell neurons 
in the cerebellum of GNC patients JCPyV variants with deletions in the C-terminus of the VP1 
gene, resulting in frame shifts and alterations of up to 13 amino acids, have been found (Dang 
and Koralnik, 2006; Agnihotri et al., 2014). Nevertheless, these GCN1 variants have also been 
detected in CSF and peripheral blood mononuclear cell (PBMC) samples from PML patients. 
These finding indicate that these deletions may originate outside of the CNS suggesting that 
these virus variants frequently co-exist as a minor species in the blood of PML patients (Dang 
and Koralnik, 2006; Dang et al., 2012a). JCVE is an infection of the cortical pyramidal neurons 
and has been associated with JCPyV variants with deletions in the agnoprotein gene leading 
to a truncated protein (Dang et al., 2012b). So far mechanisms underlying the neuronal tropism 
of the JCVE- and GCN-associated JCPyV variants remain unresolved. 
Skin-tropic Polyomaviruses: Merkel Cell Polyomavirus, Trichodysplasia spinulosa-
associated Polyomavirus and Human Polyomaviruses 6 and 7  
Our skin is the largest organ of our body, is an important physical barrier against external, 
potential aggressive agents, and it harbors a diverse microbiota comprising symbiotic bacteria, 
fungi and viruses. Four members of the polyomavirus family, MCPyV, TSPyV, HPyV6, and 
HPyV7, have been found to be associated with the human skin, whereas at least MCPyV, 
TSPyV, and HPyV7 are following the “opportunistic” strategy of polyomaviruses (Feng et al., 
2008; Schowalter et al., 2010; van der Meijden et al., 2010; Ho et al., 2014). Infections with 
these viruses are usually latent and persistent, but a symptomatic and severe reactivation can 
occur during immunosuppression of the host.  
The MCPyV genome was found to be integrated into the host genome of MCCs, which are 
rare but aggressive and highly lethal, neuroendocrine tumors of the skin in elderly and 
immunocompromised individuals (Feng et al., 2008; Houben et al., 2010; Hughes et al., 2014). 
In the initial study, viral DNA sequences were identified in eight of ten and integrated in five of 
eight MCCs, linking MCPyV to the pathogenesis of MCC (Feng et al., 2008). Others studies 
have also confirmed the association between MCC and MCPyV (Kassem et al., 2008; Shuda 
et al., 2008), but no preferential integration sites in the genome have been identified so far 
(Feng et al., 2008; Sastre-Garau et al., 2009; Laude et al., 2010). The disruption of the viral 
genome as a result of integration leads to viral sequences with mutations and deletions in the 
NCCR and in genes coding for LT and VP1, suggesting a strong selection pressure to 
eliminate viral replication within MCCs (Feng et al., 2008; Sastre-Garau et al., 2009; Laude et 
al., 2010). 
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TSPyV was discovered in 2010 in facial skin samples from a patient with Trichodysplasia 
spinulosa (TS), a skin disease that is characterized by the development of follicular papules 
and keratin spines (van der Meijden et al., 2010). Electron microscopic studies have confirmed 
the present of icosahedral viral particles in affected hair follicles, which predominantly occur in 
the face and less frequently on the trunk and limbs of the patients (Osswald et al., 2007; 
Matthews et al., 2011). Seroprevalence values of about 70% within the adult human population 
indicate that TSPyV infections occur during childhood and suggest the scenario of a persistent 
asymptomatic infection and reactivation in immunocompromised patients (van der Meijden et 
al., 2011; Nicol et al., 2013; van der Meijden et al., 2013). However, high viral loads were only 
detected in TS patients (van der Meijden et al., 2010; Kazem et al., 2012), whereas samples 
from the skin, plucked eyebrows, serum/plasma, and urine of immunocompetent and -
compromised individuals have been tested mostly negative for TSPyV DNA (Scuda et al., 
2011; van der Meijden et al., 2011; Kazem et al., 2012). Thus, a persistent infection at 
undetectable levels, persistency in an so far undiscovered latent extracutaneous reservoir, or 
primary infections during an immunosuppressive therapy or after organ transplantation are 
possible (Kazem et al., 2013). The detection of TSPyV DNA in tonsillar samples from healthy 
individuals indicates that the virus may establish a persistent infection lymphoid tissue 
(Sadeghi et al., 2014). Viral shedding and spreading from this site may then be crucial for 
transmission and reactivation during immunosuppression. The pathogenic mechanism of 
TSPyV includes uncontrolled hyperproliferation of inner root sheath (IRS) cells but remains 
otherwise largely unknown (Kazem et al., 2012; Kazem et al., 2014).  
HPyV6 and HPyV7 are commonly shed from the skin of healthy individuals together with 
MCPyV (Schowalter et al., 2010). A persistent infection with both viruses seems very common, 
resulting in seropositivity rates of 35 to 90% by adulthood (Schowalter et al., 2010; Nicol et al., 
2013). Pruritic, brown plaques on the trunk and extremities of transplant patients characterized 
by distinctive epidermal hyperplasia with HPyV7 capsid-laden keratinocytes indicates that 
HPyV7 is pathogenic in immunosuppressed individuals (Ho et al., 2014). More recently, the 
association of HPyV7 with thymic epithelial tumors has been demonstrated (Rennspiess et al., 
2015) and thus, also for HPyV6 an involvement in cutaneous diseases or tumors has to be 
considered (Duncavage and Pfeifer, 2011; Schrama et al., 2012; Scola et al., 2012). Due to 
their close sequence relationship with the two respiratory Washington University and 
Karolinska Institute Polyomaviruses (WUPyV and KIPyV, respectively) HPyV6 and HPyV7 
have been classified as Wukipolyomaviruses (Johne et al., 2011).  
Human Polyomavirus 12 
HPyV12 has been described in a study focusing on the identification of new human 
polyomaviruses in the gastrointestinal tract (esophagus, stomach, colon, rectum, liver, gall 
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bladder), spleen, and lymph nodes (Korup et al., 2013). In this study, HPyV12 was detected in 
liver tissue by PCR, but its human origin is not yet confirmed (personal communication B. 
Ehlers, Division of Viral Infections, Robert Koch Institute, Germany). However, initial 
seroprevalence studies performed with a VP1 pentamer-based enzyme-linked immunosorbent 
assay (ELISA) reveal a prevalence of 15 to 33% in healthy adults (Korup et al., 2013). A cross-
reactivity of antibodies against other known human polyomaviruses is rather unlikely because 
none of their VP1 possesses more than 60% amino acid sequence identity to HPyV12 VP1. So 
far, cross-reactivity has been only a problem with VP1 sequence identities above 75% (Kean 
et al., 2009). Nevertheless, cross-reactivity against so far unknown human polyomaviruses 
cannot be ruled out. In the phylogenetic analysis based on LT, HPyV12 was described as an 
earliest offshoot of a large and diverse clade comprising polyomaviruses from apes, bats, 
monkeys, rodent, and humans (MCPyV and TSPyV) (Korup et al., 2013), but the analysis 
based on the VP1 amino acid sequence clusters HPyV12 with Avipolyomaviruses (Figure 1).  
New Jersey Polyomavirus  
NJPyV was identified via a muscle biopsy in an organ transplant recipient with systemic 
vasculitis, myositis, and retinal blindness (Mishra et al., 2014). NJPyV is closely related to 
ChPyV and prior to its discovery its existence had been predicted in a serological study (Scuda 
et al., 2013). Origin and duration of the infection with NJPyV remain unknown, but the patient 
did not recall exposure to non-human primates (Mishra et al., 2014). Histopathology analysis 
suggests a tropism for endothelial cells and thus, NJPyV may have contributed to muscle and 
ocular damage in the patient. Further studies are needed to clarify factors and incidences for 
human infections. 
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Structure and Organization of the Polyomavirus Capsid  
The polyomavirus capsid with a diameter of approximately 45 to 50 nm comprises 72 
pentamers of the major capsid protein VP1, which are centered on the vertices of a T=7dextro 
(d) icosahedral lattice (Liddington et al., 1991; Stehle et al., 1994; Yan et al., 1996). Each VP1 
pentamer associates usually with a single molecule of either minor capsid protein VP2 or VP3, 
which is located inside the capsid (Barouch and Harrison, 1994). The tertiary structure of VP1 
can be divided into an N-terminal arm, a jelly-roll β-sheet sandwich core structure, and a long 
C-terminal extension (Liddington et al., 1991). X-ray structures of polyomavirus VP1 
pentamers feature often extended and structurally variable surface loops that emanate from 
the conserved jelly-roll core formed by β-strands B, I, D, G2 and C, H, E, F (Figure 3). These 
surface loops are named BC-, DE-, HI-, and EF-loops after the strands connected by them 
(Liddington et al., 1991; Stehle and Harrison, 1997; Neu et al., 2008; Neu et al., 2010; Neu et 
al., 2011; Neu et al., 2012; Neu et al., 2013a; Neu et al., 2013b; Khan et al., 2014). The BC-
loop is subdivided into two parts, which emanate from the top of VP1 into different directions 
(BC1- and BC2-loops).  
 
Figure 3: Structure of SV40 VP1. One VP1 monomer of a VP1 pentamer is colored in green and neighboring VP1 
monomers in grey (pdb: 1SVA). The conserved jelly-roll fold is built up by β-strands B, I, D, G2 and C, H, E, F. 
Surface loops are named BC-, DE-, HI-, and EF-loops. The extensive BC-loop is subdivided into BC1- and BC2-
loops, which are facing into different directions. The incoming C-terminal arm of a neighboring pentamer in the 
context of the virion is shown in red. A cysteine residue in the CD-loop (C104 in SV40) is highly conserved among 
polyomaviruses.  
Likewise, the G-strand is divided into the G1- and G2-strands, so that the N-terminal part (G1) 
of one monomer contributes to the CHEF-sheet of the clockwise neighboring monomer (C, H, 
E, F, G1) and the G2 to the BIDG2-sheet. In contrast to the other surface loops, the EF-loop 
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emanates from the bottom VP1 and forms a small three-stranded antiparallel β-sheet (E’’’, E’, 
E’’) at the side of the pentamer (Stehle et al., 1996). Each VP1 monomer forms extensive 
contacts with neighboring monomers in the pentamer, contributing to the large interface 
between two VP1 monomers that compromises about 2,200 to 2,800 Å2 (Protein interfaces, 
surfaces and assemblies' service PISA at the European Bioinformatics Institute; 
http://www.ebi.ac.uk/pdbe/prot_int/pistart.html; Krissinel and Henrick, 2007). 
The overall structure of the VP1 β-sheet core is essentially identical in the assembled capsid, 
but significant differences occur in the C-terminal arm (Liddington et al., 1991; Stehle et al., 
1996). This arm emerges from the base of each VP1 monomer, and interacts with a VP1 of the 
adjacent pentamer, thus tying together the pentamers with allowance for the required 
variability in geometry of the icosahedral capsid geometry (Figure 4).  
 
 
Figure 4: Structure of the polyomavirus virion. (A) The complete SV40 virion (pdb: 1SVA) in a surface 
representation created with the VIPERdb tool (Carrillo-Tripp et al., 2009). (B) Architecture of the virion shell showing 
the arrangement of the pentamers on the T=7d icosahedral lattice with 5-fold axes through the vertices of the 
icosahedron, 3-fold axes at the centers of each triangle, and 2-fold axes through the middle edges of each 
icosahedron. 5-fold and 6-fold coordinated pentamers are depicted in grey and colors, respectively. (C) Interaction 
between pentamers. C-terminal α-helical segments are shown as cylindrical tubes. Ca2+ binding sites are indicated 
with white spheres. Panels B and C were adapted from Stehle et al., 1996.  
In general, icosahedral particles follow three symmetry requirements: 5-fold axes through the 
vertices of the icosahedron, 3-fold axes at the centers of each triangle, and 2-fold axes through 
the middle edges of each icosahedron (Figure 4 B). Twelve pentamers lie on 5-fold rotation 
axes and the remaining 60 pentamers are surrounded by six other pentamers and are not 
located on any icosahedral symmetry axis. The details of the polyomavirus capsid organization 
remained a puzzle until structural analysis of SV40 with a sufficient resolution of 3.8 Å could 
answer the question with a concept of quasi-equivalence at the basis of capsid construction 
(Liddington et al., 1991). Both, 5- and 6-coordinated pentamers, donate and accept five C-
terminal arms, but three different kinds of interpentamer interactions are realized through 
alternative conformations and arrangements of the long C-terminal arm. A pseudo 3-fold axis 
(monomers α, α’ and α’’), a pseudo 2-fold axis (monomers β and β’), and a strict 2-fold 
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icosahedral axis (γ monomers) are found (Figure 4 B and C). The C-terminus possesses an α-
helical segment (αC) with the exceptions of the γ-monomers. Contacts between monomers β 
and β’ involves two helices, between α, α’, and α’’ monomers three helices, and γ-monomers 
are mediated by flexible non-helical structures. The C-terminal end can form either a short 
antiparallel terminal β-ribbon composed of strands named K and L (KL β-ribbon) or is flexible. 
However, in all cases, the β-strand A within the N-terminal arm of one pentamer clamps the 
invading C-arm of a neighboring pentamer at the J-strand resulting in a six-stranded β-sheet 
(AJBIDG2) (Figure 3). The N-terminus of VP1 binds DNA and contains a nuclear localization 
signal (NLS) (Moreland et al., 1991; Li et al., 2001).  
A cysteine residue in the tip of the CD-loop is conserved among MPyV and SV40 (Stehle et al., 
1996; Stehle and Harrison, 1996) as well as other polyomaviruses (Figure 3). In contrast, the 
CD-loop itself adopts various conformations. In SV40, cysteine residue C104 from the subunit 
α (VP1 from a 5-fold coordinated pentamer) approaches VP1 monomers α’ and α’’ from 6-fold 
coordinated pentamers and can form a disulfide bond with one of the equivalent cysteines of 
another loop, and also the CD-loops of the β and β’ monomers are bridged by disulfide 
bonding. In addition, cysteine residues C9 in the N-terminal arms may be involved in inter-
pentamer disulfide bonds, but these were not visible in the X-ray structure (Stehle et al., 1996; 
Jao et al., 1999). Pentamers of the MPyV capsid are not cross-linked by disulfide bonds in the 
X-ray structure, but the equivalent cysteine residue in the CD-loop, C114, forms a disulfide 
bond with C19 in the N-terminal arm of the counterclockwise VP1 monomer, holding the N-
terminal clamp in place (Stehle and Harrison, 1996). Additionally, the assembled SV40 capsid 
seems to be stabilized by two calcium ions (Ca2+) bridging the incoming C-terminus with core 
residues of the accepting pentamer (Liddington et al., 1991; Stehle et al., 1996). Thus, Ca2+ 
serves potentially as a trigger at the pentamer interface, and Ca2+ addition or depletion can 
switch on capsid assembly or disassembly, respectively (Salunke et al., 1986; Kawano et al., 
2009). The Ca2+-binding sites and cysteine residues are highly conserved among 
polyomaviruses, suggesting that their capsids are likely stabilized, assembled and 
disassembled in vivo in a similar manner (Stehle et al., 1996; Stehle and Harrison, 1996; 
Schelhaas et al., 2007; Walczak and Tsai, 2011). Consistently, SV40, MPyV and also other 
polyomavirus capsids only disassemble in vitro by treatment with reducing and Ca2+-chelating 
agents (Brady et al., 1977; Kosukegawa et al., 1996; Ishizu et al., 2001).  
VP1 possesses usually about 350 to 400 amino acids. Only Vervet Monkey Polyomavirus 
(VMPyV) VP1 and others such as MCPyV, ChPyV, and Bat Polyomavirus (BatPyV) VP1 are 
about 500 amino acids in length due to an extended C-terminus (Yamaguchi et al., 2014). 
Deletion of this extended C-terminus seems not to affect the overall morphology of VLPs, but 
the elongated C-terminus is important for efficient VMPyV VLP assembly (Yamaguchi et al., 
2014). In contrast, VP1 of the Avian Polyomavirus (APyV), also known as Budgerigar fledgling 
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disease Polyomavirus (BFDPyV), has a uniquely truncated C-terminus. Amino acid residues 
that are forming the KL β-ribbon in SV40 and MPyV are missing (Stehle et al., 1994; Stehle et 
al., 1996; Shen et al., 2011). The terminal KL β-ribbon may help to lock the capsid in a stable 
conformation and size variations of the APyV capsid could be explained by a missing β-ribbon 
(Shen et al., 2011).  
The Minor Capsid Proteins VP2 and VP3 
VP1 is able to self-assemble into virus-like particles (VLPs) in the absence of the minor capsid 
proteins VP2 and VP3 with similar structural properties (Kosukegawa et al., 1996; Gillock et 
al., 1997). In full virions, VP1 pentamers are usually associated with a copy of either VP2 or 
VP3, although presence and roles of both proteins seem to differ among virus species 
(Gasparovic et al., 2006; Kawano et al., 2006; Schowalter and Buck, 2013). VP2 and VP3 
share a common C-terminus but VP2 features additional amino acids at its N-terminus. VP2 
and VP3 comprise about 320-360 and 200-240 amino acid residues, respectively, in MPyV 
and SV40 as well as JCPyV and BKPyV. MPyV VP1 and VP3 interact with their C-termini with 
VP1 within the central pore, so that in one VP1 pentamer binds either one molecule of VP2 or 
VP3 (Barouch and Harrison, 1994; Chen et al., 1998). The X-ray structure of MPyV VP1 in 
complex with a C-terminal VP2 fragment (residues 214 to 318) shows that mainly an 
hydrophobic α-helical segment of VP2 is involved in interactions, but also salt bridges and 
hydrogen bonds at two positions at the inside of the VP1 pentamer are tying both proteins 
together (Chen et al., 1998) (Figure 5). However, only residues 269 to 296 of VP2 were visible 
in the electron density map and are included in the complex structure (Chen et al., 1998) 
(Figure 5 C and D). VP2 and VP3 were found to feature a NLS at their C-termini (Wychowski 
et al., 1987). The NLS of VP2 and VP3 are likely placed in close distance to the N-terminal 
NLS of VP1 in the assembled virion (Chen et al., 1998).  
During viral infection minor capsid proteins are exposed in the ER. JCPyV mutants lacking 
VP2 or VP3 are non-infectious suggesting that their exposure is likely a critical factor for viral 
entry (Gasparovic et al., 2006). Following the exposure step VP2 and VP3 of MPyV and SV40 
bind to and/or insert into cellular membranes (Magnuson et al., 2005; Daniels et al., 2006; 
Geiger et al., 2011). The N-terminus of VP2 is myristylated (Streuli and Griffin, 1987), which is 
important for infection efficiency likely due its interaction with membranes (Krauzewicz et al., 
1990; Sahli et al., 1993). 
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Figure 5: Interaction between VP1 and VP2. (A) - (D) X-ray structure of MPyV VP1 in complex with a C-terminal 
fragment of VP2 (residues 214-318), which is sufficient for complex formation of VP1-VP2 (Chen et al., 1998). Only 
VP2 residues 269-296 were defined by electron density and are included in the deposited complex structure (pdb: 
1CN3). (A) The VP1-VP2 complex seen from the inside of the virion. The VP1 pentamer is shown in surface 
representation with one VP1 monomer highlighted in green. VP2 (orange) is shown in cartoon representation. (B) 
Side view of three VP1 monomers in complex with VP2. (C) Close-up view of VP1-VP2 interactions at the N-
terminal region of VP2. (D) Interaction between VP1 and VP2 in the C-terminal region of the VP2 fragment. 
Hydrogen bonding and salt bridges are shown in dashed lines.  
Recombinant VP2 and VP3 produced in Escherichia coli (E. coli) require a N-terminal 
glutathione-S-transferase (GST)-fusion protein for solubility (Giorda et al., 2013), co-
expression of VP1 (Chen et al., 1998), or are found in inclusion bodies, but refolding of MPyV 
VP2 and VP3 in vitro for biophysical and functional characterizations is possible (Burkert et al., 
2014). Both proteins are monomeric and are highly α-helical in solution, but further 
conformational changes upon interaction with membranes may be required to allowed the 
insertion of the helices into membranes (Burkert et al., 2014). Studies report membrane 
insertion via three potential transmembrane domains for SV40 VP2 and VP3 and viroporin 
activity (Giorda et al., 2013). Such transmembrane helices may not be fully exposed in the 
soluble form of the protein (Burkert et al., 2014). 
Overall, the larger N-terminal part of VP2 seems to be more flexible and not as tightly folded as 
the common C-terminal region of VP2 and VP3, which engages VP1. Consequently, the N-
terminus may emerge more easily from the inside of the virion during infection and 
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disassembly. However, despite its critical impact on the infection, the mechanism of VP2 
exposure in the ER remains unclear. In the VP1-VP2 complex structure, the N-terminal part of 
the co-crystallized VP2 fragment adopts a hairpin-like conformation and loops back towards 
the inside of the pentamer (Figure 5). Due the pentameric assembly of VP1, there is a gap 
along the 5-fold axis, which would be in general sufficient to allow an unfolded polypeptide to 
emerge either as an elongated loop structure or after structural rearrangement, so that the N-
terminus of VP2 emerges first from the inside. Alternatively, VP2 could be exposed through 
other mechanisms that require capsid expansion or dissociation.  
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Entry Pathways and Life Cycle 
The polyomavirus life cycle starts with the attachment of the capsid to the target cell, proceeds 
with endocytosis, intracellular trafficking via early, maturating, and late endosomes to the ER 
lumen for initial uncoating and to the nucleus for genome replication, and finally ends with the 
assembly and release of progeny virions (Figure 6). Being non-enveloped viruses, 
polyomaviruses lack a surrounding lipid bilayer and must penetrate biological membranes. 
This critical step during the infection is fundamentally different from enveloped viruses, which 
normally gain access to host cells by membrane fusion. Studies with the two model systems 
SV40 and MPyV but also with JCPyV and BKPyV have revealed common as well as virus-
specific cellular mechanisms and interactions during entry and trafficking. Nonetheless, it 
remains to be investigated in the future how the current knowledge can be transferred to 
cellular entry mechanisms of the more recently discovered human polyomaviruses. 
 
 
Figure 6: Simplified model of the infectious entry pathways utilized by polyomaviruses. JCPyV enters cells 
by clathrin-dependent endocytosis. MPyV, SV40, and BKPyV utilize a caveolae/lipid raft-dependent endocytosis 
pathway. Polyomaviruses traffic to the ER for partial uncoating and then to the nucleus for replication. ERAD, ER-
associated degradation; NPC, nuclear pore complex  
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SV40, Murine Polyomavirus and BK Polyomavirus 
SV40, MPyV, and BKPyV bind to glycolipid receptors known as gangliosides (Tsai et al., 2003; 
Low et al., 2006) and undergo endocytosis in a caveolae- and lipid raft-dependent manner 
(Gilbert and Benjamin, 2000; Eash et al., 2004; Gilbert and Benjamin, 2004). The multivalent 
binding of the viral capsid to ganglioside receptors that are located on the extracellular leaflet 
of the plasma membrane is leading to membrane curvature and viruses initiate hereby their 
internalization (Ewers et al., 2010). The induced curvature of the membrane seems to be a 
critical step for viral entry, as even artificial particles coated with GD1a ganglioside antibodies 
are delivered from the plasma membrane to the ER in a similar manner as MPyV (Qian et al., 
2009). Gangliosides have been found in ER fractions, indicating that viruses stay attached to 
their receptors all the way until reaching the ER (Tsai et al., 2003). Moreover, since the affinity 
of an individual binding site on the capsid for its receptor is low (Neu et al., 2008) it is assumed 
that the multivalent binding event of viruses to several ganglioside molecules is necessary for 
the attachment. How concentration and diffusivity of the ganglioside receptor control the 
multivalent binding has been investigated for SV40 in more detail. Binding of at least four to 
five ganglioside molecules in a short time appears to be sufficient for effective viral attachment 
and initiation of the infection (Szklarczyk et al., 2013).  
In the subsequent steps of the infection polyomaviruses rely on microtubules and they are 
transferred first to maturating endosomes, late endosomes, and probably endolysosomes 
before they travel to the ER (Gilbert and Benjamin, 2004; Eash and Atwood, 2005; Qian et al., 
2009; Engel et al., 2011; Zila et al., 2014). Earlier models suggested that SV40 and MPyV 
bypass the classical endosomal pathway and accumulate instead in so-called “caveosomes,” 
which were defined as caveolin-1 (Cav-1)-positive, pH-neutral, endocytic organelles (Pelkmans 
et al., 2001). Cav-1 belongs to a family of integral membrane proteins that are key players in 
caveolae (Parton and del Pozo, 2013). However, more recent studies have demonstrated that 
caveosomes are not distinct cell organelles but instead modified late endosomes or 
endolysosomes in which Cav-1 is found after overexpression or interference with caveolae 
assembly (Hayer et al., 2010; Engel et al., 2011). After internalization, polyomaviruses 
colocalize with several endosomal Rab proteins, which belong to a family of small GTPases 
and regulate membrane trafficking through effector protein recruitment (Querbes et al., 2006; 
Qian et al., 2009; Engel et al., 2011). Rab5 is involved in formation, transport, and fusion of 
vesicles to early endosomes, whereas Rab7 and Rab9 are markers of late endosomes. 
Studies have detected MPyV and SV40 in Rab5-, as well as Rab7- and Rab9-positive 
endosomes. In addition, both viruses were also found to be associated with the lysosomal-
associated membrane protein 1 (LAMP1), which is a marker of the endolysosomes (Qian et 
al., 2009; Engel et al., 2011). The vacuolar ATPase (v-ATPase) is responsible for the 
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acidification of endosomes and lysosomes and seems to be required for pH-dependent 
conformational changes in the polyomavirus capsid (Qian et al., 2009; Engel et al., 2011). The 
subsequent retrograde transport from the late endosomes to the ER is a critical and also 
unique step during the polyomavirus infection since most extracellular ligands do not reach the 
ER after endocytosis (Querbes et al., 2006; Nelson et al., 2012).  
Upon arriving in the ER lumen chaperones and protein disulfide isomerase (PDI) family 
members such as ERp29, ERp57, ERp72, and the canonical PDI are responsible for the 
disruption of disulfide bonds to allow conformational changes of the capsid leading to partial 
exposure of VP2 and VP3 (Magnuson et al., 2005; Gilbert et al., 2006; Schelhaas et al., 2007; 
Nelson et al., 2012). The precise combination of the utilized PDI proteins differs between 
polyomviruses possibly due to differences in the disulfide bond network of the capsid (Gilbert 
et al., 2006; Walczak and Tsai, 2011). It has been postulated that the exposed hydrophobic 
and myristylated N-terminal part of VP2 helps anchoring the virus to the ER membrane, while 
the Hsp70 chaperone BiP together with the J-domain of the chaperone DNAJB11 may prevent 
aggregation of the now partial unfolded and hydrophobic viral particle (Geiger et al., 2011; 
Goodwin et al., 2011). Studies with SV40 suggests that this partial uncoated virus particle then 
employs components of the ER-associated degradation (ERAD) machinery for cytosolic entry, 
although the dependence on the ERAD pathway for ER egress seems to vary between 
polyomavirus species and furthermore between different cell types (Bennett et al., 2013). 
ERAD pathway components such as Derlin-1 (Schelhaas et al., 2007), Derlin-2 (Lilley et al., 
2006), SEL1 (Schelhaas et al., 2007), RMA1 (Geiger et al., 2011), and BAP29/BAP31 (Geiger 
et al., 2011) have been proposed to be mediators for the transport across the ER membrane. 
In the cytosol, ER membrane J proteins may stimulate interactions between the cytosolic 
chaperon Hsp70 and the virus and could help with viral release into the cytosol (Goodwin et 
al., 2011; Walczak et al., 2014).  
Next, polyomaviruses enter the nucleus likely via the nuclear pore complex (NPC) (Qu et al., 
2004). The translocation into the nucleus depends on the recognition of the NLS motif of VP1 
and/or of minor capsids proteins by alpha and beta importins (Nakanishi et al., 2002; Qu et al., 
2004; Nakanishi et al., 2007). However, polyomaviruses may also be able to enter the 
nucleoplasm directly from the ER by crossing the inner nuclear membrane by deformation 
(Butin-Israeli et al., 2011). 
Later in the virus replication cycle, capsid proteins are synthesized in the cytoplasm and are 
transported into the nucleus for assembly at nuclear domain 10 (ND10) bodies, which are also 
called promyelocytic leukemia (PML) protein nuclear bodies (Ishov and Maul, 1996; Shishido-
Hara et al., 2004). Viral DNA replication has been localized to these discrete functional 
heterogeneous nuclear scaffolds (Shishido-Hara et al., 2004), suggesting that nuclear bodies 
provide the architecture for “polyomavirus assembly factories” (Erickson et al., 2012). Virus 
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assembly occurs here in tubular structures with “budding” events at the end, but the PML 
protein itself seems not to be critical for this process (Shishido-Hara et al., 2004; Erickson et 
al., 2012). VP1 pentamers are thought to polymerize into tubes around the viral chromatin or 
the chromatin might later traverse into until a terminal event buds off icosahedral particles at 
the end. How the VP1 subunits specifically identify and bind the viral genome remains 
unknown (Oppenheim et al., 1992; Dalyot-Herman et al., 1996; Carbone et al., 2004; Erickson 
et al., 2012). After assembly, agnoproteins or remaining VP2 and VP3 may support the release 
of the virus progeny by disruption of the host cell membrane (Suzuki et al., 2010).  
Pentameric bacterial toxins such as cholera and shiga toxin share certain characteristics of 
cellular entry with polyomaviruses (Ewers et al., 2010; Nelson et al., 2013). They attach to 
gangliosides, use the cholesterol-dependent entry mechanism, and traffic to the ER (Fujinaga 
et al., 2003; Cho et al., 2012). Although multivalent receptor binding is not essential for the 
toxicity of cholera toxin, higher receptor binding avidity and/or the induced remodeling of the 
membranes through lipid clustering increase its effect (Jobling et al., 2012). However, in 
contrast to ER-targeting bacterial toxins polyomavirus particles are usually not detected in the 
trans-Golgi network or cisternae of the Golgi complex (Engel et al., 2011; Cho et al., 2012). 
JC Polyomavirus  
JCPyV attaches to cells via engagement of its glycan receptor motif lactoseries 
tetrasaccharide c (LSTc) and then enters cells by clathrin-dependent endocytosis through a 
mechanism involving serotonin 5-hydroxytryptamine-type 2 receptors (5-HT2Rs) and the 
epidermal growth factor receptor pathway substrate clone 15 (Pho et al., 2000; Elphick et al., 
2004; Querbes et al., 2004; Neu et al., 2010; Assetta et al., 2013). 5-HT2Rs are 
transmembrane-spanning G protein-coupled receptors that are abundantly expressed on 
multiple cell types, including brain and kidney cells, correlating with the major JCPyV infection 
sites (Bonhaus et al., 1995). Especially 5-HT2R type 2A (5-HT2AR) is highly expressed in the 
cerebral cortex (Bonhaus et al., 1995), a site in which JCPyV and demyelinating lesions are 
usually detected in PML patients (Du Pasquier et al., 2003; Wuthrich and Koralnik, 2012). 
Overexpression of 5-HT2Rs enhances JCPyV infection in poorly permissive cell lines and 5-
HT2AR and 5-HT2CR antibodies block infection (Elphick et al., 2004; Maginnis et al., 2010; 
Assetta et al., 2013), however, JCPyV still infects human brain microvascular endothelial cells, 
which have low levels of 5-HT2AR (Chapagain et al., 2007). The drug chlorpromazine, an 
inhibitor of clathrin-dependent endocytosis and antagonist of 5-HTRs, reduces JCPyV infection 
in glial cells and the kidney cell line HEK293, which indicates, that viral entry in the brain as 
well as kidney is mediated by clathrin-dependent uptake (Pho et al., 2000; Assetta et al., 
2013). Probing the glycosylation sites on the extracellular N-terminus of 5-HT2AR by 
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mutagenesis suggests that the sialylated glycan attachment receptor LSTc for JCPyV is not 
linked to 5-HT2R (Maginnis et al., 2010).  
Internalized JCPyV is found together with 5-HT2AR in early endosomes already 5 min post-
infection (Elphick et al., 2004). The virus enters then the endocytic system where it colocalizes 
15 min post-infection with Rab5 and 2 hours post-infection with Cav-1 (Querbes et al., 2006). 
Unlike other polyomaviruses, JCPyV does not colocalize with Rab7, which is important for the 
endosomal maturation process (Querbes et al., 2006). Thus it remains to be clarified whether 
JCPyV actually enters maturing and late endosomes like other polyomaviruses, and if the 
association with Cav-1 occurs in distinct independent organelles or in Cav-1-positive late 
endosomes (Querbes et al., 2006). The fact that JCPyV does not employ a ganglioside 
receptor for attachment and entry may impact subsequent virus accumulation and trafficking 
(Qian et al., 2009; Ströh et al., 2015). Nevertheless, intracellular pathways of JCPyV and other 
polyomaviruses seem to intersect in large parts. For example, JCPyV and SV40 infection is 
inhibited by the drug Brefeldin A, indicating that productive trafficking of both viruses to the ER 
is Arf1-GTPase-dependent and shared despite differences during the early steps of the 
infection (Querbes et al., 2006). 
Similarly to other polyomaviruses, the cellular uptake of JCPyV and intracellular transport to 
the ER is rather slow. JCPyV colocalizes with the ER protein calreticulin 6 to 16 hours post-
infection (Nelson et al., 2012). In the ER the canonical PDI and ERp57 are necessary for 
isomerization of interpentamer disulfide bonds of the JCPyV capsid and the partial exposure of 
VP2 is a critical step for the following ER egress (Nelson et al., 2012; Nelson et al., 2013).  
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1.2  Virus Glycan Receptors 
Many viruses, including several human pathogens, interact with glycans on the cell surface of 
target cells during the initial steps of the infection. Viral glycan receptors such as sialic acid-
containing carbohydrates or glycosaminoglycans (GAGs) are often negatively charged, but 
also neutral glycans such as histo-blood group antigens (HBGAs) function as receptors or 
attachment factors for viruses (Figure 7).  
 
 
Figure 7: Glycans as viral receptors. Host- and cell-specific variants of sialic acids, neutral oligosaccharides (for 
example histo-blood group antigens (HBGAs)), and glycosaminoglycans (GAGs) are used as virus receptors or 
attachment factors. Virus families with members that are known to interact with one or more glycan types are 
indicated in the respective overlapping ellipses of the Venn diagram. The most common human sialic acid Neu5Ac 
is shown. Modifications occur at several carbon positions (see also Figure 8). The type 2 core antigen (blue) is part 
of the ABO blood group determinants. R′ indicates where the core is attached to a glycoprotein. Disaccharide units 
consisting of N-acetyl- or N-sulfohexosamine and either an uronic acid (glucuronic or iduronic acid) or galactose 
form long GAG chains. Heparan sulfate (HS) is shown as an example. HS usually vary by N-sulfation or N-
acetylation at carbon position C2 of the hexosamine and sulfation at C2 of the uronic acid and at C6 of the 
hexosamine. Modified from Ströh and Stehle, 2014. 
Sialic acids, which are 9-carbon, α-acidic keto sugars, are ubiquitously expressed at cell 
membranes of higher vertebrates, where they are located at terminal ends of N-glycans, O-
glycans and lipids (Varki and Varki, 2007; Varki and Schauer, 2009). In humans, the α-5-N-
acetyl neuraminic acid (Neu5Ac), with a carboxylate group at C2, a N-acetyl group at the C5 
position and a glycerol chain at C6, is the most abundant variant, but various sialic acid 
substitutions	 (acetylation, methylation, and sulfatation) at C4, C5, C7, C8 and C9 are known 
(Angata and Varki, 2002) (Figure 8). α-5-N-glycolyl neuraminic acid (Neu5Gc) is not produced 
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by humans due to a mutation in the gene coding for the enzyme cytidine monophosphate-N-
acetyl neuraminic acid hydroxylase (CMAH), which hydroxylates Neu5Ac (Chou et al., 1998; 
Irie et al., 1998). Thus, the functional group at C5 plays an important role in human evolution, 
immunology and other sialic acid-mediated biological processes (Varki, 2001; Chou et al., 
2002; Varki, 2007; Padler-Karavani et al., 2008). Furthermore, the absence of Neu5Gc affects 
susceptibility to various pathogens, and many human-specific pathogens target Neu5Ac on 
cells (Byres et al., 2008; Deng et al., 2014). However, Neu5Gc can be absorbed from diary 
sources and is found in certain cancers (Tangvoranuntakul et al., 2003; Samraj et al., 2014).  
 
 
Figure 8: Structures of (A) Neu5Ac and (B) Neu5Gc. Neu5Ac, with an N-acetyl group at the C5 position, is the 
most abundant sialic acid variant in humans. Neu5Gc is produced in monkeys and other vertebrates but not in 
humans. Characteristic functional groups of sialic acids are the carboxylate group, glycerol and N-acetyl or N-
glycolyl chain, respectively, but also various substitutions (acetylation, methylation, and sulfation) at C4, C5, C7, C8, 
and C9 of the 9-carbon backbone are known (Angata and Varki, 2002).  
In glycoconjugates such as N- or O-linked proteins and glycolipids such as gangliosides, sialic 
acids are usually attached via α2,3- or α2,6-linkages to either a galactose (Gal) or to an N-
acetylgalactosamine (GalNAc), or via α2,8- or α2,9-linkages to one another (Yu et al., 2011a; 
Sato and Kitajima, 2013). Gangliosides are divided into four groups, or “series”, termed asialo-, 
a-, b- and c-series based on the number and on complexity of their sialic acid branching 
patterns (Schnaar et al., 2009). They occur ubiquitously in most tissues with varying 
concentrations of the different forms according to cell types. In the adult human brain, GM1, 
GD1a, GD1b, and GT1b are very abundant, comprising up to 97% of the present gangliosides, 
whereas for example the structurally simplest member of gangliosides GM3 is predominant in 
liver and kidney (Nilsson and Svennerholm, 1982; Svennerholm et al., 1989; Prokazova et al., 
2009; Yu et al., 2009; Sturgill et al., 2012). Oriented towards the extracellular matrix and 
anchored through their ceramide lipids into the outer leaflet of the plasma membrane, 
gangliosides are involved in various signaling processes, as well as cell-cell and cell-matrix 
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interactions (Lopez and Schnaar, 2009). However, they are usually not uniformly distributed in 
the membrane but clustered in lipid rafts (Lingwood and Simons, 2010).  
Occurrence and distribution of glycan receptors and pseudo receptors on target cells as well 
as binding specificity and binding affinity determine tissue and host tropism and ultimately 
pathogenicity of viruses. Hereby influenza virus A is probably the best-studied and known 
example to demonstrate the importance of a particular glycosidic linkage (recently reviewed in 
Imai and Kawaoka, 2013; de Graaf and Fouchier, 2014). Avian strains engage α2,3-linked 
sialic acids on intestine tissue in birds and usually do not infect humans, while human strains 
recognize α2,6-linked sialic acids of the human respiratory tract. However, a receptor switch 
from α2,3- to α2,6-linked sialic acids in an avian or porcine reservoir could eventually lead to 
transmission to humans causing widespread infection in humans and viral pandemics. 
Polyomavirus Sialic Acid Glycan Receptors 
Glycans featuring terminal sialic acids function as cell surface attachment receptors for several 
polyomaviruses (Table 2). SV40 uses the GM1 ganglioside, whereas MPyV attaches to GD1a 
and GT1b gangliosides and BKPyV engages GD1b and GT1b gangliosides as receptors (Tsai 
et al., 2003; Low et al., 2006). MCPyV VP1 pentamers bind the GT1b ganglioside in vitro 
(Erickson et al., 2009) and for JCPyV, LPyV, and HPyV9 several sialylated glycan receptor 
motifs have been identified although location and presentation on cells remains unclear 
(Komagome et al., 2002; Neu et al., 2010; Gorelik et al., 2011; Neu et al., 2013b; Khan et al., 
2014). Crystal structures of polymavirus VP1 in complex with specific sialylated glycan 
receptors motifs have been solved and reveal that surface loops connecting β-strands mediate 
the interactions with the terminal sialic acid residues in all cases (Neu et al., 2008; Neu et al., 
2010; Neu et al., 2012; Neu et al., 2013a; Neu et al., 2013b; Khan et al., 2014). The protruding 
functional groups of the sialic acid are commonly employed for specific engagement by VP1 in 
the same general area of the protein (Figure 9). A small number of additional contacts outside 
the binding pocket achieve glycan specificity in the case of closely related SV40, BKPyV, and 
JCPyV, which are engaging the terminal Neu5Ac in a highly conserved manner (Neu et al., 
2013a) (Figure 10). Alternatively, sialic acids are recognized in a different and unique 
orientation by applying specific binding strategies as observed for MCPyV, MPyC, LPyV, and 
HPyV9 (reviewed in Ströh and Stehle, 2014) (Figure 9). 
Introduction 
 
 27 
 
Figure 9: A highly plastic sialic acid binding site on polyomavirus VP1. The structural superposition of 
polyomavirus VP1-glycan complex structures reveals an overall conserved location of the sialic acid binding site, 
which is build up by variable surface loops connecting the β-strands of the jelly-roll core. (A) The complex structure 
of the JCPyV VP1 pentamer with the LSTc glycan (pdb: 3NXD) is shown exemplary to highlight the overall location 
of the binding site. (B) Close-up view of the binding site. Terminal sialic acid residues are shown in stick 
representations. SV40 VP1-GM1 glycan (pdb: 3BWR), BKPyV VP1-GD3 glycan (pdb: 4MJ0), JCPyV VP1-LSTc, 
MCPyV VP1-GD1a glycan (pdb: 4FMJ), LPyV VP1-α2,3 Neu5Ac-sialyllactose (pdb: 4MBY), MPyV VP1-Neu5Ac-
α2,3-Gal-β1,3-[α2,6-Neu5Ac]-GlcNAc-β1,3-Gal-β1,4-Glc (pdb: 1VPS), HPyV9 VP1-α2,3 Neu5Gc-sialyllactose (pdb: 
4POT). Modified from Ströh and Stehle, 2014. 
The pentasaccharide LSTc was identified as receptor motif for JCPyV by glycan array 
screening (Neu et al., 2010). Subsequent structural studies revealed that JCPyV VP1 from the 
prototype Mad-1 strain engages LSTc in a unique L-shaped conformation (Figure 10 A). 
Mutations of VP1 residues contacting LSTc lead to a severe defect in viral growth in glial cells 
(Neu et al., 2010). The LSTc glycan features a terminal α2,6-linked Neu5Ac, whereas previous 
studies had suggested that JCPyV can use both α2,3- and α2,6-linked sialic acid receptors for 
infection (Dugan et al., 2008). Additionally, virus-like particles (VLPs) of a urine isolate were 
found to have an altered capacity to engage sialylated receptors, suggesting a possible link to 
differences in viral tropism and spread in JCPyV pathogenesis (Gorelik et al., 2011). The urine 
isolate belongs to the genotype 3 and is therefore referred to as WT3, whereas the Mad-1 
strain is a genotype 1 strain. WT3 VLPs engage asialo-GM1, GD1a, GD1b, GD2, and GT1b 
(Gorelik et al., 2011) as well as GM1 and GM2 (Leonid Gorelik, Consortium for Functional 
Glycomics (CFG); available online at www.functionalglycomics.org according to CFG policy). 
However, Mad-1 VLPs have also been found to bind to several gangliosides, including GM3, 
GD2, GD3, GD1a, GD1b, GT1b, and GQ1b, but not GM1 or GM2, by a virus-overlay-blotting-
assay (Komagome et al., 2002). These findings suggest that JCPyV subtypes may either have 
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altered binding specificities or affinities for α2,3- and α2,6-linked Neu5Ac glycans, which may 
have then different roles and function during infection and for JCPyV pathogenicity.  
 
 
Figure 10: Glycan binding site of JCPyV, SV40, and BKPyV. (A) JCPyV VP1-LSTc (pdb: 3NXD), (B) SV40 VP1-
GM1 glycan (pdb: 3BWR), and (C) BKPyV VP1-GD3 glycan (pdb: 4MJ0) complex structures are shown with VP1 in 
surface and cartoon representations. Glycans and VP1 residues in and adjacent to binding sites are represented 
with sticks. Hydrogen bonds and salt bridges are indicated with black dashed lines. Residues highlighted in bold are 
involved in conserved interactions with the terminal Neu5Ac in all three structures. Schematic representations of 
glycans used in in crystallographic studies are shown below the structural figures. Glycan residues that are 
contacted by VP1 are highlighted in comparison to residues not involved in protein glycan interactions. Structural 
figures and glycan representations were adapted from Neu et al., 2013a.  
In simians, the natural hosts of the closely related SV40, the GM1 ganglioside contains often a 
terminal Neu5Gc instead of NeuAc as seen in humans. Indeed, glycan array screening has 
shown that the GM1 ganglioside featuring a terminal Neu5Gc is a better receptor than the 
human counterpart (Campanero-Rhodes et al., 2007). The crystal structure of a SV40 VP1-
Neu5Ac-GM1 glycan complex provides the explanation (Neu et al., 2008). The N-acetyl group 
of Neu5Ac points into a large cavity that is built up by polar and hydrophobic residues and is 
much larger than in VP1 of the related human JCPyV and BKPyV (Figure 10 C). It could 
accept the hydroxymethyl group of the Neu5Gc and the predicted conformation would even 
allow additional hydrogen bonds that result in increased affinity for Neu5Gc-GM1 compared to 
Neu5Ac-GM1 (Stehle and Khan, 2014). A single point mutation in BKPyV VP1 (K68S) 
switches the glycan receptor binding specificity from α2,8-α2,3-diNeu5Ac containing b-series 
gangliosides to the SV40 GM1 ganglioside receptor (Neu et al., 2013a). However, BKPyV 
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K68S retains the binding specificity for the human Neu5Ac-modified GM1 ganglioside due to 
its shallow cavity on VP1 compared to SV40 (Neu et al., 2013a). 
In contrast to the receptor binding specificity of SV40 and BKPyV corresponding to the most 
prevent sialic acid variant in their host, glycan array screening and structural analysis of 
HPyV9 VP1 displayed a preference for α2,3-Neu5Gc-linked linear receptors whereas the 
closely related monkey virus LPyV seems to engage an α2,3-Neu5Ac-linked motif (Neu et al., 
2013b; Khan et al., 2014). Interactions with an additional hydroxymethyl group are not favored 
in the binding pocket of LPyV VP1 that is otherwise largely conserved compared to HPyV9. 
Thus, the detailed understanding of the recognition of Neu5Ac variants by viruses is only 
beginning to emerge, but also bacterial toxins are known to engage Neu5Gc-linked glycans on 
human gut endothelium cells, which present Neu5Gc absorbed from red meat or milk products 
(Byres et al., 2008).  
Functional cell-based and structural studies demonstrate that several b-series gangliosides 
support BKPyV infection albeit with differences in affinities (Neu et al., 2013a). However, the 
increased affinity toward more complex b-series gangliosides may be only one determinant for 
receptors usage. Theoretically, lower affinity could be balanced by greater receptor abundance 
on cells, so that weaker binding gangliosides could have still implications for BKPyV tropism 
and pathogenesis (Neu et al., 2013a). BKPyV establishes a persistent infection in the human 
kidney, and here cells possess in particularly more simple gangliosides such as GM3 and GD3 
(Shayman and Radin, 1991). The relative abundance of gangliosides differs not only between 
brain and kidney, expression of gangliosides varies also between the different tissues of the 
adult human kidney (Holthofer et al., 1994; Yu et al., 2009). Consistently, developmental or 
drug-induced changes in b-series ganglioside distribution may play a role in latency and 
reactivation of BKPyV (Neu et al., 2013a).  
The impact of precisely regulated glycan-binding affinities on viral pathogenicity has been 
demonstrated for MPyV (Freund et al., 1991; Bauer et al., 1995; Bauer et al., 1999). Sialylated 
glycolipids and -proteins, two major constituents of the plasma membrane, execute opposing 
functions during MPyV infection. The engagement of “decoy” or pseudo receptors such as 
glycoproteins restricts the infection of MPyV (Qian and Tsai, 2010). A mutation in the VP1 
sialic acid binding pocket reduces the affinity for sialylated pseudo receptors on cells and 
decreased cell binding results in increasing viral dissemination and pathogenicity.  
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Studying Virus-Glycan Interactions 
There has been a large increase in studies on virus-glycan interaction over the past years due 
to recent technological advances such as reverse genetic systems for more and more viruses, 
glycan binding arrays, X-ray crystallography, and biophysical methods to study low affinity 
interactions (recently reviewed in Ströh and Stehle, 2014). However, virus-glycan interaction 
studies have still many experimental restrictions. Glycans cannot be cloned and sequenced in 
contrast to nucleic acids and proteins, the usage of established molecular biology tools is often 
limited, the chemical synthesis of complex glycans is difficult, or the available material is very 
expensive. Additionally, information about their three-dimensional structures and their 
distribution on cells is rare. Nevertheless, rapid and high-throughput approaches using glycan 
arrays have led to the identification of glycan receptors or glycan receptor motifs for several 
viruses such as influenza virus (Childs et al., 2009), polyoma- (Neu et al., 2008; Neu et al., 
2010), adeno- (Nilsson et al., 2011), reo- (Reiss et al., 2012), and picornaviruses (Imamura et 
al., 2014). Critical differences in glycan binding preferences of certain strains have also been 
determined (Stevens et al., 2006). On the array, either amine-terminating glycans are 
immobilized by covalent linkages to N-hydroxysuccinimide (NHS)-activated glass (Blixt et al., 
2004) or lipid-inked glycans are printed on nitrocellulose-coated glass, known as neoglycolipid 
(NGL)-based arrays (Palma et al., 2014). Whole virus, VLPs, or the viral attachment protein 
alone are incubated on the array and binding is usually quantified via fluorescence-based 
detection systems.  
In order to test for functionality of the interaction in cell-based infectivity assays virus-glycan 
binding can be blocked by lectins or the virus can be incubated with free glycans prior to 
infection (Neu et al., 2010; Reiss et al., 2012). The enzymatic removal of glycans using 
neuraminidases for sialic acids or heparinases and chondrotinases for glycosaminoglycans, 
respectively, is also possible (Schowalter et al., 2011). Treatment of cells with drugs that 
specifically inhibit N- and O-linked glycosylation or the synthesis of gangliosides can help to 
understand where the identified glycan is linked to in vivo (Taube et al., 2012). Moreover, small 
interfering RNAs (siRNAs) and cell lines deficient for certain glycans are useful tools to 
investigate the functional relevance of virus-glycan interactions for attachment and infection 
(O'Donnell et al., 2010; Schowalter et al., 2011).  
Ligand-based nuclear magnetic resonance (NMR) spectroscopy techniques such as saturation 
transfer difference (STD) NMR that were developed for monitoring weak protein-ligand 
interactions (Kd in the mM- to µM-range) are suitable to determine viral binding epitopes on 
glycans (Reiss et al., 2012; Neu et al., 2013a). The STD NMR experiment is based on the 
intermolecular Nuclear Overhauser Effect (NOE) between the protein and the ligand in the 
case of complex formation with fast off-rates. Resonances belonging to protons of the ligand in 
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distances of up to 5 Å to the protein during the binding event are observed in the STD NMR 
spectrum after selective excitation of the protein proton resonances (Mayer and Meyer, 1999). 
Protein resonances are selectively saturated in a spectral region of the 1H NMR spectrum that 
contains resonances of the protein but not the ligand (on resonance spectrum). The on 
resonance spectrum is then subtracted from a spectrum recorded without selective saturation 
(off resonance spectrum), usually the aromatic side chain or methyl region. In the resulting 
difference spectrum only proton resonances of the ligand that received saturation transfer from 
the protein via spin diffusion through the intermolecular NOEs are visible. A control experiment 
without the protein serves to verify that no direct excitation of the ligand takes place (Mayer 
and Meyer, 1999).  
The list of biophysical methods to determine binding affinities or kinetics of virus-glycan 
interaction are often restricted by the availability and cost of the material for the experiment. In 
general, routinely used biophysical studies require due to the low binding affinity especially 
high amounts of expensive or only rarely available glycans. Nevertheless, biophysical methods 
including isothermal titration calorimetry (ITC) (Neu et al., 2008), microscale thermophoresis 
(MST) (Xiong et al., 2013), surface plasmon resonance (SPR) (Nilsson et al., 2011), or mass 
spectrometry (MS) (Han et al., 2015) have been used to study binding affinities and to 
determine equilibrium dissociation constants for virus-glycan interactions. ITC measures the 
heat that is released when a ligand binds to a protein and from this enthalpy and entropy of the 
binding event can be calculated. During the MST experiment the motion of molecules along 
microscopic temperature gradients are measured and thereby changes in the hydration shell, 
charge, or size are detected (Jerabek-Willemsen et al., 2011). One major advantage of SPR 
techniques is the possibility to investigate binding and dissociation events separately. SPR 
was used to measure association (ka) and dissociation (kd) rates for the interaction between 
influenza virus A strains and α2,3- and α2,6-linked Neu5Ac using an immobilized lipid bilayer 
containing gangliosides on the surface of the sensor chip (Hidari et al., 2007). Moreover, the 
binding affinity of Adenovirus 37 (Ad37) towards its glycan receptor motif GD1a has been 
determined by SPR (Nilsson et al., 2011). Hereby, the Ad37 fiber knob (ligand) was 
immobilized on the sensor ship surface and the GD1a glycan (analyte) was injected in varying 
concentrations and passed over the surface. A relatively high-affinity binding site (Kd of about 
20 µM, with Kd= kd / ka) was detected at low glycan concentrations and additionally, a lower-
affinity binding event (Kd of about 270 µM) was observed at higher glycan concentrations 
(Nilsson et al., 2011). Crystal structure analysis has shown that Ad37 binds the branched 
GD1a glycan by engaging both terminal Neu5Ac residues of its two branches. Although the 
proposed two-site model for binding based on the SPR measurements requires further 
evaluations, this study shows exemplary how a bivalent binding event (Ad37-GD1a) can 
increase the overall binding affinity of the virus-glycan interaction compared to a monovalent 
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interaction (Nilsson et al., 2011). A much lower binding affinity (Kd of about 5 mM) had been 
determined for the monovalent Ad37-3’SL interaction in earlier studies (Burmeister et al., 
2004). 
1.3  Antiviral Strategies  
In addition to immunization strategies, effective antiviral agents are important for managing the 
emergence and re-emergence of viral infections. The fact that viruses are obligatory 
intracellular pathogens and rely on host cell function for replication facilitates the definition of 
suitable targets for antiviral therapy (Muller and Krausslich, 2009; Lou et al., 2014). However, a 
better understanding about structure and function of viral proteins and molecular mechanisms 
of virus-host interactions provides a useful platform for a rational development and discovery of 
new antiviral agents. Initial antiviral drugs were directed at virus-encoded enzymes, but more 
recently compounds inhibiting viral entry or release have been developed, and also strategies 
targeting host factors and the innate immune response system as well as gene silencing are 
pursued (Blake et al., 2012; Lou et al., 2014). Nevertheless, due to the rapid development of 
antiviral resistance in some cases, the use of drugs can be rather limited (Bartholomeusz and 
Locarnini, 2006; Okomo-Adhiambo et al., 2015).  
Small molecules as attachment inhibitors have been developed for several enveloped as well 
as for non-enveloped viruses. For example in the case of HIV, small molecule compounds that 
bind in a highly conserved pocket within the HIV-1 envelope protein gp120 and interfere with 
the recognition of the CD4 receptor on the cell surface are tested in clinical trials (Henrich and 
Kuritzkes, 2013). Other examples for small compound attachment inhibitors are oseltamivir 
(TamifluTM) and zanamivir (RelenzaTM), which were the first drugs approved for their usage in 
anti-flu therapy (Ison, 2011). The neuraminidase (NA) is a surface glycoprotein of influenza 
viruses that cleaves cell surface sialic acids, which are engaged by influenza HA and allows 
thereby the release of progeny virions. Oseltamivir and zanamivir bind both to the influenza 
NA. In particular structure-based drug design strategies including in silico docking- and 
pharmacophore-based virtual screening in combination with X-ray structure analysis have 
been applied to develop NA inhibitors. However, emergence and spread of viral resistance 
limit their use and have become an important concern particularly for influenza virus A (H1N1) 
and oseltamivir (Okomo-Adhiambo et al., 2015). The development and clinical approval of two 
novel inhibitors, laninamivir and peramivir, could at least partially overcome the oseltamivir 
resistance (Yamashita, 2010) or can be used when drug delivery by a route other than 
intravenous is not feasible (Mancuso et al., 2010).  
Crystal structure analysis has also inspired the design and development of a multivalent 
inhibitor against Ad37, a virus that causes the severe ocular infection Epidemic 
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keratoconjunctivitis (EKC) (Nilsson et al., 2011; Spjut et al., 2011). Ad37 engages its glycan 
receptor GD1a with its trimeric fiber knob protein (Nilsson et al., 2011). A trivalent inhibitor 
featuring sialic acid-derived head groups is more potent than the monovalent sialic acid and 
also the divalent GD1a glycan (Spjut et al., 2011). So far, several carbohydrate-based or 
glycomimetic drugs have reached the market, but the development of therapies is often 
hindered by challenges such as poor absorption of the molecules and/or their rapid elimination 
(Ernst and Magnani, 2009). However, in the case of Ad37 an administration of the inhibitor 
directly to the eye, the site of infection, may circumvent many of the pharmacokinetic hurdles 
(Spjut et al., 2011).  
Targeting interaction with sialylated receptors during viral attachment is also one rational 
antiviral approach for human polyomaviruses such as JCPyV and BKPyV. Although Neu5Ac 
binding sites of two neighboring VP1 monomers are further apart in the context of the 
pentamer or the capsid compared to the trimeric Ad37 fiber knob, compounds mimicking sialic 
acids are still promising antiviral candidates. Unique surface features on VP1 are hereby likely 
critical to improve binding affinities and kinetics compared to the VP1-glycan interaction. For 
example in the case of JCPyV, an elongated groove is connected with the Neu5Ac binding 
pocket and could be explored to improve binding characteristics of sialic-acid derived 
compounds (Neu et al., 2010). In contrast to more complex viruses, polyomaviruses possess 
only the capsid protein VP1 that mediates interaction with cell surface receptors and can be 
used as a target for attachment inhibition. However, interactions between VP1 and minor 
capsid proteins VP2 and VP3 or interactions between neighboring VP1 pentamers that are 
important for the general architecture of the virion are also rational targets (Chen et al., 1998; 
Nakanishi et al., 2006). Furthermore, alternative strategies, including inhibition of LT (Goodwin 
et al., 2009; Seguin et al., 2012; Randhawa et al., 2014) and blocking of retrograde trafficking 
to the ER (Nelson et al., 2013; Carney et al., 2014) have been tested. Antiviral effects of 
different small compounds have been observed and explored against BKPyV and JCPyV 
infection (Jiang et al., 2010; Rinaldo et al., 2010; O'Hara et al., 2014). For MCPyV, an attempt 
has been made to identify potential siRNA molecules for silencing of T antigen coding mRNA 
(Hoque et al., 2012). The specific knockdown of a gene function of interest makes the siRNA 
technology not only a powerful tool for studying gene function, but it may also be used in 
antiviral therapy. Promising antiviral effects of siRNAs have been shown for example against 
hepatitis B and C virus (HBV, HCV) (Chen et al., 2008).  
In addition to small antiviral molecules, the development of effective human neutralization 
monoclonal antibodies against the JCPyV capsid is currently pursued in order to prevent, 
manage, or treat one or more conditions associated with a JCPyV infection (Simon et al., 
2013; Burioni and Clementi, 2014). Neutralizing antibodies bind idealistically to a plurality of 
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JCPyV genotypes compromising mutations associated with PML or other clinical disorders 
caused by JCPyV. 
 
Fragment-based Drug Discovery 
Fragment-based drug discovery (FBDD) has emerged in the past decade as a popular 
alternative to high-throughput screening (HTS) for the identification of lead compounds during 
drug discovery (Davies and Tickle, 2012). The approach aims to identify very small molecules 
out of a smaller collection instead of searching huge collections containing larger molecules, 
which are potentially more active from the beginning. The chemical diversity can be 
represented in a FBDD library of only several thousand fragments, and collections with about 
1,000 molecules represent the chemical diversity of libraries containing tens of millions of 
larger and more drug-like compounds (Hajduk et al., 2011). In the FBDD approach, small 
molecules are usually expanded or linked to increase specificity as well as biological potency. 
Fragments in FBDD compound libraries have often a higher degree of binding promiscuity and 
are in line with the “rule-of-three” (Congreve et al., 2003), which was named in analogy to the 
earlier described Lipinski’s “rule-of-five” (Lipinski et al., 2001). The rule-of-three demands a 
molecular weight of less than 300 Da, no more than three hydrogen bonding donors and three 
hydrogen bonding acceptors, and a computed partition coefficient (clogP) of less than three 
(Congreve et al., 2003). The partition coefficient (P) is a quantitative descriptor of lipophilicity 
and is defined as the ratio of the concentrations of a neutral compound in organic (for example 
octanol) and aqueous phases of a two-compartment system under equilibrium conditions. It 
can be measured experientially and is mostly used in the logarithmic form. However, several 
methods have been developed in order to calculate log P values based on the molecular 
structure (Mannhold et al., 2009). Other criteria include a polar surface area (PSA) < 60 Å2, 
and a number of rotatable bonds of less or equal than three. Fragments according to these 
rules are thought to possess a high quality of binding, although they exhibit high dissociation 
constants (Kd ranging from µM to mM) (Davies and Tickle, 2012). Nevertheless, FBDD is 
facing serious problems such as the reactivity of molecules and aggregation in aqueous 
solution at the high concentrations that are needed for most assays to detect low-affinity 
binders (Erlanson, 2012). These aggregates can non-specifically inhibit proteins, thereby 
interfering with biochemical assays (Rishton, 2003). Another critical challenge is the poor 
solubility of many organic molecules at concentrations that are needed. Despite these 
drawbacks, FBDD has gained credibility in many drug discovery projects, especially together 
with improvements in complimentary methods including X-ray crystallography, biophysical 
methods such SPR, and computational approaches to establish structure-activity relationships 
(SAR) (Davies and Tickle, 2012; Murray et al., 2012).  
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2.  Objectives 
2.1  Determinants of JC Polyomavirus Cellular Attachment and Infection and the 
Development of Specific Antagonist for PML 
At the beginning of this study it was established that JCPyV engages sialic acid receptors on 
host cells in order to initiate infection. Studies with the Mad-1 prototype strain of JCPyV 
showed that the virus binds the LSTc pentasaccharide during cell attachment and/or entry, but 
interactions with several other glycans, including gangliosides, were reported in other studies. 
It was unknown how differences that occur in VP1 proteins from different virus strains, 
genotypes as well as PML isolates influence glycan receptor specificity, the infectious entry 
pathway, and ultimately pathogenicity. Therefore, experiments were conducted in order to 
answer the following questions: 
 
• What are the structural determinants of the JCPyV receptor binding specificity? 
• What is the effect of VP1 mutations frequently found in JCPyV samples isolated from 
the brain of PML patients on virus receptor binding, glycan receptor specificity, and 
virus infectivity? 
• Are there strain-specific or genotype-specific differences in glycan receptor binding that 
affect JCPyV cell tropism, the entry pathway, and pathogenicity? 
• Are gangliosides important for JCPyV infection? 
• How do binding affinities influence JCPyV VP1-glycan interactions? What are the 
requirements of the glycan receptors to promote JCPyV infection?  
• What is the role of the pore at the 5-fold axis of the VP1 pentamer during JCPyV 
infection? 
• How can the structural information be used for the development of antiviral therapies 
and treatment of PML? 
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2.2  Structural and Functional Analysis of Receptor Specificities of the Recently 
Discovered Human Polyomaviruses 
With relatively high sequence homology and conserved overall architecture across the three 
existing genera, the polyomavirus family forms an attractive platform for analyzing 
determinants of antigenicity, cell entry, cell tropism, and host range, as well as other factors 
that contribute to viral pathogenesis. By comparing the receptor specificity of several newly 
discovered human polyomaviruses with better-studied human viruses JCPyV, BKPyV, and 
MCPyV, this part of the thesis aimed at understanding how structural changes of the virion 
enable the virus to adapt to new host cells, spread to different tissues, or to infect a new host 
species since all of these events are dependent on precisely regulated virus-receptor 
interactions. In detail, the experiments presented here were designed to address the following 
questions:   
 
• What kind of cellular receptors do the more recently discovered human polyomaviruses 
HPyV6, HPyV7, TSPyV, HPyV12, and NJPyV engage? 
• Which are the structural determinants of viruses’ receptor binding specificities as well 
as antigenicity? 
• Are the structural determinants derived by X-ray structure analysis functional in the 
context of cells?   
• Where are glycan receptors located on the cell?  
• How does the virus receptor specificity explain features of cell and host tropism and 
contribute to viral pathogenicity? 
• How do close phylogenetic relationships of human and non-human polyomaviruses 
affect glycan receptor specificity, host tropism, and viral adaption?  
• Is it possible to use structure-based phylogenetic analysis to predict polyomavirus-
glycan receptor interactions in a reliable manner? 
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3.  Results and Discussion 
3.1  Progressive Multifocal Leukoencephalopathy-Associated Mutations in the JC 
Polyomavirus Capsid Disrupt Lactoseries Tetrasaccharide c Binding 
Maginnis, M.S. *, Ströh, L.J. *, Gee, G.V., O'Hara, B.A., Derdowski, A., Stehle, T., and 
Atwood, W.J. (2013). Progressive multifocal leukoencephalopathy-associated mutations in the 
JC polyomavirus capsid disrupt lactoseries tetrasaccharide c binding. mBio 4, e00247-00213. 
* Authors contributed equally to this work.  
 
Studies with the Mad-1 prototype strain of JCPyV have shown that the LSTc glycan and 5-
HT2Rs are important for attachment and endocytosis, respectively. However, the majority of 
viral isolates from PML patients contain distinct VP1 mutations that were hypothesized to arise 
from positive selection within the patient. The most common mutations are L54F and S268F, 
which account for approximately 50% of PML-associated mutations, while mutations S266F 
and S268Y are less frequent but occur still very often. All four mutations are localized within 
the LSTc binding pocket of VP1. These distinct single point mutations have never been 
detected in the urine of healthy individuals, nor are they present in the urine of PML patients, 
from whom viruses with PML-associated mutations were isolated from their CSF and blood. 
These findings suggest that specific mutations can arise within the JCPyV-infected individual. 
We sought to answer the question whether these viruses represent the pathogenic form of the 
virus that infects glial cells in the CNS by utilizing a structural-functional approach.  
First we introduced the mutations into the JCPyV infectious genomic clone with a Mad-1 VP1 
and transfected viral DNA into the permissive glial cell line SVGA. The results showed clearly 
that only wild type JCPyV was able to propagate. Similarly, the attachment of the mutants to 
SVGA cells was abolished as monitored by flow cytometry. Next, we assessed the structural 
effects and solved high-resolution X-ray structures of L54F, S268F, and S268Y VP1. Crystal 
soaking experiments with LSTc revealed that binding was abolished or severely compromised 
in all three cases. Then we used the JCPyV pseudovirus system to investigate the infectivity of 
the mutant viruses in a panel of glial and kidney cell lines. Pseudoviruses are produced by 
transfecting plasmids coding for viral capsid proteins VP1, VP2, and VP3 into HEK293FT cells 
together with a reporter plasmid that expresses the green fluorescent protein and a secreted 
form of luciferase (Gaussia luciferase). The pseudovirus assay provides a sensitive method of 
measuring the infectivity of mutant viruses that do not propagate using traditional cultural 
methods. However, also here pseudoviruses with PML-associated mutations were not 
infectious.  
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All three crystallized mutants and likely also S226F block binding to sialylated glycan motifs, 
independent of their location on gangliosides or glycoproteins and their glycosidic linkages. 
Viruses with PML-associated mutations are rendered not infectious in glial and kidney cells, 
suggesting that these distinct mutations may play alternative roles in PML pathogenesis. One 
scenario could be that PML-associated mutations arise as a strategy of immune escape. 
Mutations in the viral capsid, making these mutant viruses capable of evading the host immune 
responses, may result in increased spread to the CNS. It seems also plausible that the loss of 
sialic acid binding may be necessary for increased spread to the brain and subsequent 
infection of glial cells in a sialic acid-independent manner. This hypothesis is similar to the 
scenario demonstrated for a mutation in the VP1 sialic acid-binding pocket of MPyV, which 
leads to decreased cell binding and increases viral dissemination and thus higher 
pathogenicity of the virus. It is also possible that an unknown host cell factor, e.g. a non-sialic 
acid receptor on glial cells in the CNS, which is necessary for infection by JCPyV with PML-
associated mutations, is not expressed abundantly on the tested cell lines. Noticeable, JCPyV 
VP1 pentamers feature an elongated groove on the surface of the pentameric capsid protein 
that is unique among all polyomavirus VP1 proteins crystallized to date. This groove could be 
involved in the engagement of other receptor structures on host cells, and such an interaction 
might be favored if binding to LSTc is significantly reduced or blocked. In conclusion, this study 
illustrates that specific engagement of cell surface glycan receptors is an important 
determinant of tissue tropism and possesses a critical role for JCPyV pathogenesis.  
3.2  Increased Affinity of JC Polyomavirus Capsid for LSTc Over Other Sialylated 
Glycans is a Major Determinant of Infectivity 
Ströh, L.J. *, Maginnis, M.S. *, Blaum, B.S., Nelson, C.D., Neu, U., Gee, G.V., O'Hara, B.A., 
Motamedi, N., DiMaio, D., Atwood, W.J. and Stehle, T. (2015). Increased affinity of JC 
polyomavirus capsid for LSTc over other sialylated glycans is a major determinant of infectivity. 
Journal of Virology 89, 6364-6375.  
* Authors contributed equally to this work.  
 
The prototype Mad-1 strain of JCPyV uses the α2,6-linked LSTc glycan motif for initial 
attachment to cells, but in contrast, the JCPyV Type 3 strain “WT3”, a kidney isolate, has been 
reported to interact with several gangliosides although their role in JCPyV infection was not 
clear. In order to define whether there are strain-specific differences in glycan receptor binding 
specificity with possible impact on cell tropism, the viral entry pathway and eventually 
pathogenicity, the JCPyV brain isolate Mad-1 was compared to the WT3 strain in a structural 
and functional study. WT3 and Mad-1 differ in eight amino acid positions in their mayor capsid 
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proteins VP1 and thus, both viruses enclose the majority of strain-specific VP1 differences of 
the seven JCPyV genotypes. The WT3 VP1 amino acid changes were introduced into the 
Mad-1 capsid of infectious virus, pseudovirus, and recombinant VP1 pentamers. 
High-resolution X-ray glycan complex structures of Mad-1 and WT3 VP1 pentamers reveal that 
in addition to the LSTc glycan motif both viruses are capable of engaging gangliosides glycans 
GM1, GM2, GD1a and GD1b, which feature α2,3- and α2,8-linked sialic acids. However, 
based on the observed interaction within in the complex structures, we hypothesized that 
binding affinities may modulate differences in glycan specificities between the two JCPyV 
strains. Here it was not possible to perform reliable affinity measurements using SPR and 
other techniques such as ITC have experimental and financial drawbacks when working with 
low affinity interactions with dissociation constants in the mM-range.  
In order to obtain an estimate for binding affinities we here applied a crystallographic 
approach. Therefore, highly isomorphous crystals of Mad-1 and WT3 VP1 were soaked in 
parallel for 30 min in crystal harvesting solutions supplemented with the glycans LSTc, GM1, 
GM2, GD1a or GD1b in a concentration-dependent manner. Data sets were collected at 
beamlines X06DA and X06SA at Swiss Light Source (SLS) (Villigen, Switzerland). The data 
set of the native WT3 VP1 crystal was taken as a reference data set for data processing. 
Structure factor amplitudes and structure factor sigmas from all data sets were combined into 
one single file including one set of free R flags from the reference data set. Then all data sets 
were given the unit cell parameters from the reference data set and were also scaled to the 
reference data set using a low- and a high-resolution cutoff (12.0-2.4 Å). Refinement was 
carried out again with Refmac5 using the data set from the crystals with the respective highest 
glycan concentration to obtain previously solved Mad-1 and WT3 VP1 complex structures with 
either the LSTc, GM1, GM2, GD1a or GD1b glycan in the referenced unit cell. Simulated 
annealing Fobs-Fcalc omit electron density maps were calculated 5 Å around the glycans and 
VP1 marker residues (Y80, Y160, W200, F262) for all scaled data sets. Next, masks 1 Å 
around the respective terminal Neu5Ac residues of all five glycans and around VP1 marker 
residues from each VP1 chain in the asymmetric unit were generated. Electron densities of the 
Neu5Ac or the marker residues were then integrated for all data sets by summation of the 
values of the grid points within the respective mask. The resulting electron density-derived 
binding curves approach saturation when the ligand occupancy in the crystal reaches a value 
of 1. The data from the electron density integration shows that both JCPyV strains engage the 
LSTc glycan with the highest affinity, but possess similar lower binding affinities for GD1a, 
GD1b and GM2. Assuming a simple equilibrium of the VP1-glycan interaction, dissociation 
constants Kd crystal of about 0.5 mM and 6 mM for the strongest interaction with LSTc and the 
weakest interaction with GD1a glycan, respectively, could be determined using least squares 
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fit to the experimental data points. Of the ganglioside glycans tested GM1 binds best to both 
JCPyV VP1 pentamers, although the binding curves differ slightly between both strains.  
The GM1 and GD1b gangliosides are functional receptors of the most closely related SV40 
and BKPyV, respectively. STD NMR experiments reveal that interactions with the GM1 glycan 
in solution are strikingly similar for Mad-1, WT3, and SV40 VP1, but the exogenous addition of 
gangliosides to cells did not alter the infectivity of viruses with Mad-1 or WT3 capsids in 
permissive or non-permissive cells. In order to further test whether ganglioside expression 
contributes to JCPyV infection at all, the enzyme responsible for the ganglioside biosynthesis, 
the GM3 synthase, was silenced by siRNA. The finding that silencing does not affect JCPyV 
infection demonstrates that gangliosides are not required for attachment and infection.  
Based on our functional and structural data it is unlikely that other genotype-specific VP1 
variations alter the glycan specificity of JCPyV. While JCPyV VP1 can in principle engage 
multiple sialic acid motifs, including functional receptors of the most closely related viruses, the 
higher binding affinity of JCPyV for LSTc seems to be prerequisite for functional receptor 
engagement. It is tempting to speculate that the increased affinity for LSTc has co-evolved with 
a switch in the viral entry pathway towards the clathrin-mediated pathway, whereas BKPyV 
and SV40 employ gangliosides receptors and a cholesterol-dependent endocytosis.  
Thus, our findings reconcile divergent findings from previous studies by showing that 
differences in glycan binding affinities and the location of the glycan on the cell, rather than 
possible binding events alone, determine JCPyV infection.  
3.3  Modulation of a Pore in the Capsid of JC Polyomavirus Reduces Infectivity 
and Prevents Exposure of the Minor Capsid Proteins 
Nelson, C.D., Ströh, L.J., Gee, G.V., O'Hara, B.A., Stehle, T., and Atwood, W.J. (2015). 
Modulation of a symmetry-related pore in the capsid of JC polyomavirus reduces infectivity and 
prevents exposure of the minor capsid proteins. Journal of Virology 89, 3910-3921. 
 
The icosahedral viral capsid of JCPyV is composed primarily of the major capsid protein VP1. 
Due to the pentameric arrangement of VP1 monomers, a pore-like structure arises at the five-
fold axis of symmetry. The sequence of lining residues and architecture of this pore is rather 
conserved among polyomaviruses, with accessible gap diameters from 7.6 Å (WUPyV) to 
8.6 Å (MPyV) at the respective bottleneck. Thus, VP1 has either limited structural plasticity in 
this region or the pore could be important during viral infection or assembly of the virion. 
In order to investigate the role of the five-fold gap several amino residues mutations lining the 
five-fold gap were introduced into VP1 pentamers, pseudoviruses, and infectious viruses. 
Functional studies showed that exposure of VP2 upon arrival to the ER, a step that is critical 
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for infection, was impaired in mutated pseudoviruses, whereas viral assembly, packaging of 
minor capsid proteins, binding to cells, and transport to the host cell ER were not affected. X-
ray crystal structures of pentamers from three representative mutants demonstrate that only 
subtle changes of the five-fold gap diameter, but an increased hydrophobicity or minor 
changes of the diameter or the molecular surface might alter, and perhaps strengthen, the 
contacts with VP2. As known, VP2 egress does not appear to be accompanied by complete 
disassembly of the viral capsid and thus, an exposure through inter- and intra-pentameric gaps 
as well as the 5-fold gap seems possible. It is also possible that these substitutions alter a 
recognition site for an as of yet unidentified ER-resident chaperone or inhibit productive 
association with ER-resident chaperones. Another possibility is that these pore mutants are 
successfully transported to the ER but are deficient in transport to critical regions of the ER 
necessary for VP2 exposure and do not associate with chaperones such as BIP and DNAJ 
and retrotranslocation.  
This study demonstrates that the five-fold pore is not only an artifact due to the five-fold 
symmetry of the pentamer but is rather a very important structural feature of JCPyV and likely 
other polyomaviruses. Modifications to this structure result in a severe reduction in infectivity 
suggesting that small molecules targeting this part of VP1 may be a promising approach for 
the development of antiviral strategies.  
3.4  Structure Analysis of the Major Capsid Proteins of the Human 
Polyomaviruses 6 and 7 Reveals an Obstructed Sialic Acid Binding Site 
Ströh, L.J., Neu, U., Blaum, B.S., Buch, M.H.C., Garcea, R.L., and Stehle, T. (2014). Structure 
analysis of the major capsid proteins of human polyomaviruses 6 and 7 reveals an obstructed 
sialic acid binding site. Journal of Virology 88, 10831-10839. 
 
Serological studies within the human population suggest that a persistent infection with HPyV6 
and HPyV7 is very common, but routes of infection, cell tropism and entry pathways are 
unknown. In immunosuppressed individuals HPyV7 can cause distinctive epidermal 
hyperplasia, but although the pathogenicity of HPyV6 remains to be proven, an involvement in 
cutaneous diseases or tumors has also to be considered. In order to investigate critical 
determinantes for antigenicity and cell-surface receptor specificities that are linked to 
attachment, tropism and ultimately viral pathogenicity, high-resolution X-ray structures of 
HPyV6 and HPyV7 VP1 pentamers were determined. Our structural analysis revealed uniquely 
elongated loops that cover the bulk of the outer virion surfaces, and moreover, obstruct the 
groove that binds sialylated glycan receptors in the case of related polyomaviruses. In addition, 
NMR spectroscopy and single-cell binding studies indicate that sialylated glycans are likely not 
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required for initial attachment of both viruses to human cells. Overall findings elucidate distinct 
antigenic properties of HPyV6 and HPyV7 capsids and moreover highlight the need for 
structure-based comparisons to better define and predict phylogenetic relationships among the 
raising number of human polyomaviruses. 
3.5  Trichodysplasia Spinulosa-associated Polyomavirus Employs a Displaced 
Binding Site on VP1 to Engage Sialic Acid Containing Glycolipids 
Ströh, L.J., Gee, G.V. , Blaum, B.S., Dugan, A.S., Feltkamp, C.W., Atwood, W.J. and Stehle, 
T. (2015). Trichodysplasia spinulosa-associated polyomavirus employs a displaced binding 
site on VP1 to engage sialylated glycolipids. PLoS Pathogens 11, e1005112. 
 
The skin-tropic TSPyV is the fourth human member of the polyomavirus family for which clear 
evidence of a direct involvement in a clinical disease was shown. The pathogenic mechanism 
includes hyperproliferation of IRS cells, but molecular determinants underlying the infection 
and the associated disease remain unknown. Using cell binding and pseudovirus infection 
studies, we found that sialylated glycans are required for TSPyV attachment and infection of 
cultured human cells. To gain further knowledge about glycan specificity of the virus, X-ray 
structures of TSPyV VP1 pentamers in complex with the branched GM1 glycan and the linear 
compounds 3’SL and 6’SL were solved. TSPyV VP1 features a unique glycan binding site, 
which is shifted by about 18 Å from sialic acid binding sites of other structurally studied 
polyomaviruses. The Neu5Ac ring of all three sialylated compounds is recognized in this 
binding site, which is built up by the exposed BC2-loop of VP1. Structure-based site-directed 
mutagenesis reduces binding of VP1 pentamers to cells and pseudovirus infectivity, 
highlighting the importance of this novel sialic acid binding site for TSPyV infection. In addition, 
treatments of cells with inhibitors for glycosphingolipid synthesis, O- or N-glycosylation prior to 
cell binding and pseudovirus infection studies suggest that especially glycolipids may play an 
important role during attachment and entry.  
According to VP1 amino acid sequence alignments, TSPyV is most closely related to the 
Bornean Orangutan Polyomavirus (OraPyV-Bo). Interestingly, the core of the Neu5Ac binding 
site is shared with the most closely related simian virus and may be employed for receptor 
binding by other known or still unknown members of the growing polyomavirus family. Our 
correlation of structural and functional data provides first insights into molecular recognition 
events during TSPyV infection and, furthermore, demonstrates clearly that glycan receptor 
recognition of (polyoma-) viruses is fine-tuned to a greater extent than initially predicted, 
providing clues about determinants of host adaption and viral evolution. 
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3.6  Glycan Engagement by Viruses: Receptor Switches and Specificity 
Ströh, L.J., and Stehle, T. (2014). Glycan engagement by viruses: receptor switches and 
specificity. Annual Review of Virology 1, 285-306. 
 
Many viruses, including several human pathogens, employ cell surface glycans as attachment 
receptors or attachment factors. Hereby, the engagement of glycans facilitates not only viral 
attachment to cells and cellular entry, which are the first steps during a viral infection, but 
consequently also determines host range, tissue tropism, pathogenicity, and transmissibility of 
viruses. Based on representative crystal structures of viral attachment proteins in complex with 
glycans this review focuses on current knowledge about virus-glycan interactions including 
mainly the recognition of sialic acids and non-charged oligosaccharide such as HBGAs. 
General principles and determinants of specificity utilized by different glycan-binding viruses 
were highlighted, and in particular, we focused on the potential of these interactions for 
switching receptor specificities within or even between glycan classes. Although numerous 
viruses have been found to interact with a third class of cell surface glycans, the polyanionic 
GAGs, high-resolution complex structures of viral receptor-binding proteins with motifs or 
analogs, which were built unambiguously into electron density, are very rare due to various 
reasons such as sample heterogeneity. Thus, an understanding on the molecular level about 
specificities and conformational changes of virus-GAG interactions is still very limited.  
In conclusion, recent advances in glycan microarray screening coupled with high-resolution 
structural studies and reverse genetics systems provide a powerful platform for the 
identification and characterization of viral glycan receptors. However, further technical 
improvements are needed for the analysis and quantification of cell surface glycans densities 
and developmentally regulated host- and tissue-specific glycan distributions. In addition, a 
correlation of affinity measurements with structural studies seems to be necessary for a more 
rigorous evaluation of glycan specificity and receptor switching potentials in order to establish 
a comprehensive toolbox, which can then be used for the design of therapeutic gene vector 
and new antiviral drugs.  
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3.7  Ongoing Research  
Human Polyomavirus 12 and New Jersey Polyomavirus  
Current research focuses on the structural and functional characterization of VP1 from the two 
human polyomaviruses HPyV12 and NJPyV.  
Cloning, Expression and Protein Purification  
A synthetic E. coli codon-optimized gene (Mr.Gene GmbH) coding for amino acids 44 to 316 of 
HPyV12 VP1 (NCBI accession code: YP_007684355) was amplified by PCR and cloned into 
the pET15b vector (Novagen) via NdeI and BamHI restriction enzymes in frame with an N-
terminal hexahistidine-tag (His-tag) and a thrombin cleavage site. The pET15b-derived 
expression plasmid for NJPyV VP1 (amino acids 36 to 323; NCBI accession code: 
YP_009030020) was obtained via the InFusion HD cloning strategy according to the 
manufacturer’s protocol (Clontech). The vector was linearized via XhoI.  
Recombinant expression in E. coli Rosetta 2 (DE3) and E. coli BL21 (DE3) for N- and C-
terminal truncated NJPyV VP1 and HPyV12 VP1, respectively, was induced by addition of 
0.4 mM IPTG and carried out at 20°C for about 18 h. The truncated VP1 cannot assemble into 
a capsid but forms pentamers in solution (Stehle and Harrison, 1997). Proteins were first 
purified by nickel affinity chromatography and then by size exclusion chromatography on a 
Superdex-200 column. For crystallization, the His-tag was cleaved off in solution with thrombin 
(GE Healthcare) prior to size exclusion chromatography leaving the non-native amino acid 
sequence GSHM at the N-terminus of both VP1 proteins. After size exclusion chromatography, 
HPyV12 VP1 pentamers were kept in 20 mM HEPES pH 7.5, 150 mM NaCl, 20 mM 
Dithiothreitol (DTT). Dimers of NJPyV VP1 pentamers were stored in an equivalent buffer 
without DTT.  
Crystallization, Data Collection, and Structure Determination 
HPyV12 VP1 was concentrated to 7 mg/ml and crystallized at 20°C by hanging drop vapor 
diffusion against a reservoir solution containing 4% (v/v) Tacsimate pH 7.0 and 16% (w/v) 
polyethylene glycol (PEG) 3,350. These crystals were not suitable for crystal soaking 
experiments because all five binding sites of VP1 were blocked in the crystal by a symmetry-
related protomer. Additionally, crystals of HPyV12 VP1 were grown by hanging drop vapor 
diffusion using a protein concentration of 6 mg/ml and a reservoir solution containing 0.2 M 
ammonium acetate, 0.1 M Bis Tris pH 7.0, and 45% (v/v) 2-Methyl-2,4-pentanediol (MPD). 
These crystals were soaked for 24 h in the reservoir solution supplemented with 20 mM α2,3-
sialyllactosamine (3’SLN) in order to solve the complex structure (Table 3).  
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Crystals of NJPyV VP1 obtained at 4°C using the sitting drop vapor diffusion method, a 
reservoir solution containing 0.1 M succinic acid pH 7.0 and 15% (w/v) PEG 3,350, and a 
protein solution with a concentration of 7 mg/ml yielded the native structure of the protein 
(Table 3). Crystals grown in 0.1 M MES pH 6.5, 12% (w/v) PEG 20,000 at 20°C were 
derivatized by incubation for 10 min in a reservoir solution supplemented with 50 mM 3’SL.  
For the crystallization of HPyV12 VP1 by the hanging drop technique, drops were set up with 
1 µl protein solution and 1 µl reservoir solution. 0.4 µl of the protein and 0.4 µl of the reservoir 
solution were used for the crystallization of NJPyV VP1 using the sitting drop vapor diffusion 
method. All crystals were transferred for 2 sec into the respective reservoir or soaking solution, 
supplemented with 30% (v/v) glycerol prior to freezing in liquid nitrogen. Data sets were 
collected at beamline X06DA of the SLS and at beamline 14.1 of the Berliner 
Elektronenspeicherring Gesellschaft für Synchrotronstrahlung (BESSY), respectively. 
Diffraction data sets were processed with XDS (Kabsch, 2010). HPyV12 VP1 and NJPyV VP1 
structures were solved by Molecular replacement (MR) using Phaser MR (McCoy et al., 2007) 
included in the CCP4 program suite (Winn et al., 2011). The native MCPyV VP1 structure 
(pdb: 4FMG), modified by CHAINSAW (Stein, 2008), was taken as MR model for HPyV12 and 
NJPyV VP1. Rigid body and simulated annealing refinement was carried out with Phenix 
(Adams et al., 2010). Subsequently, alternating rounds of model building in Coot (Emsley et 
al., 2010) and refinement with Refmac5 (Murshudov et al., 1997), including 5-fold non-
crystallographic symmetry (NCS)-restraints, the translation-libration-screw (TLS) method 
(Painter and Merritt, 2006), CCP4 library restraints, and user-defined restraints for the α2,3-
glycosidic bond were performed.  
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Overall Structures of HPyV12 and NJPyV VP1 Pentamers  
The structures of the unassembled VP1 pentamer from HPyV12 and NJPyV feature the typical 
conserved jelly-roll core of the polyomavirus VP1. In the crystal of the HPyV12 VP1-3’SLN 
complex structure and in both NJPyV VP1 structures two pentamers stack against one another 
with their bottom surfaces. The conserved cysteine residues in the CD-loops, C119 of HPyV12 
VP1 and C113 of NJPyV VP1, respectively, are engaged in interpentamer disulfide bonds in 
each chain. From the structure of the SV40 virion it is already known that the CD-loops adopt 
different conformations, some of which are engaging in interpentamer disulfide bonds 
(Liddington et al., 1991; Stehle et al., 1996). In other structures of unassembled polyomavirus 
VP1 pentamers, DE-loops are also characterized by relatively high temperature factors (B-
factors) or could only be built in defined electron density when fixed by crystal contacts. 
HPyV12 shares a VP1 amino acid sequence identity of 53-58% for the full-length protein with 
human HPyV9, JCPyV, BKPyV, TSPyV, and NJPyV as well as with other structurally 
investigated viruses SV40, MPyV, and LPyV. Only Wukipolyomaviruses, MWPyV, and 
STLPyV possess a lower amino acid sequence identity for VP1 with HPyV12 (23-46%). 
Nevertheless, Cα atoms of the HPyV12 VP1 monomer superimpose with the lowest root mean 
square deviation (r.m.s.d.) value of 0.7 Å onto JCPyV VP1, but other human VP1 are also 
structurally conserved in a similar magnitude (r.m.s.d. values of 0.8 Å for BKPyV VP1 to 1.2 Å 
for NJPyV VP1). Based on the amino acid sequence of the full length VP1, NJPyV is most 
closely related with TSPyV and HPyV9 (59% sequence identity). The superimposition with VP1 
structures from other Orthopolyomaviruses reveals r.m.s.d. values between 1 Å for MCPyV 
and 1.3 Å for MPyV with a value of about 1.2 Å for TSPyV and HPyV9.  
HPyV12 VP1 Binds Specifically Terminal Sialic Acids  
In the complex structure of the HPyV12 VP1 pentamer with 3’SLN, the Neu5Ac moiety of the 
linear trisaccharide is engaged in a binding site mainly formed by the BC2-loop on top of one 
VP1 monomer (Figure 11). Well-defined electron density was seen for Neu5Ac in all ten VP1 
binding sites in the asymmetric unit, whereas in some sites the Gal could also be 
unambiguously built into the electron density (Figure 11 B). However, only specific interactions 
of VP1 with the terminal Neu5Ac were observed in the complex structure. The Gal does not 
interact with VP1, but it is likely that conformational restraints of the glycosidic bond stabilize 
the Gal ring in a preferred orientation. The N-acetyl group of Neu5Ac inserts into a shallow 
cavity (Figure 11 C), where it is recognized by a hydrogen bond between residue T85 and the -
NH group. Additionally, it depends on non-polar interactions between the methyl group and 
residues P95 and H144 of the ccw monomer at one site and on the bottom of the cavity, 
respectively. The oxygen of the N-acetyl group interacts by hydrogen bonding with the 
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backbone amine of residue R94. The glycerol chain of Neu5Ac forms hydrogen bonds to 
residue R149 from the ccw DE-loop and with the backbone amine of residue V86. On the other 
side of the BC2-loop, the C4 hydroxyl group of Neu5Ac interacts with the protein backbone. 
Interestingly, the carboxylate group of Neu5Ac is not involved in any direct interactions with 
VP1. Cα atoms of the BC2-loop (residues 83-98) from the liganded HPyV12 VP1 structure 
superpose with the respective residues of the native structure with an r.m.s.d. of 0.3 Å, 
indicating that no major conformational changes occur upon ligand binding. Neu5Ac docks into 
a preformed binding pocket.  
 
Figure 11: Structure of HPyV12 VP1 in complex with 3’SLN. (A) Structure of the HPyV12 VP1 pentamer in 
complex with 3’SLN. One VP1 monomer is highlighted in deep teal, the others are colored gray. The carbohydrate 
ligand is shown in stick representation, with oxygens in red and nitrogens in blue. (B) The simulated annealed 
difference electron density map for the terminal Neu5Ac-Gal motif of 3’SLN bound to HPyV12 VP1 is contoured at a 
σ level of 2.5 and displayed with a radius of 2 Å around the ligand. (C) Binding surface for 3’SLN. VP1 side chains 
in the BC2-loop binding site are shown in sticks. Interactions are indicated with black dashed lines. Water-mediated 
interactions are also shown with water molecules depicted as spheres. 
Next, we sought to validate the VP1-Neu5Ac interaction in solution and on the surface of cells. 
STD NMR measurements were performed with HPyV12 VP1 pentamers, 3’SL, and 6’SL as 
described in 3.2. The spectra reveal that HPyV12 VP1 interacts with both glycans in solution 
but no additional glycan rings besides the respective terminal Neu5Ac residue were involved in 
binding (Figure 12 A). These findings are consistent with the crystal structure analysis. In 
addition, attachment of HPyV12 VP1 pentamers to cultured cells depends on cell surface sialic 
acids as assessed by flow cytometry according to the protocol described in 3.5. Cells were 
mock-treated or incubated with Clostridium perfringens neuraminidase prior to the binding 
experiments (Figure 12 B). The Clostridium perfringens neuraminidase cleaves α2,3- and 
α2,6-linked sialic acids.  
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Figure 12: STD NMR spectroscopy and cell binding analysis of HPyV12 VP1 pentamers. (A) From top to 
bottom: 1H NMR reference spectrum of 50 µM HPyV12 VP1 with 1 mM of 6’SL, STD NMR difference spectrum 
recorded with the same sample, 1H NMR reference spectrum of 50 µM HPyV12 VP1 with 1 mM of 3’SL, STD NMR 
difference spectrum with the same sample. STD NMR experiments were performed by Bärbel Blaum, Tübingen. (B) 
HeLa and HEK293 cells were mock (PBS) or pretreated with 0.2 U/ml Clostridium perfringens neuraminidase 
(+ NA) for 30 min, washed and then incubated with Alexa Fluor 488 conjugated HPyV12 VP1 pentamers according 
to the protocol described in chapter 3.5. VP1 pentamer binding to cells was then analyzed by flow cytometry. 
Histograms represent the fluorescence intensity of Alexa Fluor 488 for 15,000 gated events in each case. Cells 
alone are colored gray. Three independent experiments were performed and results of a typical experiment are 
presented. 
NJPyV VP1 Binds Specifically to 3’SL 
In contrast to the broader binding specificity observed for HPyV12, the glycan complex 
structure of NJPyV VP1 suggests that the virus engages α2,3-linked sialic acids in a more 
specific manner. NJPyV VP1 interacts with the α2,3-Neu5Ac-Gal motif of 3’SL by polar and 
non-polar interactions in a binding site that is located between HI- and BC-loops of one VP1 
monomer (Figure 13). The DE-loop, which is remarkably elongated in NJPyV VP1 compared to 
other structurally characterized polyomavirus VP1 pentamers, is not involved in any 
interactions with the glycan. Instead, side chains of residues K296 and N299 from the HI-loop 
and of BC2-loop residue H80 engage the carboxylate group of Neu5Ac. Residue E77 interacts 
with the C4 hydroxyl group of Neu5Ac and the N-acetyl group is involved in a water-mediated 
hydrogen bond with the backbone of residue V78. Additionally, hydrophobic interactions 
between the methyl group of the N-acetyl group, residue L90, and the hydrophobic part of the 
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E77 side chain are observed, but the glycerol chain of Neu5Ac is pointing away and is not 
engaged by VP1. The Gal ring interacts with residue D298 via a hydrogen bond formed with by 
the C4 hydroxyl group and via hydrophobic interactions of its C6. Furthermore, there is a weak 
hydrogen bond with a distance of about 3.7 Å between K296 and O4 of the Gal. Cα atoms 
from structures of native and liganded NJPyV VP1 superpose with a r.m.s.d value of 0.2 Å and 
no major rearrangements upon glycan binding were observed.  
 
 
Figure 13: Complex structure of NJPyV VP1 with 3’SL. (A) NJPyV VP1 pentamer structure in complex with the 
3’SL glycan. One VP1 monomer is highlighted in purple, the others are colored in gray. The glycan is shown in stick 
representation with carbons in orange, oxygens in red, and nitrogens in blue. (B) The simulated annealed difference 
electron density map for the engaged ligand 3’SL is contoured at a σ level of 2.5 and is shown with a radius of 2 Å 
around the ligand. (C) Interactions with 3’SL. Side chains of VP1 in the binding site are shown in sticks. Direct and 
water-mediated interactions are indicated with dashed lines. A water molecule in the binding site is shown (red 
sphere). 
Next, STD NMR spectroscopy was used to rationalize the interaction seen in the crystal 
structure (Figure 14). The α2,3-sialic acid residue of 3’SL is bound by NJPyV VP1 pentamers 
in solution, but interactions with 6’SL and 2-O-methyl sialic acid were not detected. For 3’SL 
only resonances belonging to the sialic acid were observed and peaks for protons H1 and H3 
of the Gal are not visible in the STD NMR difference spectrum. However, although Gal 
engages in fewer contacts compared to Neu5Ac in the crystal structure and contributes only 
about 30% of the total VP1 glycan interface area (Krissinel and Henrick, 2007), its interactions 
with VP1 seems to be critical for the glycan recognition event. A terminal sialic acid alone 
represented by 2-O-methyl sialic acid is not sufficient for the interaction with VP1 (Figure 14 D 
and E). 
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Figure 14: STD NMR spectroscopy of NJPyV VP1 with 3’SL, 6’SL, and 2-O-methyl sialic acid. (A) 1H NMR 
reference spectrum of 50 µM NJPyV VP1 with 1 mM of 6’SL and 1 mM of 3’SL. (B) 1H NMR reference spectrum of 
1 mM of 3’SL. (C) STD NMR difference spectrum of the same sample as in A. (D) 1H NMR reference spectrum of 
50 µM HPyV12 VP1 with 1 mM 2-O-methyl sialic acid. (E) STD NMR difference spectrum of the same sample as in 
D. The red arrow marks the equatorial H3 resonance of α2,3-Neu5Ac, which is slightly shifted with respect to the 
same resonance of α2,6-Neu5Ac and serves to distinguish which of the two compounds receives magnetization 
transfer from the protein in spectrum C. Only peaks for the 3’SL proton are visible in the STD NMR difference 
spectrum in C. H1 (grey arrow) and H3 (black arrow) of the Gal ring are not visible in C.  
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Comparison of Glycan Receptor Binding Sites from HPyV12 and NJPyV with Those 
from Other Polyomaviruses  
The superimposition of VP1-glycan complex structures from HPyV12 and NJPyV VP1 with 
liganded VP1 structures from other polyomaviruses highlights that HPyV12 engages the 
terminal Neu5Ac highly similar to TSPyV (Figure 15).  
 
 
 
Figure 15: Glycan binding sites of HPyV12 and NJPyV VP1 in comparison with other polyomavirus sialic 
acid binding sites. The structural superposition of polyomavirus VP1-glycan complex structures highlights the 
variability of Neu5Ac engagement on VP1. HPyV12 VP1-3’SLN, NJPyV VP1-3’SL, SV40 VP1-GM1 glycan (pdb: 
3BWR), BKPyV VP1-GD3 glycan (pdb: 4MJ0), JCPyV VP1-LSTc (pdb: 3NXD), MCPyV VP1-GD1a glycan (pdb: 
4FMJ), LPyV VP1-3’SL (pdb: 4MBY), MPyV VP1-Neu5Ac-α2,3-Gal-β1,3-[α2,6-Neu5Ac]-GlcNAc-β1,3-Gal-β1,4-Glc 
(pdb: 1VPS), HPyV9 VP1-3’ Neu5Gc-SL (pdb: 4POT), TSPyV VP1-GM1 glycan (pdb: 4U60).  
A more detailed comparison reveals that residues of the binding site are highly conserved 
between VP1 from HPyV12 and TSPyV (Figure 16). Thus, the BC2-loop folds in a very similar 
manner on top of both VP1 and allows conserved contacts with Neu5Ac. 
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Figure 16: Glycan binding sites of HPyV12 and TSPyV. Neu5Ac binding sites of (A) HPyV12 and (B) TSPyV VP1 
(pdb: 4U60) are shown in the same orientation. VP1 complex structures were aligned using Cα atoms and the 
secondary-structure matching (SSM) tool in Coot (Emsley et al., 2010). One VP1 monomer is highlighted in deep 
teal and salmon for HPyV12 and TSPyV, respectively. Glycan residues are show in orange sticks with carbons in 
orange, oxygens in red and nitrogens in blue. Glycan residues are colored grey if they are not engaged by VP1. 
Direct and water-mediated hydrogen bonds between VP1 side chain residues and the terminal Neu5Ac are 
depicted as black dashed line. Conserved residues are colored on the VP1 surface and are labeled in bold.  
In contrast, NJPyV employs a Neu5Ac binding site between the BC- and HI-loops of one VP1 
monomer. This binding site is related to MCPyV, in means of its location and the orientation of 
the respective Neu5Ac engaged (Figure 15), although the amino acid sequence identity in the 
binding region is not very high. VP1 amino acid differences between MCPyV and NJPyV result 
in a shift of the binding site towards the BC2-loop (Figure 17). However, the N-acetyl chain and 
the carboxylate group of Neu5Ac are engaged in a very similar manner on NJPyV and MCPyV 
VP1, although specific interactions are realized by different amino acids. A common feature of 
the Neu5Ac binding sites of SV40, JCPyV, BKPyV, HPyV9, and LPyV is a hydrophobic pocket, 
which is formed by residues of HI- and BC-loops from one VP1 monomer and BC2-loop 
residues of the cw VP1 monomer (Neu et al., 2008; Neu et al., 2010; Neu et al., 2013a; Neu et 
al., 2013b). The location of the hydrophobic pocket is not conserved on NJPyV VP1, but 
instead BC2-loop residues E77 and L90 form a hydrophobic environment for the methyl group 
of Neu5Ac on NJPyV VP1 in a different location. 
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Figure 17: Comparison of glycan binding sites on NJPyV and MCPyV VP1. VP1 glycan binding sites from (A) 
NJPyV and (B) MCPyV (pdb: 4FMJ) are shown in the same orientation. Glycan residues not involved in 
intermolecular interactions are colored in grey. Direct and water-mediated hydrogen bonds between VP1 side chain 
residues and the terminal Neu5Ac are depicted as black dashed line. Side chains of residues interacting with the 
glycan via hydrogen bonding or charged interactions are colored in purple and cyan for NJPyV and MCPyV, 
respectively. 
The phylogenetic analysis of the polyomavirus family indicates that many human 
polyomaviruses are closely related to one or two monkey polyomaviruses. These relationships 
are also present on the amino acid level of VP1 (Figure 1). NJPyV shares a VP1 amino acid 
sequence identity of about 84% with ChPyV isolates (ChPyV-Azzi, ChPyV-Bob, and ChPyV-
Tanu) and of about 73% with two other primate polyomaviruses, Vervet monkey 
Polyomavirus 1 (VmPyV1) and the Piliocolobus rufomitratus Polyomavirus 1 (PrufPyV1). In the 
phylogenetic tree based on the VP1 amino acid sequence HPyV12 clusters with 
Avipolyomaviruses, including Finch Polyomavirus (FiPyV) and Budgerigar fledgling disease 
Polyomavirus (BFDPyV), but also Crow Polyomavirus (CrowPyV), Butcherbird Polyomavirus 
(BbPyV), Goose hemorrhagic polyomavirus (GhPyV) and Canary Polyomavirus (CaPyV) have 
amino acid sequence identities of about 60% with HPyV12 (Figure 1). In order to rationalize 
the impact of VP1 differences on receptor specificity of closely related viruses from different 
species, we mapped amino acid differences on the surfaces of HPyV12 and NJPyV VP1 
pentamer structures, respectively (Figure 18). Differences occur predominantly within the 
exposed surface loops on top of VP1. Interestingly, the elongated DE-loop, a prominent 
feature of NJPyV VP1, is unique for the human virus, whereas VP1 residues involved in the 
recognition of the Neu5Ac-Gal motif are highly conserved in ChPyV, VmPyV1, and PrufPyV1 
(Figure 18 B). The BC2-loop Neu5Ac binding region of HPyV12 VP1 may also be partially 
conserved in avian viruses FiPyV and BFDPyV, whereas most of the top surface differs 
(Figure 18 C and D). A broader VP1 sequence alignment reveals that key residues of the 
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HPyV12 BC2-loop Neu5Ac binding region, in contrast to the rest of the VP1 top surfaces, are 
conserved across Avipolyomavirus species, EPyV, and TSPyV but not in other 
Orthopolyomaviruses (Figure 18 E). Nevertheless, predictions of the surface loop architecture 
can be rather error-prone, hampering modeling and mapping of glycan binding sites and the 
prediction of glycan receptor specificities based on sequence information.  
 
 
Figure 18: Features of the NJPyV and HPyV12 VP1 Neu5Ac binding sites are conserved in closely related 
polyomaviruses from different species. (A), (B) VP1 differences between NJPyV, ChPyV-Azzi (GFR692336), 
ChPyV-Bob (FR692334), ChPyV-Tanu (FR692335), VmPyV1 (NC_019844), and PrufPyV1 (JX159984) are mapped 
onto the NJPyV VP1-3’SL complex structure and shown in overall and close-up views. (C), (D) Based on the 
HPyV12 VP1-3’SLN complex structure, VP1 differences between HPyV12 and two representative 
Avipolyomaviruses FiPyV (NC_007923) and BFDPyV (AY672646) are shown. Amino acid differences are coloured 
according to their chemical conservations in panel A-D. Amino acid sequence alignments were done with Clustal 
Omega (Sievers et al., 2011) and JalView (Waterhouse et al., 2009) to assign values for the conservation of their 
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chemical properties from 10 (conserved; grey) to 0 (non-conserved; red). Values of 2 to 0 are coloured in red. In the 
close-up views conserved residues of the glycan binding site are highlighted in sticks representations. (E) Structure-
based sequence alignment of BC2- and DE-loop regions from HPyV12, Avipolyomaviruses, and representative 
Orthopolyomaviruses. Canary Polyomavirus (CaPyV; NC_017085), Goose hemorrhagic Polyomavirus (GhPyV; 
HQ681903), Butcherbird Polyomavirus (BbPyV; NC_023008), Crow Polyomavirus (CrowPyV; NC_007922), and 
Equine Polyomavirus (EPyV; NC_017982). Conserved key residues of the Neu5Ac binding site are highlighted in 
green. NCBI gene bank numbers are given in parenthesis. 
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Fragment-based Screening with JCPyV VP1  
Fragment-based screening by 19F and transverse relaxation time (T2)-filtered (Carr-Purcell-
Meilboom-Gill, CPMG) NMR spectroscopy experiments were performed in collaboration with 
Christoph Rademacher (Max Planck Institute of Colloids and Interfaces, Potsdam) to identify 
small compounds that bind to JCPyV VP1 pentamers. Both NMR methods are 1D ligand-
based approaches that are often used in FBDD. For NMR studies 19F has excellent properties 
that are comparable to those of 1H (Chen et al., 2013). The 19F nucleus has a 1/2 spin that 
exists in 100% natural abundance, but also the intrinsic sensitivity of the 19F nucleus and its 
chemical shift to changes in the local chemical environment are useful for FBDD (Jordan et al., 
2012; Chen et al., 2013). A library consisting of 300 low molecular weight fluorinated 
compounds was used for JCPyV VP1. All compounds in the library contain one mono fluoro 
group or a trifluorometyl group. 1D NMR spectra were analyzed for changes in peak intensity 
and chemical shift. In the case of a binding event, a shift of the characteristic peak for the 
compound occurs in the spectrum with the protein compared to the spectrum of the sample 
without protein (Figure 19). The screening resulted in 40 double positive hits obtained by both 
NMR spectroscopy methods.  
 
 
Figure 19: Fragment-based screening by NMR. 19F NMR spectroscopy was performed to identify small 
compounds that bind to JCPyV VP1 pentamers. NMR spectroscopy measurements were carried out by Jonas Aretz 
and Christoph Rademacher, Max Planck Institute of Colloids and Interfaces, Potsdam. Typical results are shown 
exemplarily for three different compounds A, B, and C. Binding was observed for compound B and C (bold letters). 
Two identical sets of spectra were acquired. In the case of binding, a peak shift occurs in the spectrum with JCPyV 
VP1 (+ JCPyV) compared to the spectrum of the sample without protein (- JCPyV). The figure shown here was 
adapted from a figure prepared by Jonas Aretz (unpublished data).  
A B
C
+ JCPyV
- JCPyV
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So far 10 compounds out of the 40 positive hits have been further analyzed via crystal soaking 
experiments with JCPyV Mad-1 VP1 crystals (Figure 20).  
 
 
Figure 20: Fragments used for soaking experiments. Displayed are 10 out of 40 double hits identified by 19F and 
T2-filtered NMR spectroscopy. The fragment screening was performed and analyzed by Christoph Rademacher 
and Jonas Aretz, Max Planck Institute of Colloids and Interfaces in Potsdam. The figure was prepared using 
ChemDraw 14.0.0.118 (PerkinElmer, Inc.). 
Crystallization and Crystal Soaking Experiments  
Crystals were grown using the sitting drop vapor diffusion method, a 4.5 mg/ml JCPyV VP1 
solution in 20 mM HEPES pH 7.5, 150 mM NaCl, a reservoir solution containing 0.1 M HEPES 
pH 7.5, 0.2 M KSCN, 12% (w/v) PEG 3,350, and a microseed solution obtained from previous 
grown JCPyV VP1 crystals (Neu et al., 2010). The hydrophobicity and thus poor solubility of 
compounds in aqueous solutions is often a problem during early steps of FBDD. Thus, JCPyV 
VP1 crystals were tested for their resistance against two common organic solvents, dimethyl 
sulfoxide (DMSO) and methanol, prior to the crystal soaking experiments. Crystals were 
incubated overnight in the reservoir solution supplemented with different concentrations of 
DMSO or methanol, respectively. They were harvested similar to native crystals and tested for 
diffraction. JCPyV VP1 crystals tolerate up to 30% (v/v) DMSO or 20% (v/v) methanol. At 
higher concentrations of DMSO or methanol, crystals break to pieces or diffract only to a low 
resolution (≥ 3.5 Å). Stock solutions of the 10 compounds (Figure 20) were prepared in DMSO 
and a maximum concentration of 25% DMSO was used for the soaking experiment (Table 4). 
However, differences in solubility of the fragments and the stability of the crystal in the 
presence of the respective fragments had influence on the final soaking conditions. 
Compounds 15B02 and 6A04 are not well soluble in aqueous solutions. At concentrations of 
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50 mM and above, compound solutions with 15C05, 15H02, and 13G08 destroyed the crystals 
and the compound concentration was reduced to 25 mM. 
 
Table 4: Soaking experiment with 10 hits from the fragment-based screening. JCPyV VP1 Mad-1 crystals 
were grown for two days against a reservoir containing 0.1 M HEPES pH 7.5, 0.2 M KSCN, 12% (w/v) PEG 3,350. 
Crystals were transferred into drops of the harvesting solution supplemented with compound and DMSO as 
indicated. 15B02 is not well soluble and the soaking solution with 100 mM compound was a saturated solution. 
Soaking experiments were performed stepwise used in some cases and values for the used solution are listed then 
with semicolons. Prior to flash freezing in liquid nitrogen, crystals were incubated for 2 sec in a soaking solution 
supplemented with 30% (v/v) glycerol.  
Compound ID Compound [mM] DMSO [%] Duration [h] 
15A01 25; 100 25; 25 1; 1 
25 25  approx. 16 
15B02 10  25 2 
 25; 100  25; 25 1; 1 
15C05 25 6.25  approx. 16  
15H02 25  25  2  
13B11 100  25  approx. 16 
13G08 25 6.25  approx. 16 
9E08 25; 100 25; 25 1; 1 
 100 25 approx. 16 
 25 6.25 approx. 16 
6A04 20  25  2  
5A03 25; 100  25; 25 1; 1 
25  25  approx. 16 
1E08 25; 100 25; 25 1; 1 
25 25 approx. 16 
 
Diffraction data sets were collected at beamline X06DA of the SLS and were processed with 
XDS (Kabsch, 2010). Structures were solved by MR using Phaser MR (McCoy et al., 2007) 
and the native JCPyV VP1 structure (pdb: 3NXG) without solvent molecules as a model. Rigid 
body and simulated annealing refinement was carried out with Phenix (Adams et al., 2010). 
Alternating rounds of model building in Coot (Emsley et al., 2010) and refinement with 
Refmac5 (Murshudov et al., 1997) were carried out. JCPyV crystals grow in space group C2 
with one monomer in the asymmetric unit. Contacts between neighboring VP1 pentamers in 
the crystal do not block any side of all the monomers simultaneously and consequently, 
binding sites are likely accessible in the context of the VP1 pentamer. Additional electron 
density in the simulated annealing electron difference map was observed for all three crystals 
that were soaked with the fragment 9E08 (Figure 21). The fragment was built using model 
coordinates and restraints created by PRODRG2 Server (Schuttelkopf and van Aalten, 2004) 
with subsequent refinement via Refmac5. The compound 9E08 could be built into the electron 
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density of all three crystals, but only the data set collected from the crystal soaked with 
100 mM was used for further refinement (Table 5).  
 
Table 5: Statistics of the data collection and ongoing refinement. Values in parentheses are for the highest 
resolution shell. The occupancy of the ligand 9E08 is 0.8.  
 9E08 
(100 mM; 16 h) 
Beamline SLS X06DA  
Data collection  
Space group C2 
a, b, c [Å] 49.2, 95.5, 128.5 
β [°] 110.2 
Resolution [Å] 50-1.85 (1.90-1.85) 
Unique reflections  142,639 (10,321) 
Total reflections 963,586 (63,607) 
Rmeas [%]  11.3 (110.6) 
I/σI 13.26 (1.75)  
CC1/2 [%] 99.8 (75.2) 
Completeness [%] 98.9 (97.3) 
Wilson B-factors [Å2] 30.1 
  
Refinement  
Rwork / Rfree [%] 20.4 / 21.3  
No. of atoms  
  protein  9,879 
  ligand 60 
  water 593 
B-factor [Å2]  
  protein  25.3 
  ligand 38.7 
  water 29.9 
R.m.s.d.  
  Bond length [Å] 0.007 
  Bond angles [°] 1.238 
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The Binding Site for 9E08 is Located Inside the Hydrophobic Cavity of the VP1 
Pentamer 
The compound 9E08 binds inside the VP1 pentamer in a location next to β-strands E, F, and 
the ccw G1 of the core CHEFG1-sheet (Figure 21). All five binding sites of the VP1 pentamer 
in the asymmetric unit are occupied. Non-polar residues F144 and F213 enclose the binding 
site together with hydrophobic parts of side chains from residues H142, H227ccw, and 
T229ccw. These residues and the β-strand backbone form a shallow, relatively hydrophobic 
pocket, but charged interactions or strong hydrogen bonds between 9E08 and VP1 were not 
observed. The electron density for 9E08 can be explained by ligand occupancies from 0.8 to 1, 
which result in temperature factor (B-factor) values of 38.7 to 47.4 Å2, respectively. Thus, B-
factors are only little elevated for 9E08 compared to VP1 residues forming the binding pocket. 
B-factors reflect the relative vibrational motion of atoms and a bound ligand is expected to 
have similar values as interacting and neighboring protein residues. Side chain atoms possess 
here B-factors of about 22 Å2 and main chain atoms of about 18 to 20 Å2. However, residues of 
the conserved β-sheet core have in general relatively low B-factors as known from other 
polyomavirus VP1 structures and thus, B-factor values for the compound are within the 
expected range.  
 
 
Figure 21: The simulated annealing Fobs-Fcalc omit electron density map shows features of the compound 
9E08. (A) View from the bottom of the JCPyV pentamer along the five-fold axis. The VP1 pentamer is shown in 
surface representation with one monomer highlighted in pink. The simulated annealed omit electron density map is 
contoured at a σ level of 2.5 with a radius of 2 Å around the ligand 9E08. (C) β-sheets E, F, and the ccw G1 form 
the binding site for 9E08. The compound 9E08 is shown in stick representation with carbons in green, nitrogens in 
blue, and fluor in light blue.  
The electron density observed for 9E08 is absent in simulated annealing Fobs-Fcalc electron 
density maps of the native JCPyV VP1 and other crystals soaked with different ligands. 
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However, it seems that a DMSO molecule partially occupies the binding site in other soaked 
crystals due to its high concentration in the soaking solution.  
In order to further examine the VP1-9E08 interaction in the scenario of the assembled JCPyV 
virion, we superimposed the complex structure with the MPyV VP1-VP2 complex using Cα 
atoms and the SSM superimposition tool in Coot (Krissinel and Henrick, 2004) (Figure 22). 
Molecular details of the JCPyV VP1 and VP2 interactions are not known, but the interaction of 
VP1 with minor capsid proteins VP2 and VP3 and their exposure in the ER is critical for JCPyV 
entry (Nelson et al., 2015). Consistently, JCPyV mutants lacking VP2 or VP3 are non-
infectious (Gasparovic et al., 2006). The hydrophobic core of VP1 is structurally highly 
conserved and both structures align well in the region of the 9E08 binding site (Figure 22 C). It 
becomes clear that the binding site for 9E08 may partially overlap with the binding site for VP2 
inside the pentamer cavity (Figure 5 and Figure 22). Since structural data for the interaction of 
JCPyV VP1-VP2 is not available, a sequence alignment was carried out for VP2 (Figure 22 D). 
The VP2 amino acid sequence is only partially conserved in the 9E08 binding site. Residues of 
MPyV VP2 that are involved in backbone-mediated interactions with VP1 are not present in 
JCPyV VP2 (Figure 5 C). However, the electron density for VP2 in the MPyV VP1-VP2 
complex structure did not allow to model side chains in that region and thus it is not possible to 
make a clear statement what critical role specific side chains play in the interaction between 
VP1 and VP2. The sequence of the C-terminal part of the VP2 fragment, which was visible and 
involved in interaction with VP1 in the complex structure, is in contrast well conserved between 
MPyV and JCPyV (Figure 5 D). Therefore, observations allow only vague speculations about 
the role of the 9E08 binding site for the JCPyV VP1-VP2 interaction so far.  
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Figure 22: The binding site of 9E08 could partially overlap with the VP2 binding site. (A) Superimposition of 
the JCPyV VP1-9E08 structure with the MPyV VP1-VP2 structure (pdb: 1CN3) using Cα atoms and the SSM 
algorithm in Coot. Cartoon representations are colored grey for JCPyV and orange for MPyV, respectively. The part 
of MPyV VP2 that was visible in the MPyV VP1-VP2 complex structure is shown in blue (see also Figure 5). The 
compound 9E08 is shown in stick representation with carbons in green, nitrogens in blue and fluor in light blue. (B) 
The 9E08 binding site on JCPyV VP1 is located in the region of VP1 that contacts the N-terminal part of VP2 in the 
MPyV VP1-VP2 complex structure. JCPyV is shown in surface representation, MPyV VP2 in cartoon (blue), and 
9E08 in sticks. (C) Close-up view of the 9E08 binding site in comparison with the MPyV VP1-VP2 structure. The 
view is equivalent to Figure 21 C. VP1 side chains of in the binding site and MPyV VP2 residues 271-277 are 
shown in stick representations. Proteins are colored in orange (MPyV VP1), blue (MPyV VP2), and grey (JCPyV 
VP1). (D) Sequence alignment of VP2 from the MPyV strain PTA (used for the structural studies), JCPyV 
(NC_001699), SV40 (NC_001669), and BKPyV (NC_001538). Only the sequence for the VP2 fragment that was 
visible in the X-ray structure is shown. The part of VP2 shown in panel C is highlighted in bold for MPyV. The 
positions of the two VP2 amino acids interacting with VP1 via backbone-mediated hydrogen bonds in the case of 
MPyV are marked with an asterisk in panel C and D.  
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4.  Outlook  
The work presented in this thesis has established that JCPyV engages LSTc as a functional 
receptor motif and that gangliosides do not play a role during JCPyV infection. However, 
questions where LSTc is linked to and what role its cellular context plays for early step during 
JCPyV infections remain to be answered in the future. Commonly used techniques to identify 
virus receptors such as broad genome-wide siRNA screening or virus overlay protein assays 
would be rational approaches (Cao et al., 1998; Tayyari et al., 2011; Konopka-Anstadt et al., 
2014). Pull-down experiments with isolated membrane fractions could be conducted in order to 
fish out the protein backbone of LSTc glycan. Such experiments using immobilized VP1 
pentamers would be technically straightforward, but the low binding affinity of the VP1-glycan 
interaction could hamper the experimental outcome. Alternatively, similar experiments could be 
performed with virions or with an antibody against LSTc. Possible receptor candidates could 
then be identified by mass spectrometry. In addition, a genome-wide siRNA screening could 
not only help to identify the proteinous backbone for LSTc, but may also shed light on 
additional viral receptors or cellular factors that are critical for JCPyV infection. A differential 
approach in kidney and glial cells or even neurons could substantial uncover viral mechanism 
and cell-specific factors leading to the diseases PML, GCN, and JCVE. 
4.1  Role of Serotonin Type 2 Receptors during JCPyV Infection 
Further insights into the interaction between JCPyV and 5-HT2Rs could help to answer the 
question why JCPyV uses a clathrin-dependent pathway, whereas closely related 
polyomaviruses such as SV40 and BKPyV take a lipid-dependent entry route. JCPyV and 5-
HT2AR colocalize 5 min post-infection, suggesting an involvement of 5-HT2ARs in the early 
entry process (Elphick et al., 2004). 5-HT2Rs are not important for initial viral attachment, but 
transient direct interactions on the cell surface cannot be completely excluded (Assetta et al., 
2013). However, JCPyV infections occur also in the absence of 5-HT2AR in human brain 
microvascular endothelial cells, suggesting that 5-HTRs function in a redundant manner 
(Chapagain et al., 2007). In order to investigate if 5-HT2Rs are critical for intracellular signaling 
events during JCPyV infection, mutations studies, for example at the C-terminus of 5-HT2Rs 
located in the cytosol, might clarify the role of 5-HT2Rs. Conserved amino acid regions or 
residues at the C-terminus could be deleted or mutated and effects on JCPyV infectious entry 
could then be monitored by infection assays and co-localization experiments by fluorescence 
microscopy.  
Available structural-functional data of JCPyV and related polyomaviruses offer a unique 
opportunity to explore and identify parameters that define the importance of 5-HT2Rs receptor 
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engagement, and viral entry pathways. Established hypotheses could be tested with 
engineering viruses that engage different receptors and switch their host and cell specificities 
and perhaps their entry pathways. Since GM1 and GD1b glycan binding was observed for 
JCPyV VP1, a receptor retargeting approach towards engagement of the GM1 ganglioside has 
been tested via site-directed mutagenesis at JCPyV VP1 residue N123 (data not shown). The 
asparagine at this position in JCPyV VP1, which is a glycine in SV40 and BKPyV VP1, is a key 
residue of the binding site that makes contacts with both arms of the L-shaped LSTc. 
Evaluation of mutated VP1 pentamers by crystal structure analysis revealed abolished binding 
to LSTc in the L-shape conformation and conserved engagement of the GM1 glycan, but 
supplementation of cells with GM1 ganglioside did not alter cell binding or infection of these 
mutants. Thus, it cannot be ruled out that there are, in addition to the increased binding affinity 
for LSTc, other evolutionary constraints for utilizing LSTc, so that this virus-glycan interaction is 
favored over engagement of GM1 or b-series gangliosides. A reverse approach via site-
directed mutagenesis in SV40 and BKPyV VP1 may help to determine if enhanced LSTc 
binding is sufficient for targeting the viruses to the clathrin-dependent entry pathway and if this 
binding event is a prerequisite for involvement of 5-HT2Rs in the early steps of infection.  
4.2  Development of Antiviral Strategies for JC Polyomavirus 
The development of antiviral compounds for JCPyV could focus in the future on several steps 
during the virus lifecycle. Proceeding with strategies to block the interaction between JCPyV 
VP1 and LSTc during attachment, competition experiments with LSTc or GM1 glycans by STD 
NMR spectroscopy could be carried out to further evaluate the 40 hits from the fragment-based 
screening approach. Although the GM1 ganglioside is not a functional receptor for JCPyV, the 
non-reducing end of the GM1 glycan binds in a unique groove on the VP1 surface in the 
JCPyV VP1 complex structure, highlighting a potential binding site for small compounds on the 
top of VP1. In further experiments, such fragments engaged in this binding site could be 
chemically linked with positive hits engaged in the Neu5Ac binding pocket. The extension of 
fragments by adding chemical groups that are pointing into the direction of the core Neu5Ac 
binding site might also be possible in order to increase the number of specific interactions and 
hence the binding affinities for compounds. Furthermore, the introduction of a multivalent 
binding mode may drastically enhance the binding affinities of promising compounds 
(Rademacher et al., 2011; Spjut et al., 2011). Potent antiviral compounds inhibiting the binding 
of JCPyV to Neu5Ac on the host cell surface may provide then a novel route for the 
development of similar antiviral therapies for other viruses that initiate infection through the 
recognition of sialylated glycans.  
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However, the fact that the role of the PML-associated VP1 mutations in JCPyV pathogenicity 
remains still unclear weakens this approach to develop antiviral strategies. It is plausible that 
the loss of sialic acid binding of PML-associated viruses may be critical for the increased 
spread to the brain and the subsequent infection of glial cells in a sialic acid-independent 
manner. Moreover, it is possible that there is an unknown host cell factor, for example a non-
sialic acid receptor on glial cells in the CNS, which is important for infection by JCPyV with 
PML-associated VP1 mutations. This receptor may be not abundantly expressed on cell lines 
that have been used in available model systems. Consequently, the development of inhibitors 
against the wild type VP1 variants might be a dead end and other strategies are needed. It 
was shown in this thesis that the 5-fold pore of the VP1 pentamer is an important structural 
feature and likely an important interaction platform during the infection. Studies with VP1 
mutants interfering with the VP1-VP2 interaction could help to further establish the role of VP2 
for infection, possible pointing out alternative strategies for the development of antiviral 
compounds. Starting from the compound 9E08, chemically related compounds with better 
solubility could be tested in crystal soaking experiments to validate the binding inside the pore 
and the addition of chemical groups interacting with VP1 could enhance the binding affinity of 
the 9E08 fragment. With better binding compounds in hand, cell-based assays are the next 
step to test their antiviral potentials in cell culture. In contrast to attachment inhibitors, it is 
necessary that compounds reach the nucleus during virus assembly, facilitating the 
development of antiviral compounds. Nevertheless, such an assembly inhibitor would be 
equally effective against other virus variants, since the interaction between VP1 and VP2 is 
rather conserved between JCPyV genotypes and viral subgroups, but a high-resolution 
structural analysis is needed to define molecular details of the VP1-VP2 interaction for a 
rational structure-based approach. Similarly, compounds binding at the C-terminus VP1 may 
interfere with the correct assembly of VP1 pentamers into the capsid. However, molecular 
details of VP1 pentamer-VP1 pentamer interactions in the assembled capsid are only available 
for SV40 and MPyV so far (Liddington et al., 1991; Stehle et al., 1994; Yan et al., 1996). In 
addition, it remains unclear how the interface between pentamers is involved in virus-host 
interactions during the infection. The observation that the disease JCPyV GCN is associated 
with mutations and deletions at the C-terminus of VP1 suggests that canyons between VP1 
pentamers may be important during the infection and for the pathogenicity (Dang and Koralnik, 
2006; Agnihotri et al., 2014). Hence, further studies are definitely needed to explore the 
importance of the canyons for JCPyV receptor binding and its applicability as a target for 
antiviral strategies.  
In general, X-ray crystallography has been approved to be very useful during FBDD 
approaches although several experimental factors could prevent protein-ligand complex 
formation hampering the experimental outcome (Davies and Tickle, 2012). Crystallization 
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cocktails differ often significantly from biologically relevant environments, crystal contacts may 
block the binding sites, or the crystal lattice may not allow conformational change that are 
necessary for ligand binding during crystal soaking experiments. In some cases co-
crystallization experiments can overcome these problems but may require extensive 
crystallization screening for each ligand due to induced conformational changes upon ligand 
binding that disrupt crystal contacts or addition of organic solvents such as DMSO, which is 
necessary to solubilize fragments, may alter the crystallization system.  
JCPyV VP1 crystallizes under a relative physiological condition at pH 7.5 (0.1 M HEPES pH 
7.5, 0.2 M KSCN, 12% (v/v) PEG 3,350). Chances that binding sites for fragments are 
accessible in the preformed crystal during soaking experiments are relatively high, because 
neighboring VP1 pentamers in the crystal do not contact each VP1 monomers in an identical 
manner. Nevertheless, only one of the ten hits from the screening by NMR was observed in 
the electron density map, a validation hit rate that is not very high but still comparable with 
observations from other FBDD projects (Wielens et al., 2013). Different cascades of 
biophysical methods have been used during FBDD projects with various success of hit 
validation and hit overlap (Wielens et al., 2013). FBDD strategies include in addition to NMR 
spectroscopy or fluorescence-based thermal shift assays often a technique to estimate binding 
affinities such as ITC or SPR (Ciulli and Abell, 2007; Giannetti, 2011). Thus, it is worth to 
consider implementing such a technique into the FBDD workflow after initial screening by 
NMR. In contrast, the initial screening step is now more often performed directly by X-ray 
crystallography (Murray et al., 2007; Davies and Tickle, 2012). The potential of X-ray 
crystallography for early steps of FBDD was historically underappreciated due to relatively low 
throughput and the subjective time consuming interpretation of electron density maps, but it 
does usually not suffer from the problem of false positive such as other screening techniques 
(Chilingaryan et al., 2012). If hit identification is difficult in poorly defined electron densities due 
to alternative conformations or low fragment occupancies for example bromide-containing 
fragments and anomalous scattering could be used to overcome such problems (Tiefenbrunn 
et al., 2014). In conclusion, FBDD in combination with or carried out by high-throughput X-ray 
crystallography is a promising strategy for future development of antiviral compounds 
interfering with several steps during the JCPyV lifecycle in order to develop effective 
treatments against PML.  
4.3  Identification of Glycan Receptor Candidates for Recently Discovered 
Human Polyomaviruses 
This thesis provides structural and functional insights into receptor recognition of five recently 
discovered polyomaviruses widely circulating within the human population. Clear evidence for 
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the importance of sialylated glycans during viral infection has been generated for TSPyV, 
NJPyV, and HPyV12, whereas HPyV6 and HPyV7 engage likely non-sialylated receptors. 
Initially, polyomaviruses were thought to bind sialic acids in the same general area of VP1. 
This common binding site is plastic and allows the engagement of the same ligand in different 
orientations (Ströh and Stehle, 2014). In contrast, a novel sialic acid binding site within the 
BC2-loop of VP1 has been identified for TSPyV. Subsequent structural studies with HPyV12 
VP1 pentamers identified a very similar glycan-binding site. Together with phylogenetic 
analysis, these structural data suggest that the BC2-loop binding site may also be employed 
for receptor binding by other polyomaviruses.  
In order to identify potentially more complex and specific sialic acid receptors glycan array 
screening is currently ongoing with TSPyV, HPyV12, and NJPyV VP1 pentamers. Previous 
glycan array screening approaches with either N-terminal His-tagged TSPyV VP1 pentamers 
or directly Alexa Fluor 647-labeled VP1 pentamers did not result in significant binding signals 
on microarrays that were composed of 128 sequence-defined lipid-linked oligosaccharide 
probes, including 122 sialylated and six neutral probes. Results with Alexa Fluor 647-labelled 
TSPyV pseudoviruses were similar (Ten Feizi, unpublished data). It is known that recombinant 
VP1 pentamers form disulfide bond-mediated dimers (“tail-to-tail”) and higher multimers in 
solution due to the conserved and exposed cysteine in the CD-loop. Disulfide bond formation 
might result in a scenario where the N-terminal His-tag is less accessible, hampering common 
glycan array detection systems using an anti-His tag antibody. For the ongoing glycan array 
screening, cysteine residues were mutated to serine residues in TSPyV (C107), HPyV12 
(C119), and NJPyV (C113) VP1 pentamers. The respective mutations are distant from the 
surface loops of VP1 and should not alter glycan binding.  
Based on the structural analyses, it is also tempting to speculate about a broader glycan 
receptor specificity of TSPyV and HPyV12. The shallow BC2-loop binding groove allows 
interactions with terminal α2,3-, α2,6-, and likely α2,8-linked sialic acids without steric 
hindrance. These findings might explain why specific binding events above the background 
binding level could not be identified on the glycan array. In contrast, cell binding and infection 
studies have revealed that neither N- nor O-linked glycans are involved in the TSPyV infection, 
suggesting instead that a specific lipid-based virus receptor with a more complex binding 
epitope than terminal sialic acids is present on infected cells. The recognition of non-sialylated 
glycan epitopes in the “old” binding site might be realized due to the plasticity of the VP1 
surface loops. A similar switch in receptor specificity between different glycans classes has 
been described for rotaviruses. The porcine rotavirus CRW-8 binds the GM3 glycan in a 
conserved overall location on the capsid protein VP8*, whereas the human rotavirus strain 
HAL1166 engages a neutral tetrasaccharide corresponding to the terminal structure of A-type 
HBGA in the same area (Yu et al., 2011b; Hu et al., 2012). However, one could only speculate 
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so far about such a switching scenario in the case of TSPyV and HPyV12 without experimental 
data from glycan array screening or molecular details from X-ray crystal structures in hand.  
4.4  Cell-based Model Systems and Functional Infection Studies  
Model systems are clearly required for functional studies of receptor specificity and cell entry 
mechanisms. However, the pseudovirus system provides already a sensitive method for 
studying determinants and mechanisms of the infectious entry of newly discovered 
polyomaviruses, mutant viruses, and virus variants or strains that do not propagate using 
traditional cell culture methods. Structure-based mutagenesis of pseudoviruses and cell 
supplementation assays would be the next steps to study the importance of the virus-glycan 
interaction for NJPyV and HPyV12 infection. A reverse approach, starting from exploring the 
cell tropism of the virus in order to identify receptor candidates is possible but challenging 
because systematic data sets about cell-type specific glycans are not available or rather 
incomplete. Nevertheless, the development of model cell culture systems allowing the 
propagation of virus in tissue culture is a requirement to study the molecular biology of newly 
discovered polyomaviruses besides cell attachment and endocytosis. Similar systems are 
available of JCPyV, including a primary human fetal astrocyte cell culture system 
(Radhakrishnan et al., 2003), the glial cell line SVGA (Major et al., 1985; Gee et al., 2003), and 
more recently described oligodendrocyte precursor cells (Darbinyan et al., 2013). 
The link to a human disease is not clear for all human polyomaviruses although a persistent 
infection with these viruses is very common within the healthy human population. There is now 
clear evidence that the infection with HPyV7 can lead to pruritic, brown plaques on the trunk 
and extremities of immunosuppressed individuals such as transplant patients (Ho et al., 2014). 
More recently, and almost five years after its discovery, HPyV7 has also been linked to thymic 
epithelial tumors (Rennspiess et al., 2015). Thus, an involvement in human diseases and 
tumors is likely for HPyV6 and has to be considered for other recently discovered human 
polyomaviruses.  
The first confirmed human oncogenic member of the polyomavirus family is MCPyV. 
Interestingly, mechanisms and characteristics of cellular infections with MCPyV differ in 
several aspects from human pathogenic polyomviruses such as BKPyV and JCPyV. The 
genome of MCPyV is integrated into the genome of MCC cells in a large percentage of cases, 
whereas clonal integration is not observed for other human polyomaviruses. MCPyV engage 
sialic acids and additionally GAGs during the early stages of the infection. While cellular 
receptors for HPyV6 and HPyV7 are unknown it remains to be investigated if other skin-tropic 
polyomaviruses employ similar strategies and require for GAGs attachment. Glycan array 
screening with pseudoviruses instead of VP1 pentamers samples also the surface between 
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pentamers in the assembled virion for possible glycan interactions. However, HPyV6 and 
HPyV7 may also engage proteinous receptors. Screening for infectivity in different cell lines 
would be required to identify host cells that express potential receptors. Subsequent genome-
wide siRNA screening approaches or virus overlay protein assays could be used to identify 
proteinous receptors for the more recently discovered polyomaviruses (Cao et al., 1998; 
Tayyari et al., 2011; Konopka-Anstadt et al., 2014).  
4.5  Host Tropism, Viral Adaptation, and Pathogenicity 
The phylogenetic analysis of the polyomavirus family highlights occurring pairwise 
relationships of human and monkey viruses, including species such as HPyV9 and LPyV, 
NJPyV and ChPyV, and TSPyV and OraPyV-Bo (Figure 1). Critical differences in glycan 
binding specificities of LPyV and HPyV9 have enhanced our understanding of principles that 
underlie pathogen selectivity based on sialic acid modifications (Khan et al., 2014), but the 
influence on host specificity remains speculative or unclear in most cases. Further 
investigations are also needed to understand the molecular basis for switching events in host 
tropism and viral adaptation and especially pathogenicity. Typically, the polyomavirus infection 
is latent but asymptomatic in immunocompetent hosts whereas infections can result in severe 
outcomes during immunosuppression or in an altered pathogenicity in other hosts. For 
example, SV40 infections are mostly asymptomatic in healthy monkeys, but the virus can lead 
to tumors in small rodents (Vilchez and Butel, 2004). Similarly, JCPyV induces formation of 
tumor formation in animal model systems, whereas its reactivation in humans during 
immunosuppression results in brain diseases such as PML with different pathogenic 
characteristics (Walker et al., 1973; London et al., 1978; Ohsumi et al., 1986). The resulting 
lack of a good animal model hampers in vivo studies with JCPyV. However, although a 
humanized mouse model does not recapitulate the disease PML, it may be still useful to study 
for example the immune response during the infection, viral adaption, and tissue tropism (Tan 
et al., 2013).  
In conclusion, with relatively high sequence homology and conserved architecture across the 
family, polyomaviruses form a useful platform for analyzing determinants of antigenicity, cell 
entry, cell tropism and host range, as well as other factors that contribute to viral pathogenesis. 
Combined data sets including structural data about specific (glycan) receptor engagement and 
receptor-switching potential of viruses provide hereby a powerful platform for exploring new 
ways forward in the rational development of antiviral strategies and a more reliable prediction 
of virus-host interactions, viral evolution, and cross-species transmission where no structural 
data is at hand. The detailed understanding of underlying principles of glycan-virus and its 
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impact on cell tropism is also important for new approaches in the design of therapeutic gene 
vectors. 
Overall, an increased understanding how polyomaviruses and in particular JCPyV evolve to 
evade the host immune system and antibody-mediated neutralization could open the door to 
clinical developments of vaccines against JCPyV and PML and other diseases caused by 
human polyomaviruses in the future. 
 
References 
 
 73 
5.  References 
Abend, J.R., Joseph, A.E., Das, D., Campbell-Cecen, D.B., and Imperiale, M.J. (2009). A 
truncated T antigen expressed from an alternatively spliced BK virus early mRNA. J Gen Virol 
90, 1238-1245. 
Adams, P.D., Afonine, P.V., Bunkoczi, G., et al. (2010). PHENIX: a comprehensive Python-
based system for macromolecular structure solution. Acta Crystallographica Section D-
Biological Crystallography 66, 213-221. 
Agnihotri, S.P., Dang, X., Carter, J.L., Fife, T.D., Bord, E., Batson, S., and Koralnik, I.J. (2014). 
JCV GCN in a natalizumab-treated MS patient is associated with mutations of the VP1 capsid 
gene. Neurology 83, 727-732. 
Ahmed, W., Wan, C., Goonetilleke, A., and Gardner, T. (2010). Evaluating sewage-associated 
JCV and BKV polyomaviruses for sourcing human fecal pollution in a coastal river in Southeast 
Queensland, Australia. J Environ Qual 39, 1743-1750. 
Angata, T., and Varki, A. (2002). Chemical diversity in the sialic acids and related alpha-keto 
acids: an evolutionary perspective. Chem Rev 102, 439-469. 
Asselin, C., Gelinas, C., Branton, P.E., and Bastin, M. (1984). Polyoma middle T antigen 
requires cooperation from another gene to express the malignant phenotype in vivo. Mol Cell 
Biol 4, 755-760. 
Assetta, B., Maginnis, M.S., Gracia Ahufinger, I., Haley, S.A., Gee, G.V., Nelson, C.D., O'Hara, 
B.A., Allen Ramdial, S.A., and Atwood, W.J. (2013). 5-HT2 receptors facilitate JC 
polyomavirus entry. J Virol 87, 13490-13498. 
Atwood, W.J., and Norkin, L.C. (1989). Class-I major histocompatibility proteins as cell-surface 
receptors for Simian Virus-40. J Virol 63, 4474-4477. 
Banerji, J., Rusconi, S., and Schaffner, W. (1981). Expression of a beta-globin gene is 
enhanced by remote SV40 DNA sequences. Cell 27, 299-308. 
Barouch, D.H., and Harrison, S.C. (1994). Interactions among the major and minor coat 
proteins of polyomavirus. J Virol 68, 3982-3989. 
Bartholomeusz, A., and Locarnini, S. (2006). Hepatitis B virus mutations associated with 
antiviral therapy. J Med Virol 78 Suppl 1, S52-55. 
Bauer, P.H., Bronson, R.T., Fung, S.C., Freund, R., Stehle, T., Harrison, S.C., and Benjamin, 
T.L. (1995). Genetic and structural analysis of a virulence determinant in polyomavirus VP1. J 
Virol 69, 7925-7931. 
Bauer, P.H., Cui, C.Q., Stehle, T., Harrison, S.C., DeCaprio, J.A., and Benjamin, T.L. (1999). 
Discrimination between sialic acid-containing receptors and pseudoreceptors regulates 
polyomavirus spread in the mouse. J Virol 73, 5826-5832. 
Bauman, Y., Nachmani, D., Vitenshtein, A., Tsukerman, P., Drayman, N., Stern-Ginossar, N., 
Lankry, D., Gruda, R., and Mandelboim, O. (2011). An identical miRNA of the human JC and 
BK polyoma viruses targets the stress-induced ligand ULBP3 to escape immune elimination. 
Cell Host Microbe 9, 93-102. 
References 
 
 74 
Bellizzi, A., Anzivino, E., Rodio, D.M., Palamara, A.T., Nencioni, L., and Pietropaolo, V. (2013). 
New insights on human polyomavirus JC and pathogenesis of progressive multifocal 
leukoencephalopathy. Clin Dev Immunol 2013, 839719. 
Bennett, S.M., Broekema, N.M., and Imperiale, M.J. (2012). BK polyomavirus: emerging 
pathogen. Microbes Infect 14, 672-683. 
Bennett, S.M., Jiang, M., and Imperiale, M.J. (2013). Role of cell-type-specific endoplasmic 
reticulum-associated degradation in polyomavirus trafficking. J Virol 87, 8843-8852. 
Benoist, C., and Chambon, P. (1981). In vivo sequence requirements of the SV40 early 
promotor region. Nature 290, 304-310. 
Blake, S.J., Bokhari, F.F., and McMillan, N.A. (2012). RNA interference for viral infections. Curr 
Drug Targets 13, 1411-1420. 
Blixt, O., Head, S., Mondala, T., et al. (2004). Printed covalent glycan array for ligand profiling 
of diverse glycan binding proteins. Proc Natl Acad Sci U S A 101, 17033-17038. 
Bloomgren, G., Richman, S., Hotermans, C., et al. (2012). Risk of natalizumab-associated 
progressive multifocal leukoencephalopathy. N Engl J Med 366, 1870-1880. 
Bofill-Mas, S., Formiga-Cruz, M., Clemente-Casares, P., Calafell, F., and Girones, R. (2001). 
Potential transmission of human polyomaviruses through the gastrointestinal tract after 
exposure to virions or viral DNA. J Virol 75, 10290-10299. 
Bollag, B., Kilpatrick, L.H., Tyagarajan, S.K., Tevethia, M.J., and Frisque, R.J. (2006). JC virus 
T'135, T'136 and T'165 proteins interact with cellular p107 and p130 in vivo and influence viral 
transformation potential. J Neurovirol 12, 428-442. 
Bonhaus, D.W., Bach, C., DeSouza, A., Salazar, F.H., Matsuoka, B.D., Zuppan, P., Chan, 
H.W., and Eglen, R.M. (1995). The pharmacology and distribution of human 5-
hydroxytryptamine2B (5-HT2B) receptor gene products: comparison with 5-HT2A and 5-HT2C 
receptors. Br J Pharmacol 115, 622-628. 
Brady, J.N., Winston, V.D., and Consigli, R.A. (1977). Dissociation of polyoma virus by the 
chelation of calcium ions found associated with purified virions. J Virol 23, 717-724. 
Brew, B.J., Davies, N.W., Cinque, P., Clifford, D.B., and Nath, A. (2010). Progressive 
multifocal leukoencephalopathy and other forms of JC virus disease. Nat Rev Neurol 6, 667-
679. 
Broekema, N.M., and Imperiale, M.J. (2013). miRNA regulation of BK polyomavirus replication 
during early infection. Proc Natl Acad Sci U S A 110, 8200-8205. 
Burioni, R., and Clementi, M. (2014). A human monoclonal antibody against the VP1 protein of 
JC virus. In WO2014002035 A1. 
Burkert, O., Kressner, S., Sinn, L., Giese, S., Simon, C., and Lilie, H. (2014). Biophysical 
characterization of polyomavirus minor capsid proteins. Biol Chem 395, 871-880. 
Burmeister, W.P., Guilligay, D., Cusack, S., Wadell, G., and Arnberg, N. (2004). Crystal 
structure of species D adenovirus fiber knobs and their sialic acid binding sites. J Virol 78, 
7727-7736. 
References 
 
 75 
Butin-Israeli, V., Ben-nun-Shaul, O., Kopatz, I., Adam, S.A., Shimi, T., Goldman, R.D., and 
Oppenheim, A. (2011). Simian virus 40 induces lamin A/C fluctuations and nuclear envelope 
deformation during cell entry. Nucleus 2, 320-330. 
Byres, E., Paton, A.W., Paton, J.C., et al. (2008). Incorporation of a non-human glycan 
mediates human susceptibility to a bacterial toxin. Nature 456, 648-652. 
Campanero-Rhodes, M.A., Smith, A., Chai, W.G., et al. (2007). N-glycolyl GM1 ganglioside as 
a receptor for Simian Virus 40. J Virol 81, 12846-12858. 
Cao, W., Henry, M.D., Borrow, P., Yamada, H., Elder, J.H., Ravkov, E.V., Nichol, S.T., 
Compans, R.W., Campbell, K.P., and Oldstone, M.B.A. (1998). Identification of alpha-
dystroglycan as a receptor for lymphocytic choriomeningitis virus and lassa fever virus. 
Science 282, 2079-2081. 
Carbone, M., Ascione, G., Chichiarelli, S., Garcia, M.I., Eufemi, M., and Amati, P. (2004). 
Chromosome-protein interactions in polyomavirus virions. J Virol 78, 513-519. 
Carney, D.W., Nelson, C.D.S., Ferris, B.D., Stevens, J.P., Lipovsky, A., Kazakov, T., DiMaio, 
D., Atwood, W.J., and Sello, J.K. (2014). Structural optimization of a retrograde trafficking 
inhibitor that protects cells from infections by human polyoma- and papillomaviruses. 
Bioorganic & Medicinal Chemistry 22, 4836-4847. 
Carrillo-Tripp, M., Shepherd, C.M., Borelli, I.A., Venkataraman, S., Lander, G., Natarajan, P., 
Johnson, J.E., Brooks, C.L., 3rd, and Reddy, V.S. (2009). VIPERdb2: an enhanced and web 
API enabled relational database for structural virology. Nucleic Acids Research 37, D436-442. 
Carter, J.J., Daugherty, M.D., Qi, X., Bheda-Malge, A., Wipf, G.C., Robinson, K., Roman, A., 
Malik, H.S., and Galloway, D.A. (2013). Identification of an overprinting gene in Merkel Cell 
polyomavirus provides evolutionary insight into the birth of viral genes. Proc Natl Acad Sci U S 
A 110, 12744-12749. 
Carter, J.J., Paulson, K.G., Wipf, G.C., et al. (2009). Association of Merkel Cell polyomavirus-
specific antibodies with Merkel Cell carcinoma. J Natl Cancer Inst 101, 1510-1522. 
Caruso, M., Belloni, L., Sthandier, O., Amati, P., and Garcia, M.I. (2003). Alpha 4 beta 1 
integrin acts as a cell receptor for murine polyomavirus at the postattachment level. J Virol 77, 
3913-3921. 
Chapagain, M.L., and Nerurkar, V.R. (2010). Human polyomavirus JC (JCV) infection of 
human B lymphocytes: a possible mechanism for JCV transmigration across the blood-brain 
barrier. J Infect Dis 202, 184-191. 
Chapagain, M.L., Verma, S., Mercier, F., Yanagihara, R., and Nerurkar, V.R. (2007). 
Polyomavirus JC infects human brain microvascular endothelial cells independent of serotonin 
receptor 2A. Virology 364, 55-63. 
Chen, C.J., Cox, J.E., Azarm, K.D., Wylie, K.N., Woolard, K.D., Pesavento, P.A., and Sullivan, 
C.S. (2014). Identification of a polyomavirus microRNA highly expressed in tumors. Virology 
476C, 43-53. 
Chen, H., Viel, S., Ziarelli, F., and Peng, L. (2013). F-19 NMR: a valuable tool for studying 
biological events. Chemical Society Reviews 42, 7971-7982. 
References 
 
 76 
Chen, X.S., Stehle, T., and Harrison, S.C. (1998). Interaction of polyomavirus internal protein 
VP2 with the major capsid protein VP1 and implications for participation of VP2 in viral entry. 
EMBO J 17, 3233-3240. 
Chen, Y., Cheng, G., and Mahato, R.I. (2008). RNAi for treating hepatitis B viral infection. 
Pharm Res 25, 72-86. 
Childs, R.A., Palma, A.S., Wharton, S., et al. (2009). Receptor-binding specificity of pandemic 
influenza A (H1N1) 2009 virus determined by carbohydrate microarray. Nat Biotechnol 27, 
797-799. 
Chilingaryan, Z., Yin, Z., and Oakley, A.J. (2012). Fragment-based screening by protein 
crystallography: successes and pitfalls. Int J Mol Sci 13, 12857-12879. 
Cho, J.A., Chinnapen, D.J., Aamar, E., te Welscher, Y.M., Lencer, W.I., and Massol, R. (2012). 
Insights on the trafficking and retro-translocation of glycosphingolipid-binding bacterial toxins. 
Front Cell Infect Microbiol 2, 51. 
Chou, H.H., Hayakawa, T., Diaz, S., Krings, M., Indriati, E., Leakey, M., Paabo, S., Satta, Y., 
Takahata, N., and Varki, A. (2002). Inactivation of CMP-N-acetylneuraminic acid hydroxylase 
occurred prior to brain expansion during human evolution. Proc Natl Acad Sci U S A 99, 
11736-11741. 
Chou, H.H., Takematsu, H., Diaz, S., Iber, J., Nickerson, E., Wright, K.L., Muchmore, E.A., 
Nelson, D.L., Warren, S.T., and Varki, A. (1998). A mutation in human CMP-sialic acid 
hydroxylase occurred after the Homo-Pan divergence. Proc Natl Acad Sci U S A 95, 11751-
11756. 
Ciulli, A., and Abell, C. (2007). Fragment-based approaches to enzyme inhibition. Curr Opin 
Biotechnol 18, 489-496. 
Congreve, M., Carr, R., Murray, C., and Jhoti, H. (2003). A 'rule of three' for fragment-based 
lead discovery? Drug Discov Today 8, 876-877. 
Coric, P., Saribas, A.S., Abou-Gharbia, M., Childers, W., White, M.K., Bouaziz, S., and Safak, 
M. (2014). Nuclear magnetic resonance structure revealed that the human polyomavirus JC 
virus agnoprotein contains an alpha-helix encompassing the Leu/Ile/Phe-rich domain. J Virol 
88, 11000-11000. 
Dalianis, T., and Hirsch, H.H. (2013). Human polyomaviruses in disease and cancer. Virology 
437, 63-72. 
Dalyot-Herman, N., Ben-nun-Shaul, O., Gordon-Shaag, A., and Oppenheim, A. (1996). The 
Simian Virus 40 packaging signal ses is composed of redundant DNA elements which are 
partly interchangeable. J Mol Biol 259, 69-80. 
Dang, X., and Koralnik, I.J. (2006). A granule cell neuron-associated JC virus variant has a 
unique deletion in the VP1 gene. J Gen Virol 87, 2533-2537. 
Dang, X., Vidal, J.E., Oliveira, A.C., Simpson, D.M., Morgello, S., Hecht, J.H., Ngo, L.H., and 
Koralnik, I.J. (2012a). JC virus granule cell neuronopathy is associated with VP1 C terminus 
mutants. J Gen Virol 93, 175-183. 
Dang, X., Wuthrich, C., Gordon, J., Sawa, H., and Koralnik, I.J. (2012b). JC virus 
encephalopathy is associated with a novel agnoprotein-deletion JCV variant. PLoS One 7, 
e35793. 
References 
 
 77 
Daniels, R., Rusan, N.M., Wadsworth, P., and Hebert, D.N. (2006). SV40VP2 and VP3 
insertion into ER membranes is controlled by the capsid protein VP1: Implications for DNA 
translocation out of the ER. Mol Cell 24, 955-966. 
Daniels, R., Sadowicz, D., and Hebert, D.N. (2007). A very late viral protein triggers the lytic 
release of SV40. PLoS Pathog 3, e98. 
Darbinyan, A., Kaminski, R., White, M.K., Darbinian-Sarkissian, N., and Khalili, K. (2013). 
Polyomavirus JC infection inhibits differentiation of oligodendrocyte progenitor cells. J Neurosci 
Res 91, 116-127. 
Davies, T.G., and Tickle, I.J. (2012). Fragment screening using X-ray crystallography. Top 
Curr Chem 317, 33-59. 
De Gascun, C.F., and Carr, M.J. (2013). Human polyomavirus reactivation: disease 
pathogenesis and treatment approaches. Clin Dev Immunol 2013, 373579. 
DeCaprio, J.A., and Garcea, R.L. (2013). A cornucopia of human polyomaviruses. Nat Rev 
Microbiol 11, 264-276. 
Delbue, S., Elia, F., Carloni, C., Tavazzi, E., Marchioni, E., Carluccio, S., Signorini, L., Novati, 
S., Maserati, R., and Ferrante, P. (2012). JC virus load in cerebrospinal fluid and 
transcriptional control region rearrangements may predict the clinical course of progressive 
multifocal leukoencephalopathy. J Cell Physiol 227, 3511-3517. 
Deng, L., Song, J., Gao, X., Wang, J., Yu, H., Chen, X., Varki, N., Naito-Matsui, Y., Galan, 
J.E., and Varki, A. (2014). Host adaptation of a bacterial toxin from the human pathogen 
Salmonella Typhi. Cell 159, 1290-1299. 
Diotti, R.A., Nakanishi, A., Clementi, N., Mancini, N., Criscuolo, E., Solforosi, L., and Clementi, 
M. (2013). JC polyomavirus (JCV) and monoclonal antibodies: friends or potential foes? Clin 
Dev Immunol 2013, 967581. 
Drayman, N., Glick, Y., Ben-nun-Shaul, O., Zer, H., Zlotnick, A., Gerber, D., Schueler-Furman, 
O., and Oppenheim, A. (2013). Pathogens use structural mimicry of native host ligands as a 
mechanism for host receptor engagement. Cell Host Microbe 14, 63-73. 
Du Pasquier, R.A., Corey, S., Margolin, D.H., Williams, K., Pfister, L.A., De Girolami, U., Mac 
Key, J.J., Wuthrich, C., Joseph, J.T., and Koralnik, I.J. (2003). Productive infection of 
cerebellar granule cell neurons by JC virus in an HIV+ individual. Neurology 61, 775-782. 
Dugan, A.S., Gasparovic, M.L., and Atwood, W.J. (2008). Direct correlation between sialic acid 
binding and infection of cells by two human polyomaviruses (JC virus and BK virus). J Virol 82, 
2560-2564. 
Duncavage, E.J., and Pfeifer, J.D. (2011). Human Polyomaviruses 6 and 7 (HPyV6/7) are not 
detectable in Merkel Cell carcinoma. Modern Pathology 24, 115A-115A. 
Eash, S., and Atwood, W.J. (2005). Involvement of cytoskeletal components in BK virus 
infectious entry. J Virol 79, 11734-11741. 
Eash, S., Querbes, W., and Atwood, W.J. (2004). Infection of vero cells by BK virus is 
dependent on caveolae. J Virol 78, 11583-11590. 
Ehlers, B., and Moens, U. (2014). Genome analysis of non-human primate polyomaviruses. 
Infect Genet Evol 26, 283-294. 
References 
 
 78 
Elphick, G.F., Querbes, W., Jordan, J.A., et al. (2004). The human polyomavirus, JCV, uses 
serotonin receptors to infect cells. Science 306, 1380-1383. 
Emsley, P., Lohkamp, B., Scott, W.G., and Cowtan, K. (2010). Features and development of 
Coot. Acta Crystallogr D Biol Crystallogr 66, 486-501. 
Engel, S., Heger, T., Mancini, R., Herzog, F., Kartenbeck, J., Hayer, A., and Helenius, A. 
(2011). Role of endosomes in Simian Virus 40 entry and infection. J Virol 85, 4198-4211. 
Erickson, K.D., Bouchet-Marquis, C., Heiser, K., Szomolanyi-Tsuda, E., Mishra, R., Lamothe, 
B., Hoenger, A., and Garcea, R.L. (2012). Virion assembly factories in the nucleus of 
polyomavirus-infected cells. PLoS Pathog 8. 
Erickson, K.D., Garcea, R.L., and Tsai, B. (2009). Ganglioside GT1b is a putative host cell 
receptor for the Merkel Cell polyomavirus. J Virol 83, 10275-10279. 
Erlanson, D.A. (2012). Introduction to fragment-based drug discovery. Top Curr Chem 317, 1-
32. 
Ermis, U., Weis, J., and Schulz, J.B. (2013). Case reports of PML in patients treated for 
psoriasis. N Engl J Med 369, 1081. 
Ernst, B., and Magnani, J.L. (2009). From carbohydrate leads to glycomimetic drugs. Nature 
Reviews Drug Discovery 8, 661-677. 
Ewers, H., Romer, W., Smith, A.E., et al. (2010). GM1 structure determines SV40-induced 
membrane invagination and infection. Nat Cell Biol 12, 11-18; sup pp 11-12. 
Feltkamp, M.C., Kazem, S., van der Meijden, E., Lauber, C., and Gorbalenya, A.E. (2013). 
From Stockholm to Malawi: recent developments in studying human polyomaviruses. J Gen 
Virol 94, 482-496. 
Feng, H., Shuda, M., Chang, Y., and Moore, P.S. (2008). Clonal integration of a polyomavirus 
in human Merkel Cell carcinoma. Science 319, 1096-1100. 
Ferenczy, M.W., Marshall, L.J., Nelson, C.D., Atwood, W.J., Nath, A., Khalili, K., and Major, 
E.O. (2012). Molecular biology, epidemiology, and pathogenesis of progressive multifocal 
leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain. Clin 
Microbiol Rev 25, 471-506. 
Freund, R., Garcea, R.L., Sahli, R., and Benjamin, T.L. (1991). A single-amino-acid 
substitution in polyomavirus VP1 correlates with plaque size and hemagglutination behavior. J 
Virol 65, 350-355. 
Frisque, R.J. (1983). Nucleotide sequence of the region encompassing the JC virus origin of 
DNA replication. J Virol 46, 170-176. 
Frisque, R.J., Bollag, B., Tyagarajan, S.K., and Kilpatrick, L.H. (2003). T' proteins influence JC 
virus biology. J Neurovirol 9 Suppl 1, 15-20. 
Frisque, R.J., Bream, G.L., and Cannella, M.T. (1984). Human polyomavirus JC virus genome. 
J Virol 51, 458-469. 
Fromm, M., and Berg, P. (1983). Simian Virus 40 early- and late-region promoter functions are 
enhanced by the 72-base-pair repeat inserted at distant locations and inverted orientations. 
Mol Cell Biol 3, 991-999. 
References 
 
 79 
Fujinaga, Y., Wolf, A.A., Rodighiero, C., Wheeler, H., Tsai, B., Allen, L., Jobling, M.G., 
Rapoport, T., Holmes, R.K., and Lencer, W.I. (2003). Gangliosides that associate with lipid 
rafts mediate transport of cholera and related toxins from the plasma membrane to 
endoplasmic reticulm. Molecular Biology of the Cell 14, 4783-4793. 
Gardner, S.D., Field, A.M., Coleman, D.V., and Hulme, B. (1971). New human papovavirus 
(B.K.) isolated from urine after renal transplantation. Lancet 1, 1253-1257. 
Gasparovic, M.L., Gee, G.V., and Atwood, W.J. (2006). JC virus minor capsid proteins VP2 
and VP3 are essential for virus propagation. J Virol 80, 10858-10861. 
Gee, G.V., Manley, K., and Atwood, W.J. (2003). Derivation of a JC virus-resistant human glial 
cell line: implications for the identification of host cell factors that determine viral tropism. 
Virology 314, 101-109. 
Geiger, R., Andritschke, D., Friebe, S., Herzog, F., Luisoni, S., Heger, T., and Helenius, A. 
(2011). BAP31 and BiP are essential for dislocation of SV40 from the endoplasmic reticulum to 
the cytosol. Nat Cell Biol 13, 1305-1314. 
Giannetti, A.M. (2011). From Experimental Design to Validated Hits: A Comprehensive Walk-
through of Fragment Lead Identification Using Surface Plasmon Resonance. Fragment-Based 
Drug Design: Tools, Practical Approaches, and Examples 493, 169-218. 
Gilbert, J., and Benjamin, T. (2004). Uptake pathway of polyomavirus via ganglioside GD1a. J 
Virol 78, 12259-12267. 
Gilbert, J., Ou, W., Silver, J., and Benjamin, T. (2006). Downregulation of protein disulfide 
isomerase inhibits infection by the mouse polyomavirus. J Virol 80, 10868-10870. 
Gilbert, J.M., and Benjamin, T.L. (2000). Early steps of polyomavirus entry into cells. J Virol 74, 
8582-8588. 
Gillock, E.T., Rottinghaus, S., Chang, D., Cai, X., Smiley, S.A., An, K., and Consigli, R.A. 
(1997). Polyomavirus major capsid protein VP1 is capable of packaging cellular DNA when 
expressed in the baculovirus system. J Virol 71, 2857-2865. 
Giorda, K.M., Raghava, S., Zhang, M.W., and Hebert, D.N. (2013). The viroporin activity of the 
minor structural proteins VP2 and VP3 is required for SV40 propagation. Journal of Biological 
Chemistry 288, 2510-2520. 
Goodwin, E.C., Atwood, W.J., and DiMaio, D. (2009). High-throughput cell-based screen for 
chemicals that inhibit infection by simian virus 40 and human polyomaviruses. J Virol 83, 5630-
5639. 
Goodwin, E.C., Lipovsky, A., Inoue, T., et al. (2011). BiP and multiple DNAJ molecular 
chaperones in the endoplasmic reticulum are required for efficient Simian Virus 40 infection. 
MBio 2, e00101-00111. 
Gorelik, L., Reid, C., Testa, M., et al. (2011). Progressive multifocal leukoencephalopathy 
(PML) development is associated with mutations in JC virus capsid protein VP1 that change its 
receptor specificity. Journal of Infectious Diseases 204, 103-114. 
Gray, F., Bazille, C., Adle-Biassette, H., Mikol, J., Moulignier, A., and Scaravilli, F. (2005). 
Central nervous system immune reconstitution disease in acquired immunodeficiency 
syndrome patients receiving highly active antiretroviral treatment. J Neurovirol 11 Suppl 3, 16-
22. 
References 
 
 80 
Griffith, J.D. (1975). Chromatin structure: deduced from a minichromosome. Science 187, 
1202-1203. 
Gross, L. (1953). Neck tumors, or leukemia, developing in adult C3H mice following 
inoculation, in early infancy, with filtered (Berkefeld N), or centrifugated (144,000 X g), Ak-
leukemic extracts. Cancer 6, 948-958. 
Hajduk, P.J., Galloway, W.R., and Spring, D.R. (2011). Drug discovery: A question of library 
design. Nature 470, 42-43. 
Hamza, I.A., Jurzik, L., Stang, A., Sure, K., Uberla, K., and Wilhelm, M. (2009). Detection of 
human viruses in rivers of a densly-populated area in Germany using a virus adsorption elution 
method optimized for PCR analyses. Water Research 43, 2657-2668. 
Han, L., Kitova, E.N., Tan, M., Jiang, X., Pluvinage, B., Boraston, A.B., and Klassen, J.S. 
(2015). Affinities of human histo-blood group antigens for norovirus capsid protein complexes. 
Glycobiology 25, 170-180. 
Hayer, A., Stoeber, M., Ritz, D., Engel, S., Meyer, H.H., and Helenius, A. (2010). Caveolin-1 is 
ubiquitinated and targeted to intralumenal vesicles in endolysosomes for degradation. Journal 
of Cell Biology 191, 615-629. 
Henrich, T.J., and Kuritzkes, D.R. (2013). HIV-1 entry inhibitors: recent development and 
clinical use. Curr Opin Virol 3, 51-57. 
Hidari, K.I., Shimada, S., Suzuki, Y., and Suzuki, T. (2007). Binding kinetics of influenza 
viruses to sialic acid-containing carbohydrates. Glycoconj J 24, 583-590. 
Ho, J., Jedrych, J.J., Feng, H., et al. (2014). Human Polyomavirus 7-associated pruritic rash 
and viremia in transplant recipients. J Infect Dis. 
Holthofer, H., Reivinen, J., and Miettinen, A. (1994). Nephron segment and cell-type specific 
expression of gangliosides in the developing and adult kidney. Kidney Int 45, 123-130. 
Hoque, K.M., Azim, M.F., Mia, M.R., Kayesh, R., Ali, M.H., Islam, M.J., Shakil, S.K., and 
Shuvra, T.M. (2012). Design of potential siRNA molecules for T antigen gene silencing of 
Merkel Cell Polyomavirus. Bioinformation 8, 924-930. 
Houben, R., Shuda, M., Weinkam, R., Schrama, D., Feng, H., Chang, Y., Moore, P.S., and 
Becker, J.C. (2010). Merkel Cell polyomavirus-infected Merkel Cell carcinoma cells require 
expression of viral T antigens. J Virol 84, 7064-7072. 
Hu, L.Y., Crawford, S.E., Czako, R., Cortes-Penfield, N.W., Smith, D.F., Le Pendu, J., Estes, 
M.K., and Prasad, B.V.V. (2012). Cell attachment protein VP8*of a human rotavirus specifically 
interacts with A-type histo-blood group antigen. Nature 485, 256-U147. 
Hughes, M.P., Hardee, M.E., Cornelius, L.A., Hutchins, L.F., Becker, J.C., and Gao, L. (2014). 
Merkel Cell carcinoma: epidemiology, target, and therapy. Curr Dermatol Rep 3, 46-53. 
Imamura, T., Okamoto, M., Nakakita, S., et al. (2014). Antigenic and receptor binding 
properties of enterovirus 68. J Virol 88, 2374-2384. 
Irie, A., Koyama, S., Kozutsumi, Y., Kawasaki, T., and Suzuki, A. (1998). The molecular basis 
for the absence of N-glycolylneuraminic acid in humans. J Biol Chem 273, 15866-15871. 
Ishizu, K.I., Watanabe, H., Han, S.I., Kanesashi, S.N., Hoque, M., Yajima, H., Kataoka, K., and 
Handa, H. (2001). Roles of disulfide linkage and calcium ion-mediated interactions in assembly 
References 
 
 81 
and disassembly of virus-like particles composed of Simian Virus 40 VP1 capsid protein. J 
Virol 75, 61-72. 
Ishov, A.M., and Maul, G.G. (1996). The periphery of nuclear domain 10 (ND10) as site of 
DNA virus deposition. Journal of Cell Biology 134, 815-826. 
Ison, M.G. (2011). Antivirals and resistance: influenza virus. Curr Opin Virol 1, 563-573. 
Jao, C.C., Weidman, M.K., Perez, A.R., and Gharakhanian, E. (1999). Cys9, Cys104 and 
Cys207 of simian virus 40 VP1 are essential for inter-pentamer disulfide-linkage and 
stabilization in cell-free lysates. J Gen Virol 80 ( Pt 9), 2481-2489. 
Jay, G., Nomura, S., Anderson, C.W., and Khoury, G. (1981). Identification of the SV40 
agnogene product: a DNA binding protein. Nature 291, 346-349. 
Jensen, P.N., and Major, E.O. (2001). A classification scheme for human polyomavirus JCV 
variants based on the nucleotide sequence of the noncoding regulatory region. J Neurovirol 7, 
280-287. 
Jerabek-Willemsen, M., Wienken, C.J., Braun, D., Baaske, P., and Duhr, S. (2011). Molecular 
interaction studies using microscale thermophoresis. Assay and Drug Development 
Technologies 9, 342-353. 
Jiang, Z.G., Cohen, J., Marshall, L.J., and Major, E.O. (2010). Hexadecyloxypropyl-cidofovir 
(CMX001) suppresses JC virus replication in human fetal brain SVG cell cultures. Antimicrob 
Agents Chemother 54, 4723-4732. 
Jobling, M.G., Yang, Z., Kam, W.R., Lencer, W.I., and Holmes, R.K. (2012). A single native 
ganglioside GM1-binding site is sufficient for cholera toxin to bind to cells and complete the 
intoxication pathway. MBio 3. 
Johne, R., Buck, C.B., Allander, T., Atwood, W.J., Garcea, R.L., Imperiale, M.J., Major, E.O., 
Ramqvist, T., and Norkin, L.C. (2011). Taxonomical developments in the family 
Polyomaviridae. Archives of Virology 156, 1627-1634. 
Jordan, J.B., Poppe, L., Xia, X.Y., Cheng, A.C., Sun, Y., Michelsen, K., Eastwood, H., Schnier, 
P.D., Nixey, T., and Zhong, W.G. (2012). Fragment based drug discovery: practical 
implementation based on F-19 NMR spectroscopy. J Med Chem 55, 678-687. 
Kabsch, W. (2010). Xds. Acta Crystallogr D Biol Crystallogr 66, 125-132. 
Kassem, A., Schopflin, A., Diaz, C., Weyers, W., Stickeler, E., Werner, M., and Zur Hausen, A. 
(2008). Frequent detection of Merkel Cell polyomavirus in human Merkel Cell carcinomas and 
identification of a unique deletion in the VP1 gene. Cancer Res 68, 5009-5013. 
Kawamoto, E., Nakahashi, S., Okamoto, T., Imai, H., and Shimaoka, M. (2012). Anti-integrin 
therapy for multiple sclerosis. Autoimmune Dis 2012, 357101. 
Kawano, M., Inoue, T., Tsukamoto, H., et al. (2006). The VP2/VP3 minor capsid protein of 
Aimian Virus 40 promotes the in vitro assembly of the major capsid protein VP1 into particles. 
Journal of Biological Chemistry 281, 10164-10173. 
Kawano, M.A., Xing, L., Tsukamoto, H., Inoue, T., Handa, H., and Cheng, R.H. (2009). 
Calcium bridge triggers capsid disassembly in the cell entry process of Simian Virus 40. J Biol 
Chem 284, 34703-34712. 
References 
 
 82 
Kazem, S., van der Meijden, E., and Feltkamp, M.C. (2013). The trichodysplasia spinulosa-
associated polyomavirus: virological background and clinical implications. Apmis 121, 770-782. 
Kazem, S., van der Meijden, E., Kooijman, S., et al. (2012). Trichodysplasia spinulosa is 
characterized by active polyomavirus infection. Journal of Clinical Virology 53, 225-230. 
Kazem, S., van der Meijden, E., Wang, R.C., Rosenberg, A.S., Pope, E., Benoit, T., Fleckman, 
P., and Feltkamp, M.C. (2014). Polyomavirus-associated trichodysplasia spinulosa involves 
hyperproliferation, pRB phosphorylation and upregulation of p16 and p21. PLoS One 9, 
e108947. 
Kean, J.M., Rao, S., Wang, M., and Garcea, R.L. (2009). Seroepidemiology of human 
polyomaviruses. PLoS Pathog 5, e1000363. 
Khan, Z.M., Liu, Y., Neu, U., Gilbert, M., Ehlers, B., Feizi, T., and Stehle, T. (2014). 
Crystallographic and glycan microarray analysis of Human Polyomavirus 9 VP1 identifies N-
glycolyl neuraminic acid as a receptor candidate. J Virol 88, 6100-6111. 
Knowles, W.A., Pipkin, P., Andrews, N., Vyse, A., Minor, P., Brown, D.W., and Miller, E. 
(2003). Population-based study of antibody to the human polyomaviruses BKV and JCV and 
the simian polyomavirus SV40. J Med Virol 71, 115-123. 
Komagome, R., Sawa, H., Suzuki, T., Suzuki, Y., Tanaka, S., Atwood, W.J., and Nagashima, 
K. (2002). Oligosaccharides as receptors for JC virus. J Virol 76, 12992-13000. 
Konopka-Anstadt, J.L., Mainou, B.A., Sutherland, D.M., Sekine, Y., Strittmatter, S.M., and 
Dermody, T.S. (2014). The Nogo receptor NgR1 mediates infection by mammalian reovirus. 
Cell Host Microbe 15, 681-691. 
Koralnik, I.J., Wuthrich, C., Dang, X., Rottnek, M., Gurtman, A., Simpson, D., and Morgello, S. 
(2005). JC virus granule cell neuronopathy: A novel clinical syndrome distinct from progressive 
multifocal leukoencephalopathy. Annals of Neurology 57, 576-580. 
Korup, S., Rietscher, J., Calvignac-Spencer, S., Trusch, F., Hofmann, J., Moens, U., Sauer, I., 
Voigt, S., Schmuck, R., and Ehlers, B. (2013). Identification of a novel human polyomavirus in 
organs of the gastrointestinal tract. PLoS One 8, e58021. 
Kosukegawa, A., Arisaka, F., Takayama, M., Yajima, H., Kaidow, A., and Handa, H. (1996). 
Purification and characterization of virus-like particles and pentamers produced by the 
expression of SV40 capsid proteins in insect cells. Biochimica Et Biophysica Acta-General 
Subjects 1290, 37-45. 
Krauzewicz, N., Streuli, C.H., Stuart-Smith, N., Jones, M.D., Wallace, S., and Griffin, B.E. 
(1990). Myristylated polyomavirus VP2: role in the life cycle of the virus. J Virol 64, 4414-4420. 
Krissinel, E., and Henrick, K. (2004). Secondary-structure matching (SSM), a new tool for fast 
protein structure alignment in three dimensions. Acta Crystallogr D Biol Crystallogr 60, 2256-
2268. 
Krissinel, E., and Henrick, K. (2007). Inference of macromolecular assemblies from crystalline 
state. J Mol Biol 372, 774-797. 
Lane, D.P., and Crawford, L.V. (1979). T-antigen is bound to a host protein in SV40-
transformed cells. Nature 278, 261-263. 
References 
 
 83 
Laude, H.C., Jonchere, B., Maubec, E., et al. (2010). Distinct Merkel Cell polyomavirus 
molecular features in tumour and non tumour specimens from patients with Merkel Cell 
carcinoma. PLoS Pathog 6, e1001076. 
Lee, S., Paulson, K.G., Murchison, E.P., Afanasiev, O.K., Alkan, C., Leonard, J.H., Byrd, D.R., 
Hannon, G.J., and Nghiem, P. (2011). Identification and validation of a novel mature microRNA 
encoded by the Merkel Cell polyomavirus in human Merkel Cell carcinomas. J Clin Virol 52, 
272-275. 
Li, J.J., and Kelly, T.J. (1984). Simian Virus 40 DNA replication in vitro. Proc Natl Acad Sci U S 
A 81, 6973-6977. 
Li, P.P., Nakanishi, A., Shum, D., Sun, P.C.K., Salazar, A.M., Fernandez, C.F., Chan, S.W., 
and Kasamatsu, H. (2001). Simian Virus 40 VP1 DNA-binding domain is functionally separable 
from the overlapping nuclear localization signal and is required for effective virion formation 
and full viability. J Virol 75, 7321-7329. 
Liddington, R.C., Yan, Y., Moulai, J., Sahli, R., Benjamin, T.L., and Harrison, S.C. (1991). 
Structure of Simian Virus 40 at 3.8-A resolution. Nature 354, 278-284. 
Lilley, B.N., Gilbert, J.M., Ploegh, H.L., and Benjamin, T.L. (2006). Murine polyomavirus 
requires the endoplasmic reticulum protein Derlin-2 to initiate infection. J Virol 80, 8739-8744. 
Lim, E.S., Reyes, A., Antonio, M., et al. (2013). Discovery of STL polyomavirus, a 
polyomavirus of ancestral recombinant origin that encodes a unique T antigen by alternative 
splicing. Virology 436, 295-303. 
Lingwood, D., and Simons, K. (2010). Lipid rafts as a membrane-organizing principle. Science 
327, 46-50. 
Linzer, D.I., and Levine, A.J. (1979). Characterization of a 54K dalton cellular SV40 tumor 
antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell 17, 
43-52. 
Lipinski, C.A., Lombardo, F., Dominy, B.W., and Feeney, P.J. (2001). Experimental and 
computational approaches to estimate solubility and permeability in drug discovery and 
development settings. Adv Drug Deliv Rev 46, 3-26. 
London, W.T., Houff, S.A., Madden, D.L., et al. (1978). Brain tumors in owl monkeys 
inoculated with a human polyomavirus (JC virus). Science 201, 1246-1249. 
Lopez, P.H.H., and Schnaar, R.L. (2009). Gangliosides in cell recognition and membrane 
protein regulation. Current Opinion in Structural Biology 19, 549-557. 
Lou, Z., Sun, Y., and Rao, Z. (2014). Current progress in antiviral strategies. Trends 
Pharmacol Sci 35, 86-102. 
Low, J.A., Magnuson, B., Tsai, B., and Imperiale, M.J. (2006). Identification of gangliosides 
GD1b and GT1b as receptors for BK virus. J Virol 80, 1361-1366. 
Maginnis, M.S., Haley, S.A., Gee, G.V., and Atwood, W.J. (2010). Role of N-linked 
glycosylation of the 5-HT2A receptor in JC virus infection. J Virol 84, 9677-9684. 
Magnuson, B., Rainey, E.K., Benjamin, T., Baryshev, M., Mkrtchian, S., and Tsai, B. (2005). 
ERp29 triggers a conformational change in polyomavirus to stimulate membrane binding. Mol 
Cell 20, 289-300. 
References 
 
 84 
Major, E.O. (2010). Progressive multifocal leukoencephalopathy in patients on 
immunomodulatory therapies. Annu Rev Med 61, 35-47. 
Major, E.O., Miller, A.E., Mourrain, P., Traub, R.G., de Widt, E., and Sever, J. (1985). 
Establishment of a line of human fetal glial cells that supports JC virus multiplication. Proc Natl 
Acad Sci U S A 82, 1257-1261. 
Mancuso, C.E., Gabay, M.P., Steinke, L.M., and Vanosdol, S.J. (2010). Peramivir: an 
intravenous neuraminidase inhibitor for the treatment of 2009 H1N1 influenza. Ann 
Pharmacother 44, 1240-1249. 
Mannhold, R., Poda, G.I., Ostermann, C., and Tetko, I.V. (2009). Calculation of molecular 
lipophilicity: State-of-the-art and comparison of log P methods on more than 96,000 
compounds. J Pharm Sci 98, 861-893. 
Martin, J.D., King, D.M., Slauch, J.M., and Frisque, R.J. (1985). Differences in regulatory 
sequences of naturally occurring JC virus variants. J Virol 53, 306-311. 
Matthews, M.R., Wang, R.C., Reddick, R.L., Saldivar, V.A., and Browning, J.C. (2011). Viral-
associated trichodysplasia spinulosa: a case with electron microscopic and molecular 
detection of the trichodysplasia spinulosa-associated human polyomavirus. J Cutan Pathol 38, 
420-431. 
Mayer, M., and Meyer, B. (1999). Characterization of ligand binding by saturation transfer 
difference NMR spectroscopy. Angewandte Chemie-International Edition 38, 1784-1788. 
McCoy, A.J., Grosse-Kunstleve, R.W., Adams, P.D., Winn, M.D., Storoni, L.C., and Read, R.J. 
(2007). Phaser crystallographic software. Journal of Applied Crystallography 40, 658-674. 
McQuaig, S.M., Scott, T.M., Lukasik, J.O., Paul, J.H., and Harwood, V.J. (2009). Quantification 
of human polyomaviruses JC Virus and BK Virus by TaqMan quantitative PCR and 
comparison to other water quality indicators in water and fecal samples. Appl Environ Microbiol 
75, 3379-3388. 
Mishra, N., Pereira, M., Rhodes, R.H., An, P., Pipas, J.M., Jain, K., Kapoor, A., Briese, T., 
Faust, P.L., and Lipkin, W.I. (2014). Identification of a novel polyomavirus in a pancreatic 
transplant recipient with retinal blindness and vasculitic myopathy. J Infect Dis. 
Moens, U., Van Ghelue, M., and Ehlers, B. (2014). Are human polyomaviruses co-factors for 
cancers induced by other oncoviruses? Reviews in Medical Virology 24, 343-360. 
Monaco, M.C., Atwood, W.J., Gravell, M., Tornatore, C.S., and Major, E.O. (1996). JC virus 
infection of hematopoietic progenitor cells, primary B lymphocytes, and tonsillar stromal cells: 
implications for viral latency. J Virol 70, 7004-7012. 
Monaco, M.C., Jensen, P.N., Hou, J., Durham, L.C., and Major, E.O. (1998). Detection of JC 
virus DNA in human tonsil tissue: evidence for site of initial viral infection. J Virol 72, 9918-
9923. 
Moreland, R.B., Montross, L., and Garcea, R.L. (1991). Characterization of the DNA-binding 
properties of the polyomavirus capsid protein VP1. J Virol 65, 1168-1176. 
Muller, B., and Krausslich, H.G. (2009). Antiviral strategies. Handb Exp Pharmacol, 1-24. 
Murray, C.W., Callaghan, O., Chessari, G., Cleasby, A., Congreve, M., Frederickson, M., 
Hartshorn, M.J., McMenamin, R., Patel, S., and Wallis, N. (2007). Application of fragment 
screening by X-ray crystallography to beta-secretase. J Med Chem 50, 1116-1123. 
References 
 
 85 
Murray, C.W., Verdonk, M.L., and Rees, D.C. (2012). Experiences in fragment-based drug 
discovery. Trends Pharmacol Sci 33, 224-232. 
Murshudov, G.N., Vagin, A.A., and Dodson, E.J. (1997). Refinement of macromolecular 
structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr 53, 240-255. 
Nakanishi, A., Li, P.P., Qu, Q., Jafri, Q.H., and Kasamatsu, H. (2007). Molecular dissection of 
nuclear entry-competent SV40 during infection. Virus Res 124, 226-230. 
Nakanishi, A., Nakamura, A., Liddington, R., and Kasamatsu, H. (2006). Identification of amino 
acid residues within Simian Virus 40 capsid proteins VP1, VP2, and VP3 that are required for 
their interaction and for viral infection. J Virol 80, 8891-8898. 
Nakanishi, A., Shum, D., Morioka, H., Otsuka, E., and Kasamatsu, H. (2002). Interaction of the 
VP3 nuclear localization signal with the importin alpha-2/beta heterodimer directs nuclear entry 
of infecting Simian Virus 40. J Virol 76, 9368-9377. 
Nelson, C.D., Carney, D.W., Derdowski, A., Lipovsky, A., Gee, G.V., O'Hara, B., Williard, P., 
DiMaio, D., Sello, J.K., and Atwood, W.J. (2013). A retrograde trafficking inhibitor of ricin and 
Shiga-like toxins inhibits infection of cells by human and monkey polyomaviruses. MBio 4, 
e00729-00713. 
Nelson, C.D., Ströh, L.J., Gee, G.V., O'Hara, B.A., Stehle, T., and Atwood, W.J. (2015). 
Modulation of a pore in the capsid of JC polyomavirus reduces infectivity and prevents 
exposure of the minor capsid proteins. J Virol. 
Nelson, C.D.S., Derdowski, A., Maginnis, M.S., O'Hara, B.A., and Atwood, W.J. (2012). The 
VP1 subunit of JC polyomavirus recapitulates early events in viral trafficking and is a novel tool 
to study polyomavirus entry. Virology 428, 30-40. 
Neu, U., Allen, S.A., Blaum, B.S., et al. (2013a). A structure-guided mutation in the major 
capsid protein retargets BK polyomavirus. PLoS Pathog 9, e1003688. 
Neu, U., Hengel, H., Blaum, B.r.S., et al. (2012). Structures of Merkel Cell polyomavirus VP1 
complexes define a sialic acid binding site required for infection. PLoS Pathog 8, e1002738. 
Neu, U., Khan, Z.M., Schuch, B., Palma, A.S., Liu, Y., Pawlita, M., Feizi, T., and Stehle, T. 
(2013b). Structures of B-lymphotropic polyomavirus VP1 in complex with oligosaccharide 
ligands. PLoS Pathog 9, e1003714. 
Neu, U., Maginnis, M.S., Palma, A.S., Ströh, L.J., Nelson, C.D., Feizi, T., Atwood, W.J., and 
Stehle, T. (2010). Structure-function analysis of the human JC polyomavirus establishes the 
LSTc pentasaccharide as a functional receptor motif. Cell Host Microbe 8, 309-319. 
Neu, U., Wang, J., Macejak, D., Garcea, R.L., and Stehle, T. (2011). Structures of the major 
capsid proteins of the human Karolinska Institutet and Washington University polyomaviruses. 
J Virol 85, 7384-7392. 
Neu, U., Woellner, K., Gauglitz, G., and Stehle, T. (2008). Structural basis of GM1 ganglioside 
recognition by simian virus 40. Proc Natl Acad Sci U S A 105, 5219-5224. 
Nicol, J.T., Leblond, V., Arnold, F., Guerra, G., Mazzoni, E., Tognon, M., Coursaget, P., and 
Touze, A. (2014). Seroprevalence of human Malawi polyomavirus. J Clin Microbiol 52, 321-
323. 
Nicol, J.T., Robinot, R., Carpentier, A., Carandina, G., Mazzoni, E., Tognon, M., Touze, A., and 
Coursaget, P. (2013). Age-specific seroprevalences of Merkel Cell polyomavirus, Human 
References 
 
 86 
Polyomaviruses 6, 7, and 9, and Trichodysplasia Spinulosa-associated polyomavirus. Clin 
Vaccine Immunol 20, 363-368. 
Nicol, J.T., Touze, A., Robinot, R., Arnold, F., Mazzoni, E., Tognon, M., and Coursaget, P. 
(2012). Seroprevalence and cross-reactivity of human polyomavirus 9. Emerg Infect Dis 18, 
1329-1332. 
Nilsson, E.C., Storm, R.J., Bauer, J., et al. (2011). The GD1a glycan is a cellular receptor for 
adenoviruses causing epidemic keratoconjunctivitis. Nature Medicine 17, 105-U279. 
Nilsson, O., and Svennerholm, L. (1982). Characterization and quantitative-determination of 
gangliosides and neutral glycosphingolipids in human-liver. Journal of Lipid Research 23, 327-
334. 
O'Donnell, C.D., Kovacs, M., Akhtar, J., Valyi-Nagy, T., and Shukla, D. (2010). Expanding the 
role of 3-O sulfated heparan sulfate in herpes simplex virus type-1 entry. Virology 397, 389-
398. 
O'Hara, B.A., Rupasinghe, C., Yatawara, A., Gaidos, G., Mierke, D.F., and Atwood, W.J. 
(2014). Gallic acid-based small-molecule inhibitors of JC and BK polyomaviral infection. Virus 
Res 189, 280-285. 
Ohsumi, S., Motoi, M., and Ogawa, K. (1986). Induction of undifferentiated tumors by JC virus 
in the cerebrum of rats. Acta Pathol Jpn 36, 815-825. 
Okada, Y., Sawa, H., Endo, S., Orba, Y., Umemura, T., Nishihara, H., Stan, A.C., Tanaka, S., 
Takahashi, H., and Nagashima, K. (2002). Expression of JC virus agnoprotein in progressive 
multifocal leukoencephalopathy brain. Acta Neuropathol 104, 130-136. 
Okomo-Adhiambo, M., Fry, A.M., Su, S., et al. (2015). Oseltamivir-resistant influenza 
A(H1N1)pdm09 viruses, United States, 2013-14. Emerg Infect Dis 21, 136-141. 
Oppenheim, A., Sandalon, Z., Peleg, A., Shaul, O., Nicolis, S., and Ottolenghi, S. (1992). A 
cis-acting DNA signal for encapsidation of Simian Virus 40. J Virol 66, 5320-5328. 
Osswald, S.S., Kulick, K.B., Tomaszewski, M.M., and Sperling, L.C. (2007). Viral-associated 
trichodysplasia in a patient with lymphoma: a case report and review. J Cutan Pathol 34, 721-
725. 
Padgett, B.L., Walker, D.L., ZuRhein, G.M., Eckroade, R.J., and Dessel, B.H. (1971). 
Cultivation of papova-like virus from human brain with progressive multifocal 
leucoencephalopathy. Lancet 1, 1257-1260. 
Padler-Karavani, V., Yu, H., Cao, H., Chokhawala, H., Karp, F., Varki, N., Chen, X., and Varki, 
A. (2008). Diversity in specificity, abundance, and composition of anti-Neu5Gc antibodies in 
normal humans: potential implications for disease. Glycobiology 18, 818-830. 
Painter, J., and Merritt, E.A. (2006). Optimal description of a protein structure in terms of 
multiple groups undergoing TLS motion. Acta Crystallogr D Biol Crystallogr 62, 439-450. 
Palma, A.S., Feizi, T., Childs, R.A., Chai, W., and Liu, Y. (2014). The neoglycolipid (NGL)-
based oligosaccharide microarray system poised to decipher the meta-glycome. Curr Opin 
Chem Biol 18, 87-94. 
Parton, R.G., and del Pozo, M.A. (2013). Caveolae as plasma membrane sensors, protectors 
and organizers. Nat Rev Mol Cell Biol 14, 98-112. 
References 
 
 87 
Pelkmans, L., Kartenbeck, J., and Helenius, A. (2001). Caveolar endocytosis of Simian Virus 
40 reveals a new two-step vesicular-transport pathway to the ER. Nat Cell Biol 3, 473-483. 
Peretti, A., FitzGerald, P.C., Bliskovsky, V., Pastrana, D.V., and Buck, C.B. (2015). Genome 
sequence of a fish-associated polyomavirus, Black Sea Bass (Centropristis striata) 
Polyomavirus 1. Genome Announc 3. 
Pho, M.T., Ashok, A., and Atwood, W.J. (2000). JC virus enters human glial cells by clathrin-
dependent receptor-mediated endocytosis. J Virol 74, 2288-2292. 
Pietropaolo, V., Videtta, M., Fioriti, D., Mischitelli, M., Arancio, A., Orsi, N., and Degener, A.M. 
(2003). Rearrangement patterns of JC virus noncoding control region from different biological 
samples. J Neurovirol 9, 603-611. 
Prokazova, N.V., Samovilova, N.N., Gracheva, E.V., and Golovanova, N.K. (2009). 
Ganglioside GM3 and its biological functions. Biochemistry (Mosc) 74, 235-249. 
Qian, M., Cai, D., Verhey, K.J., and Tsai, B. (2009). A lipid receptor sorts polyomavirus from 
the endolysosome to the endoplasmic reticulum to cause infection. PLoS Pathog 5, e1000465. 
Qian, M., and Tsai, B. (2010). Lipids and proteins act in opposing manners to regulate 
polyomavirus infection. J Virol 84, 9840-9852. 
Qu, Q.M., Sawa, H., Suzuki, T., Semba, S., Henmi, C., Okada, Y., Tsuda, M., Tanaka, S., 
Atwood, W.J., and Nagashima, K. (2004). Nuclear entry mechanism of the human 
polyomavirus JC virus-like particle - Role of importins and the nuclear pore complex. Journal of 
Biological Chemistry 279, 27735-27742. 
Querbes, W., Benmerah, A., Tosoni, D., Di Fiore, P.P., and Atwood, W.J. (2004). A JC virus-
induced signal is required for infection of glial cells by a clathrin- and eps15-dependent 
pathway. J Virol 78, 250-256. 
Querbes, W., O'Hara, B.A., Williams, G., and Atwood, W.J. (2006). Invasion of host cells by JC 
virus identifies a novel role for caveolae in endosomal sorting of noncaveolar ligands. J Virol 
80, 9402-9413. 
Rademacher, C., Guiard, J., Kitov, P.I., Fiege, B., Dalton, K.P., Parra, F., Bundle, D.R., and 
Peters, T. (2011). Targeting norovirus infection-multivalent entry inhibitor design based on 
NMR experiments. Chemistry 17, 7442-7453. 
Radhakrishnan, S., Otte, J., Enam, S., Del Valle, L., Khalili, K., and Gordon, J. (2003). JC 
virus-induced changes in cellular gene expression in primary human astrocytes. J Virol 77, 
10638-10644. 
Raghava, S., Giorda, K.M., Romano, F.B., Heuck, A.P., and Hebert, D.N. (2011). The SV40 
late protein VP4 is a viroporin that forms pores to disrupt membranes for viral release. PLoS 
Pathog 7. 
Raghava, S., Giorda, K.M., Romano, F.B., Heuck, A.P., and Hebert, D.N. (2013). SV40 late 
protein VP4 forms toroidal pores to disrupt membranes for viral release. Biochemistry 52, 
3939-3948. 
Randhawa, P., Zeng, G., Bueno, M., et al. (2014). Inhibition of large T antigen ATPase activity 
as a potential strategy to develop anti-polyomavirus JC drugs. Antiviral Res 112, 113-119. 
Reid, C.E., Li, H., Sur, G., et al. (2011). Sequencing and analysis of JC virus DNA from 
natalizumab-treated PML patients. J Infect Dis 204, 237-244. 
References 
 
 88 
Reiss, K., Stencel, J.E., Liu, Y., Blaum, B.S., Reiter, D.M., Feizi, T., Dermody, T.S., and 
Stehle, T. (2012). The GM2 glycan serves as a functional coreceptor for serotype 1 reovirus. 
PLoS Pathog 8, e1003078. 
Rennspiess, D., Pujari, S., Keijzers, M., et al. (2015). Detection of human polyomavirus 7 in 
human thymic epithelial tumors. J Thorac Oncol 10, 360-366. 
Riley, M.I., Yoo, W., Mda, N.Y., and Folk, W.R. (1997). Tiny T antigen: an autonomous 
polyomavirus T antigen amino-terminal domain. J Virol 71, 6068-6074. 
Rinaldo, C.H., Gosert, R., Bernhoff, E., Finstad, S., and Hirsch, H.H. (2010). 1-O-
hexadecyloxypropyl cidofovir (CMX001) effectively inhibits polyomavirus BK replication in 
primary human renal tubular epithelial cells. Antimicrob Agents Chemother 54, 4714-4722. 
Rinaldo, C.H., and Hirsch, H.H. (2013). The human polyomaviruses: from orphans and 
mutants to patchwork family. Apmis 121, 681-684. 
Rinaldo, C.H., Traavik, T., and Hey, A. (1998). The agnogene of the human polyomavirus BK 
is expressed. J Virol 72, 6233-6236. 
Rinaldo, C.H., Tylden, G.D., and Sharma, B.N. (2013). The human polyomavirus BK (BKPyV): 
virological background and clinical implications. Apmis 121, 728-745. 
Rishton, G.M. (2003). Nonleadlikeness and leadlikeness in biochemical screening. Drug 
Discov Today 8, 86-96. 
Sadeghi, M., Aaltonen, L.M., Hedman, L., Chen, T., Soderlund-Venermo, M., and Hedman, K. 
(2014). Detection of TS polyomavirus DNA in tonsillar tissues of children and adults: Evidence 
for site of viral latency. J Clin Virol 59, 55-58. 
Sahli, R., Freund, R., Dubensky, T., Garcea, R., Bronson, R., and Benjamin, T. (1993). Defect 
in entry and altered pathogenicity of a polyoma virus mutant blocked in VP2 myristylation. 
Virology 192, 142-153. 
Salunke, D.M., Caspar, D.L., and Garcea, R.L. (1986). Self-assembly of purified polyomavirus 
capsid protein VP1. Cell 46, 895-904. 
Samraj, A.N., Laubli, H., Varki, N., and Varki, A. (2014). Involvement of a non-human sialic 
acid in human cancer. Front Oncol 4, 33. 
Saribas, A.S., White, M.K., and Safak, M. (2012). JC virus agnoprotein enhances large T 
antigen binding to the origin of viral DNA replication: evidence for its involvement in viral DNA 
replication. Virology 433, 12-26. 
Sariyer, I.K., Saribas, A.S., White, M.K., and Safak, M. (2011). Infection by agnoprotein-
negative mutants of polyomavirus JC and SV40 results in the release of virions that are mostly 
deficient in DNA content. Virology Journal 8. 
Sastre-Garau, X., Peter, M., Avril, M.F., et al. (2009). Merkel Cell carcinoma of the skin: 
pathological and molecular evidence for a causative role of MCV in oncogenesis. J Pathol 218, 
48-56. 
Sato, C., and Kitajima, K. (2013). Disialic, oligosialic and polysialic acids: distribution, functions 
and related disease. J Biochem 154, 115-136. 
Sauvage, V., Foulongne, V., Cheval, J., et al. (2011). Human polyomavirus related to African 
green monkey lymphotropic polyomavirus. Emerg Infect Dis 17, 1364-1370. 
References 
 
 89 
Schelhaas, M., Malmstrom, J., Pelkmans, L., Haugstetter, J., Ellgaard, L., Grunewald, K., and 
Helenius, A. (2007). Simian Virus 40 depends on ER protein folding and quality control factors 
for entry into host cells. Cell 131, 516-529. 
Schippling, S., Kempf, C., Buchele, F., et al. (2013). JC virus granule cell neuronopathy and 
GCN-IRIS under natalizumab treatment. Annals of Neurology 74, 622-626. 
Schnaar, R.L., Suzuki, A., and Stanley, P. (2009). Glycosphingolipids. In Essentials of 
Glycobiology, A. Varki, R.D. Cummings, J.D. Esko, H.H. Freeze, P. Stanley, C.R. Bertozzi, et 
al., eds. (Cold Spring Harbor (NY)). 
Schowalter, R.M., and Buck, C.B. (2013). The Merkel Cell polyomavirus minor capsid protein. 
PLoS Pathog 9, e1003558. 
Schowalter, R.M., Pastrana, D.V., and Buck, C.B. (2011). Glycosaminoglycans and sialylated 
glycans sequentially facilitate Merkel Cell polyomavirus infectious entry. PLoS Pathog 7, 
e1002161. 
Schowalter, R.M., Pastrana, D.V., Pumphrey, K.A., Moyer, A.L., and Buck, C.B. (2010). Merkel 
Cell polyomavirus and two previously unknown polyomaviruses are chronically shed from 
human skin. Cell Host Microbe 7, 509-515. 
Schrama, D., Buck, C.B., Houben, R., and Becker, J.C. (2012). No evidence for association of 
HPyV6 or HPyV7 with different skin cancers. J Invest Dermatol 132, 239-241. 
Schuttelkopf, A.W., and van Aalten, D.M. (2004). PRODRG: a tool for high-throughput 
crystallography of protein-ligand complexes. Acta Crystallogr D Biol Crystallogr 60, 1355-1363. 
Scola, N., Wieland, U., Silling, S., Altmeyer, P., Stucker, M., and Kreuter, A. (2012). 
Prevalence of human polyomaviruses in common and rare types of non-Merkel Cell carcinoma 
skin cancer. Br J Dermatol 167, 1315-1320. 
Scuda, N., Hofmann, J., Calvignac-Spencer, S., Ruprecht, K., Liman, P., Kuhn, J., Hengel, H., 
and Ehlers, B. (2011). A novel human polyomavirus closely related to the african green 
monkey-derived lymphotropic polyomavirus. J Virol 85, 4586-4590. 
Scuda, N., Madinda, N.F., Akoua-Koffi, C., et al. (2013). Novel polyomaviruses of nonhuman 
primates: genetic and serological predictors for the existence of multiple unknown 
polyomaviruses within the human population. PLoS Pathog 9. 
Seguin, S.P., Ireland, A.W., Gupta, T., Wright, C.M., Miyata, Y., Wipf, P., Pipas, J.M., 
Gestwicki, J.E., and Brodsky, J.L. (2012). A screen for modulators of large T antigen's ATPase 
activity uncovers novel inhibitors of Simian Virus 40 and BK virus replication. Antiviral Res 96, 
70-81. 
Seo, G.J., Fink, L.H., O'Hara, B., Atwood, W.J., and Sullivan, C.S. (2008). Evolutionarily 
conserved function of a viral microRNA. J Virol 82, 9823-9828. 
Shah, K., and Nathanson, N. (1976). Human exposure to SV40: review and comment. Am J 
Epidemiol 103, 1-12. 
Shah, K.V. (2007). SV40 and human cancer: a review of recent data. Int J Cancer 120, 215-
223. 
Shayman, J.A., and Radin, N.S. (1991). Structure and function of renal glycosphingolipids. Am 
J Physiol 260, F291-302. 
References 
 
 90 
Shen, P.S., Enderlein, D., Nelson, C.D.S., et al. (2011). The structure of avian polyomavirus 
reveals variably sized capsids, non-conserved inter-capsomere interactions, and a possible 
location of the minor capsid protein VP4. Virology 411, 142-152. 
Shishido-Hara, Y., Ichinose, S., Higuchi, K., Hara, Y., and Yasui, K. (2004). Major and minor 
capsid proteins of human polyomavirus JC cooperatively accumulate to nuclear domain 10 for 
assembly into virions. J Virol 78, 9890-9903. 
Shuda, M., Feng, H., Kwun, H.J., Rosen, S.T., Gjoerup, O., Moore, P.S., and Chang, Y. 
(2008). T antigen mutations are a human tumor-specific signature for Merkel Cell 
polyomavirus. Proc Natl Acad Sci U S A 105, 16272-16277. 
Sievers, F., Wilm, A., Dineen, D., et al. (2011). Fast, scalable generation of high-quality protein 
multiple sequence alignments using Clustal Omega. Molecular Systems Biology 7. 
Simon, K., Cameron, T., RUSHE, M., Caravella, J., and KAYNOR, G.C. (2013). JCV 
neutralizing antibodies. In WO2013142300 A3. 
Spjut, S., Qian, W., Bauer, J., Storm, R., Frangsmyr, L., Stehle, T., Arnberg, N., and Elofsson, 
M. (2011). A potent trivalent sialic acid inhibitor of adenovirus type 37 infection of human 
corneal cells. Angew Chem Int Ed Engl 50, 6519-6521. 
Stehle, T., Gamblin, S.J., Yan, Y., and Harrison, S.C. (1996). The structure of Simian Virus 40 
refined at 3.1 A resolution. Structure 4, 165-182. 
Stehle, T., and Harrison, S.C. (1996). Crystal structures of murine polyomavirus in complex 
with straight-chain and branched-chain sialyloligosaccharide receptor fragments. Structure 4, 
183-194. 
Stehle, T., and Harrison, S.C. (1997). High-resolution structure of a polyomavirus VP1-
oligosaccharide complex: implications for assembly and receptor binding. EMBO J 16, 5139-
5148. 
Stehle, T., and Khan, Z.M. (2014). Rules and exceptions: sialic acid variants and their role in 
determining viral tropism. J Virol 88, 7696-7699. 
Stehle, T., Yan, Y., Benjamin, T.L., and Harrison, S.C. (1994). Structure of murine 
polyomavirus complexed with an oligosaccharide receptor fragment. Nature 369, 160-163. 
Stein, N. (2008). CHAINSAW: a program for mutating pdb files used as templates in molecular 
replacement. Journal of Applied Crystallography 41, 641-643. 
Stergiou, L., Bauer, M., Mair, W., Bausch-Fluck, D., Drayman, N., Wollscheid, B., Oppenheim, 
A., and Pelkmans, L. (2013). Integrin-mediated signaling induced by Simian Virus 40 leads to 
transient uncoupling of cortical actin and the plasma membrane. PLoS One 8. 
Stevens, J., Blixt, O., Glaser, L., Taubenberger, J.K., Palese, P., Paulson, J.C., and Wilson, 
I.A. (2006). Glycan microarray analysis of the hemagglutinins from modern and pandemic 
influenza viruses reveals different receptor specificities. J Mol Biol 355, 1143-1155. 
Streuli, C.H., and Griffin, B.E. (1987). Myristic acid is coupled to a structural protein of polyoma 
virus and SV40. Nature 326, 619-622. 
Ströh, L.J., Maginnis, M.S., Blaum, B.S., et al. (2015). The Greater Affinity of JC Polyomavirus 
Capsid for alpha2,6-Linked Lactoseries Tetrasaccharide c than for Other Sialylated Glycans Is 
a Major Determinant of Infectivity. J Virol 89, 6364-6375. 
References 
 
 91 
Ströh, L.J., and Stehle, T. (2014). Glycan engagement by viruses: receptor switches and 
specificity. Annual Review of Virology 1, 285-306. 
Sturgill, E.R., Aoki, K., Lopez, P.H.H., et al. (2012). Biosynthesis of the major brain 
gangliosides GD1a and GT1b. Glycobiology 22, 1289-1301. 
Sullivan, C.S., Grundhoff, A.T., Tevethia, S., Pipas, J.M., and Ganem, D. (2005). SV40-
encoded microRNAs regulate viral gene expression and reduce susceptibility to cytotoxic T 
cells. Nature 435, 682-686. 
Sullivan, C.S., Sung, C.K., Pack, C.D., Grundhoff, A., Lukacher, A.E., Benjamin, T.L., and 
Ganem, D. (2009). Murine polyomavirus encodes a microRNA that cleaves early RNA 
transcripts but is not essential for experimental infection. Virology 387, 157-167. 
Suzuki, T., Orba, Y., Okada, Y., Sunden, Y., Kimura, T., Tanaka, S., Nagashima, K., Hall, 
W.W., and Sawa, H. (2010). The human polyoma JC virus agnoprotein acts as a viroporin. 
PLoS Pathog 6. 
Svennerholm, L., Bostrom, K., Fredman, P., Mansson, J.E., Rosengren, B., and Rynmark, 
B.M. (1989). Human brain gangliosides: developmental changes from early fetal stage to 
advanced age. Biochim Biophys Acta 1005, 109-117. 
Sweetser, M.T., Dawson, K.T., and Bozic, C. (2013). Manufacturer's response to case reports 
of PML. N Engl J Med 368, 1659-1661. 
Szklarczyk, O.M., Gonzalez-Segredo, N., Kukura, P., Oppenheim, A., Choquet, D., 
Sandoghdar, V., Helenius, A., Sbalzarini, I.F., and Ewers, H. (2013). Receptor concentration 
and diffusivity control multivalent binding of SV40 to membrane bilayers. PLoS Comput Biol 9, 
e1003310. 
Tan, C.S., Broge, T.A., Jr., Seung, E., Vrbanac, V., Viscidi, R., Gordon, J., Tager, A.M., and 
Koralnik, I.J. (2013). Detection of JC virus-specific immune responses in a novel humanized 
mouse model. PLoS One 8, e64313. 
Tan, C.S., and Koralnik, I.J. (2010). Progressive multifocal leukoencephalopathy and other 
disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol 9, 425-437. 
Tangvoranuntakul, P., Gagneux, P., Diaz, S., Bardor, M., Varki, N., Varki, A., and Muchmore, 
E. (2003). Human uptake and incorporation of an immunogenic nonhuman dietary sialic acid. 
Proc Natl Acad Sci U S A 100, 12045-12050. 
Taube, S., Perry, J.W., McGreevy, E., Yetming, K., Perkins, C., Henderson, K., and Wobus, 
C.E. (2012). Murine noroviruses bind glycolipid and glycoprotein attachment receptors in a 
strain-dependent manner. J Virol 86, 5584-5593. 
Tayyari, F., Marchant, D., Moraes, T.J., Duan, W.M., Mastrangelo, P., and Hegele, R.G. 
(2011). Identification of nucleolin as a cellular receptor for human respiratory syncytial virus. 
Nature Medicine 17, 1132-U1140. 
Tiefenbrunn, T., Forli, S., Happer, M., Gonzalez, A., Tsai, Y.S., Soltis, M., Elder, J.H., Olson, 
A.J., and Stout, C.D. (2014). Crystallographic Fragment-Based Drug Discovery: Use of a 
Brominated Fragment Library Targeting HIV Protease. Chemical Biology & Drug Design 83, 
141-148. 
References 
 
 92 
Tornatore, C., Berger, J.R., Houff, S.A., Curfman, B., Meyers, K., Winfield, D., and Major, E.O. 
(1992). Detection of JC virus-DNA in peripheral lymphocytes from patients with and without 
progressive multifocal leukoencephalopathy. Annals of Neurology 31, 454-462. 
Trowbridge, P.W., and Frisque, R.J. (1995). Identification of three new JC virus proteins 
generated by alternative splicing of the early viral mRNA. J Neurovirol 1, 195-206. 
Tsai, B., Gilbert, J.M., Stehle, T., Lencer, W., Benjamin, T.L., and Rapoport, T.A. (2003). 
Gangliosides are receptors for murine polyoma virus and SV40. EMBO J 22, 4346-4355. 
Unterstab, G., Gosert, R., Leuenberger, D., Lorentz, P., Rinaldo, C.H., and Hirsch, H.H. 
(2010). The polyomavirus BK agnoprotein co-localizes with lipid droplets. Virology 399, 322-
331. 
van der Meijden, E., Bialasiewicz, S., Rockett, R.J., Tozer, S.J., Sloots, T.P., and Feltkamp, 
M.C. (2013). Different serologic behavior of MCPyV, TSPyV, HPyV6, HPyV7 and HPyV9 
polyomaviruses found on the skin. PLoS One 8, e81078. 
van der Meijden, E., Janssens, R.W., Lauber, C., Bouwes Bavinck, J.N., Gorbalenya, A.E., 
and Feltkamp, M.C. (2010). Discovery of a new human polyomavirus associated with 
trichodysplasia spinulosa in an immunocompromized patient. PLoS Pathog 6, e1001024. 
van der Meijden, E., Kazem, S., Burgers, M.M., Janssens, R., Bouwes Bavinck, J.N., de 
Melker, H., and Feltkamp, M.C. (2011). Seroprevalence of trichodysplasia spinulosa-
associated polyomavirus. Emerg Infect Dis 17, 1355-1363. 
Van Loy, T., Thys, K., Ryschkewitsch, C., Lagatie, O., Monaco, M.C., Major, E.O., Tritsmans, 
L., and Stuyver, L.J. (2015). JC virus quasispecies analysis reveals a complex viral population 
underlying progressive multifocal leukoencephalopathy and supports viral dissemination via 
the hematogenous route. J Virol 89, 1340-1347. 
Varki, A. (2001). Loss of N-glycolylneuraminic acid in humans: Mechanisms, consequences, 
and implications for hominid evolution. Am J Phys Anthropol Suppl 33, 54-69. 
Varki, A. (2007). Glycan-based interactions involving vertebrate sialic-acid-recognizing 
proteins. Nature 446, 1023-1029. 
Varki, A., and Schauer, R. (2009). Sialic acids. In Essentials of Glycobiology, A. Varki, R.D. 
Cummings, J.D. Esko, H.H. Freeze, P. Stanley, C.R. Bertozzi, et al., eds. (Cold Spring Harbor 
(NY)). 
Varki, N.M., and Varki, A. (2007). Diversity in cell surface sialic acid presentations: implications 
for biology and disease. Lab Invest 87, 851-857. 
Vilchez, R.A., and Butel, J.S. (2004). Emergent human pathogen Simian Virus 40 and its role 
in cancer. Clin Microbiol Rev 17, 495-508, table of contents. 
Viscidi, R.P., and Clayman, B. (2006). Serological cross reactivity between polyomavirus 
capsids. Polyomaviruses and Human Diseases 577, 73-84. 
Waga, S., and Stillman, B. (1994). Anatomy of a DNA replication fork revealed by 
reconstitution of SV40 DNA replication in vitro. Nature 369, 207-212. 
Walczak, C.P., Ravindran, M.S., Inoue, T., and Tsai, B. (2014). A cytosolic chaperone 
complexes with dynamic membrane J-proteins and mobilizes a nonenveloped virus out of the 
endoplasmic reticulum. PLoS Pathog 10, e1004007. 
References 
 
 93 
Walczak, C.P., and Tsai, B. (2011). A PDI family network acts distinctly and coordinately with 
ERp29 to facilitate polyomavirus infection. J Virol 85, 2386-2396. 
Walker, D.L., Padgett, B.L., ZuRhein, G.M., Albert, A.E., and Marsh, R.F. (1973). Human 
papovavirus (JC): induction of brain tumors in hamsters. Science 181, 674-676. 
Waterhouse, A.M., Procter, J.B., Martin, D.M.A., Clamp, M., and Barton, G.J. (2009). Jalview 
Version 2-a multiple sequence alignment editor and analysis workbench. Bioinformatics 25, 
1189-1191. 
Wattjes, M.P., Richert, N.D., Killestein, J., de Vos, M., Sanchez, E., Snaebjornsson, P., 
Cadavid, D., and Barkhof, F. (2013). The chameleon of neuroinflammation: magnetic 
resonance imaging characteristics of natalizumab-associated progressive multifocal 
leukoencephalopathy. Mult Scler 19, 1826-1840. 
Wielens, J., Headey, S.J., Rhodes, D.I., et al. (2013). Parallel screening of low molecular 
weight fragment libraries: do differences in methodology affect hit identification? J Biomol 
Screen 18, 147-159. 
Winn, M.D., Ballard, C.C., Cowtan, K.D., et al. (2011). Overview of the CCP4 suite and current 
developments. Acta Crystallographica Section D-Biological Crystallography 67, 235-242. 
Wuthrich, C., Cheng, Y.M., Joseph, J.T., Kesari, S., Beckwith, C., Stopa, E., Bell, J.E., and 
Koralnik, I.J. (2009a). Frequent infection of cerebellar granule cell neurons by polyomavirus JC 
in progressive multifocal leukoencephalopathy. J Neuropathol Exp Neurol 68, 15-25. 
Wuthrich, C., Dang, X., Westmoreland, S., McKay, J., Maheshwari, A., Anderson, M.P., 
Ropper, A.H., Viscidi, R.P., and Koralnik, I.J. (2009b). Fulminant JC virus encephalopathy with 
productive infection of cortical pyramidal neurons. Annals of Neurology 65, 742-748. 
Wuthrich, C., and Koralnik, I.J. (2012). Frequent infection of cortical neurons by JC virus in 
patients with progressive multifocal leukoencephalopathy. J Neuropathol Exp Neurol 71, 54-
65. 
Wychowski, C., Benichou, D., and Girard, M. (1987). The intranuclear location of Simian Virus 
40 polypeptide VP2 and polypeptide VP3 depends on a specific amino acid sequence. J Virol 
61, 3862-3869. 
Xie, H., Lee, L., Caramuta, S., Hoog, A., Browaldh, N., Bjornhagen, V., Larsson, C., and Lui, 
W.O. (2014). MicroRNA expression patterns related to Merkel Cell polyomavirus infection in 
human Merkel Cell carcinoma. J Invest Dermatol 134, 507-517. 
Xiong, X., Coombs, P.J., Martin, S.R., et al. (2013). Receptor binding by a ferret-transmissible 
H5 avian influenza virus. Nature 497, 392-396. 
Yamaguchi, H., Kobayashi, S., Maruyama, J., Sasaki, M., Takada, A., Kimura, T., Sawa, H., 
and Orba, Y. (2014). Role of the C-terminal region of vervet monkey polyomavirus 1 VP1 in 
virion formation. J Vet Med Sci 76, 637-644. 
Yamashita, M. (2010). Laninamivir and its prodrug, CS-8958: long-acting neuraminidase 
inhibitors for the treatment of influenza. Antivir Chem Chemother 21, 71-84. 
Yan, Y., Stehle, T., Liddington, R.C., Zhao, H., and Harrison, S.C. (1996). Structure 
determination of Simian Virus 40 and murine polyomavirus by a combination of 30-fold and 5-
fold electron-density averaging. Structure 4, 157-164. 
References 
 
 94 
Yogo, Y., Kitamura, T., Sugimoto, C., Ueki, T., Aso, Y., Hara, K., and Taguchi, F. (1990). 
Isolation of a possible archetypal JC virus DNA sequence from nonimmunocompromised 
individuals. J Virol 64, 3139-3143. 
Yu, R.K., Nakatani, Y., and Yanagisawa, M. (2009). The role of glycosphingolipid metabolism 
in the developing brain. Journal of Lipid Research 50 Suppl, S440-445. 
Yu, R.K., Tsai, Y.T., Ariga, T., and Yanagisawa, M. (2011a). Structures, biosynthesis, and 
functions of gangliosides--an overview. J Oleo Sci 60, 537-544. 
Yu, X., Coulson, B.S., Fleming, F.E., Dyason, J.C., von Itzstein, M., and Blanchard, H. 
(2011b). Novel structural insights into rotavirus recognition of ganglioside glycan receptors. J 
Mol Biol 413, 929-939. 
Zerrahn, J., Knippschild, U., Winkler, T., and Deppert, W. (1993). Independent expression of 
the transforming amino-terminal domain of SV40 large I antigen from an alternatively spliced 
third SV40 early mRNA. EMBO J 12, 4739-4746. 
Zila, V., Difato, F., Klimova, L., Huerfano, S., and Forstova, J. (2014). Involvement of 
microtubular network and its motors in productive endocytic trafficking of mouse polyomavirus. 
PLoS One 9, e96922. 
 
 
Appendix 
 
 95 
6.  Appendix 
6.1  Phylogenetic Analysis 
Abbreviation Full Name NCBI Reference 
AfricanElephantPyV African elephant polyomavirus 1 NC_022519 
ApanPyV1 Ateles paniscus polyomavirus 1 NC_019853 
BatPyV-A1055 Bat polyomavirus isolate A1055 JQ958886 
BatPyV-A504 Bat polyomavirus isolate A504 JQ958890 
BatPyV-AT7 Bat polyomavirus isolate AT7 JQ958892 
BatPyV-B0454 Bat polyomavirus isolate B0454 JQ958888 
BatPyV-B1130 Bat polyomavirus isolate B1130 JQ958893 
BatPyV-C1109 Bat polyomavirus isolate C1109 JQ958889 
BatPyV-CardiodermaPyV1-
KY336 
Cardioderma polyomaviurs isolate KY336 NC_020067 
BatPyV-ChaerephonPyV1-
KY397 
Chaerephon polyomavirus 1 isolate KY397 NC_020065 
BatPyV-EidolonPyV1-
KY270 
Eidolon polyomavirus 1 isolate KY270 NC_020068 
BatPyV-MiniopterusPyV-
KY369 
Miniopterus polyomavirus isolate KY369 NC_020069 
BatPyV-OtomopsPyV1-
KY156 
Otomops polyomavirus 2 isolate KY156 NC_020066 
BatPyV-OtomopsPyV1-
KY157 
Otomops polyomavirus 1 isolate KY157 NC_020071 
BatPyV-PteronotusPyV-
GTM203 
Pteronotus polyomavirus isolate GTM203 NC_020070 
BatPyV-R104 Bat polyomavirus isolate R104 JQ958887 
BatPyV-R266 Bat polyomavirus isolate R266 JQ958891 
BatPyV-TbPyV1 Tadarida brasiliensis polyomavirus 1 AJA41149.1 
BatPyV-TbPyV2 Tadarida brasiliensis polyomavirus 2 AJA41153.1 
BbPyV Butcherbird polyomavirus isolate AWH19840 NC_023008 
BFDPyV Budgerigar fledgling disease polyomavirus AY672646 
BKPyV BK Polyomavirus NC_001538 
BoPyV Bovine polyomavirus NC_001442 
CalbPyV1 Cebus albifrons polyomavirus 1 NC_019854 
CaPyV Canary polyomavirus NC_017085 
CeryPyV1 Cercopithecus erythrotis polyomavirus 1 JX159985 
ChPyV-Azzie Chimpanzee polyomavirus complete genome FR692336 
ChPyV-Bob Chimpanzee polyomavirus complete genome, FR692334 
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isolate Bob 
ChPyV-Tanu Chimpanzee polyomavirus complete genome, 
isolate Tanu 
FR692335 
CrowPyV Crow polyomavirus NC_007922 
CSLPyV California sea lion polyomavirus 1 YP_003429322.1 
DolphinPyV1 Dolphin polyomavirus 1 isolate DPyV-
1/Trachea/2010 
KC594077 
EPyV Equine polyomavirus NC_017982 
FiPyV Finch polyomavirus NC_007923 
GgorgPyV1 Gorilla gorilla gorilla polyomavirus 1 isolate 5766 HQ385752 
GhPyV Goose hemorrhagic polyomavirus isolate 
Toulouse Goose 2000 
HQ681903 
HaPyV Hamster polyomavirus YP_009111410.1 
HPyV12 Human Polyomavirus 12 NC_020106 
HPyV6 Human Polyomavirus 6 NC_014406 
HPyV7 Human Polyomavirus 7  NC_014407 
HPyV9 Human Polyomavirus 9 NC_015150 
JCPyV JC Polyomavirus NC_001699 
KIPyV Karolinska Institute Polyomavirus  NC_009238 
LPyV Monkey B-lymphotropic papovavirus M30540 
MCPyV Merkel Cell Polyomavirus  NC_010277 
MfasPyV1 Macaca fascicularis polyomavirus 1 NC_019851 
MPtPyV Murine pneumotropic virus strain Kilham clone 
pKV (37-1) 
EF186666 
MPyV-PTA Murine polyomavirus strain PTA U27812 
MWPyV Malawi Polyomavirus  NC_018102 
MyoPyV Myotis polyomavirus VM-2008 NC_011310 
NJPyV New Jersey Polyomavirus  NC_024118 
OraPyV-Bo Orangutan polyomavirus complete genome, 
isolate Bo 
NC_013439 
OraPyV-PI Orangutan polyomavirus complete genome, 
isolate Pi 
FN356901 
PrufPyV1 Piliocolobus rufomitratus polyomavirus 1 JX159984 
PtrosPyV2 Pan troglodytes schweinfurthii polyomavirus 2 NC_019858 
PtrovPyV1a Pan troglodytes verus polyomavirus 1a isolate 
6444 
HQ385746 
PtrovPyV1b Pan troglodytes verus polyomavirus 1b isolate 
6520 
HQ385747 
PtrovPyV2a Pan troglodytes verus polyomavirus 2a isolate 
6512 
HQ385748 
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PtrovPyV2c Pan troglodytes verus polyomavirus 2c isolate 
5924 
HQ385749 
PtrovPyV3 Pan troglodytes verus polyomavirus 3 NC_019855 
PtrovPyV4 Pan troglodytes verus polyomavirus 4 NC_019856 
PtrovPyV5 Pan troglodytes verus polyomavirus 5 NC_019857 
SA12 Simian virus 12 DQ435829 
SqPyV Squirrel monkey polyomavirus NC_009951 
SsciPyV1 Saimiri sciureus polyomavirus 1 JX159989 
STLPyV  Saint Louis Polyomavirus  NC_020890 
SV40 Simian virus 40 NC_001669 
TSPyV Trichodysplasia spinulosa- associated 
Polyomavirus  
NC_014361 
VmPyV1 Vervet monkey polyomavirus 1 NC_019844 
VmPyV2 Vervet monkey polyomavirus 2 AB767299 
VmPyV3 Vervet monkey polyomavirus 3 AB767297 
WUPyV Washington University Polyomavirus  NC_009539 
YbPyV1 Yellow baboon polyomavirus 1 AB767294 
YbPyV2 Yellow baboon polyomavirus 2 AB767295 
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Abstract
Trichodysplasia spinulosa-associated Polyomavirus (TSPyV) was isolated from a patient
suffering from trichodysplasia spinulosa, a skin disease that can appear in severely immu-
nocompromised patients. While TSPyV is one of the five members of the polyomavirus fam-
ily that are directly linked to a human disease, details about molecular recognition events,
the viral entry pathway, and intracellular trafficking events during TSPyV infection remain
unknown. Here we have used a structure-function approach to shed light on the first steps
of TSPyV infection. We established by cell binding and pseudovirus infection studies that
TSPyV interacts with sialic acids during attachment and/or entry. Subsequently, we solved
high-resolution X-ray structures of the major capsid protein VP1 of TSPyV in complex with
three different glycans, the branched GM1 glycan, and the linear trisaccharides α2,3- and
α2,6-sialyllactose. The terminal sialic acid of all three glycans is engaged in a unique bind-
ing site on TSPyV VP1, which is positioned about 18 Å from established sialic acid binding
sites of other polyomaviruses. Structure-based mutagenesis of sialic acid-binding residues
leads to reduction in cell attachment and pseudovirus infection, demonstrating the physio-
logical relevance of the TSPyV VP1-glycan interaction. Furthermore, treatments of cells
with inhibitors of N-, O-linked glycosylation, and glycosphingolipid synthesis suggest that
glycolipids play an important role during TSPyV infection. Our findings elucidate the first
molecular recognition events of cellular infection with TSPyV and demonstrate that receptor
recognition by polyomaviruses is highly variable not only in interactions with sialic acid itself,
but also in the location of the binding site.
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Author Summary
Viruses engage receptors on their host cell to initiate entry and infection. Members within
a virus family are known to target different tissues and hosts and exploit different patho-
genic mechanisms due to critical changes in receptor specificity. The human Trichodyspla-
sia spinulosa-associated Polyomavirus (TSPyV) is known to cause a rare skin disease in
immunocompromised individuals. The pathogenic mechanism includes hyperprolifera-
tion of inner root sheath cells, but molecular determinants underlying the infection and
the associated disease remain unknown. Here we applied a structural and functional
approach to investigate the recognition events during early infection steps of the virus. We
found that TSPyV engages sialic acid receptors but employs a novel binding site on the
capsid that is shifted in comparison to other structurally characterized polyomaviruses.
Cell-based studies demonstrate the relevance of the observed interaction for attachment
and infection and suggest that glycolipids, rather than N- and O-linked glycoproteins, are
important for infection. Our findings demonstrate exemplarily that receptor recognition
by (polyoma-) viruses is highly variable not only in interactions with sialic acids, but also
in the location of the binding site on the capsid, providing insights about structural deter-
minants of receptor and host specificity and evolution of these viruses.
Introduction
Trichodysplasia spinulosa-associated Polyomavirus (TSPyV) was discovered in 2010 in facial
skin samples from a patient with the skin disease trichodysplasia spinulosa (TS) [1]. TS is char-
acterized by the development of folliculocentric papules and keratin spines, predominantly
localized to the face and less frequently on the trunk and limbs of immunocompromised indi-
viduals [1, 2–4, 5]. The pathogenic mechanism of TSPyV during the symptomatic infection
includes uncontrolled hyperproliferation of inner root sheath (IRS) cells, but molecular deter-
minants underlying TSPyV infection and disease remain largely unknown [2,6,7]. Electron
microscopic studies have confirmed the presence of icosahedral viral particles in affected hair
follicles [2,4,8,9]. However, high viral loads have been detected only in TS patients, whereas
samples from the skin, plucked eyebrows, serum/plasma, and urine of immunocompetent and-
compromised individuals were mostly negative for TSPyV DNA [1,6,10]. In contrast, seroprev-
alence values of about 70% within the human population suggest that initial infections with
TSPyV occur during childhood [11–13], and thus persistent infections at undetectable levels or
in undiscovered latent extracutaneous reservoirs are very likely [10,14]. The detection of
TSPyV DNA in tonsillar samples from healthy individuals indicates that the virus infects lym-
phoid tissue establishing a persistent infection [10,14]. Viral shedding and spreading from this
persistent site may then be crucial for transmission and reactivation during immunosuppres-
sion [14].
Among the recently discovered human members of the growing polyomavirus family,
TSPyV and the carcinogenic Merkel Cell Polyomavirus (MCPyV) have gained particular atten-
tion due to clear links to a human disease or human cancer, respectively [15,16]. Furthermore,
the skin-tropic Human Polyomavirus 7 (HPyV7) has recently been associated with thymic epi-
thelial tumors [17]. While these three viruses share skin tropism, characteristics of the infection
and pathogenicity seem to differ. For example, MCPyV is clonally integrated in the host cell
genome in the majority of the neuroendocrine Merkel cell carcinomas (MCC) [15], but there is
no evidence for genomic integration of TSPyV to date.
Carbohydrate Receptor Engagement of TSPyV
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TSPyV has a 5232-nucleotide dsDNA genome encapsulated in its non-enveloped icosahe-
dral capsid made up of the proteins VP1, VP2 and VP3 [1]. X-ray crystallographic studies of
the pentameric major capsid proteins (VP1s) from several polyomaviruses have revealed a con-
served jell-roll fold topology [18–27]. On the outer surface of the virion, structurally distinct
loops connect the β-sheet core, and these loops are chiefly responsible for viral antigenicity.
They also form a virus-host interaction platform that contributes to host range, cell tropism,
viral spread, and pathogenicity. Although sialylated glycans are functional receptors for several
polyomaviruses, the role and importance of these glycans for infectious entry remain unknown
for other more recently discovered family members. The engagement of non-sialylated recep-
tor types has been suggested in several cases [22,27].
Sialic acids are commonly connected by either α2,3- or α2,6-linkages to a galactose (Gal),
by an α2,6-linkage to N-acetylgalactosamine (GalNAc) or via α2,8-linkages to one another.
They are abundantly expressed on N- or O-linked glycoproteins as well as on gangliosides, and
several chemical modifications are known [28]. The predominant sialic acid species in humans
is α-5-N-acetylneuraminic acid (Neu5Ac), which is a central building block of cell surface
receptors for many human viruses [29,30]. In contrast, α-5-N-glycolylneuraminic acid
(Neu5Gc), the predominant type of sialic acid in many other mammals, cannot be synthesized
by humans due to a species-specific inactivating deletion in the gene encoding the hydroxylase
that converts CMP-Neu5Ac to CMP-Neu5Gc [31,32]. However, Neu5Gc can be metabolically
incorporated into human tissues from dietary sources [33] and its role in receptor engagement
by viruses and in defining viral tropism is only beginning to emerge [34].
The same binding region at the surface of VP1 is employed for the interaction with terminal
sialic acids in all structurally investigated sialic acid-engaging polyomaviruses so far, but amino
acid differences in or near the core binding pocket can modulate the recognition of specific sia-
lylated glycan receptors or receptor motifs [30]. Subtle VP1 amino acid changes in the binding
pocket can have a critical impact on infection and viral pathogenicity [35,36,24,26]. This is
illustrated by a single amino residue mutation in the binding pocket of the human BK Poly-
omavirus (BKPyV), which allows for a switch in the ganglioside receptor specificity [24]. Affin-
ity is also critical, as the closely related JC Polyomavirus (JCPyV) binds several ganglioside
motifs, including GM1 and GD1b, but the increased affinity for the α2,6-linked lactoseries tet-
rasaccharide c (LSTc) is crucial for its function as a receptor [21,37]. Murine Polyomavirus
(MPyV), MCPyV, B-lymphotropic Polyomavirus (LPyV), and Human Polyomavirus 9
(HPyV9) recognize sialic acids in distinct orientations within the conserved location of the
binding pocket on VP1 by applying different interaction strategies [19,23,25,26]. In contrast,
Human Polyomaviruses 6 (HPyV6) and 7 possess elongated VP1 surface loops that obstruct
the Neu5Ac-binding region, indicating that these viruses utilize non-sialylated receptors [27].
To enhance our understanding of the cell and host tropism of TSPyV, and ultimately its
pathogenicity, we aimed to shed light on molecular determinants and principles during the
early steps of infection. Following cell attachment studies, we determined high-resolution X-
ray structures of TSPyV VP1 pentamers alone and in complex with glycans bearing α2,3- or
α2,6-linked terminal Neu5Ac. TSPyV engages sialic acid receptors but the virus uses a novel
binding site on VP1 that is shifted in comparison to all other structurally characterized poly-
omaviruses so far. Cell-based studies demonstrate the relevance of this binding site for cell
attachment and infectivity, and also suggest that glycolipids rather than N- and O-linked glyco-
proteins play an important role during TSPyV infection. In conclusion, our findings highlight
the complexity and plasticity of virus-glycan receptor interactions, and provide clues about the
determinants of host specificity and evolution of TSPyV.
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Results
Sialic acids promote TSPyV VP1 cell attachment
To determine if TSPyV interacts with sialic acids on cell surfaces, we first examined binding of
unassembled TSPyV VP1 pentamers to cultured human cells by flow cytometry (Fig 1A and S1
Fig). For these experiments, TSPyV VP1 was recombinantly expressed in E. coli. The VP1 pro-
tein forms the characteristic homopentamer but cannot assemble further into viral capsids due
to N- and C-terminal truncations of the expression construct. Cells were mock treated or incu-
bated with Clostridium perfringens neuraminidase type V to remove terminal α2,3-, α2,6-, and
α2,8-linked sialic acids from the cell surface prior to the flow cytometry experiment. The bind-
ing signal of TSPyV VP1 pentamers to enzyme-treated cells is significantly reduced compared
to binding to mock-treated cells (Fig 1A and S1 Fig). BKPyV VP1 pentamers were used as posi-
tive control for neuraminidase-sensitive cell attachment (S1 Fig).
Sialic acids are important for TSPyV pseudovirus infection
Next, we investigated the role of sialic acids in TSPyV infection. To our knowledge, a cell cul-
ture system for growing TSPyV is not available. However, virus-like particles (VLPs) or
reporter vector particles, known also as pseudoviruses (PsV), have been generated for other
polyomaviruses and are useful model systems for infection studies reflecting the viral tropisms
[38–40,36]. We therefore developed a TSPyV pseudovirus system (TSPsV), which uses the
TSPyV structural proteins expressed in the producer cells HEK293TT to package a reporter
plasmid coding for secreted luciferase that can be detected by relative luminescence units
(RLU) for quantification of PsV infection [39,40]. A mock control for PsV infections was gen-
erated by transforming the reporter plasmid together with a control plasmid instead of plas-
mids coding for structural proteins into producer cells. First, multiple common cell lines were
screened for efficient transduction of the reporter plasmid to identify suitable cell lines for
TSPsV infection studies (S2 Fig). Significant transduction in comparison to the mock transfec-
tion control was seen for HEK293 cells and the human glial cell line SVGA, but not for HeLa,
monkey kidney (Vero) and Chinese Hamster Ovary (CHO) cells. TSPsV cell attachment and
transduction in SVGA and HEK293 is sensitive to pretreatment with neuraminidase (Fig 1B–
1D). Together with the cell binding analysis, the PsV infection studies suggest that TSPyV
engages sialic acids on the cell surface during viral attachment and prior to infectious entry.
Crystal structure of TSPyV VP1 pentamers in complex with α2,3- and
α2,6-linked sialylated glycan motifs
To establish a platform for understanding the specificity of the interaction with sialic acid, we
solved crystal structures of TSPyV VP1 alone and in complex with three different sialylated
compounds, the branched α2,3-linked GM1 pentasaccharide and the linear glycans α2,3- and
α2,6-sialyllactose (3’SL and 6’SL, respectively) (Table 1 and Fig 2). TSPyV VP1 pentamers were
co-crystallized in the presence of either 10 mM GM1 glycan or 10 mM 6’SL, while preformed
native TSPyV VP1 pentamer crystals were derivatized by soaking them in a 10 mM 3’SL solu-
tion for complex formation. As is typical for polyomaviruses [18–27], the TSPyV VP1 mono-
mer adopts the iconic jelly-roll fold with a conserved core comprising two β-sheets that are
formed by strands B, I, D, G and C, H, E, F, respectively (Fig 2A). Extensive loops connect the
strands on the top of the VP1 pentamer and are named BC-, DE-, HI- and EF-loops according
to the strands they connect. The long BC-loop folds into two different directions on top of the
protein and is divided for clarity into BC1-loop, BC-linker and BC2-loop [18,22]. In the unbi-
ased difference (Fobs-Fcalc) electron density map of the glycan complex structures, we observed
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well-defined electron density for the terminal Neu5Ac residues of 3’SL, 6’SL and the GM1 gly-
can. The highest occupancy was obtained for GM1 in all five binding sites of the VP1 pentamer
Fig 1. Cell surface glycans featuring terminal sialic acids promote TSPyV attachment and
pseudovirus infection. (A) Binding of Alexa Fluor 488-conjugated TSPyV VP1 pentamers to mock (PBS) or
with 1 U/ml Clostridium perfringens type V neuraminidase pre-treated cells was analysed by flow cytometry.
30,000 gated events were measured for each sample. The average from three independent experiments is
shown, and error bars indicate the standard deviation. Data was standardized to signals of mock treated cells
alone. S1 Fig shows non-standardized data of individual experimental replicates. (B) Attachment of Alexa
Fluor 488-conjugated TSPsV to mock (PBS) or with 1 U/ml Clostridium perfringens type V neuraminidase
pre-treated HEK293 and SVGA cells. The analysis was carried out by flow cytometry with 10,000 events
measured for each sample. The average from three replicates is shown, and error bars indicate the standard
deviation. (C-D) TSPyV pseudovirus (TSPsV) infections of HEK293 and SVGA cells (mock-treated cells and
cells incubated with Clostridium perfringens neuraminidase for 30 min prior to PsV infection). BK
Polyomavirus pseudovirus (BKPsV) was used as positive control for a neuraminidase-sensitive infection. The
efficiency of the PsV infection was measured by transduction of the reporter plasmid phGluc coding for a
secreted form ofGaussia luciferase 72 h post infection by detection of the secreted luciferase (measured in
relative light units, RLUs using the BioLuxGaussia Luciferase Assay Kit). PsV experiments were done in
quadruplicate and repeated three times and the average relative transduction is shown. Error bars indicate
standard deviations and statistic analysis was performed using the two-tailed unpaired t test. The data was
standardized to mock PsV transfections. The mock PsV control was generated by harvesting HEK293TT
cells transfected with control plasmid instead of the capsid expression plasmids and then purifying according
to the PsV purification protocol to measure background signal and non-specific transfer of luciferase to
infected cells.
doi:10.1371/journal.ppat.1005112.g001
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in the asymmetric unit, and so additional glycan residues besides Neu5Ac could be built unam-
biguously into well-defined electron density (Fig 2B). Nevertheless, three of the five binding
sites were not considered for further structural analysis because the ligand participates in crys-
tal contacts. In the remaining two sites of the VP1 pentamer, the Neu5Ac residue and the Gal-
NAcβ1-3(Neu5Acα2–3)Gal trisaccharide (Fig 2B and 2C), respectively, are well-defined by
electron density and distant from crystal contacts. These two binding sites are therefore dis-
cussed below in detail.
Table 1. Crystallographic data collection and structure refinement statistics.
TSPyV VP1 TSPyV VP1—GM1 glycan TSPyV VP1–6’SL TSPyV VP1–3’SL
PDB code 4U5Z 4U60 4U61 4U62
Data collection
Space group P21 P21212 P212121 P21
Unit cell
a, b, c [Å] 64.10, 153.64, 143.98 144.99, 152.05, 67.97 139.56, 146.35, 151.54 66.24, 152.84, 147.24
β [°] 91.83 90.00 90.00 92.34
Resolution [Å] 30–2.10 (2.16–2.10) 50–1.50 (1.54–1.50) 30–1.65 (1.69–1.65) 40–1.55 (1.59–1.55)
Unique reﬂections 158,871 (11,115) 238,315 (17,410) 368,928 (27,122) 412,698 (29,151)
Total reﬂections 749,166 (48,901) 1,312,931 (92,629) 3,423,638 (224,558) 1,584,158 (106,332)
Rmeas [%] 9.0 (94.9) 8.1 (88.2) 9.5 (98.6) 6.2 (70.8)
I/σI 12.0 (1.7) 16.0 (2.0) 15.8 (2.3) 13.4 (2.2)
CC1/2 [%] 99.8 (65.2) 99.9 (66.3) 99.9 (75.3) 99.9 (76.3)
Completeness [%] 98.3 (92.8) 99.4 (99.0) 99.7 (100.0) 97.8 (93.5)
Wilson B factors [Å2] 44.1 21.5 27.3 29.2
Reﬁnement
Rwork/Rfree [%] 20.5/24.9 15.8/18.0 16.5/18.5 15.5/18.0
No. of atoms
Protein 20,375 10,611 20,747 20,892
Glycans - 251 146 63
Water 551 1,637 2,267 2,355
Other solvent molecules* - 74 24 46
Average B factors [Å2]
Protein 43.0 17.3 23.5 27.5
Glycans - 24.2 35.5 38.4
Water 38.5 26.9 30.6 32.4
Other solvent molecules* - 33.2 34.0 37.0
RMSD
Bond length [Å] 0.008 0.009 0.008 0.009
Bond angles [°] 1.273 1.419 1.309 1.356
Ramachandran plot
Favored [%] 96.0 95.7 97.0 97.1
Allowed [%] 4.0 4.3 3.0 2.9
Values for the highest resolution shell are given in parentheses. Rfree was calculated with 5% of the data. RMSD, root-mean-square deviation. The
Ramachandran plot statistics were calculated with MolProbity [69].
*Other solvent molecules are glycerol and 1,2-ethandiol.
doi:10.1371/journal.ppat.1005112.t001
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Specific recognition of terminal sialic acids
The N-acetyl group of Neu5Ac inserts into a shallow cavity that is built by the BC2-loop on top
of a VP1 monomer, thereby forming hydrogen bonds via its NH-group towards the hydroxyl
side chain of threonine 73 and via its oxygen with the backbone amino group of lysine 82 (Fig
2D). The side chain of the arginine residue 137 from the DE-loop of the counterclockwise
(ccw) VP1 monomer interacts with the glycerol chain of Neu5Ac. The backbone amino and
carbonyl groups of residue V74 recognize the glycerol chain at one side, and the carbonyl
group of residue K82 contacts the O4 of Neu5Ac on the other side of the BC2-loop. Residue
H132 of the ccw monomer forms the bottom of the shallow binding groove so that the methyl
group of Neu5Ac is recognized via hydrophobic interactions by the non-polar part of the ccw
H132 side and by BC2-loop residues A75 and P83. Additionally, water-mediated hydrogen
bonds are found between O4 and the glycerol chain of Neu5Ac and the VP1 backbone.
The VP1 surface area that is buried by the Neu5Ac interaction comprises 197 Å2 [41].
Because of the inherent flexibility of glycosidic linkages, complex glycans do not have a single,
well-defined three-dimensional structure in solution and the mobility of the sugar rings are
reflected in their temperature factors (B-factors). The average B-factor of the Neu5Ac ring of
GM1 is in the same range as those of the neighboring protein residues, indicating that the occu-
pancy is near 1.0 for the ligand. In contrast, the GalNAc and the branched Gal ring have ele-
vated B-factors. This is in agreement with their lack of contacts to protein residues and
resultant higher mobility. Neu5Ac moieties of 3’SL, 6’SL, and the branched GM1 glycan are
bound in an identical manner in all three glycan-VP1 complex structures. Interactions with
glycan residues other than the terminal Neu5Ac were not observed in any of the three complex
Fig 2. TSPyV VP1 specifically binds to terminal Neu5Ac. (A) Crystal structure of the unassembled TSPyV VP1 pentamer in complex with the GM1 glycan.
The TSPyV VP1 pentamer is shown in cartoon representation with one monomer depicted in purple. Glycan residues are shown in stick representations and
glycan atoms are coloured according to the atom type, with oxygen in red, nitrogen in blue, and carbon in orange. (B) Close-up view of the Neu5Ac binding
site. The simulated annealing omit difference map contoured at 3.0 σ is shown with a radius of 2.0 Å around glycan residues Neu5Ac-α2,3-Gal-β1,4GalNAc
of the GM1 glycan. (C) Schematic representation of the GM1 glycan. Glycan rings built into electron density in panel B are highlighted in colours. (D)
Interaction between TSPyV VP1 and the terminal Neu5Ac residue of the GM1 glycan in a binding site that is formed by the BC2-loop. Side chains and
backbone atoms of VP1 interacting with the glycan are shown in stick representation, and atoms are coloured as in panel A. Water molecules are shown as
spheres, hydrogen bonds between VP1 and Neu5Ac are drawn as black dashed lines, water-mediated contacts between VP1 and Neu5Ac are depicted in
cyan, and intramolecular Neu5Ac hydrogen bonds are shown in orange.
doi:10.1371/journal.ppat.1005112.g002
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structures. However, the branched “ganglioside core” GalNAcβ1-3(Neu5Acα2–3)Gal is likely
more restricted in its conformational mobility than the linear glycan ligands 3’SL and 6’SL, and
this could explain the better defined density for the GM1 glycan.
We next performed saturation transfer difference (STD) NMR spectroscopy experiments to
provide evidence for the observed interaction between VP1 and the GM1 glycan in solution
(S3 Fig). In this approach, saturation from a macromolecule, such as the VP1 pentamer, is
transferred to a bound small-molecule ligand, such as a glycan, within a distance of up to 5 Å
from the protein. Thus, this technique can be used to identify the protein-bound parts of the
ligand [42]. We found that TSPyV VP1 interacts with the GM1 glycan in solution. Protons of
the engaged glycerol chain (H7 and H9) and the methyl group (Me) of the N-acetyl chain of
Neu5Ac are readily identified in the STD NMR difference spectrum. These findings are in
good agreement with the crystal structure analysis, where mainly interactions with the terminal
Neu5Ac and in particular with its glycerol and acetyl groups were observed. Protons of the
α2,3-linked Gal and the GalNAc residues receive comparably little magnetization, and these
protons are also not engaged by VP1 in the crystal structure.
The sialic acid binding site on TSPyV VP1 mediates cell attachment and
infection
In order to verify the functionality of the binding site on TSPyV VP1 for sialic acid-dependent
cell binding, mutations in the sialic acid binding site were introduced into the unassembled
TSPyV VP1 pentamer construct. To analyze the importance of threonine 73, which recognizes
the N-acetyl group of Neu5Ac, this residue was mutated to alanine (T73A) in order to remove
the hydrogen bond, and to glutamine (T73Q) and glutamic acid (T73E) in order to introduce
steric hindrance. In addition, residues 71, 84, and 137 were also mutated (K71L, T84A, and
R137A). The design of relevant VP1 mutations was limited because the TSPyV VP1-Neu5Ac
interactions are mainly mediated by the protein backbone.
We used a thio-labeling strategy to standardize the labeling efficiency of TSPyV VP1 wild
type and mutants for the flow cytometry experiment. TSPyV possesses a conserved cysteine,
C107, within the CD-loop of VP1. This cysteine lies at the base of the pentamer, distant from
the ligand binding site, and while it is the only solvent-exposed cysteine in the pentamer avail-
able for thio-labeling, it faces towards the interior and is not exposed in the assembled virus.
For all mutants, the binding to HEK293 and SVG-A was significantly reduced (Fig 3A). Next,
three of the mutations (K71L, T73E, and T84A) were introduced into TSPsV particles. All
three mutations reduce cell binding of PsV and infectivity in HEK293 and SVGA cells (Fig 3B
and 3C). The PsV infection assay reveals small differences between the mutants with T73E hav-
ing the largest influence on infectivity in both cell lines tested. This finding is in accord with
the VP1-Neu5Ac interaction seen in our structures. Residue T73 recognizes the N-acetyl group
of Neu5Ac and has to be considered a central component of the binding site. Although none of
the selected mutations abolishes PsV infection completely, each one of them reduces binding
of VP1 pentamers and PsVs, indicating that the identified binding site on TSPyV clearly medi-
ates attachment to sialylated glycans on cells, and thus defines an important event during early
steps of TSPyV infection.
A new location of the sialic binding site on the polyomavirus VP1 protein
To date, X-ray structures of seven different polyomavirus VP1 proteins in complex with sialy-
lated glycans have been solved [19–21,23–26]. The human JCPyV, BKPyV, MCPyV and
HPyV9 viruses, but also the two simian viruses LPyV and SV40 and the murine virus MPyV
engage sialic acids of their specific glycan receptor motifs in the same general area of VP1
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Fig 3. Cell binding and PsV infection of TSPyVmutants. (A) Cell binding analysis of TSPyV wild type (WT) and mutant VP1 pentamers to HEK293 and
SVGA cells by flow cytometry. VP1 pentamers were covalently thio-labelled using Alexa Fluor 488 C5 maleimide. The histogram depicts the relative
Carbohydrate Receptor Engagement of TSPyV
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(Fig 4). This shallow binding site is located at the interface between two monomers, with con-
tributions from the DE-, HI- and BC1-loops and the BC-linker of one monomer and ccw BC2-
and EF-loops from the neighboring VP1 chain. In contrast, TSPyV engages Neu5Ac in a
unique, exposed binding site that lies about 18 Å away from the sialic-acid binding groove of
all other polyomaviruses. This new binding site is formed by the BC2-loop of a single VP1
monomer on top of the pentamer. The comparison of all seven structures reveals that TSPyV
VP1 does not differ drastically in its amino acid sequence, length and fold of the surface loops.
Full-length TSPyV VP1 shares 52–61% amino sequence identity with these seven other VP1
proteins. BKPyV and JCPyV VP1 are most closely related to TSPyV VP1 in terms of the overall
VP1 structures as well as the amino acid sequences with 52 and 54% VP1 sequence identities,
respectively. The TSPyV VP1 structure superposes on the BKPyV and JCPyV VP1 structures
with small root-mean-square deviation (RMSD) values of about 0.8 Å (calculated for Cα atoms
of the VP1 monomers).
fluorescence signal of mutants compared to the binding signal of wild type pentamers. Data was measured in three independent experiments and was
standardized for the background signal from cells alone. Error bars indicate standard deviations. (B) WT and mutant TSPsV binding (Alexa Fluor 488 amine-
conjugated) to HEK293 and SVGA cells (mock-treated cells and cells incubated withClostridium perfringens neuraminidase for 30 min prior to PsV infection)
examined by flow cytometry. Relative fluorescence signals of mutants compared to the binding signal of WT PsV were plotted and error bars indicate
standard deviations for three experimental replicates. Labeled PsV content was normalized by western blotting detection with purified PAB597, a hybridoma
supernatant that produces a monoclonal antibody against JCPyV VP1, which cross-reacts with TSPyV VP1. The two-tailed unpaired t test was performed for
binding of WT and mutant TSPsVs to mock-treated cells. (C) TSPsV infection of HEK293 and SVGA cells assayed 72 h post infection by detection of the
secreted luciferase due to transduction of the reporter plasmid phGluc. The luciferase was quantified using a BioLuxGaussia Luciferase Assay Kit. The
secreted luciferase catalyzes a photo-oxidation that emits light, which is measured in relative light units, RLUs. RLUs are given in logarithmic scale. Mock
PsV infections were done with a control sample obtained according the PsV purification protocol from cells only transfected with phGluc and control plasmid
measure background and nonspecific transfer of luciferase. PsV experiments were done in quadruplicate and repeated two times. Statistic analysis was
performed using the two-tailed unpaired t test.
doi:10.1371/journal.ppat.1005112.g003
Fig 4. Unique location of the TSPyV Neu5Ac binding site. The location of the Neu5Ac binding site on
TSPyV VP1 is shifted compared to binding sites of polyomaviruses SV40, BKPyV, JCPyV, MCPy, LPyV,
HPyV9 and MPyV, which all engage sialylated glycans by employing a Neu5Ac binding site in a conserved
location on VP1. For clarity, only terminal Neu5Ac residues are shown in stick representations and are
coloured according as assigned for each virus. TSPyV VP1-GM1 glycan (purple), SV40 VP1-GM1 glycan
(blue; pdb 3BWR), BKPyV VP1-GD3 glycan (light green; pdb 4MJ0), JCPyV VP1-LSTc pentasaccharide
(pink; pdb 3NXD), MCPyV VP1-GD1a glycan (cyan; pdb 4FMJ), LPyV-α2,3-sialyllactose (dark green; pdb
4MBY), HPyV9 VP1-α2,3-Neu5Gc-sialyllactose (brown; pdb 4POT), MPyV VP1-Neu5Ac-α2,3-Gal-β1,3-
[α2,6-Neu5Ac]–GlcNAc-β1,3-Gal-β1,4-Glc (orange; pdb 1VPS).
doi:10.1371/journal.ppat.1005112.g004
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Structural basis for the relocation of the sialic binding site on VP1
To understand the molecular basis for the relocation of the Neu5Ac binding site we compared
the TSPyV VP1-GM1 complex structure with known VP1-glycan complex structures in more
detail. Usually, the terminal sialic acids is recognized by HI-loop residues of VP1 via direct
interactions with the protruding functional groups of the Neu5Ac, the carboxylate group, the
N-acetyl group and the glycerol chain [30]. In TSPyV VP1, only small differences in structure
and amino acid sequence within the HI-loop binding region are sufficient to switch the loca-
tion of the Neu5Ac binding site to the BC2-loop region as shown in an exemplary manner for
the comparison with the BKPyV VP1-GD3 glycan structure (Fig 5). The groove forming the
binding site for the terminal sialic acid in VP1 of BKPyV and other polyomaviruses next to the
HI-loop is still present on TSPyV VP1. This groove is often hydrophobic at the bottom and
recognizes the methyl group of N-acetyl chain of Neu5Ac [21,23–25] through a hydrophobic
patch formed by residues L62, F65, F270 and F75cw of BKPyV VP1. With Y68 and L276, the
Fig 5. Comparison of the Neu5Ac binding sites of HI- loop and BC2- loop regions. (A, C) HI-loop regions of TSPyV VP1 and of BKPyV VP1 in complex
with the GD3 glycan (pdb 4MJ0), are shown in the same orientation. The terminal Neu5Ac of GD3 is show in orange sticks. Residues that do not allow
interaction with Neu5Ac in a manner similar to BKPyV are colored on the surface of VP1. Direct hydrogen bonds between BKPyV VP1 side chain residues
and Neu5Ac are depicted as dashed lines. (B, D) BC2-loop regions of TSPyV VP1 and BKPyV VP1 are shown. Direct hydrogen bonds between side chain
residues of TSPyV VP1 and the terminal Neu5Ac of the GM1 glycan and an intramolecular BKPyV VP1 hydrogen bond are shown as black dashed lines. The
structures were aligned using their Cα atoms. One VP1 monomer is highlighted in purple for TSPyV and light green for BKPyV, respectively.
doi:10.1371/journal.ppat.1005112.g005
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equivalent region of TSPyV VP1 is similarly hydrophobic (Fig 5A and 5C). However, while the
carboxylate group of Neu5Ac is recognized by two hydrogen bonds from side chains of resi-
dues S274 and T276 in BKPyV VP1, similar interactions are not possible in TSPyV as the rec-
ognition of the sialic acid carboxylate group appears to be electrostatically hindered through
residues D280 and D282. In addition, residue G278 in TSPyV, which substitutes for residue
N272 of BKPyV, cannot recognize the N-acetyl group of Neu5Ac in the HI-binding loop. Resi-
due K71 may also interfere with binding of Neu5Ac in the HI-loop region of TSPyV VP1,
although the K71 side chain has elevated temperature factors. On the other hand, the shifted
Neu5Ac-binding site in TSPyV VP1 is unable to bind sialic acid in BKPyV VP1 as residue N73
forms a hydrogen bonds with residue S70, thereby widening the BC2-loop and interfering with
Neu5Ac binding. Hence, subtle differences seem to modulate the recognition of Neu5Ac both
in the HI-loop region and also in the BC2-loop region (Fig 5B and 5D).
Glycolipids are important for TSPyV infection
Sialic acids are abundantly expressed on N- or O-linked glycoproteins, and they are also key
components of glycolipids and in particular gangliosides. In order to elucidate the cellular scaf-
fold of the sialic acids engaged by TSPyV we treated HEK293 cells with inhibitors interfering
with the synthesis of these molecular scaffolds for terminal sialic acids and monitored TSPyV
pentamers binding (Fig 6). Tunicamycin inhibits the synthesis of N-linked glycans, Benzyl-α-
N-acetylgalactosamine (BenzylGalNAc) specifically blocks the synthesis of O-linked glycans,
and D,L-threo-phenyl-2-hexadecanoylamino-3-morpholino-propanol (PPMP) is a structural
analogue of a ceramide and inhibits the UDP-glucose-ceramide glucosyltransferase leading to
decreased glycosphingolipid expression on cells. The effects of the cell treatment were assessed
with two positive controls: (i) cholera toxin B subunit, which binds GM1 gangliosides, and (i)
the lectins Concanavalin A (ConA) andMaackia amurensis II (MALII), which bind to N- and
O-glycans. In addition, the toxicity of either drug was monitored using a cell proliferation
assay, confirming that drug treatments did not reduce the cell viability. Tunicamycin and Ben-
zylGalNAc did not affect cell binding of TSPyV pentamers, whereas a significant reduction of
attachment to HEK293 cells was observed after treatment with PPMP. Similar flow cytometry
experiments were carried out with SVGA cells. Tunicamycin and BenzylGalNAc treatments
did not reduced TSPyV VP1 pentamer binding to SVGA cells. However, cholera toxin B sub-
unit and TSPyV VP1 pentamer binding to PPMP-treated SVGA cells was also not significantly
reduced, suggesting that inhibition of the glycosphingolipid expression by PPMP is not very
effective in this cell line.
TSPsV transduction in PPMP-treated HEK293 cells was significantly impaired, suggesting
that glycolipids are important for TSPyV infection of these cells (Fig 7). Additionally, the
human lung cell line A549 could be infected with TSPsV resulting in a reduction after cell treat-
ment with PPMP (S4 Fig). However, we could not observe reduced binding of TSPyV VP1 pen-
tamer to A549 cells after PPMP treatment. Hence, these experiments establish that a glycolipid
is likely important for viral entry, but TSPyV might also bind to other sialylated glycans on the
cell surface during initial cell attachment, possibly in a cell type-specific manner.
Phylogenetic and structural analysis highlights the close relationship to
Orangutan Polyomavirus
The phylogenetic analysis based on VP1 amino acid sequence reveals that TSPyV is most
closely related to two simian polyomaviruses, Bornean Orangutan Polyomavirus (OraPyV1)
and Ateles paniscus polyomavirus 1 (ApanPyV1) [1,43]. TSPyV shares VP1 amino acid
sequence identities of 79% and 69% with OraPyV and ApPyV1, respectively. To investigate
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common features and differences between capsids of these three viruses, we compared their
VP1 sequences and mapped conservations onto the molecular surface of TSPyV VP1 (Fig 8).
Differences occur predominantly on the top surface of the VP1 pentamer, which is especially
accessible to antibodies in the context of the assembled virion. VP1 residues within the
BC2-loop binding site are highly conserved in OraPyV (Fig 8A) but the HI-loop region differs
in the human and in the monkey virus. The comparison of VP1 proteins from TSPyV, OraPyV
and ApanPyV1 highlights that BC2-loop residues T73, V74 and P83 are conserved in contrast
to the rest of the upper VP1 surface. In addition, DE-loop residue R137, which interacts with
Fig 6. TSPyV binds to sialic acid containing glycolipids.Cell binding analysis of thio-labelled Alexa Fluor
488 TSPyV VP1 pentamers to HEK293 cells treated with inhibitors interfering with the synthesis of
glycosphingolipids, N. and O-linked glycoproteins. Cells were treated with (A, D) PPMP, (B, E) tunicamycin,
(C, F) BenzylGalNAc, and the respective carrier controls. The binding of TSPyV pentamers was standardized
to binding signals to mock (PBS) treated cells. 30,000 gated events were measured for each sample. Cell
binding of cholera toxin B subunit and the lectins ConA and MALII was used to monitor the effect of the
inhibitors on the cellular expression of glycans. Data was measured in three independent experiments. Error
bars indicate standard deviations.
doi:10.1371/journal.ppat.1005112.g006
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the glycerol chain of Neu5Ac in TSPyV VP1, is also present in OraPyV and ApanPyV1 VP1.
Consequently, based on the structure-based sequence alignment, we predict that TSPyV shares
its sialic acid binding site with OraPyV and ApanPyV1.
Discussion
Although a large number of new polyomavirus family members have been identified in recent
years [16], details about their receptor-binding specificities and cell attachment strategies are
not known with the exception of MCPyV and HPyV9 [23,26]. We demonstrate here that the
skin-tropic TSPyV binds sialylated glycans in a binding site formed by the BC2-loop on top of
the VP1 protein that is not utilized by any other structurally characterized member of the poly-
omavirus family. This new site is highly exposed to solvent and, apart from its location, also
unique in that the sialic acid carboxylate group is not engaged by the protein, in contrast to all
other known virus-sialic acid interactions [44]. The binding site has functional relevance, as
site-directed mutations decrease binding of VP1 pentamers and PsVs to cells as well as PsV
transduction. However, since the introduced mutations did not abolish PsV transduction
completely, we cannot rule out that additional glycan residues on sialylated oligosaccharides, a
different type of glycans such as glycosaminoglycans, or proteinous receptors are involved in
the initial steps of TSPyV infection.
Our structures show that TSPyV VP1 can interact with terminal sialic acids in α2,3- and
α2,6-linkages. Due to the exposed location of the binding site, glycans bearing terminal
α2,8-linked sialic acid may be engaged in a similar manner. It is likely that TSPyV recognizes a
more complex glycan motif or receptor similar to other polyomavirus members on its target
cells to mount an infection. This hypothesis is supported by the observation that TSPsV
Fig 7. Glycolipids are important for TSPsV infection. TSPsV infection of HEK293 pre-treated with PPMP
or the carrier control for 6 days was assayed 72 h post infection by quantification of the secreted luciferase
due to transduction of the reporter plasmid phGluc. BKPsV were used as a positive control for a ganglioside-
dependent infection. Mock PsV infections were done with a control sample obtained according the PsV
protocol from cells only transfected with phGluc and control plasmid to test for background signal of the
luciferase assay for uninfected cells. PsV experiments were done in quadruplicate and repeated three times.
The results from one representative quadruplicate experiment is shown here as an example. Statistic
analysis was performed using the two-tailed unpaired t test.
doi:10.1371/journal.ppat.1005112.g007
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transduction of HEK293 and A549 cells is reduced after interfering with the glycolipid synthe-
sis by drug treatment. However, the cell treatment with PPMP did only reduce binding of
TSPyV VP1 pentamers to HEK293, but not to A549 cells suggesting that different glycans may
support cell attachment in different cells lines. To identify the complete glycan receptor(s) for
TSPyV, further studies are required such as glycan array screening or the use of cutaneous cell
lines or primary cells for infection studies. Importantly, functional data are needed to define
the role of glycolipids for the TSPyV infection of IRS cells resulting in hyperproliferation and
TS in immunocompromised patients [7]. Compared to normal hair follicles, TS hair follicles
seem devoid of normal hair shafts and papilla but include instead large numbers of eosino-
philic, trichohyalin-positive IRS cells [45]. The composition of cell surface glycans in different
skin cells, for example the expression of mostly non-sialylated glycoconjugates in hair follicles
Fig 8. Conserved binding site for terminal Neu5Ac build up by the BC2-loop.Mapping amino acid differences between (A, C) TSPyV VP1 and OraPyV
VP1 and (B, D) TSPyV, OraPyV and ApanPyV based on the TSPyV VP1-GM1 complex structure. Amino acid differences between the two or three closely
related viruses are coloured according their conservations on the surface of TSPyV VP1. An amino acid sequence alignment was done with Clustal Omega.
JalView [67] was also used to assign values for the respective conservation of the chemical acid amino acid properties from 10 (conserved; grey) to 0 (non-
conserved; red). Values of 2 to 0 are colored in red. (C-D) Close-up views of the HI- and BC2-loop regions. The backbone of the BC2- and the ccw DE-loops
are depicted in cartoon representations. Side chains of conserved key amino acids within the BC2-binding site are shown in sticks in panel C.
doi:10.1371/journal.ppat.1005112.g008
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during the keratinization process, has been investigated by lectin histochemistry, but these
studies are often incomplete [46–48]. In addition, quantitative data and detailed information
about the prevalence of sialic acid-containing glycoconjugates and chemical modifications of
sialic acids would advance an understanding of the tropism of TSPyV for IRS cells. With regard
to sialic acids, keratinization has also been shown to include reduction of these glycan residues
in the plasma membrane of feline hair cortex during the differentiation [49]. Thus, it remains
to be investigated if additional factors besides sialic acids support TSPyV infection of these
cells. However, it is also important to realize that TSPyV is able to infect other, non-cutaneous
cell types, for example tonsillar tissue [14].
Previous functional and structural studies established that polyomaviruses have a plastic
binding site for Neu5Ac in a highly conserved region on top of VP1 that can engage the
Neu5Ac ring in at least four different orientations [30]. Exceedingly small alterations in or near
this binding site of polyomavirus VP1 have been found to modulate receptor specificity, which
can render cells refractory to infection [35,24] or are critical for pathogenicity [50,51,36]. The
case of TSPyV provides an example of a different strategy for modulating receptor interactions,
as the typical binding site is no longer accessible and a new, alternate site has been developed.
This new site is likely also present in related polyomaviruses. Examples for virus families in
which members use different sites to engage a similar glycan receptor epitope are rare and
include reoviruses [52,53] and adenoviruses [54–56]. While the physiologic reason for such
alternate binding sites is not clear in either of these cases, virus-glycan interactions seem well
suited for such shifts as they are usually of low affinity and depend on only a few specific con-
tacts that can easily be modulated.
Many polyomaviruses form ‘pairs’ in which a human and a non-human version are most
similar in sequence and therefore most likely closely linked in evolution [43,57]. A recent
example is the HPyV9-LPyV pair, which displays subtle differences in sialic acid specificity
[25,26]. In most cases, however, we lack knowledge about how such pairs differ in structure
and receptor recognition, and how differences might relate to host tropism [34]. The architec-
ture and the location of the BC2-loop binding region in TSPyV is likely conserved in OraPyV
and ApnPyV1, and it is tempting to speculate that sequence differences near the conserved HI-
loop binding region modulate binding to more complex, and perhaps subtly differing, sialy-
lated glycan structures expressed on cells in the respective hosts.
Our analysis of TSPyV glycan binding properties provides a useful platform for further
studies to define role of glycans for the TSPyV entry pathway, cell and host tropism as well as
pathogenicity in order to understand structural determinants of receptor and host switching
events. Such studies will inform not only polyomavirus research but also help to provide guide-
lines for rationalizing the receptor-binding specificities and tropism of other glycan-binding
viruses.
Materials and Methods
Cell culture
Cells were maintained in a humidified 37°C CO2 chamber in Dulbecco’s Modified Eagle Media
(DMEM) or Minimum Essential Media (MEM) supplemented with 1% penicillin/streptomycin
and 10% heat-inactivated fetal bovine serum (FBS). SVGA cells have been derived from the
original SVG human glial cell line established by SV40 transformation of human fetal glial cells
[58]. HEK293 cells (human embryonic kidney cell line), HeLa cells (human epithelial cell line
derived from cervical carcinoma), Vero cells (monkey kidney epithelial cell line), CHO cells
(epithelial cell line derived from hamster ovaries), and A549 cells (human lung epithelial) were
purchased from the American Type Culture Collection (ATCC). HEK293TT cells are HEK
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cells transformed with two copies of SV40 large T antigen (a gift from Dan DiMaio, Yale
University).
Protein expression, purification and fluorescence labeling
cDNA sequence (GenBank accession code ADK12664) coding for amino acids 31–304 of
TSPyV VP1 was amplified by PCR and cloned into the NheI and BamHI restriction sites of
pET28b (Novagen). To be consistent with the previously described polyomavirus VP1 penta-
mer structures and to facilitate structural comparisons, the amino acid numbering of TSPyV
VP1 (amino acids 30–303) used here in this study excludes the N-terminal methionine. The N-
and C-terminal truncated TSPyV VP1 expression construct possesses an N-terminal hexahisti-
dine tag (His-tag) followed by a thrombin cleavage site. Site-directed mutagenesis was done
using 5’ to 3’ primers as follows (mismatched nucleotides are highlighted in boldface):
K71L: CTAAGGACAACTATGGTTACAGTGAACTAGTAACTGTTGCTAACAGCAG,
CTGCTGTTAGCAACAGTTACTAGTTCACTGTAACCATAGTTGTCCTTAG; T74A:
GGTTACAGTGAAAAAGTAGCTGTTGCTAACAGCAGTGACCAG,
CTGGTCACTGCTGTTAGCAACAGCTACTTTTTCACTGTAACC;
T73E: GGTTACAGTGAAAAAGTAGAAGTTGCTAACAGCAGTGACCAGGACAAGC,
GCTTGTCCTGGTCACTGCTGTTAGCAACTTCTACTTTTTCACTGTAACC; T74Q: GGTTACAGT-
GAAAAAGTACAGGTTGCTAACAGCAGTGACCAGGACAAGC, GCTTGTCCTGGTCACTGCTGTTAG-
CAACCTGTACTTTTTCACTGTAACC T85A:
CAGTGACCAGGACAAGCCTGCTTCTGGAGAGATAC,
GTATCTCTCCAGAAGCAGGCTTGTCCTGGTCACTG;
R137A: CTGGTAAATGTTCATATGGCTACTAAAGCAATGTATGATGACAAAGGTATTG,
CAATACCTTTGTCATCATACATTGCTTTAGTAGCCATATGAACATTTACCAG
Expression was performed in E. coli BL21 (DE3), and His-tagged VP1 was purified by nickel
affinity chromatography from the crude cell extract. For crystallization, the His-tag was cleaved
off in solution using thrombin (GE Healthcare). Six non-native residues (GSHMAS) are pres-
ent at the N-terminus of VP1 after thrombin cleavage. His-tagged and cleaved wild type and
mutant VP1 pentamers were further purified by gel filtration (Superdex 200). Prior to flow
cytometry experiments, His-tagged VP1 pentamers were labeled with Alexa Fluor 488 C5 mal-
eimide (Invitrogen). VP1 pentamers (1 mg/ml) were incubated for 16–18 h with 80 mM dithio-
threitol (DTT) at 4°C. Excess DTT was removed using 2 x 5 ml HiTrap Desalting columns (GE
Healthcare) and then the dye (10 mM in 20 mMHEPES pH 7.0, 150 mMNaCl) was added
dropwise by gently mixing to the protein solution (0.2–0.3 mg/ml in 20 mMHEPES pH 7.0,
150 mMNaCl) to give a 10 molar excess of the dye. The reaction was incubated for 18 h at 4°C.
10 mMDTT were added and excess of the dye and DTT were removed by desalting. The label-
ing efficiency was determined by absorption according to the manufacturer's protocol. The
molecular ratio was about 1: 4 (VP1 pentamer: dye) for wild type and mutant VP1 pentamers.
Flow cytometry experiments
Cells that were 80–90% confluent were detached non-enzymatically from flasks by incubation
with Cellstripper (Corning) for 10–20 min at 37°C. Cells were washed twice with PBS. Next,
106 cells were suspended in 75 μl of labeled wild type and mutant TSPyV VP1 pentamer solu-
tion (20 μg/ml in PBS) for incubation on ice for 2 h with agitation every 20 min. Cells were
washed twice in PBS and then fixed in 500 μl of 1% paraformaldehyde. Analysis was done
using a BD FACSCalibur (Becton, Dickinson and Company) flow cytometer equipped with a
488-nm excitation line. Between 30,000 to 50,000 gated events were measured for each sample.
Data were analyzed using FlowJo software (Tree Star, Inc.).
The flow cytometry experiments with the PsV were performed on purified PsV labeled with
Alexa Fluor 488 carboxylic acid succinimidyl ester (Invitrogen). After labeling, PsVs were
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dialyzed into 10 mM Tris pH 7.4, 50 mMNaCl, 0.01 mM CaCl2 using 10,000 MWCO Slide-
A-Lyzer dialysis cassettes (Life Technologies) to remove excess dye.
Labeled PsV preparations were normalized for VP1 content by Western blot. 6 x 105 cells
were mixed with equal amounts of labeled PsV as determined by Western Blot (about 50 μg
τοταλ προτειν, measured via absorption at 280 nm) in 50 μl allowed to bind on ice for 30 min-
utes, washed and resuspended in PBS and then analyzed as pentamers counting 10,000 events.
Experiments were performed in triplicate.
Fluorescein-labeled Concanavalin A (ConA, Vector Laboratories, USA) was added at a con-
centration of 1 μg/ml in 100 μl PBS to 106 cells and was incubated on ice for 1 h with agitation
every 20 min. Biotin-labeledMaackia amurensis II lectin, (MALII; Vector Laboratories, USA)
at a concentration of 1 μg/ml was incubated with 106 cells in 100 μl PBS on ice for 1 h. In the
case of MALII, cells were washed 2x in PBS and detection of MALII was carried out with Alexa
Fluor 488-labeled Streptavidin (488-Strep, Invitrogen), which was added at 2 μg/ml to about
106 cells in 100 μl PBS for 30 min. Mock treated cells were incubated with 488-Strep as a nega-
tive control. The cholera toxin subunit B Alexa Fluor 488 conjugate (Invitrogen) was added at
10–20 μg/ml in 100 μl PBS to 106 cells and was incubated with 106 cells in 100 μl PBS on ice for
2 h. Prior to measurement by flow cytometry, cells were washed again twice with PBS and were
then fixed in 500 μl of PBS, 1% paraformaldehyde.
PsV production
For expression in the human derived cell line HEK293TT, codon optimization of TSPyV VP1,
VP2 and VP3 genes was performed according the guidelines from the National Cancer Insti-
tute Center for Cancer Research Lab of Cellular Oncology Technical Files (http://home.ccr.
cancer.gov/LCO/production.asp). DNA was synthesized by BlueHeron Biotechnology, LLC
(Bothell, WA, USA). The VP1 gene was subcloned into the pwP vector in place of the MPyV
VP1 gene and VP2 and VP3 genes into the ph2p vectors in place of the respective MPyV genes.
Sequences are based on VP1, VP2 and VP3 sequences (NCBI reference YP_003800006,
YP_003800004, YP_003800005) from the full length TSPyV genome (NCBI reference
NC_014361). The luciferase reporter vector phGluc expresses a secreted form of Gaussia lucif-
erase under control of the EF1α promoter. The parent PsV plasmids were obtained from
AddGene (Cambridge, MA, USA). Site-directed mutagenesis of PsV VP1 was done using 5’ to
3’ primers as follows (mismatched nucleotides are highlighted in boldface):
K71L: GATAATTACGGCTATTCCGAGCTGGTGACCGTCGCCAATTCATC;
GATGAATTGGCGACGGTCACCAGCTCGGAATAGCCGTAATTATC;
T73E: CTATTCCGAGAAGGTGGAAGTCGCCAATTCATCCGATC;
GATCGGATGAATTGGCGACTTCCACCTTCTCGGAATAG;
T84A: CGATCAAGATAAACCCGCCAGCGGCGAAATCCCCAC;
GTGGGGATTTCGCCGCTGGCGGGTTTATCTTGATCG;
TSPsV were purified by a sucrose gradient followed by a CsCl gradient as described earlier
[59].
Titers of purified PsV were determined according the encapsidated reported plasmid
phGluc for infections studies. PsV preparations were treated with DNAse I (New England Bio-
loabs) for 60 min. DNAse I was then inactivated by 75°C for 10 min and protected phGluc was
extracted using the DNeasy Blood and Tissue kit (Qiagen). The titer of packaged reporter plas-
mid was determined by TaqMan quantitative PCR (Applied Biosystems) and a standard curve
for serial dilutions of phGluc.
For PsV binding studies, labeled PsV content was normalized by Western blotting detection
with purified PAB597, a hybridoma supernatant that produces a monoclonal antibody against
JCPyV VP1, which we found to cross-react with TSPyV VP1.
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PsV infections
For PsV infection assay cells were seeded to 6,000–7,000 cells per well in a 96-well plate 18 h
prior the infection. PsV Infections were performed by adding 5.5 x 105 or 5.5 x 106 PsV parti-
cles to each well in 35 μl serum free media for 2 h at 37°C with 30 min agitations. Cells were
washed twice with PBS and media was the replaced with phenol red free media with FBS.
Mock PsV controls were generated by transfecting 293TT cells with control plasmid and the
phGluc reporter plasmid in a 7:1 ratio and then purifying according to the PsV purification
protocol. PsV infection was measured after 3 days by detection of secreted luciferase according
to the manufacturer’s instructions (BioLux Gaussia Luciferase Assay Kit, New England Bio-
labs) using an opaque 96-well microplate in a GloMax Multi-Detection System Luminometer
(Promega) equipped with an autoinjector. Infection assays were done in quadruplicate and
repeated three times. The Cell Titer 96 Aqueous Non-Radioactive Cell Proliferation Assay
(Promega) was used according to the manufactor’s protocol to test for toxicity after cell treat-
ments and the absorption was measured at 450 nm.
Treatment of cells with neuraminidase
Prior to flow cytometry experiments, cells were detached non-enzymatically and washed twice
with PBS (see above). Then, 106 cells were resuspended in 100 μl PBS and treated with 1 U/ml
neuraminidase (Clostridium perfringens neuraminidase type V, Sigma-Aldrich) for 30 min at
37°C with agitation every 10 min. Prior to PsV infection or binding, cells were washed once
with serum free media for infection studies or PBS for binding studies and incubated with 1 U/
ml neuraminidase in PBS or in PBS (Mock) for 30 min at 37°C with agitation every 10 min.
Cells were then washed with media and serum free media before PsV infection or twice with
PBS before binding studies.
Treatment of cells with inhibitors of N- and O-linked glycosylations and
inhibitor of glycosphingolipid synthesis
Cells were plated in 6-well plates (5 x 105 cells/per well) for the flow cytometry experiment and
in a 96-well plate (104 cells/per well) for PsV infections. Glycosylation inhibitors were mixed in
media containing 10% FBS at various concentrations to plated cells. Cells were preincubated
with tunicamycin (Sigma-Aldrich) in methanol at 37°C for 16–18 h and with BenzylGalNAc
(Calbiochem, USA) in DMSO for 48 h prior to the flow cytometry experiment. D,L-threo-phe-
nyl-2-hexadecanoylamino-3-morpholino-propanol (PPMP) (Matreya LLC, USA) in ethanol
was added to the media of cells for 6 days, and media supplemented with PPMP was changed
after days 2 and 4. Vehicle controls with equivalent volumes of methanol, DMSO or ethanol
for the highest concentration were used in each case. The Cell Titer 96 Aqueous Non-Radioac-
tive Cell Proliferation Assay (Promega) was used according to the manufacturer's protocol to
assess toxicity of the inhibitors (absorption at 450 nm).
Crystallization and data collection
TSPyV VP1 was concentrated to 4.8 mg/ml in 20 mMHEPES pH 7.5, 150 mMNaCl, 20 mM
dithiothreitol (DTT) and crystallized at 20°C by sitting drop vapor diffusion against a reservoir
containing 100 mM sodium malonate pH 5.0, 10% (w/v) PEG 3350. Drops were set up using
1 μl protein solution, 1 μl reservoir solution and 0.2 μl microseeding solution, which was pre-
pared from previously obtained TSPyV VP1 microcrystals. For complex formation with the
GM1 glycan and 6’SL, crystals were grown in a drop supplemented with 10 mMGM1 penta-
saccharide (Elicityl, France) or 10 mM 6’SL (Carbosynth, UK). Crystals were harvested after
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five days and transferred stepwise into reservoir solution complemented with the respective
glycan and 30% (v/v) glycerol for cryoprotection before flash-freezing them in liquid nitrogen.
For complex formation with 3’SL, preformed native TSPyV VP1 crystals were soaked for 15
min in the reservoir solution supplemented with 10 mM 3’SL (Carbosynth, UK) before flash
freezing. Data sets were collected at beam lines X06DA and X06SA at the Swiss Light Source
(Villigen, Switzerland).
Structure determination
Diffraction data was processed with XDS [60], and structures were solved by molecular
replacement with Phaser in CCP4 [61,62]. The MCPyV VP1 core structure (pdb: 4FMG) was
taken as a homology search model for the native TSPyV VP1 structure, which was then used
for structure determination of glycan complex structures. Rigid body and simulated annealing
refinement was carried out with Phenix [63]. Alternating rounds of model building in Coot
[64] and restrained refinement including the translation-libration-screw (TLS) method [65]
and 5-fold noncrystallographic symmetry (NCS) restrained refinement were done with
Refmac5 [66]. The carbohydrate ligands were located in 2Fo-Fc and Fo-Fc electron density
maps. After incorporation into the model, ligands were refined using restraints from the CCP4
library and user defined restraints for the α2,3 and α2,3- glycosidic bonds. The native TSPyV
VP1 structure and the structures complexed with 3’SL and 6’SL possess ten VP1 chains in the
asymmetric unit, while the asymmetric unit of the VP1-GM1 glycan complex structure com-
prises five chains. The final VP1 structures contain amino acid residues 33–40, 44–101 and
110–303 for all chains. Residues of the short loop region between the Anew- and the B-strand
(residues 40–44) and the CD-loop (residues 101–110) could be built into defined electron den-
sity for some VP1 chains. However, these residues generally display elevated temperature fac-
tors, indicating flexibility of these two regions at the bottom of the unassembled VP1 pentamer
if not involved in crystal contacts. To assess amino acid conservations on the VP1 surface, an
alignment was carried out with Clustal Omega and JalView [67] with the VP1 sequences from
OraPyV (NCBI reference YP_003264533) and ApanPyV1 (NCBI reference YP_007195272).
Assign values for the conservation of the chemical acid amino acid properties from 10 (con-
served; grey) to 0 (non-conserved; red) in JalView were than highlighted on the TSPyV
VP1-GM1 complex surface. Values of 2 to 0 are coloured in red.
Structure figures were prepared with PyMOL (The PyMOL Molecular Graphics System,
Version 1.3, Schrödinger, LLC).
Saturation transfer difference (STD) NMR
STD NMR spectra were recorded using 3 mm tubes on a Bruker AVIII-600 MHz spectrome-
ter equipped with a room temperature probe head at 288 K. Data was processed with TOP-
SPIN 3.0 (Bruker). The sample contained 2 mM GM1 oligosaccharide (Elicityl, France) or
20 μM TSPyV VP1 and 2 mM GM1 oligosaccharide, respectively, in 20 mM K2HPO4/
KH2PO4 pH 7.4, 150 mM NaCl, 99%D2O. Off- and on-resonance frequencies were -30 ppm
and 7.3 ppm, respectively. The irradiation power and length of the selective pulse train was
57 Hz and 2 s, respectively. In order to suppress residual protein resonances a continuous-
wave spin-lock pulse with a strength of 3.2 kHz was employed. The relaxation delay was 3 s
and a total of 5 k scans were recorded. Spectra were multiplied with a Gaussian window func-
tion prior to Fourier transform and referenced to the a-D-Glc anomeric proton as an internal
standard [68].
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Accession numbers
Coordinates and structure factor amplitudes were deposited in the RCSB Protein Data Bank
(www.pdb.org) under accession codes 4U5Z (unliganded TSPyV VP1), 4U60 (TSPyV
VP1-GM1 glycan), 4U61 (TSPyV VP1-6’SL) and 4U62 (TSPyV VP1-3’SL).
Supporting Information
S1 Fig. The binding of Alexa Fluor 488-labelled VP1 pentamers from TSPyV and BKPyV
to Mock (PBS) or Clostridium perfringens neuraminidase type V pre-treated cells measured
by flow cytometry. Non-standardized raw data is shown here for individual experiments. Data
was standardized for signals of mock treated cells to obtain the histogram in Fig 1A showing
the relative binding of TSPyV VP1 pentamers. The relative average fluorescence from three
independent experiments is shown compared to binding to untreated cells. 30,000 gated events
were measured for each sample.
(TIF)
S2 Fig. Screening cell lines for TSPsV infection. TSPyV pentamers bind to all tested cell lines
in a sialic acid-dependent manner (see Fig 1 and S2 Fig panel B), but TSPsV transduction
could only be detected for HEK293 and SVGA cells. (A) Common cell lines were infected with
TSPsV to obtain information about the tropism. At 72 h post infection the luciferase expression
was measured to determine transfection efficiency of TSPsV. Cell lines where TSPsV infection
was undetectable are in general able to express the reporter plasmid [40]. The average relative
luciferase units (RLUs) for one experiment performed in quadruplet are shown in log scale.
Error bars represent standard deviations. Two different dilutions of particles were used and
compared to Mock PsV control. The mock PsV control was generated by harvesting
HEK293TT cells transfected with control plasmid instead of the capsid expression plasmids
and then purifying according to the PsV purification protocol to measure background signal
and non-specific transfer of luciferase to infected cells. (B) The binding of Alexa Fluor
488-labelled TSPyV VP1 pentamers to Mock (PBS) or Clostridium perfringens neuraminidase
type V pre-treated Vero and CHO cells was measured by flow cytometry. BKPyV VP1 penta-
mers were used as a positive control. Non-standardized raw data is shown here for representa-
tive individual experiments. Three independent experiments were performed and 30,000 gated
events were measured for each sample.
(TIF)
S3 Fig. Mapping the GM1 glycan binding epitope of TSPyV VP1 in solution. Saturation
transfer difference (STD) NMR of TSPyV VP1 with the GM1 glycan. From top to bottom:
STD-NMR difference spectrum of 50 μMTSPyV VP1 with 1 mM GM1 glycan; 1H reference
spectrum recorded with the same sample; STD spectrum of the GM1 glycan alone.
(TIF)
S4 Fig. Glycolipids are important for TSPsV infection in A549 cells. TSPsV transduction of
A549 cells pre-treated with PPMP or the carrier control for 6 days was assayed 72 h post infec-
tion by quantification of the secreted luciferase due to transduction of the reporter plasmid
phGluc. BKPsV were used as a positive control for a ganglioside-dependent infection. Mock
PsV infections were done with a control sample obtained according the PsV purification proto-
col from cells only transfected with phGluc and control plasmid to assess the background sig-
nal of the luciferase assay. PsV experiments were done in triplicate or quintuplicate. The data
from the quintuplicate experiment is shown as a representative example. Statistic analysis was
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performed using the two-tailed unpaired t test.
(TIF)
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S1 Fig.: The binding of Alexa Fluor 488-labelled VP1 pentamers from TSPyV and BKPyV to 
Mock (PBS) or Clostridium perfringens neuraminidase type V pre-treated cells was measured 
by flow cytometry. Non-standardized raw data is shown here for individual experiments. To 
obtain the histogram in Fig. 1 B and C showing the relative binding of TSPyV VP1 pentamers 
data was standardized for signals of mock treated cells. The relative average fluorescence from 
three separated experiments is shown compared to binding to untreated cells. 30,000 gated 
events were measured for each sample.  
 
 
S2 Fig.: Screening cell lines for TSPsV infection. TSPyV pentamers bind to all tested cell lines 
in a sialic acid-dependent manner (see Fig. 1 and S1 Fig., and panel B), but TSPsV 
transduction could only be detected for HEK293 and SVG-A cells. 
(A) Common cell lines were infected with TSPsV to obtain information about the tropism. At 72 
h post infection the luciferase expression was measured to determine transfection efficiency of 
TSPsV. Cell lines where TSPsV infection was undetectable are in general able to express the 
reporter plasmid [39]. The average relative luciferase units (RLUs) for one experiment 
performed in quadruplet are shown in log scale. Error bars represent standard deviations. Two 
different dilutions of particles were used and compared to Mock PsV control. The mock PsV 
control was generated by harvesting HEK293TT cells transfected with control plasmid instead 
of the capsid expression plasmids and then purifying according to the PsV purification protocol 
to measure background signal and non-specific transfer of luciferase to infected cells. 
(B) The binding of Alexa Fluor 488-labelled TSPyV VP1 pentamers to Mock (PBS) or 
Clostridium perfringens neuraminidase type V pre-treated Vero and CHO cells was measured 
by flow cytometry. BKPyV VP1 pentamers were used as a positive control. Non-standardized 
raw data is shown here for representative individual experiments. Three independent 
experiments were performed and 30,000 gated events were measured for each sample.  
 
 
S3 Fig.: Glycolipids are important for TSPsV infection in A549 cells. 
TSPsV transduction of A549 cells pre-treated with PPMP or the carrier control for 6 days was 
assayed 72 h post infection by quantification of the secreted luciferase due to transduction of 
the reporter plasmid phGluc. BKPsV were used as a positive control for a ganglioside-
dependent infection. Mock PsV infections were done with a control sample obtained according 
the PsV purification protocol from cells only transfected with phGluc and control plasmid to 
assess the background signal of the luciferase assay. PsV experiments were done in triplicate 
or quintuplicate. The data from the quintuplicate experiment is shown as a representative 
example. Statistic analysis was performed using the two-tailed unpaired t test.  
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ABSTRACT
The human JCpolyomavirus (JCPyV) establishes an asymptomatic, persistent infection in the kidneys of themajority of the popula-
tion and is the causative agent of the fatal demyelinating disease progressivemultifocal leukoencephalopathy (PML) in immunosup-
pressed individuals. TheMad-1 strain of JCPyV, a brain isolate, was shown earlier to require2,6-linked sialic acid on the lactoseries
tetrasaccharide c (LSTc) glycan for attachment to host cells. In contrast, a JCPyVkidney isolate type 3 strain,WT3, has been reported to
interactwith sialic acid-containing gangliosides, but the role of these glycans in JCPyV infection has remained unclear. To help ratio-
nalize these findings and probe the effects of strain-specific differences on receptor binding, we performed a comprehensive analysis of
the glycan receptor specificities of these two representative JCPyV strains using high-resolutionX-ray crystallography andnuclear
magnetic resonance (NMR) spectroscopy, and correlated these datawith the results of infectivity assays.We showhere that capsid pro-
teins ofMad-1 andWT3 JCPyV can both engage LSTc aswell asmultiple sialylated gangliosides.However, the binding affinities exhibit
subtle differences, with the highest affinity observed for LSTc. Engagement of LSTc is a prerequisite for functional receptor engage-
ment, while themoreweakly binding gangliosides are not required for productive infection.Our findings highlight the complexity of
virus-carbohydrate interactions anddemonstrate that subtle differences in binding affinities, rather than the binding event alone, help
determine tissue tropismand viral pathogenesis.
IMPORTANCE
Viral infection is initiated by attachment to receptors on host cells, and this event plays an important role in viral disease. We
investigated the receptor-binding properties of human JC polyomavirus (JCPyV), a virus that resides in the kidneys of the ma-
jority of the population and can cause the fatal demyelinating disease progressive multifocal leukoencephalopathy (PML) in the
brains of immunosuppressed individuals. JCPyV has been reported to interact with multiple carbohydrate receptors, and we
sought to clarify how the interactions between JCPyV and cellular carbohydrate receptors influenced infection. Here we demon-
strate that JCPyV can engage numerous sialylated carbohydrate receptors. However, the virus displays preferential binding to
LSTc, and only LSTc mediates a productive infection. Our findings demonstrate that subtle differences in binding affinity, rather
than receptor engagement alone, are a key determinant of viral infection.
JC polyomavirus (JCPyV) infects 50% of healthy individualsand causes an asymptomatic, lifelong persistent infection in the
kidney (1, 2). The form of the virus that resides in the kidney is
nonpathogenic and is excreted in the urine (3, 4). In immunosup-
pressed individuals, JCPyV can spread from the site of persistence
to the central nervous system (CNS) (5, 6) and infect the glial cells
astrocytes and oligodendroctyes (7, 8). Oligodendrocytes are my-
elin-producing cells, and astrocytes have been demonstrated to be
critical to the process of CNS myelination (9–11). Infection of
astrocytes and glial progenitor cells (GPCs), together with virus-
induced cytolytic destruction of oligodendrocytes, causes the de-
myelinating disease progressive multifocal leukoencephalopathy
(PML) (12–14). The disease, once considered fatal, is now managed
with immune reconstitution therapy, but surviving patients remain
severely debilitated (15). PML affects approximately 3 to 5% of HIV-
1-positive individuals and patients receiving immunomodulatory
therapies such as natalizumab and rituximab for immune-mediated
diseases such as multiple sclerosis (MS), Crohn’s disease, and rheu-
matoid arthritis (13, 16, 17). As of December 2014, there had been
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517 cases of natalizumab-induced PML, and 23% of these PML pa-
tients have died, since the introduction of the drug in 2004 (Biogen
Idec, 2014). Newly marketed therapies such as dimethyl fumarate
and other fumaric acid ester-containing drugs prescribed for MS and
psoriasis have also led to PML (18, 19), indicating an urgent need to
better understand the disease pathogenesis of JCPyV.
Polyomaviruses have an icosahedral, nonenveloped protein
capsid that is comprised of VP1, VP2, and VP3. VP1 is a pen-
tameric protein present as 360 copies on the surface of the
capsid, which are connected to neighboring pentamers
through C-terminal extensions (20). Each VP1 pentamer also
interacts with a VP2 or a VP3 molecule in the interior of the
capsid (21), and together they encase the double-stranded
DNA (dsDNA) genome. Surface loops connecting the -strand
core structure of VP1 mediate interactions with sialic acid re-
ceptors (22–27). The Mad-1 strain of JCPyV utilizes the sialic
acid receptor motif 2,6-linked lactoseries tetrasaccharide c
(LSTc) for attachment (24) and then enters by clathrin-depen-
dent endocytosis supported by the 5-hydroxytryptamine 2 (5-
HT2) family of serotonin receptors (28). Other members of the
Polyomaviridae family, such as BK polyomavirus (BKPyV),
Merkel cell polyomavirus (MCPyV), simian virus 40 (SV40), and
mouse polyomavirus (MPyV), engage ganglioside receptors con-
taining2,3- and2,8-linked sialic acids (23–25, 29, 30) and enter
cells by caveola-dependent endocytosis (31). Gangliosides are a
group of glycosphingolipids expressed on eukaryotic cells with a
ceramide chain embedded in the membrane and an extracellular
oligosaccharide (32).
JCPyV strains are classified into seven genotypes that possess
amino acid differences at up to 13 positions within the VP1 capsid
protein (33) (Fig. 1A). The JCPyV brain isolate Mad-1 strain, with a
type 1 capsid, was found to specifically engage2,6-linked sialic acid
in the context of the LSTc pentasaccharide to mediate infection (24).
However, other laboratories have demonstrated that virus-like parti-
cles (VLPs) of a strain referred to as WT3, with a type 3 capsid that
differs from type 1 at 8 amino acid positions, are capable of engaging
multiple sialic acid-containing ganglioside receptors (6). WT3 VLPs
have been reported to bind to asialo-GM1, GD1a, GD1b, GD2, and
GT1b (6) and GM1 and GM2 (Leonid Gorelik, Consortium for
Functional Glycomics [CFG] [available at www.functionalglycomics
.org]). Additionally, Mad-1 VLPs were demonstrated by virus overlay
blotting assay to bind to a number of gangliosides, including GM3,
GD2, GD3, GD1a, GD1b, GT1b, and GQ1b, but not GM1 or GM2
(34). However, the relevance of the interactions of JCPyV with mul-
tiple sialylated glycans in the context of JCPyV infection remained
unclear.
Cellular entry of the JCPyV strain Mad-1 has been shown to be
mediated by 5-HT2 receptors (5-HT2Rs) (28), and infection of
5-HT2R-expressing HEK293A cells with Mad-1 and WT3 is
equivalent (M. S. Maginnis and W. J. Atwood, unpublished re-
sults), suggesting that both strains utilize 5-HT2Rs for internaliza-
tion. Further, the expression of 5-HT2Rs at the cell surface does
not increase viral attachment to host cells (28). Therefore, JCPyV
attachment and entry steps are likely related but distinct steps, and
viral attachment to sialic acid receptors prior to entry plays a key
regulatory role in infection and disease (24, 35). Viral isolates
from the brains of individuals with PML contain polymorphisms
in the capsid that are representative of both type 1 and type 3
strains (36), suggesting that if JCPyV utilizes multiple sialic acid-
containing receptors, these polymorphisms might play a role in
viral pathogenesis.
The goal of this study was to unravel the molecular details of
carbohydrate receptor engagement by JCPyV in order to under-
stand how recognition and specificity contribute to a pathogenesis
that ultimately culminates in a devastating CNS disease. To clarify
the role of sialic acid-containing receptors in JCPyV infection, we
utilized a structure-function approach to define the role of these
polymorphisms in JCPyV attachment to cellular receptors and
infection of glial cells by generating WT3 VP1 in an infectious viral
clone, in pseudoviruses, and in purified VP1 pentamers using the
Mad-1 prototype PML strain as the backbone.
MATERIALS AND METHODS
Cells, viruses, and antibodies. SVGA cells (37) were grown in minimum
essential medium (MEM) supplemented to contain 10% fetal bovine se-
rum (FBS) and 1% penicillin-streptomycin (P-S) (Mediatech, Inc.) in a
humidified incubator at 37°C with 5% CO2. HEK293A cells (ATTC) were
grown in Dulbecco’s modified Eagle medium (DMEM) supplemented to
FIG1 VP1 amino acid variations in JCPyV genotypes and crystal structure of WT3 VP1. (A) Classification of JCPyV strains into seven genotypes by phylogenetic
analysis reveals VP1 amino acid variations (33). Colored spheres highlight residues differing between Mad-1 and WT3 VP1. Strain specific variations can be
found within single genotypes. Bold letters indicate amino acids in Mad-1 VP1. N- and C-terminal residues (gray) are not included in the JCPyV Mad-1 VP1
crystal structure (24). (B) Crystal structure of WT3 VP1 pentamer with one VP1 monomer depicted in green. Spheres highlight residues (colored as in panel A)
that differ between WT3 and Mad-1 VP1.
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contain 10% FBS and 1% P-S. 293TT cells are derived from human em-
bryonic kidney cells transformed with two copies of the SV40 large T
antigen (a gift from Dan DiMaio’s laboratory) and were grown in DMEM
supplemented to contain 10% FBS, 0.1 mM nonessential amino acids
(NEAA), and 250 g/ml hygromycin B.
Generation and propagation of the virus strain Mad-1/SVEwas pre-
viously described (38, 39). Mad-1/WT3C virus (PubMed accession code
AAQ88264) was generated by introducing the VP1 mutations R74K,
S116T, G133A, L157V, and K163T into the genomic JCPyV DNA of strain
JC12 with a Mad-1 VP1 (40) subcloned into pUC19 (41). Mutations
R74K, S116T, G133A, and K163T were introduced by site-directed mu-
tagenesis using the Agilent QuikChange II site-directed mutagenesis kit
(Qiagen) according to the manufacturer’s instructions and the following
mutagenesis primers (5= to 3=): R74K, ACATTTGAAAAGTGACTCCCC
AAATAAGGACATGCTTCCTT and AAGGAAGCATGTCCTTATTTG
GGGAGTCACTTTCAAATGT; S116T, AGGTTATAGGGGTGACAACT
TTGATGAATGTGCACTC and GAGTGCACATTCATCAAAGTTGTC
ACCCCTATAACCT; G133A, TGACAATGGTGCAGCGAAGCCAGTG
CAGG and CCTGCACTGGCTTCGCTGCACCATTGTA; and K163T,
GGGGTGCTTTTTAATTACAGAACAACGTACCCAGATGGAACAAT
TTTT and AAAAATTGTTCCATCTGGGTACGTTGTTCTGTAATTAA
AAAGCACCC. L157V was introduced by Phusion mutagenesis using the
primers (5= to 3=) ATTACAGGGGGTGGTCTTTAATTACAGAAC and
TCTAAAGCCTCCCCCCCAACAGA. Sequencing was performed at
Genewiz Inc.
Mad-1 and Mad-1/WT3C viruses were propagated by transfecting 2 to
4 T150 flasks of SVGA cells with 32g of the infectious JCPyV clone with
either the Mad-1 or Mad-1/WT3C VP1 that had been digested from the
pUC19 plasmid using BamHI using Fugene. At 48 h posttransfection, cells
were split into roller bottles (1,650 cm2) and incubated with complete
MEM in a humidified roller cabinet at 37°C with 5% CO2. Infected cells
were incubated for 2 weeks, with the medium changed at 1 week postin-
fection with complete MEM. Cells were harvested by scraping, and viruses
were purified as described previously (39).
GM3 siRNA treatment. siGENOME human ST3GAL5 small interfer-
ing RNAs (siRNAs) 1, 3, 4, and 17 were purchased from Thermo Scien-
tific. The siRNA target sequences are as follows: 1, CAAUGGCGCUGUU
AUUUGA; 3, GACCAUGCAUAAUGUGACA; 4, CGGAAGUUCUCCAG
UAAAG; and 17, AGGAAUACUGCACGGAUUA. SignalSilence control
siRNA (Cell Signaling Technology) was used as a control siRNA. SVGA cells
were reverse transfected with siRNAs using RNAiMax transfection reagent
(Invitrogen) by mixing transfection complexes in Opti-MEM in 24-well
plates and incubating at room temperature for 20 min. Following incubation,
3  104 cells/well were added, and cells were incubated at 37°C for 72 h.
Transfection efficiency was confirmed using BLOCK-iT Alexa Fluor Red con-
trol oligonucleotide (Life Technologies). At 72 h posttransfection, cells were
either harvested for mRNA analysis or infected with JCPyV or SV40 as de-
scribed below. For mRNA analysis, cells were harvested using CellStripper,
washed in phosphate-buffered saline (PBS), and pelleted by centrifugation at
2,000 rpm at 4°C for 5 min. Cells were washed in PBS and pelleted, and RNA
was extracted using the RNeasy minikit (Qiagen) with a DNase treatment
(Qiagen). One microgram of RNA was reverse transcribed using Bio-Rad
iScript cDNA synthesis according to the manufacturer’s instructions, and 1l
of the total reaction product was used for quantitative PCR (qPCR) analysis
using Bio-Rad iQ SYBR green Supermix and Bio-Rad iQ5. Primers used for
qPCR to detect ST3GAL5 (5= to 3=) were CTGCCTTTGACATCCTTCAGT
and CGATTGTGGGGACGTTCTTA, and those for the GAPDH (glyceral-
dehyde-3-phosphate dehydrogenase) housekeeping gene were AGTCAGCC
GCATCTTCTTTTGC and CAATACGACCAAATCCGTTGACT. Relative
ST3GAL5 gene expression was determined by calculating the change in
threshold cycle (CT) relative to GAPDH (housekeeping) gene expression,
andCT was calculated relative to scrambled control siRNA.
JCPyV infection. SVGA or HEK293A cells were washed following
ganglioside treatment, infected with purified Mad-1 and Mad-1/WT3C
JCPyV at a multiplicity of infection (MOI) of 5 focus-forming units
(FFU)/cell in MEM containing 2% FBS in a volume of 100 to 200 l, and
incubated at 37°C for 1.5 h, and then complete MEM was added and cells
were incubated at 37°C for 48 h (T antigen) or 72 h (VP1).
LSTc and GM1 pentasaccharide inhibition assay. Purified Mad-1
and Mad-1/WT3C were pretreated with 5 mM LSTc (V Labs, Inc.) or
GM1 (Enzo Life Sciences) pentasaccharides (diluted in sterile distilled
water) in medium containing 2% fetal calf serum (FCS) on ice for 1 h.
SVGA cells in 96-well plates were prechilled at 4°C for 30 min. Virus-
pentasaccharide complexes were added to cells and incubated at 4°C for 1
h. Cells were washed with PBS twice, complete medium was added, and
cells were incubated at 37°C for 72 h. Cells were fixed and stained by
indirect immunofluorescence as described below.
Indirect immunofluorescence. Cells were washed in PBS, fixed in
cold methanol, and incubated at 20°C. Fixed cells were stained using
PAB597, a hybridoma supernatant that produces a monoclonal antibody
against JCPyV VP1 that was generously provided by Ed Harlow, as de-
scribed previously (35) or using PAB962, a JCPyV-specific T antigen an-
tibody that does not cross-react with SV40 T antigen and was provided by
the Tevethia laboratory (Penn State University), as described previously
(42). Cells were analyzed for nuclear VP1 or T antigen staining under a
10 or 20 objective using an Eclipse TE2000-U microscope (Nikon).
JCPyV pseudovirus production. Pseudoviruses were produced by
transfection of the VP1, VP2, VP3, and phGluc plasmids into 293TT cells
using FuGENE 6 transfection reagent (Promega) in a 5:1:1:1 ratio. Mock
pseudovirus controls were generated by transfecting 293TT cells with
pUC19 control plasmid and the phGluc reporter plasmid in a 7:1 ratio.
Cells were split 1:3 at 48 h posttransfection and harvested at 7 days post-
transfection, and titers for properly encapsidated genomes were deter-
mined (43).
Pseudovirus luciferase infectivity assay.Cells were plated in a 24 well
or 96-well plate to 70% confluence and infected with equal particle equiv-
alents (1  106 or 1  107 particles/well) of Mad-1 or Mad-1/WT3C
pseudovirus in incomplete medium without phenol red. Infected cells
were incubated at 37°C for 1.5 h and washed with PBS, and complete
medium without phenol red was added and cells were incubated at 37°C
for 72 h. Secreted luciferase was quantitated in 20 to 50 l of cellular
supernatants using the BioLux Gaussia luciferase assay (NE BioLabs) ac-
cording to the manufacturer’s instructions with an opaque 96-well micro-
plate in a GloMax Multi detection system luminometer (Promega). Num-
bers of infected cells were also measured by quantifying green fluorescent
protein (GFP)-positive cells by fluorescence microscopy using an Eclipse
TE2000-U microscope (Nikon).
Protein expression, purification, and crystallization. DNA coding
for amino acids 22 to 289 of VP1 from the WT3 strain (UniProtKB acces-
sion number AAQ88264), obtained by gene synthesis (Eurofins MWG
Operons, Germany), was subcloned into the pET15b vector (EMD Milli-
pore) in frame with an N-terminal hexahistidine tag (His tag) and a
thrombin cleavage site using the NcoI and BamHI restriction sites (24).
Mad-1 and WT3 VP1 were expressed, purified, and crystallized as de-
scribed earlier (24, 44). The C-terminal truncation of VP1 prevents as-
sembly of VP1 pentamers to capsids and other incorrectly multimeric
particles, whereas the N-terminal truncation was shown to help with the
crystallization in the case of MPyV VP1 (22). Prior to crystallization, the
His tag was cleaved off with thrombin (GE Healthcare) in solution, result-
ing in a short nonnative sequence at the (GSHM) N termini of Mad-1 and
WT3 VP1.
Crystals of Mad-1 and WT3 VP1 pentamers, grown in space group C2
with one VP1 pentamer in the asymmetric unit, are highly isomorphous
(see Tables S1 to S7 in the supplemental material). For comparative soak-
ing experiments, crystals grown for 2 days with similar sizes (120 by 120
by 20 m3) were soaked for 30 min in the reservoir solution comple-
mented with oligosaccharide LSTc (5, 2.5, 1.25, 0.62, or 0.31 mM; Dextra,
United Kingdom), GD1a, GD1b, or GM1 (10, 5, 2.5, or 1.25 mM; Elicityl
SA, France), or GM2 (20, 10, 5, 2.5, or 1.25 mM; Elicityl SA, France). For
cryoprotection, crystals were transferred for 2 s into a reservoir solution
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supplemented with 30% (vol/vol) glycerol and the respective ligand prior
to freezing in liquid nitrogen.
Data collection and structure determination. Diffraction data sets
were collected at beamlines X06DA and X06SA at SLS (Villigen, Switzer-
land) and processed with XDS (45). The JCPyV Mad-1 VP1 pentamer
structure (RCSB Protein Data Bank [PDB] accession number 3NXD) was
used for molecular replacement with Phaser MR (46), included in the
CCP4 program suite (47). Rigid-body and simulated annealing refine-
ment was carried out with Phenix (48). Alternating rounds of model
building in Coot (49) and refinement with Refmac5 (50), including 5-fold
noncrystallographic symmetry restraints, the translation-libration-screw
method (51), and CCP4 library- and user-defined restraints for the 2,3-
and2,6-glycosidic bond were performed. Coordinates and structure fac-
tor amplitudes have been deposited in PDB for the native and complex
structures of WT3 VP1 pentamer with 5 mM LSTc, 10 mM GM1, 10 mM
GD1a, 10 mM GD1b, and 20 mM GM2. Deposited Mad-1 VP1 pentamer
complex structures were obtained with either 10 mM GM1, 10 mM GD1a,
10 mM GD1b, or 20 mM GM2. Structure figures were prepared with
PyMOL (PyMOL Molecular Graphics System, version 1.3; Schrödinger,
LLC).
Calculation of ligand electron density. Unit cell parameters of all
soaked crystals were treated as isomorphous. The unliganded WT3 VP1
data set was taken as a reference data set during data processing in XDS.
CAD of CCP4 (47) was used to combine structure factor amplitudes and
structure factor sigmas from all data sets of a concentration-dependent
soaking experiment into one single file including free R flags and unit cell
parameters from the reference data set (native WT3 VP1). Data sets were
scaled (low- and high-resolution cutoff, 12.0 to 2.4 Å) to the reference
data set with SCALEIT (52). Refinement with Refmac5 was done to obtain
complex structure models in the referenced unit cell. Simulated annealing
omit maps were calculated 5 Å around Neu5Ac or marker residues (Y80,
Y160, and W200) with Phenix and FFT (CCP4 program suite) under each
soaking condition. Masks 1 Å around the Neu5Ac moiety of the respective
glycan ligand and around marker residues were generated with the CCP4
program NCSMASK (47). MAPMAN (53, 54) was used to estimate the
Neu5Ac and marker residue electron densities by summation of the values
for the grid points within the respective mask using the mstats command.
Maps and masks were calculated with a grid spacing of dmax/5, with
maximum resolution dmax. Integrated electron densities were plotted
against the ligand concentration. Data were analyzed and fitted assuming
a simple equilibrium of the VP1-glycan interaction using GraphPad Prism
6 (GraphPad Software, San Diego, CA, USA). Assuming a simple equilib-
rium, a dissociation constants Kd crystal for the interactions within the
crystal can be estimated by applying a least-squares fit to the experimental
data points and the equation electron densityobserved	 [Cligand/(Cligand

Kd crystal)](electron densitymax  electron densitynat) 
 electron densi-
tynat, where Cligand is the concentration of the ligand used for the soaking
experiment. Electron densityobserved is the output from the MAPMAN
electron density integration, whereas electron densitynat is the electron
density at the respective position within the native crystal and electron
densitymax is that observed for the glycan ligand in a fully occupancy
binding site. Electron densitymax was not set to a defined value for the fit.
Saturation transfer difference (STD) NMR measurements. All nu-
clear magnetic resonance (NMR) spectra were recorded using 3-mm
tubes on a Bruker AVIII 600-MHz spectrometer fitted with a 5-mm cryo-
genic probe at 285 K and processed with TOPSPIN 3.0 (Bruker). Samples
were prepared in D2O buffer containing 20 mM potassium phosphate
(pH 7.4) and 150 mM NaCl. Protein concentrations were 20M VP1, and
the GM1 glycan was added to 1 mM. A protein-free GM1 sample was used
as a reference. The off- and on-resonance frequencies were set to 30
ppm and 6.9 ppm, respectively. The total relaxation delay was 3 s. A
cascade of 40 Gaussian-shaped pulses with 50-ms duration each, corre-
sponding to a strength of 65 Hz, and a saturation time of 2 s were used for
selective excitation. A 10-ms continuous-wave spin lock filter with a
strength of 3.7 kHz was employed. A total of 32,000 points were collected,
and zero filling to 64,000 data points was employed. Spectra were multi-
plied with an exponential line broadening factor of 1 Hz prior to Fourier
transformation.
Protein structure accession numbers.Coordinates and structure fac-
tor amplitudes were deposited in PDB for the native (accession number
4X0Y) and the complex structures of WT3 VP1 pentamer with LSTc
(4X13), GM1 (4X0Z), GD1a (4X11), GD1b (4X12), and GM2 (4X10).
The Mad-1 VP1 pentamer complex structures obtained with GM1
(4X14), GD1a (4X16), GD1b (4X17), and GM2 (4X15) were deposited in
PDB with the indicated accession numbers.
RESULTS
VP1 amino acid variations in JCPyV genotypes and glycan re-
ceptor specificity. JCPyV strains are classified into seven geno-
types that possess amino acid differences at up to 13 positions
within VP1 (33) (Fig. 1A). Full-length VP1 from the prototype
Mad-1 strain, a genotype 1 strain, differs at eight positions (resi-
dues 74, 116, 133, 157, 163, 320, 331, and 344) from VP1 of the
urine isolate WT3 (genotype 3). Five of those residues are in-
cluded in the crystal structure of the truncated, assembly-incom-
petent JCPyV Mad-1 VP1 pentamer comprising residues 22 to 289
(24). The remaining three residues are located in the C-terminal
arms of VP1, where they help mediate assembly of the virion par-
ticle but are distant from the receptor-binding site (20). In order
to assess strain- and genotype-specific glycan receptor engage-
ment on the molecular level, we introduced WT3 polymorphisms
into our VP1 construct and solved its X-ray structure (Fig. 1B; see
Table S1 in the supplemental material). Structures of Mad-1 and
WT3 VP1 are very similar and superimpose with root mean
square deviation (RMSD) values of 0.2 Å and 0.5 Å for C atoms
of monomers and pentamers, respectively. VP1 adopts the iconic
jelly-roll fold of virus capsid proteins with two four-stranded
-sheets (strands B, I, D, and G and C, H, E and F) packed against
each other, which assemble around a 5-fold axis and are linked on
the outside of the virion by extended loops (24). Amino acid dif-
ferences between Mad-1 and WT3 occur predominantly within or
in close proximity to these surface loops (Fig. 1B).
WT3VP1 engages sialic acids in diverse linkages. In order to
analyze glycan binding specificities of WT3, we solved structures
of WT3 VP1 in complex with the glycan portions of a-series gan-
gliosides GM1, GM2, and GD1a, b-series ganglioside GD1b, and
the2,6-linked Mad-1 receptor motif LSTc (Fig. 2; see Table S1 in
the supplemental material). WT3 pentamers bound to all glycans,
specifically interacting with terminal sialic acids in an almost iden-
tical manner independent of the presence of an 2,3-, 2,6-, or
2,8-linkage (Fig. 2; see Fig. S1 in the supplemental material). The
conserved sialic acid-binding site is located in a groove at the
junction of the extended BC1, BC2, DE, and HI loops of a VP1
monomer and the BC2 and DE loops of the counterclockwise
(CCW) and clockwise (CW) neighboring VP1 monomers, respec-
tively. The majority of interactions with the five different glycans
involves functional groups of Neu5Ac (described in detail in ref-
erence 24). Glycan residues of LSTc, GM1, GM2, and GD1b con-
tribute additional interactions. VP1 residue N123 forms a hydro-
gen bond with the carbonyl group of the GlcNAc N-acetyl group
and fixes LSTc in a unique L-shaped conformation on top of the
pentamer (Fig. 2A). The Glc and two Gal residues contribute to
the buried surface area upon ligand engagement and are well or-
dered in the structure due to van der Waals interactions with VP1.
In contrast, the Gal-(1,3)-GalNAc arm of the GM1 glycan points
in a different direction, resting in an elongated groove on the
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protein surface (Fig. 2B). The terminal Gal residue is recognized
by hydrogen bonds to the side chains of N130 of the CCW VP1
monomer, S60, and the backbone of residue 61, as well as van der
Waals interactions with N130CCW and S268 (Fig. 2B). However,
this interaction is not seen in all binding sites, indicating structural
flexibility of the terminal Gal. In contrast, the branched “ganglio-
side core” Neu5Ac-(2,3)-(GalNAc-(1,3))-Gal is conforma-
tionally more restrained through intramolecular interactions, and
it is recognized by a hydrogen bond to K59 and van der Waals
interactions with N130CW, S266, and S268. The Glc residue,
which is linked to the membrane-anchoring ceramide in the con-
text of the GM1 ganglioside, is pointing away from the protein and
is not involved in contacts with VP1.
Similar interactions hold GalNAc-(1,4)-Gal in place in the
FIG 2 JCPyV WT3 interacts with 2,3-, 2,6-linked Neu5Ac and 2,8-, 2,3-di-Neu5Ac in a highly plastic binding site. (A to E) Structures of WT3 VP1 bound
to LSTc (A), GM1 (B), GM2 (C), GD1b (D), and GD1a (E) glycans. VP1 is shown in surface and cartoon representation. Residues involved in polar or van der
Waals interactions in only one of the glycan complex structures are highlighted in pink or purple, respectively. Interactions are depicted using dashed lines, with
direct and water-mediated contacts with the glycans in black, intramolecular interactions of glycans in blue, and interaction with either LSTc, GM1, or GM2 in
pink. Glycans are shown in stick representation and colored according to atom type, with nitrogens in blue, oxygens in red, and carbons in orange for LSTc and
in yellow for ganglioside-derived glycans, respectively. Water molecules are shown as red spheres. Black arrows indicate the part of LSTc that is linked to a lipid
or protein (A), the direction of Glc that is further linked to the lipid in the context of the GM1 and GM2 gangliosides (B and C), and the O2 of the second Neu5Ac,
to which the Gal residue within the branched GD1b ganglioside motif is attached (D). (F) Glycans used for comparative binding studies. Additionally, the GT1b
ganglioside was used in cell supplementation assays. GT1b features, compared to GD1b, an additional 2,3-linked Neu5Ac at the Gal in the left arm of the
branched motif.
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GM2 complex structure, which shows interactions primarily with
Neu5Ac (Fig. 2C). In the GD1b complex structure, the second
Neu5Ac of the 2,8-2,3-diNeu5Ac motif adds nonpolar interac-
tions to the protein-glycan interaction network (Fig. 2D). The
methyl group of the N-acetyl group is pointing against a hydro-
phobic platform formed by parts of the N130CW, S266, and S268
side chains. Interactions with the second arm of the branched
motif GD1b are not observed. In the case of GD1a, defined elec-
tron density was observed only for a single Neu5Ac (Fig. 2E). We
also solved equivalent complex structures of JCPyV Mad-1 VP1
(Fig. 3; see Table S2 and Fig. S1 in the supplemental material).
Mad-1 VP1 engages GM1, GM2, GD1a, and GD1b glycans using
the same contacts described above (Fig. 3 and 4).
Binding affinities for LSTc and ganglioside glycans. We hy-
pothesized that binding affinities could modulate differences in
glycan specificities between the two JCPyV strains. A comparative
crystallographic approach, similar to strategies previously used for
adenovirus fibers (55) and MPyV VP1 (56), was applied to obtain
estimates for binding affinities. Isomorphous crystals of Mad-1
and WT3 VP1 were soaked in parallel in solutions supplemented
with GM1, GM2, GD1a, GD1b, and LSTc glycans in a concentra-
tion-dependent manner, and structures were solved. With in-
creasing glycan concentrations, simulated annealing Fobs  Fcalc
FIG 3 JCPyV Mad-1 engages2,3-,2,6-linked Neu5Ac and2,8-,2,3-di-Neu5Ac highly similarly to WT3. Complex structures of Mad-1 VP1 with GM1 (A),
GM2 (B), GD1b (C), and GD1a (D) ganglioside glycans are shown. VP1 is shown in surface and cartoon representation. Interactions are depicted by dashed lines,
with direct and water-mediated contacts with the glycans in black and intramolecular interactions of glycans in blue. VP1 amino acid differences between Mad-1
and WT3 are located predominantly within or close to the surface loops. Residue glycine 133 (green), which is an alanine in WT3, is located beneath N123, which
undergoes an induced-fit movement to accommodate the terminal Neu5Ac during glycan engagement (21). Mad-1 residue serine 116, a threonine in WT3, is
located below the hydrophobic cavity of the binding site that is formed by F67CW, F158CW, F57, and F262 and encloses the Neu5Ac N-acetyl group. The three
additional mutations in WT3 VP1, R74K, L157V, and K163T, are distant from the binding site and are not shown in the close-up views.
FIG 4 Strain-specific amino acid differences and engagement of GM1 and
LSTc. Two VP1 monomers from JCPyV Mad-1 and WT3 are shown in cartoon
representations with glycans depicted in orange (LSTc) or yellow (GM1). VP1
residues characteristic for either one of the two strains are colored in pink
(Mad-1) or green (WT3). Other genotype-specific amino acid differences are
shown in light blue and are labeled in black. Key residues of the glycan binding
pocket, the hydrophobic cavity, and N123 are shown in gray sticks.
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omit electron density maps reveal better-defined features of the
bound ligand until saturation is reached (Fig. 5A). The electron
density within a 1.0-Å mask around the terminal Neu5Ac moieties
was integrated and plotted against the respective glycan concen-
tration (Fig. 5B and C). In the outcome of this, electron density
binding curves could be fitted assuming a simple equilibrium of
the VP1-glycan interaction. In the nonliganded VP1, water mole-
cules are present in the binding site, contributing to the overall
electron density at the position of Neu5Ac, when the occupancy is
1.0. Dissociation constants of about 0.5 mM and 6 mM for the
strongest interaction with LSTc and the weakest interaction with
GD1a, respectively, could be determined. Both strains engage
LSTc with the highest affinity but possess similar, lower binding
affinities for GD1a, GD1b, and GM2 (Fig. 5B and C). GD1a is
engaged with the lowest affinity, consistent with the observation
that only a single terminal Neu5Ac is engaged in all complexes
(Fig. 2E). A reduced binding affinity is also observed for GD1b, in
which only the second Neu5Ac contributes additional hydropho-
bic contacts with VP1, and for GM2 (Fig. 2D). Of the ganglioside
glycans tested, GM1 binds best to JCPyV VP1, although the bind-
ing curves differ slightly between the two strains. While the esti-
mated dissociation constant is about 1.2 mM for Mad-1 VP, WT3
VP1 engages the GM1 glycan with a binding affinity very similar to
that seen for LSTc, with a dissociation constant of about 0.7 mM.
In the crystal, only one binding site in the asymmetric unit is
completely open toward the solvent, allowing engagement of all
five glycans without steric hindrance or favorable interaction for a
particular ligand. Therefore, a cross-validation between binding
sites to estimate errors of the measurements is not possible. Elec-
tron densities for marker residues on the surface and in the hydro-
phobic core were instead integrated to test for the nonisomor-
phism of crystals and resulting differences of the electron density
(see Fig. S2 in the supplemental material). The electron density of
all marker atoms is clearly independent of the ligand concentra-
tions. Therefore, measured differences in electron density values
and binding affinities for the different ligands could be treated as
significant.
WT3, Mad-1, and SV40 engage the GM1 glycan in a similar
manner. GM1 is the functional receptor of the closely related
SV40 (23, 57). We therefore compared interactions of JCPyV and
SV40 with GM1 in solution using saturation transfer difference
(STD) NMR spectroscopy (58). This technique can be used to
map protein-bound parts of the ligand in order to analyze and
compare binding epitopes. STD NMR spectra clearly show that
WT3 and Mad-1 VP1 interactions with GM1 are highly similar to
the functional SV40 VP1-GM1 receptor interaction (Fig. 6A).
Moreover, the superposition of VP1-GM1 complex structures il-
lustrates a conserved binding mode, with distinct differences lim-
ited to the GalNAc-(1,3)-Gal arm of GM1 (Fig. 6B).
LSTc andGM1 glycans block JCPyV infection. For functional
characterization of the strain-related VP1 polymorphisms, we
generated a Mad-1/WT3C virus by introducing WT3 sequences at
positions 74, 116, 133, 157, and 163 into VP1 in the genomic
Mad-1 DNA. To determine if the GM1 glycan could inhibit JCPyV
infection, the purified JCPyV Mad-1 and Mad-1/WT3C viruses
were pretreated with GM1 or LSTc pentasaccharide prior to addi-
tion to cells. Both glycans reduced JCPyV infection of SVGA cells
(Fig. 6C). Interestingly, the infection was reduced to a greater
extent with LSTc than with GM1, which likely reflects the in-
creased affinity for LSTc. Furthermore, LSTc and GM1 binding
sites are overlapping, and therefore, binding of either glycan to
VP1 could block binding to either LSTc or GM1.
FIG 5 Mad-1 and WT3 bind to LSTc with higher affinity than gangliosides. (A) Example for the concentration-dependent crystal soaking experiment. The
simulated annealing omit map contoured at 3.0 around 2.0 Å of LSTc at 2-4 Å resolution for JCPyV WT3 shows better defined features of the ligand with higher
concentration. LSTc (yellow) is shown as a reference in all panels. Data from soaked crystals were scaled to a reference data set, and density around the Neu5Ac
moiety was used for electron density integration. (B and C) Concentration-dependent crystal soaking experiments and electron density integration of Fobs Fcalc
simulated annealing omit maps within a 1.0-Å mask around Neu5Ac moieties of LSTc, GM1, GM2, GD1a, or GD1b within the conserved binding site of Mad-1
and WT3 VP1. Values for the electron density obtained by MAPMAN (53, 54) are plotted against the ligand concentration. Water molecules in the binding site
contribute to the overall electron density of Neu5Ac when the occupancy is1.0.
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Exogenous addition of gangliosides does not enhance JCPyV
infection. JCPyV Mad-1 and WT3 demonstrate affinity for gan-
gliosides GM1, GM2, GD1a, and GD1b as determined by struc-
tural analysis of the pentamers in complex with the respective
glycans. To determine whether JCPyV is able to utilize ganglio-
sides as functional receptors for infection, SVGA cells were sup-
plemented with a panel of gangliosides prior to infection with
JCPyV Mad-1, Mad-1/WT3C, BKPyV, and SV40. BKPyV utilizes
the gangliosides GD1b and GT1b as functional receptors, while
SV40 utilizes GM1, and exogenous ganglioside addition has been
previously demonstrated to enhance infection (25, 59). Interest-
ingly, supplementation of cells with gangliosides GM1, GM2,
GD1a, GD1b, and GT1b did not alter JCPyV infection compared
to that for the dimethyl sulfoxide (DMSO)-treated control. In
contrast, addition of GD1b and GT1b enhanced BKPyV infection,
and GM1 supplementation enhanced SV40 infection (Fig. 7A).
Given the subtle differences in affinity of JCPyV Mad-1 and Mad-
1/WT3C for ganglioside-derived glycans compared to LSTc, we
hypothesized that these small differences might not be appreciable
in a permissive cell type that has been demonstrated to require
LSTc for infection (24). Therefore, we also tested whether gangli-
oside supplementation had an effect in a kidney cell line that is
poorly permissive for JCPyV infection (28, 42). HEK293A cells
were supplemented with gangliosides overnight and then infected
with JCPyV Mad-1, Mad-1/WT3C, BKPyV, and SV40. While sup-
plementation of cells with GD1b and GT1b enhanced BKPyV in-
fection and exogenous GM1 addition resulted in increased SV40
infection, ganglioside supplementation had no effect on JCPyV
infection (Fig. 7B). Additionally, supplementation of cells with
gangliosides was not toxic to cells as measured by a 3-(4,5-di-
methylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophe-nyl)-2H-tetrazolium (MTS) assay (data not shown).
To extend these findings, we used the JCPyV pseudovirus sys-
tem, which is more robust and has greater sensitivity. JCPyV pseu-
doviruses contain only the capsid components and a reporter ge-
nome, allowing for examination of only the initial steps in the
virus life cycle from viral attachment through trafficking and tran-
scription. We tested whether addition of gangliosides to SVGA
(Fig. 7C) and HEK293A (data not shown) cells could enhance
infection by JCPyV Mad-1, Mad-1/WT3C, and BKPyV pseudovi-
rus infection. Addition of GD1b and GT1b enhanced BKPyV in-
fection, while ganglioside supplementation had no effect on
JCPyV infection (Fig. 7C).
Silencing of the GM3 synthase has no effect on JCPyV infec-
tion. JCPyV Mad-1 and Mad-1/WT3C are both capable of bind-
ing to a panel of ganglioside structures. However, supplementa-
tion of cells with these gangliosides neither enhances nor reduces
JCPyV infection. To test whether ganglioside expression contrib-
FIG 6 Interactions of JCPyV VP1 with the GM1 glycan reduces virus infection. (A) VP1 engages the GM1 glycan in solution in a manner similar to that for SV40
VP1. From top to bottom: NMR spectrum of the GM1 glycan and STD NMR difference spectra of WT3 VP1, Mad-1 VP1, and SV40 VP1 with GM1 glycan
(50-fold molecular excess). (B) GM1 glycan engagement by SV40, Mad-1, and WT3 VP1. GM1 glycans are colored blue, pink, or green for SV40 (PDB 3BWR),
Mad-1, and WT3, respectively. The Glc residue of GM1, which is not in contact with VP1, is not shown for clarity. (C) Pretreatment of Mad-1 or Mad-1/WT3C
virus with LSTc or GM1 glycan reduces infection. Data represent the average number of infected cells per visual field (10) for 4 fields of view of triplicate
samples. Error bars indicate standard deviations (SD).
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utes to JCPyV infection, GM3 synthase, the enzyme responsible
for ganglioside biosynthesis, was silenced by siRNA. SVGA cells
were transfected with RNA oligonucleotides specific for human
ST3 -galactoside -2,3-sialyltransferase 5 (ST3GAL5), and the
expression of GM3 synthase mRNA was determined by qPCR
(Fig. 8A). The siRNA treatment of SVGA cells resulted in an
85% reduction in GM3 mRNA expression (Fig. 8A). SVGA cells
treated with siRNA to GM3 synthase were infected with JCPyV
Mad-1, Mad-1/WT3C, and SV40 (Fig. 8B). Only the GM3-17
siRNA resulted in a modest reduction in infection of Mad-1 and
Mad-1/WT3C, while the other siRNAs did not reduce JCPyV in-
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FIG 7 Exogenous addition of gangliosides does not alter JCPyV infection. (A)
Permissive SVGA cells in a 24-well plate were supplemented with a 30 M
concentration of the indicated gangliosides or DMSO (vehicle control) over-
night and then washed with medium and infected with JCPyV Mad-1, Mad-
1/WT3C, or BKPyV and SV40 as controls. Infected cells were scored by indi-
rect immunofluorescence for nuclear VP1 at 72 h. (B) Poorly permissive
HEK293A cells were supplemented and infected as for panel A, and infected
cells were scored by indirect immunofluorescence for nuclear T antigen at 48 h
postinfection. Data represent the average number of infected cells per visual
field for five 10 fields of view for triplicate samples. Error bars indicate SD.
(C) SVGA cells were supplemented as for panel A and then infected with
Mad-1, Mad-1/WT3C, or BK pseudovirus (control). Supernatant from in-
fected cells was collected and analyzed for secreted luciferase. The average
relative luciferase units (RLU) for triplicate samples are shown in log scale.
Error bars represent SD. These data are representative of 3 experiments.
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FIG 8 Gene silencing of GM3 synthase does not affect JCPyV infection in
SVGA cells. SVGA cells were transfected with siRNAs targeted to the ST3GAL5
or control (scrambled) siRNA. At 72 h posttransfection, cells were either har-
vested for analysis of GM3 synthase mRNA expression (A) or infected (B). (A)
RNA was extracted from 2 wells and reverse transcribed by reverse transcrip-
tion-PCR (RT-PCR), and real-time PCR was performed with 1g cDNA using
primers specific for GM3 synthase or GAPDH (housekeeping gene). Results
are represented as the relative gene expression for triplicate real-time PCR
samples relative to the GAPDH siRNA control. The percent reduction in gene
expression relative to the scrambled control is expressed for each siRNA. (B)
SVGA cells transfected with ST3GAL5 siRNAs or controls were infected with
JCPyV or SV40. Infected cells were scored by indirect immunofluorescence.
Data represent the average number of infected cells per visual field for four
10 fields of view for triplicate samples. Error bars indicate SD.
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fection. Treatment of SVGA cells with GM3 synthase siRNAs re-
duces SV40 infection by 75%, indicating that SV40 infection is
dependent on ganglioside expression while JCPyV infection is not.
DISCUSSION
It was previously shown that JCPyV requires the2,6-linked LSTc
glycan for attachment and that engagement of LSTc is critical for
infection and spread in culture (24). In addition to the linear LSTc
motif, different sialylated glycans, as well as a number of a- and
b-series ganglioside structures, have been implicated as receptor
candidates for JCPyV (6, 34). However, it has remained unclear
whether JCPyV can utilize all of these glycans to mount an infec-
tion, particularly as different JCPyV strains and genotypes were
used in different studies. To help reconcile the existing findings
about JCPyV glycan receptors and strain- or genotype-specific
differences, we performed a comprehensive analysis of the
binding specificities and affinities of the two representative
JCPyV strains Mad-1 and WT3 for a range of glycan receptors
using X-ray crystallography and NMR spectroscopy, and we
correlated these data with infectivity assays. Our analysis un-
ambiguously shows that both JCPyV strains are able to bind a
range of sialylated receptors, including LSTc and several gan-
glioside motifs. The shallow, surface-exposed JCPyV VP1
binding site allows the engagement of various sialylated ligands
without steric clashes, independent from the linkage of the
terminal Neu5Ac residue. However, there are critical differ-
ences in binding affinities for the analyzed glycans, with the
linear 2,6-linked LSTc glycan binding best to both strains.
Distinct differences in affinities correlate with infectivity as-
says, which show that LSTc is utilized by both strains as a func-
tional receptor whereas the other ganglioside-type receptors
are not.
We estimate the dissociation constants (Kd crystal) for LSTc and
ganglioside glycans to be in the millimolar range, i.e., 0.5 mM for
the strongest interaction with LSTc and 6 mM for the weakest
interaction with GD1a. Of the ganglioside glycans tested here,
GM1 binds best to Mad-1 and WT3 VP1, with dissociation con-
stants of about 1.2 and 0.7 mM, respectively. These estimated
affinities are in line with affinities observed for other virus-glycan
interactions (23, 55). Glycans with dissociation constants higher
than 0.5 mM seem not to bind tightly enough to promote JCPyV
infection. Thus, one could argue that a putative threshold for re-
ceptor binding might lie between 0.5 mM and 0.7 mM for the
interaction of one glycan in one binding site. While differences in
binding affinities are small, they will be amplified by a virus par-
ticle engaging a cell surface due to the availability of multiple low-
affinity binding sites (60). For example, a relationship between the
typically millimolar affinities for single protein-glycan interac-
tions and femtomolar avidities observed for virus binding has
been established for influenza virus, explaining how a relatively
modest decrease in the affinity of one binding site can abolish
virus binding (61).
As the SV40 GM1 and BKPyV GD1b binding is still conserved
in JCPyV, we aimed to retarget JCPyV toward engagement of
GM1 gangliosides rather than LSTc via site-directed mutagenesis
at residue N123 of JCPyV. This amino acid, which is a glycine in
SV40 and BKPyV (25), is the key residue that makes contacts with
both arms of the L-shaped LSTc, yet potential Neu5Ac contacts
would be preserved. Evaluation by crystal structure analysis re-
vealed abolished binding to LSTc in the L-shape conformation
and conserved engagement of GM1, but supplementation of cells
with GM1 ganglioside did not alter cell binding or infection (data
not shown). Thus, it seems that there are additional evolutionary
constraints on JCPyV toward utilizing LSTc, leading JCPyV VP1
to favor this interaction over GM1 (or GD1b) ganglioside engage-
ment. In contrast to the case for SV40 and BKPyV, JCPyV entry is
achieved by clathrin-mediated rather than cholesterol-dependent
endocytosis (28, 62, 63). It is tempting to speculate that the in-
creased affinity for LSTc has coevolved with changes in the viral
entry pathway of JCPyV. Only a few amino acid changes in the
VP1 binding site are sufficient for switching glycan binding spec-
ificity, but the adaption of alternative attachment and entry mech-
anisms may require additional genetic changes. JCPyV infects
only a narrow range of cell types and entry, and subsequent infec-
tion is supported by 5-HT2 family of serotonin receptors (28). In
fact, infection of 5-HT2R-expressing HEK293A cells with viruses
containing either a Mad-1 or WT3 capsid is equivalent (28; Mag-
innis and Atwood, unpublished results), yet exogenous addition
of gangliosides in HEK293A cells, which express low levels of
5-HT2Rs, does not lead to a productive infection (Fig. 7B), indi-
cating that both strains of JCPyV require 5-HT2Rs for productive
infection. In contrast, BKPyV and SV40 can still switch their gly-
can receptor specificity through a single VP1 point mutation, but
these viruses both utilize lipid-linked ganglioside receptors and
share a cholesterol-dependent entry mechanism (25, 59). Binding
of JCPyV to LSTc may induce organizational and/or structural
changes at the plasma membrane that favor interactions with the
entry receptor 5-HT2R.
Sialic acid receptors commonly govern outcomes in viral in-
fection and pathogenesis due to evolution and switches of recep-
tor specificity (64). For instance, avian influenza A virus hemag-
glutinin (HA) attachment protein engages2,3-linked sialic acids,
which are abundant in the gastrointestinal tracts of birds, but it
cannot infect humans due to the scarcity of these receptors on cells
of the human respiratory tract (65). However, when a switch in
sialic acid utilization from 2,3-Neu5Ac to 2,6-Neu5Ac occurs
in avian or porcine reservoirs, influenza viruses from nonhuman
species can be transmitted to human hosts, as 2,6-linked sialic
acids are highly expressed on cells of the human respiratory tract.
Influenza A virus strains with HA preference for human 2,6-
linked receptors can lead to further human-to-human transmis-
sibility and cause widespread infection in humans and viral pan-
demics (65). It was recently shown that certain BKPyV serotypes
engage a distinct spectrum of cell surface attachment receptors,
resulting in different cellular attachment mechanisms and cell tro-
pism (66). Consequently, these findings raise questions whether
different JCPyV genotypes use distinct glycan receptors besides
LSTc and therefore exhibit altered tissue tropism resulting in dif-
ferent levels of virulence in vivo and are a possible risk factor for
PML as proposed earlier (67). The VP1 amino acid differences in
the two strains investigated here comprise the majority of geno-
type-specific variability (Fig. 1A). Due to the location of remain-
ing VP1 amino acid changes not investigated in this study (Fig. 4),
it is unlikely that other genotypes possess altered LSTc specificities
not detected here. Consequently, genotype- and strain-related
variations differ from PML-associated VP1 mutations, which are
located within the central Neu5Ac binding site and render JCPyV
variants noninfectious in cell culture (35). PML-associated muta-
tions are commonly found in patients with PML in the back-
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ground of different genotypes, but mechanisms by which they
arise and their effects on cellular tropism remain undefined.
Our findings help explain conflicting reports on JCPyV glycan
specificity. Biochemical methods such as glycan microarray screen-
ing, virus overlay blotting, and enzyme-linked immunosorbent as-
says to investigate glycan binding in vitrohave variable detection lim-
its and drawbacks. Binding alone does not indicate whether a glycan is
a receptor or a pseudoreceptor. Due to the relatively low affinity of
virus-glycan interactions and avidity effects, the virus and the pre-
sented glycan have a significant impact on the experimental outcome
and its meaning for the physiological tissue tropism (68). Critical
differences in binding affinities, rather than the binding events alone,
can therefore determine receptor usage. Although a varying suscep-
tibility of certain genotypes for PML development cannot be ex-
cluded, our study shows that it is unlikely that genotype-specific VP1
variations alter JCPyV attachment mechanisms or influence the risk
for PML development. Our findings resolve a long-standing question
in the field and also provide a proper framework for interpreting how
interactions with viral receptors must be analyzed for functionality in
infectious assays to define the outcomes on viral pathogenicity.
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FIG. S1. Simulated annealing omit difference electron density maps for glycan complex 
structures of Mad-1 and WT3 VP1. Proteins are shown in cartoon representations and 
glycans as sticks colored according to the atom type (nitrogens in blue, oxygens in red and 
carbons in yellow). Fobs-Fcalc simulated annealing omit maps are shown at 3.0 sigma 
around 2.0 Å of the respective ligand. 
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FIG. S2. Electron density integration within a 1.0 Å mask around marker 
residues of Mad-1 and WT3 VP1. In the JCPyV VP1 crystal environment only 
one binding site in the asymmetric unit is completely open towards the solvent, 
allowing engagement of all five ligands without steric hindrance or favorable 
interactions with a particular ligand. Therefore, statistic data analysis, 
calculation of the standard deviation, and cross-validation between binding 
sites was not possible for the electron density integration. Instead, Fobs-Fcalc 
simulated annealing omit electron densities maps for marker residues on 
the surface and in the hydrophobic core were integrated to test for the 
non-isomorphism of crystals and background differences of the electron 
density. Values for the electron density obtained by MAPMAN (53, 54) are 
plotted against the ligand concentrations, which were used in the 
concentration-dependent crystal soaking experiments. Representative 
examples are shown for experiments with LSTc, GM1, and GM2 glycans. 
The integrated electron density of marker atoms is independent of the ligand
concentrations with standard deviations of about 1.5% to maximal 7% 
in rare cases. 
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Table S5: D
ata collection statistics of the additional data sets used for the concentration dependent density integration for the G
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glycan. C
rystals have the space group C
2.  
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Modulation of a Pore in the Capsid of JC Polyomavirus Reduces
Infectivity and Prevents Exposure of the Minor Capsid Proteins
Christian D. S. Nelson,a Luisa J. Ströh,b Gretchen V. Gee,a Bethany A. O’Hara,a Thilo Stehle,b,c Walter J. Atwooda
Department of Molecular Biology, Cell Biology and Biochemistry, Brown University, Providence, Rhode Island, USAa; Interfaculty Institute of Biochemistry, University of
Tübingen, Tübingen, Germanyb; Department of Pediatrics, Vanderbilt University, School of Medicine, Nashville, Tennessee, USAc
ABSTRACT
JC polyomavirus (JCPyV) infection of immunocompromised individuals results in the fatal demyelinating disease progressive
multifocal leukoencephalopathy (PML). The viral capsid of JCPyV is composed primarily of the major capsid protein virus pro-
tein 1 (VP1), and pentameric arrangement of VP1monomers results in the formation of a pore at the 5-fold axis of symmetry.
While the presence of this pore is conserved among polyomaviruses, its functional role in infection or assembly is unknown.
Here, we investigate the role of the 5-fold pore in assembly and infection of JCPyV by generating a panel of mutant viruses con-
taining amino acid substitutions of the residues lining this pore. Multicycle growth assays demonstrated that the fitness of all
mutants was reduced compared to that of the wild-type virus. Bacterial expression of VP1 pentamers containing substitutions to
residues lining the 5-fold pore did not affect pentamer assembly or prevent association with the VP2minor capsid protein. The
X-ray crystal structures of selected pore mutants contained subtle changes to the 5-fold pore, and no other changes to VP1 were
observed. Pore mutant pseudoviruses were not deficient in assembly, packaging of the minor capsid proteins, or binding to cells
or in transport to the host cell endoplasmic reticulum. Instead, these mutant viruses were unable to expose VP2 upon arrival to
the endoplasmic reticulum, a step that is critical for infection. This study demonstrated that the 5-fold pore is an important
structural feature of JCPyV and that minor modifications to this structure have significant impacts on infectious entry.
IMPORTANCE
JCPyV is an important human pathogen that causes a severe neurological disease in immunocompromised individuals. While
the high-resolution X-ray structure of the major capsid protein of JCPyV has been solved, the importance of a major structural
feature of the capsid, the 5-fold pore, remains poorly understood. This pore is conserved across polyomaviruses and suggests
either that these viruses have limited structural plasticity in this region or that this pore is important in infection or assembly.
Using a structure-guidedmutational approach, we showed that modulation of this pore severely inhibits JCPyV infection. These
mutants do not appear deficient in assembly or early steps in infectious entry and are instead reduced in their ability to expose a
minor capsid protein in the host cell endoplasmic reticulum. Our work demonstrates that the 5-fold pore is an important struc-
tural feature for JCPyV.
The JC polyomavirus (JCPyV) is a common human pathogenthat causes severe disease in immunocompromised individu-
als. Serological studies have demonstrated that primary infection
occurs early in childhood, and it is estimated that over 50% of the
adult population is seropositive for JCPyV (1). In healthy individ-
uals, JCPyV has been reported to establish a persistent infection in
tissues of the kidney, bone marrow, and B cells. However, condi-
tions of immunosuppression result in dissemination of JCPyV to
the central nervous system, leading to a lytic infection of astrocytes
and oligodendrocytes (reviewed in reference 2). Destruction of
oligodendrocytes results in demyelination of neurons and causes
the fatal demyelinating disease progressive multifocal leukoen-
cephalopathy (PML) (3). There are currently no effective treat-
ments for PML.
JCPyV is a small nonenveloped double-stranded DNA virus
with a capsid diameter of approximately 50 nm. The viral capsid is
composed of the major capsid protein viral protein 1 (VP1) and
minor capsid proteins VP2 and VP3 (4). The exterior surface of
the virus is formed by 360 copies of VP1 that are arrayed in T7d
pentameric symmetry to form 72 pentamers (5). VP1 also con-
tains residues that are necessary for binding to the sialic acid-
containing motif lactoseries tetrasaccharide c (LSTc) (6). A prom-
inent feature of the JCPyV pentamer is a cavity located at the
5-fold axis of symmetry (6). One copy of either VP2 or VP3 is
incorporated into each VP1 pentamer and is sequestered within
the viral capsid. In the X-ray costructure of mouse polyomavirus
(MPyV) VP1 and a VP2 fragment, electron density corresponding
to the C terminus of VP2 was observed bound to the wall of the
interior axial cavity of VP1 (7). Thus, it is likely that VP2 occupies
much of the space of the interior axial cavity of the VP1 pentamer.
The axial cavity connects to the exterior of the viral capsid through
a 12.5-Å opening, referred to in this paper as the 5-fold pore. The
importance of this pore in entry or assembly of JCPyV is un-
known.
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JCPyV utilizes complex intracellular transport pathways to
gain access to the host cell nucleus for viral replication. JCPyV
initiates infection by binding to LSTc on the surface of cells. This
virus-receptor interaction is highly specific, as closely related mol-
ecules such as LSTb do not bind to JCPyV (6). JCPyV then enters
cells by clathrin-mediated endocytosis, and the human serotonin
receptor 2A family has been reported to enhance uptake of virus
(8–11). After endocytosis, JCPyV enters the endocytic system and
associates with Rab5-positive endosomes prior to retrograde
transport to the endoplasmic reticulum (ER) (12, 13). Upon de-
livery to the ER, it is likely that JCPyV depends on isomerization of
intrapentameric disulfide bonds to allow partial uncoating of the
virus, as pharmacological treatments that reduce ER function or
knockdown of the ER chaperones PDI and ERp57 decrease infec-
tivity (13). The VP2 minor capsid protein of JCPyV is also exposed
upon delivery to the ER (14). From there, JCPyV is likely retro-
translocated into the cytoplasm prior to nuclear transport and the
initiation of viral replication.
Exposure of VP2 is a critical aspect of viral entry, and JCPyV
mutants that lack VP2 or VP3 are noninfectious (15). Studies in
MPyV or simian virus 40 (SV40) have demonstrated that VP2 and
VP3 bind to cellular membranes or liposomes following exposure
(16, 17). Additionally, VP2 is able to perforate membranes, likely
by the insertion of additional predicted transmembrane regions or
the myristolyated N terminus of VP2 (18). Antibodies raised to
the N terminus of VP2 were able to prevent association of virions
with liposomes, suggesting that the N terminus of VP2 mediates
association of SV40 with membranes (16). Despite this impor-
tance, the mechanism by which VP2 is exposed from within the
viral capsid remains unclear.
In this study, we sought to define the role of the 5-fold pore in
JCPyV infection. JCPyV mutants were generated that contained
amino acid substitutions to residues lining this pore and were
expected to reduce the diameter of this pore. We demonstrated
that alteration of this pore significantly reduces viral infectivity
but does not interfere with viral assembly or packaging of VP2 and
VP3. Using JCPyV pseudoviruses (PSVs) that contain these mu-
tations, we show that these mutant PSVs are defective in transduc-
ing cells, despite showing no morphological changes compared to
wild-type PSVs. Finally, these mutant PSVs are defective in expos-
ing VP2 in the ER of cells, despite being transported to these com-
partments. These data suggest that amino acid substitutions to
residues lining the 5-fold pore prevent exposure of the minor cap-
sid proteins.
MATERIALS AND METHODS
Viruses, cells, and plasmids. The Mad-1 strain of JCPyV and the human
fetal glial (SVGA) cells used in these experiments have been previously
described (19, 20). SVGA cells were maintained in complete media (min-
imum essential media [MEM] supplemented with 10% fetal bovine se-
rum, 0.5% penicillin, and 0.5% streptomycin). 293TT cells were main-
tained in Dulbecco’s modified Eagle medium that was supplemented with
10% fetal bovine serum and MEM nonessential amino acids (Cellgro).
Western blotting. Protein samples were loaded onto 12% SDS-PAGE
gels (Mini-Protean TGX; Bio-Rad) and transferred to nitrocellulose
membranes (Trans-Blot SD semidry transfer cell; Bio-Rad). Membranes
were blocked with 1% (wt/vol) bovine serum albumin–phosphate-buff-
ered saline (PBS). VP1 was then detected using a mouse monoclonal an-
tibody to VP1 (PAB597; a kind gift from Ed Harlow), and VP2 and VP3
were detected using a rabbit polyclonal antibody to SV40 VP2 that is
cross-reactive with VP3 (ab53983; Abcam). Both antibodies were diluted
in PBS containing 0.05% Tween 20 (PBS-T) and incubated overnight at
4°C. Membranes were washed in PBS-T and then incubated with second-
ary antibodies to mouse (goat anti-mouse Alexa Fluor 800; Life Technol-
ogies) or rabbit (goat anti-rabbit Alexa Fluor 680; Life Technologies).
Antibodies were diluted 1:5,000 in PBS-T and incubated for 1 h at 21°C.
Membranes were washed three times in PBS-T and once in PBS, and
fluorescence was visualized and analyzed using an Odyssey infrared im-
aging system (Li-COR).
PSV production. Viral genes were codon optimized for optimal
expression in the 293TT human-derived cell line using the National
Cancer Institute Center for Cancer Research Laboratory of Cellular
Oncology Technical Files (http://home.ccr.cancer.gov/LCO/production
.asp). Codon-optimized sequences were based on the Mad-1 Polyomaviri-
dae orthopolyomavirus strain (NC_001699.1) and commercially synthe-
sized (Blue Heron Biotech). These genes were then subcloned into pwP
expression vector in place of the MPyV VP1 gene (22519; Addgene). PSVs
were produced by transfection of the codon-optimized VP1, VP2, VP3,
and phGluc plasmids into 293TT cells using FuGENE 6 transfection re-
agent (Promega) in a 3:1:1:2 ratio. Cells were split 1:3 at 48 h posttrans-
fection (hpi) and harvested at 7 d posttransfection by scraping and then
pelleted and resuspended in buffer A with EDTA-free protease inhibitors
(Roche Applied Science). Cells were lysed by three rounds of freezing and
thawing, sonicated and treated with 0.25% deoxycholic acid at 37°C for 30
min, and then sonicated three times on ice (Branson) (50% amplitude,
50% duty cycle, power 4, 1 min). The pH was lowered to 6.0, and the
lysates were treated with type V neuraminidase (Sigma) at 37°C for 1 h to
release JCPyV still bound to cells. The pH was then raised to 7.5, cellular
debris was pelleted by centrifugation, and the viral supernatant was pel-
leted through a 20% sucrose cushion in a SW40ti rotor (Beckman
Coulter) at 150,000  g at 4°C for 3 h. The viral pellet was resuspended
into buffer A (10 mM Tris-HCl [pH 7.4], 50 mM NaCl, 0.1 mM CaCl2)
and sonicated 3 times (30% amplitude, 50% duty cycle, power 3, 1 min).
The resuspended pellet was loaded onto a CsCl step gradient (1.29 to 1.35
g/ml) and spun at 115,000 g at 4°C for 18 h in a SW55ti rotor (Beckman
Coulter). The band corresponding to DNA-containing virions was iso-
lated and dialyzed against buffer A.
PSVs were quantified by absolute genome copy numbers. Purified
virions were treated with DNase I, and encapsidated phGluc plasmid was
extracted using a DNeasy blood and tissue kit (Qiagen). Absolute quan-
tification was performed using TaqMan quantitative PCR (Applied Bio-
systems), based on a standard curve of phGluc plasmid. The number of
copies for the known plasmid was plotted in a scatter plot against the
threshold cycle (CT) value determined for each dilution. A best-fit line was
generated, and the trend line equation from regression analysis was used
to calculate the absolute number of genomes in each virus sample.
PSV luciferase infectivity assay. SVGA cells were seeded in 96-well
plates at 70% confluence and infected with 1 107 genomes/well of wild-
type and mutant PSV in 35 l of serum-free medium. Cells were incu-
bated at 37°C for 1 h and washed with PBS, complete medium without
phenol red was added, and cells were incubated at 37°C for 72 h.
Secreted luciferase was quantitated in 50 l of cellular supernatants
using the BioLux Gaussia luciferase assay (New England BioLabs) accord-
ing to the manufacturer’s instructions using an opaque 96-well micro-
plate in a GloMax multidetection system luminometer (Promega)
equipped with an autoinjector.
Mutagenesis. An infectious clone of JCPyV (Mad-1 strain, pUC19
backbone) was mutagenized by Phusion site-directed mutagenesis ac-
cording to the protocol of the manufacturer (New England BioLabs). The
mutagenic primers used in this study are listed in Table 1. The entire
genome of each mutant was sequenced to ensure that no erroneous point
mutations were generated during the PCR amplification. Mutagenesis of
VP1 pentamers was performed using a pET15b plasmid encoding JCPyV
VP1 (residues 22 to 289) from the Mad-1 strain and an N-terminal hexa-
histidine tag (6). The same primers were used to mutagenize this penta-
mer expression plasmid as were used for the infectious clone. Mutants
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were maintained in the JM109 cells, and Escherichia coli BL21(DE3) cells
were used for pentamer expression (Invitrogen).
Pentamer expression and purification. Purification of JCPyV pen-
tamers has previously been described (6). Briefly, 2 liters of Luria broth
was inoculated with E. coli BL21(DE3) cells containing a pET15b-derived
plasmid expressing wild-type or mutant VP1. These cultures were grown
at 37°C to an optical density of 0.8. These cultures were then induced with
0.2 mM isopropyl -D-1-thiogalactopyranoside and grown at 21°C for 18
h. Cultures were pelleted by centrifugation, resuspended in 20 ml of load-
ing buffer (50 mM Tris-HCl [pH 7.5], 250 mM NaCl, 10 mM imidazole,
5% [vol/vol] glycerol), and frozen in liquid nitrogen. After thawing, the
pellet was sonicated for 1 min on ice using a 50% duty cycle and 50%
amplitude followed by a 5-min cooldown. After five rounds of sonication,
bacterial debris was separated from the supernatant centrifugation at
17,640  g for 20 min at 4°C. The supernatant was filtered through a
0.22-m-pore-size filter and purified by immobilized metal ion affinity
chromatography (IMAC) using a HisTrap 5-ml column and an Akta Pu-
rifier system (GE Healthcare). Pentamers were eluted from the column
with a linear gradient of 10 to 500 mM imidazole, and fractions corre-
sponding to pentamers were collected and dialyzed against a reaction
mixture consisting of 20 mM Tris base (pH 7.5), 5% (vol/vol) glycerol,
250 mM NaCl, and 10 mM dithiothreitol (DTT). The sample was then
concentrated, and nonaggregated VP1 pentamers were purified by size
exclusion chromatography (SEC) using a Superdex S200 column and
eluted in 20 mM HEPES (pH 7.5)–150 mM NaCl–50 mM DTT (GE
Healthcare). All samples were concentrated to 1 mg/ml using a molar
extinction coefficient of 28,030 M1 cm1 at 280 nm. For crystallization,
the N-terminal hexahistidine tag was cleaved off in solution by incubation
with 10 U thrombin (GE Healthcare) per mg VP1 for 20 h at 20°C prior to
size exclusion chromatography (Superdex S200 column).
Coexpression and purification of VP1 and VP2 pentamers. Full-
length JCPyV VP2 lacking affinity tags was cloned into the pACYC-duet
plasmid. E. coli BL21(DE3) cells were then cotransformed with full-length
VP2 and wild-type or mutant VP1. VP1 and VP2 pentamers were then
purified as described for the VP1-only pentamers.
Reconstitution of mutants and multicycle growth assay. The infec-
tious clone of each mutant was digested with EcoRI to liberate the viral
genome from the plasmid backbone. SVGA cells were seeded onto 18-
mm-diameter coverslips, and 1 g of this digestion product was trans-
fected using Fugene 6, according to the instructions of the manufacturer
(Roche). Wild-type JCPyV was included as a positive control, and pUC19
alone was included as a negative control. Replicate samples were then
assayed every 3 days, and the number of infected cells was scored to de-
termine viral spread. At the time points specified, replicates for each mu-
tant were fixed with methanol and stained with a monoclonal antibody
against JCPyV VP1 (PAb 597). A goat anti-mouse Alexa 488 antibody was
used as a secondary antibody, and nuclei were counterstained with DAPI
(4=,6-diamidino-2-phenylindole; Life Technologies). Positive cells were
counted on a T2000E inverted fluorescence microscope (Nikon), using
the DAPI filter block to find a field of representative cells. Five represen-
tative fields for each replicate were counted, and samples were processed
in a blind manner to minimize bias.
Crystallization. JCPyV VP1 pentamers with an N221W, N221Q, or
P223M mutation were concentrated to 4.5 mg/ml in 20 mM HEPES (pH
7.5)–150 mM NaCl. Crystals were set up at 20°C using the sitting-drop
vapor diffusion technique and a reservoir solution containing 100 mM
HEPES (pH 7.5), 200 mM KSCN, and 12% (wt/vol) polyethylene glycol
(PEG) 3350. Drops (1 l protein solution and 1 l reservoir solution)
were cross-seeded by adding microseeds obtained from previously grown
JCPyV Mad-1 VP1 crystals. Crystals were flash-cooled in liquid nitrogen
using a harvesting solution supplemented with 30% (vol/vol) glycerol.
Data collection and structure determination. Diffraction data were
collected at beamline X06DA at the Swiss Light Source (Villigen, Switzer-
land) and processed with XDS (21). Structures were solved by molecular
replacement with Phaser (22) in CCP4 (23) using the JCPyV Mad-1 VP1
pentamer structure (PDB: 3NXG) lacking a solvent molecule(s) as a
search model. In order to remove model bias, rigid-body and simulated
annealing refinement was carried out with Phenix (24). Crystals of mutant
VP1 pentamers have the same space group and very similar unit cell pa-
rameters. Mutations were introduced into the respective structural mod-
els, water molecules were added, and alternating rounds of model build-
ing in Coot (25) were performed. Refmac5 (26) was used for restrained
refinement, including 5-fold NCS restraints and the translation-libration-
screw (TLS) method (27). Simulated annealing Fobs-Fcalc omit electron
density maps were calculated after refinement with Phenix by omitting the
respective mutated amino acid residue for the validation of the final struc-
tural models. Coordinates and structure factor amplitudes have been de-
posited with the RCSB Protein Data Bank (www.pdb.org). Structural
characteristics and radii of the 5-fold VP1 pore tunnels were visualized
and analyzed with CAVER 3.0 (28). Structure figures were prepared with
PyMOL (The PyMOL Molecular Graphics System, version 1.3;
Schrödinger LLC). All amino acids are numbered without the inclusion of
the N-terminal methionine, consistent with the previously described
JCPyV VP1 structures (6, 29).
For the P223L mutant, a homology model was manually prepared in
the Coot program by selecting possible rotamer conformations of P223L.
Additionally, homology modeling was carried out with the program
MODELLER (30). MODELLER implements comparative protein struc-
ture modeling via energy minimization and spatial restraints. The two
models are highly similar and feature a diameter more similar to those
seen with the wild type, N221W, and N221Q. However, due to the sur-
rounding of the P223L, only a more uncommon side chain rotamer of
L223 is allowed in the context of VP1 without steric hindrance.
Differential scanning fluorometry. In order to assess the stability of
wild-type and mutant pentamers, differential scanning fluorometry was
performed using Sypro Orange, as previously described (31). Briefly, 4
M VP1 monomers (0.8 M VP1 pentamers) and 20 mM HEPES (pH
7.5)–150 mM NaCl–50 mM dithiothreitol (DTT) were mixed with a 10
solution of Sypro Orange in a final volume of 50 l (Sypro Orange is
provided as a 5,000 solution). Fluorescence was then monitored at the
TABLE 1 Primers used to generate pore mutations
Mutation Orientation Primer sequence (5=–3=)
P223V F GGAGAAAATGTTGUACCAGTTCTTC
R TCCTGTTAGTGTCCCAAAATATCTTG
P223I F GGAGAAAATGTTATCCCAGTTCTTC
R TCCTGTTAGTGTCCCAAAATATCTTG
P223L F GGAGAAAATGTTCTACCAGTTCTTC
R TCCTGTTAGTGTCCCAAAATATCTTG
P223M F GGAGAAAATGTTATGCCAGTTCTTC
R TCCTGTTAGTGTCCCAAAATATCTTG
N221Q F GGAGGAGAACAAGTTCCTCCAG
R TGTTAGTGTCCCAAAATATCTTGTG
N221Y F GGAGGAGAATACGTTCCTCCAG
R TGTTAGTGTCCCAAAATATCTTGTG
N221W F GGAGGAGAATGGGTTCCTCCAG
R TGTTAGTGTCCCAAAATATCTTGTG
Q137Y F GCCAGTGTACGGCACCAG
R TTCCCTGCACCATTGTCATGAG
137W F GCCAGTGTGGGGCACCAG
R TTCCCTGCACCATTGTCATGAG
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indicated temperatures in a Bio-Rad IQ5 real-time PCR machine, using
the excitation filter for 6-carboxyfluorescein (FAM) and emission filter
for ROX (Bio-Rad). A blank sample containing buffer but not pentamers
was used as a negative control. The fluorescence from the negative control
was subtracted from that measured for each sample. Six replicates were
performed for each sample.
Negative-staining electron microscopy. PSV virion formation was
determined using negative-staining transmission electron microscopy
(TEM). A 5-l sample of each purified PSV was adsorbed onto carbon-
coated Formvar copper grids for 2 min. Grids were washed with water,
and 5l of nanoW, a tungsten-based pH neutral stain, was added to each
grid for 1 min. Excess stain was blotted, and samples were visualized on a
Phillips 410 transmission electron microscope. Micrographs were ac-
quired at 80 kV and112,000 magnification.
Flow cytometry. SVGA cells were seeded into 6-well plates at a density
of 5 105 cells per well and incubated overnight. The following day, cells
were detached using a nonenzymatic dissociation agent (Cellstripper;
Cellgro) and incubated on ice for 30 min. For each PSV, an equivalent
number of genomes was then added to each sample and allowed to incu-
bate on ice for 2 h. Samples were then washed in cold PBS and immuno-
stained with a fluorescence-conjugated monoclonal antibody to VP1
(PAB597-488). After incubation for 1 h on ice, excess antibody was
washed away with PBS and samples were read on a BD FACSCalibur II
flow cytometer (Becton Dickinson).
PLA. Colocalization between JCPyV and the ER was performed as
previously described (14). The primary antibodies used for the proximity
ligation assay (PLA) were rabbit anti-VP1 and (in the case of JCPyV)
mouse anti-PDI. Cells were either left untreated or pretreated for 30 min
with 0.1 mM Retro-2cycl (Chembridge) and inoculated with 2  105 ge-
nome equivalents of JCPyV per cell. Virus was removed by aspiration, and
any unbound virus was removed by washing with media. Fresh media
containing 0.1 mM Retro-2cycl or media alone were added. Cells were then
incubated at 37°C for 8 h prior to fixation with 4% paraformaldehyde
(PFA). Cells were permeabilized with PBS containing 0.5% Triton X-100
for 0.5 h, washed three times in PBS, and then blocked in 5% donkey
serum for 1 h at 37°C and stained for VP1 (ab53977; Abcam) (1:1,000
dilution) and PDI (ab2792; Abcam) (1:100 dilution) by overnight incu-
bation at 4°C. Colocalization between VP1 and PDI was then assessed
using the proximity ligation assay (PLA), following the manufacturer’s
instructions (Bethyl Labs). Cells were washed, and the cell nuclei were
counterstained using DAPI. Fluorescence micrographs were collected by
confocal microscopy, and maximal z-projections were displayed. Fluores-
cent foci were quantified using the Blobfinder program (http://www.cb
.uu.se/amin/BlobFinder/). Threshold levels were set using a PLA-pro-
cessed uninfected sample, and the same threshold levels were used across
all samples. Blobfinder analysis was performed using a 7-by-7-pixel blob
size, and at least 50 cells per sample were analyzed. The average number of
blobs per cell was normalized to the wild-type PSV sample. Experiments
were performed in triplicate, and error bars denote standard deviations.
VP2 exposure assays. SVGA cells were seeded in 12-well plates at a
concentration of 5 104 cells per well and incubated overnight. Cells were
either left untreated or pretreated with 0.1 mM Retro-2cycl for 30 min.
Samples were then inoculated with equivalent numbers of genome copies
of JCPyV PSVs for 1 h at 37°C. Excess virus was washed off, and samples
were incubated in either complete media or complete media with 0.1 mM
Retro-2cycl. The cells were then stained with a polyclonal antibody to VP2
(ab53983; Abcam) and counterstained with DAPI. Randomized fields of
view were imaged, and the number of cells with exposed VP2 was deter-
mined. Results were normalized to the wild-type PSV sample. Experi-
ments were performed in triplicate, and error bars denote standard devi-
ations.
Protein structure accession numbers. Coordinates and structure
factor amplitudes have been deposited with the RCSB Protein Data Bank
(www.pdb.org) under accession codes 4WDY (N221Q), 4WDZ (N221W),
and 4WE0 (P223M).
RESULTS
The 5-fold pore is conserved among all polyomaviruses. The
polyomavirus 5-fold pore is formed by pentameric arrangement
of VP1 monomers around the 5-fold axis of symmetry, as shown
in the crystal structure of SV40 (Fig. 1A). Alignment of six diver-
gent polyomavirus VP1 crystal structures demonstrates that the
architecture of the 5-fold pore is conserved across polyomaviruses
(Fig. 1B). In JCPyV, the N221 and P223 residues line the surface of
the pore at its narrowest point, and Q137 is in close proximity to
the 5-fold pore (Fig. 1C and D). This narrow constriction is in
close proximity to VP2, as seen in the crystal structure of the
VP1-VP2 complex in MPyV (Fig. 1E). The diameter of this pore is
well conserved across structurally characterized polyomaviruses,
with diameters ranging from 7.6 Å (WUPyV) to 8.6 Å (MPyV) at
the respective bottlenecks describing the accessibility of the pore.
The diameter of the pore was calculated by employing the Caver
3.0 algorithm (28). The sequence identity of amino acids lining the
VP1 pore, including the highly conserved proline at position 223
in JCPyV VP1, which is present at corresponding positions in all
analyzed polyomaviruses (Fig. 1F), is rather high among polyo-
maviruses.
Amino acid substitutions to residues lining the pore restrict
growth. Using mutational analysis, we first sought to determine
whether the 5-fold pore played a role in viral assembly or infec-
tious cellular entry. A panel of mutant viruses were generated that
contained amino acid substitutions to residues lining or near the
5-fold pore at its narrowest point. These residues, P223, N221, and
Q137, were replaced with bulky amino acids that were predicted to
reduce the diameter of the 5-fold pore. In addition, one mutation,
N221W, was predicted to increase the hydrophobicity of this pore.
Infectious clones of wild-type or mutant JCPyV were transfected
into SVGA cells, and viral replication was assessed by multicycle
growth assays. Transfection efficiencies were equivalent, and all
samples expressed VP1, with an average of 4 VP1-positive cells per
20 field (data not shown). This result indicated that these mu-
tants were not defective in expressing the viral capsid protein.
Whereas wild-type JCPyV spread throughout the tissue culture
monolayer over a time period of 22 days, the 5-fold pore mutants
were severely restricted in viral spread (Fig. 2). Only N221Q and
N221Y, with 30% and 17% of wild-type levels, respectively, dem-
onstrated limited viral spread. In order to verify that reversion
mutations had not occurred in N221Q and N221Y, PCR and se-
quencing were performed on samples from the day 22 time point.
VP1 sequencing demonstrated that these viruses had not reverted
to a wild-type sequence. Thus, substitution of residues lining the
5-fold pore significantly reduced viral spread.
Substitutions to the 5-fold pore do not inhibit assembly of
theVP1 pentamer. Since Q137, N221, and P223 are spatially close
to the 5-fold axis, it is likely that any steric clashes resulting from
amino acid substitutions would be amplified due to the close
proximity of symmetry-related VP1 monomers also containing
these substitutions. We therefore sought to determine whether
amino acid substitutions to residues lining the 5-fold pore would
interfere with assembly of the VP1 pentamer. Five-fold pore mu-
tations were introduced into a bacterial expression plasmid en-
coding a truncated VP1 pentamer that has been used extensively
to characterize the structures of polyomaviruses (6). Recombinant
VP1 pentamers containing these 5-fold pore mutations were ex-
pressed in bacteria and purified by affinity and size exclusion
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chromatography to determine if these substitutions either inhib-
ited protein expression or resulted in pentamers of altered size.
Size exclusion chromatography demonstrated that the elution
times of all pentamers were similar, indicating that substitution of
the 5-fold pore does not result in larger structural defects in the
VP1 pentamer (Fig. 3A). A secondary peak is seen in some chro-
matographs and is due to the formation of interpentameric disul-
fide bonds.
Pentamers containing pore mutations package the minor
capsid proteins. Previous studies have shown that a segment of
VP2 is close to the 5-fold pore in MPyV (7). To address the pos-
sibility that substitutions to residues lining the 5-fold pore inhibit
association with VP2, wild-type or mutant VP1 pentamers were
coexpressed with full-length VP2 lacking any affinity tags. There-
fore, VP2 should copurify with VP1 only when these proteins can
still interact. After coexpression and purification, immunoblot-
ting was used to assay for the presence of VP2 (Fig. 3B). The results
demonstrate that wild-type VP1 and each mutant VP1 are able to
bind to VP2 (Fig. 3B).
Poremutant pentamers are not reduced in thermal stability.
We next sought to determine whether substitutions to residues
lining the 5-fold pore reduced the stability of recombinant pen-
tamers. To test this, differential scanning fluorometry was em-
ployed. This method involves the use of Sypro Orange, a fluo-
rophore that fluorescences brightly when bound to nonpolar
and, usually, buried residues. Assaying Sypro Orange fluores-
cence at various temperatures should therefore give an indica-
tion of the relative stability of each mutant pentamer. The re-
sults show an increase in Sypro Orange binding at between 40
and 50°C and no subsequent fluorescence at higher tempera-
tures (Fig. 3C). Increased fluorescence was also seen for some
mutants below 35°C. The cause of this increased fluorescence at
low temperatures is not readily apparent but may be due to an
increase in the levels of surface-accessible nonpolar residues in
some mutants. The results were similar when VP1 and VP2
pentamers were used (data not shown). These results show that
the wild-type VP1 pentamer and most 5-fold pore mutants are
very similar with respect to thermal stability, with the excep-
FIG 1 The VP1 5-fold pore is conserved across polyomaviruses. (A) The X-ray crystal structure of SV40 (PDB: 1SVA), represented by a ball and stick rendering.
A single VP1 pentamer, containing the 5-fold pore, is colored red. (B) Alignment of the VP1 structures from six divergent polyomaviruses: JCPyV (PDB: 3NXG),
SV40 (PDB: 3BWQ), MPyV (PDB: 1VPN), Merkel cell polyomavirus (MCPyV) (PDB: 4FMG), unassembled KI polyomavirus (KIPyV) (PDB: 3S7V), and
unassembled Washington University polyomavirus (WUPyV) (PDB: 3S7X). (C) Exterior view of the 5-fold pore, illustrating that residues Q137, N221, and P223
line the pore at its narrowest point. (D) Interior view of the 5-fold pore. (E) Cross-sectional view of the interior axial cavity, showing the relationship of the
indicated residues to VP2 in the MPyV VP1-VP2 complex structure (PDB: 1CN3). (F) Alignment of VP1 amino acid residues from seven different polyomavi-
ruses. Red letters indicate residues that were substituted in this study; asterisks indicate residues that are conserved in all seven polyomaviruses.
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tion of the Q137W mutant, which exhibits increased resistance
to thermal denaturation.
VP1 mutations alter the pore morphology. Next, in order to
assess structural effects of the pore mutations on the atomic level,
we solved X-ray structures of VP1 pentamers containing N221Q,
N221W, and P223M substitutions at resolutions of 1.9, 1.8, and
2.1 Å, respectively (Table 2). Well-defined electron density was
observed in all cases in the simulated annealing Fobs-Fcalc omit
maps for the respective mutations. VP1 pentamer structures su-
perpose with equivalent C atoms with root mean square devia-
tion (RMSD) values of about 0.2 Å and are, as expected, very
similar. A detailed analysis of the 5-fold pore shows very minor
local structural changes due to the introduced mutations (Fig. 4).
The diameter of the accessible pore of wild-type JCPyV VP1
was calculated to be about 8.2 Å at the narrowest point formed
by residue N221 (28). Very minor local changes of the VP1
backbone were seen for N221Q and N221W (Fig. 4A and B).
The glutamine alters the pore morphology and slightly narrows
the accessible bottleneck diameter to about 7.1 Å, which is the
tightest constriction of the pore, whereas the rather drastic
N221W mutation does not reduce the pore diameter (the bot-
tleneck diameter at W221 was calculated to be 8.6 Å) (Fig. 4D).
Additional bulky electron density was observed within the pore
of the N221W VP1 pentamer around the 5-fold axis. This den-
sity is unique for the N221W VP1 structure. It source could not
be conclusively identified, but it is likely a hydrophobic solvent
molecule that has no physiological relevance. The 5-fold clus-
ter of hydrophobic tryptophans within the narrow pore favors
hydrophobic interactions, including small hydrophobic sol-
vent molecules also. The P223M substitution constrains the
pore to a reduced diameter of about 5.2 Å at the bottleneck,
where methionines face toward the 5-fold axis (Fig. 4C and D).
Furthermore, additional minor structural rearrangements of
the C backbone within the FG1-loop, such that N221 moves
by about 2.3 Å toward the center of the pore (Fig. 4C), are seen.
Because the P223L mutation was to be used in later experi-
ments, a homology model of this mutant was generated. The
diameter of the pore in the P223L homology model is much less
restricted than in the P223M model and contains an accessible
diameter of about 8.3 Å that is more similar to those seen with
the wild type and the N221W and N221Q mutants (Fig. 4D).
FIG 2 Amino acid substitutions to residues lining the 5-fold pore reduce
infectivity. Infectious clones of wild-type JCPyV or pore mutants were trans-
fected into SVGA cells, and viral spread was monitored over 22 days. Data
represent the means of the results of three independent experiments, and the
error bars indicate standard deviations.
FIG 3 VP1 pentamers with altered 5-fold pores are not deficient in assembly.
(A) A truncated VP1 containing a hexahistidine tag was expressed in bacteria
and purified in order to assess the ability of pore mutants to form pentamers.
(B) Truncated VP1 containing a hexahistidine tag and full-length VP2 lacking
affinity tags were expressed in bacteria and purified by IMAC and SEC. West-
ern blotting was used to determine whether the indicated pore mutants were
able to copurify VP2. (C) Differential scanning fluorometry of VP1 pore mu-
tants. The indicated VP1 was mixed with Sypro Orange, and fluorescence was
monitored over the indicated range of temperatures. Max, maximum.
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JCPyV PSVs containing 5-fold pore substitutions are not
morphologically altered or deficient in packaging VP2 or VP3.
In order to study the effect of these pore mutations on infectious
entry of JCPyV, we next generated wild-type or mutant JCPyV
PSVs. PSVs have been extensively used to characterize events in
infectious entry of polyomaviruses and additionally allow the
study of mutants that could not otherwise be propagated. We
selected two pore mutants, N221W and P223L, for further study
in order to directly assess the effect of amino acid substitutions of
residues lining the surface of the 5-fold pore. PSVs were generated
for Q137W, but large variations in the number of infectious par-
ticles recovered between preparations were observed, suggesting
that amino acid substitutions at this residue may alter virion sta-
bility. Additionally, since the Q138W pentamer appeared to have
altered stability in our thermal denaturation experiments com-
pared to wild-type or other mutant pentamers, Q137W was ex-
cluded from further analysis.
After purification, these PSVs were examined by negative-
staining transmission electron microscopy to determine the effect
of these substitutions on virion assembly. Wild-type and mutant
PSVs appeared to be similar in morphology, demonstrating that
PSVs containing these substitutions to the 5-fold pore are not
grossly distorted or deficient in assembly (Fig. 5A). Immunoblot-
ting also demonstrated that N221W and P223L PSVs packaged the
minor capsid protein, further suggesting that substitution of res-
idues lining the 5-fold pore does not interfere with minor capsid
protein packaging (Fig. 5B).
Pore mutant PSVs are deficient in transduction. To deter-
mine whether modulation of residues surrounding the 5-fold pore
affected viral entry, we performed single-cycle growth assays using
wild-type or mutant PSVs that package a reporter plasmid ex-
pressing luciferase. Previous studies have demonstrated that ex-
pression of this reporter is directly proportional to the number of
cells infected (32). Equivalent numbers of genome copies of each
PSV were added to SVGA cells, and transduction efficiency was
determined by determinations of relative luciferase expression
levels. The results of these studies demonstrated that both N221W
and P223L PSVs were deficient in transducing cells, suggesting a
defect in viral entry (Fig. 5C).
Mutants are not defective in binding to host cells. We next
sought to determine what step in the infectious life cycle is inhib-
ited as a result of amino acid substitutions in residues lining the
5-fold pore. Binding assays were used to determine whether mu-
tant PSVs were deficient in binding to cells. Equivalent numbers of
genome copies of each PSV were added to SVGA cells, and binding
was determined using a fluorescently labeled monoclonal anti-
body to VP1. This analysis demonstrated that wild-type, N22Q,
and P223L PSVs all bound to cells equivalently and suggests that
these amino acid substitutions do not reduce the ability of these
mutant virions to bind to cells (Fig. 5D).
Poremutant PSVs are transported to the ERbut are deficient
in exposing VP2. Transport of JCPyV to the ER is a critical step in
infectious entry of JCPyV. Using proximity ligation assays, a
method for reporting specific colocalization, we sought to deter-
TABLE 2 Data collection and structural refinement statisticsa
Statistic
Result
VP1 N221Q VP1 N221W VP1 P223M
Space group C2 C2 C2
Unit cell dimensions
a, b, c (Å) 149.71, 95.79, 128.51 149.34, 95.98, 128.5 149.72, 95.63, 128.51
, , 	 (°) 90.0, 110.4, 90.0 90.0, 110.5, 90.0 90.0, 110.40, 90.0
Resolution (Å) 50–1.90 (1.95–1.90) 50–1.8 (1.85–1.80) 50–2.10 (2.15–2.10)
No. of unique reflections 131,987 (8,272) 155,280 (10,329) 98,969 (7,258)
No. of observed reflections 538,018 (24,462) 633,087 (29,258) 378,369 (27,027)
Rmeas (%) 11.9 (91.0) 9.2 (84.9) 17.3 (96.6)
I/
I 9.43 (1.7) 11.7 (1.5) 9.2 (1.7)
CC1/2 (%) 99.7 (82.1) 99.8 (59.1) 99.2 (65.2)
Completeness (%) 98.1 (83.5) 98.8 (88.5) 99.8 (99.3)
Wilson B-factor (Å2) 31.9 30.7 29.8
Refinement
Rwork, Rfree (%) 19.1, 22.9 16.0, 18.6 18.0, 21.8
No. of atoms
Protein 10,061 10,096 10,058
Water 724 873 530
Avg B-factor (Å2)
Protein 31.2 26.7 29.1
Water 35.8 33.7 30.8
RMS deviations
Bond length (Å) 0.008 0.007 0.008
Bond angle (°) 1.315 1.269 1.308
a Values for the highest resolution bins are given in parentheses. meas, measured; RMS, root mean square.
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mine whether these pore mutants were defective in ER transport.
Cells were inoculated with equivalent numbers of genome copies
of each virus, and samples were fixed and stained at 8 h postinfec-
tion, a time point that has been shown to correspond to the arrival
of JCPyV at the ER (14). PLA using antibodies to VP1 and PDI
demonstrated that the pore mutants were transported to the ER as
efficiently as wild-type viruses. Conversely, treatment of cells with
Retro-2, a recently described inhibitor of JCPyV retrograde trans-
port, prevented colocalization of JCPyV and PDI (Fig. 6).
Upon delivery to the ER, JCPyV interacts with ER resident
chaperones and exposes the VP2 minor capsid protein. Since these
pore mutations are in close proximity to the packaging site of VP2,
we next determined whether these mutants are able to expose VP2
in the ER. Cells were inoculated with equivalent numbers of ge-
nome copies of each virus, and samples were fixed and immuno-
stained for VP2 at 8 h hpi. This analysis revealed that VP2 foci
could be observed for wild-type PSVs. In contrast, Retro-2 treat-
ment of cells reduced the level of VP2 exposure. Surprisingly, both
of the pore mutants failed to expose VP2, suggesting that these
mutants were deficient in undergoing productive conformational
changes in the ER needed to expose VP2 (Fig. 7).
DISCUSSION
Our report demonstrates that relatively subtle changes in residues
lining the 5-fold pore of JCPyV result in dramatic decreases in
infectivity. We show that these mutants are not deficient in assem-
bly, binding to cells, or intercellular transport. Instead, these pore
mutants are unable to expose the VP2 minor capsid protein in the
ER during viral entry. This report suggests that contacts between
the 5-fold pore and VP2 residues are a critical feature in the JCPyV
capsid.
We initially suspected that this 5-fold pore was merely gener-
ated by the capsid symmetry and that residues occupying this
space would result in significant structural clashes due to the close
proximity of symmetry-related monomers. However, our results
demonstrate that none of these substitutions results in assembly
defects. In the case of N221Q, N221W, and P223M, only subtle
changes were seen in the X-ray structure of VP1 pentamers, and
similar minor changes were seen in the homology model of P223L.
N221Q and N221W alter the pore diameter to only a very minor
extent, but (in particular) the bulky N221W substitution muta-
tion and, likely, also N221Y drastically change the molecular sur-
face within the narrow pore and, likely, the interaction between
VP1 and VP2. The structural impact of the P223M mutation on
the FG1-loop conformation might explain why the prolines at
equivalent VP1 positions are highly conserved. Although P223I,
P223V, and P223L were not analyzed by X-ray crystallography,
one could speculate about similar minor changes within the FG-
loop. Leucine, valine, and isoleucine are smaller than methionine,
so that the bottleneck radius might be less reduced; however, the
nonpolar character at position 223 is preserved in all cases. Sub-
stitutions at amino acid position 137 (Q137Y and Q137W) were
not reviewed by structural analysis, so the possibility cannot be
ruled out that local structural rearrangement may occur. Indeed,
differential scanning fluorometry analysis suggested that VP1
pentamers containing the Q137W substitution were altered in
their thermal stability. The amino acid at position 137 does not
directly line the 5-fold pore.
Our structural studies, demonstrating no significant structural
differences between wild-type and mutant pentamers, coupled
with the ability of both pentamers and PSVs to incorporate the
minor capsid proteins, suggest that the mutant viruses do not
display any drastic overall structural defects. This interpretation is
additionally supported by the lack of differences in pentamer sta-
FIG 4 Crystal structures of VP1 pentamers with N221Q, N221W, and P223M pore mutations. (A to C) Structural superposition of pore mutants N221Q (A),
N221W (B), and P221M (C) with wild-type Mad-1 VP1. VP1 pentamers are shown in cartoon representations with side chains of key amino acid residues
highlighted in stick representations and colored according to atom type (oxygens are shown in red, nitrogens in blue, and carbons in the colors assigned for the
respective mutants). Wild-type VP1 is shown in gray. The accessible diameter at the narrowest constriction of the 5-fold pore was determined (28). The diameter
was calculated to be 8.2 Å for wild-type VP1 and to be 7.1 Å and 8.6 Å for N221Q and N222W, respectively. The P223M mutation results in a constrained
accessible pore diameter of 5.2 Å. (D) Surface representations of the 5-fold pore. Views are equivalent in all cases, and mutated amino acids are colored on the
surface. A VP1 homology model for P223L was generated, and the most favorable rotamer conformation of Leu is shown in a surface representation using sticks.
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bility, as measured by differential scanning fluorometry. How-
ever, we cannot rule out the possibility that subtle structural
changes in the capsid of these mutant viruses are responsible for
the decrease seen in our multicycle growth assays.
PSVs containing these pore mutants were severely restricted in
their ability to transduce susceptible cells, and the results sug-
gested that these mutants were deficient at some step in viral entry.
P223L and N221W were as efficient as wild-type PSVs in binding
to cells and in transport to the ER, suggesting that that these pore
mutants are still able to productively interact with cellular recep-
tors and host transport factors. Instead, our VP2 exposure exper-
iments demonstrate that these pore mutants do not expose VP2 in
the ER. At present, the exact mechanism which causes these mu-
tants to be deficient in exposure of VP2 is unclear.
The viral capsid of polyomaviruses is stabilized by interpenta-
meric disulfide bonds, coordination of calcium ions, and hydro-
phobic interactions between the C terminus of VP1 and residues
on the neighboring VP1 pentamer. It is likely that complete disas-
sembly of the viral capsid requires disruption of the majority of
these stabilizing factors. In SV40, virions remain largely intact
following disulfide bond isomerization in the ER and retrotrans-
location across the ER membrane occurs with virions in the form
of large and intact particles (33). In vitro studies support this no-
tion and demonstrate that treatment with the disulfide bond-re-
ducing agent DTT is not sufficient for shedding of viral pentam-
ers. Virions are seen to shed VP1 pentamers only after treatment
with DTT and the calcium-sequestering molecule EGTA (34).
Thin-section transmission electron microscopy studies have dem-
onstrated that SV40 virions in the ER appear smaller in diameter
and show visible VP2 in the form of extrusions (16). These studies
suggested that VP2 is exposed in the absence of capsid disassem-
bly. One possibility would be that the isomerization of intrapen-
tameric disulfide bonds loosens the contacts between neighboring
pentamers enough to allow exposure of the N terminus of VP2
though this opening. Alternatively, the 5-fold pore is situated near
VP2, and previous studies have postulated that the 5-fold pore
may provide a site of egress for the N terminus of VP2 (7). How-
ever, it should be noted that in vitro treatment of purified SV40
with ER luminal extracts results in distorted particles from which
viral genomic DNA can be extracted, which suggests that capsid
disassembly has occurred (16). It is unclear whether an analogous
situation occurs during normal infectious entry of polyomavi-
ruses.
At least four distinct possibilities exist for this observed defect
in VP2 exposure. First, it is possible that these amino acids alter
the interaction of VP1 with VP2, thereby interfering with the abil-
ity of the virion to expose VP2 during infectious cellular entry.
Second, it is possible that these substitutions alter a recognition
FIG5 PSVs containing pore mutations are not deficient in assembly or binding to cells. (A) Wild-type or mutant PSVs were produced, and assembly was assessed
by TEM. Scale bars denote 50 nm. (B) Western blotting was performed to demonstrate that all of the mutants were able to package VP2 and VP3. (C) Pore mutant
PSVs are deficient in viral entry. SVGA cells were inoculated with equivalent numbers of genome copies of the indicated PSV, and luciferase expression was
determined 72 hpi. (D) Pore mutant PSVs are not deficient in binding to cells. SVGA cells were inoculated with equivalent numbers of genome copies of the
indicated PSV, and binding was determined by flow cytometry.
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site for an as-yet-unidentified ER-resident chaperone or inhibit
productive association with ER-residing chaperones, thereby in-
hibiting the conformational changes needed to expose the minor
capsid proteins. Third, while these mutant viruses do not appear
to be defective in ER transport, recent studies have shown that
only a small percentage of virions that are transported to the ER
actually expose VP2 or VP3. The identity of these parts of the ER is
not well understood, but they appear to recruit chaperones such as
BIP and DNAJ proteins to the foci where VP2 is exposed (35). It is
therefore possible that these pore mutants are successfully trans-
ported to the ER but are deficient in transport to critical regions of
the ER necessary for VP2 exposure and retrotranslocation. Finally,
it is possible that the 5-fold pore of VP1 serves as a conduit for
egress of the N terminus of VP2.
Definitively determining the site of VP2 egress from JCPyV is
challenging. VP2 must be exposed for productive infection, and
yet this exposure does not appear to be accompanied by complete
disassembly of the viral capsid (16, 33). If disassembly of the viral
capsid prior to VP2 exposure does not occur, then it is possible
that VP2 is externalized either through the interpentameric gaps
between monomers or through the pore present at the 5-fold axis
of symmetry. While our results do not definitively determine the
site of VP2 egress, they clearly demonstrate that modulation of
this pore hampers exposure of VP2. Increased hydrophobicity
within the pore and minor alterations of the pore diameter might
alter, and perhaps strengthen, the contacts with VP2. Most of VP2
and VP3 is not resolved in the atomic resolution structures of
MPyV, and it is therefore difficult to determine the extent to which
the minor capsid proteins interacted with either the wild-type or
the pore mutant in these studies. Further studies will be needed to
FIG 6 Pore mutant PSVs are transported to the ER as efficiently as wild-type
PSVs. (A) SVGA cells were inoculated with equivalent numbers of genome
copies of each PSV, and ER colocalization was assessed at 8 hpi by proximity
ligation assays. (B) Quantification of the data presented in panel A. Results
represent the means of the results of three independent experiments, and error
bars denote standard deviations. *, P 0.05.
FIG 7 Pore mutants are deficient in exposing VP2 in the ER. (A) SVGA cells
were inoculated with equivalent numbers of genome copies of each PSV, and
VP2 exposure was assessed at 10 hpi by immunostaining for VP2. (B) Quan-
tification of the data presented in panel A. Results represent the means of the
results of three independent experiments, and error bars denote standard de-
viations. *, P 0.05.
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definitively determine the mechanism by which these minor cap-
sid proteins are exposed.
In conclusion, we demonstrate that the 5-fold pore of JCPyV is
an important structural feature and that modification of this pore
results in a severe reduction in infectivity. These mutations do not
hamper assembly of the virion but instead prevent the exposure of
the minor capsid proteins. This work suggests that the 5-fold pore
is important for the function of infectious cellular entry and that
implementation of small molecules targeting this pore may prove
to be an effective antiviral therapy.
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Structure Analysis of the Major Capsid Proteins of Human
Polyomaviruses 6 and 7 Reveals an Obstructed Sialic Acid Binding
Site
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ABSTRACT
Human polyomavirus 6 (HPyV6) and HPyV7 are commonly found on human skin. We have determined the X-ray structures of
their major capsid protein, VP1, at resolutions of 1.8 and 1.7 Å, respectively. In polyomaviruses, VP1 commonly determines anti-
genicity as well as cell-surface receptor specificity, and the protein is therefore linked to attachment, tropism, and ultimately,
viral pathogenicity. The structures of HPyV6 and HPyV7 VP1 reveal uniquely elongated loops that cover the bulk of the outer
virion surfaces, obstructing a groove that binds sialylated glycan receptors in many other polyomaviruses. In support of this
structural observation, interactions of VP1 with 2,3- and2,6-linked sialic acids could not be detected in solution by nuclear
magnetic resonance spectroscopy. Single-cell binding studies indicate that sialylated glycans are likely not required for initial
attachment to cultured human cells. Our findings establish distinct antigenic properties of HPyV6 and HPyV7 capsids and indi-
cate that these two viruses engage nonsialylated receptors.
IMPORTANCE
Eleven new human polyomaviruses, including the skin viruses HPyV6 and HPyV7, have been identified during the last decade.
In contrast to better-studied polyomaviruses, the routes of infection, cell tropism, and entry pathways of many of these new vi-
ruses remain largely mysterious. Our high-resolution X-ray structures of major capsid proteins VP1 from HPyV6 and from
HPyV7 reveal critical differences in surface morphology from those of all other known polyomavirus structures. A groove that
engages specific sialic acid-containing glycan receptors in related polyomaviruses is obstructed, and VP1 of HPyV6 and HPyV7
does not interact with sialylated compounds in solution or on cultured human cells. A comprehensive comparison with other
structurally characterized polyomavirus VP1 proteins enhances our understanding of molecular determinants that underlie re-
ceptor specificity, antigenicity, and, ultimately, pathogenicity within the polyomavirus family and highlight the need for struc-
ture-based analysis to better define phylogenetic relationships within the growing polyomavirus family and perhaps also for
other viruses.
Polyomaviruses are a group of nonenveloped double-strandedDNA (dsDNA) viruses that were initially identified inmice (1)
but have been found since then in birds and in several species of
mammals, including humans (reviewed in references 2, 3, and 4).
Due to recently developed techniques such as high-throughput
sequencing and rolling-circle amplification, a number of new
polyomaviruses, including 11 new human polyomaviruses, have
been identified during the last decade (5–14). This expansion of
the Polyomaviridae family led to its division into three genera, the
ortho-, wuki-, and avipolyomaviruses (15). With high sequence
homology and conserved overall architecture across genera, the
family forms an attractive platform for analyzing determinants of
cell entry, cell tropism, and host range as well as other factors that
contribute to pathogenesis (4). Asymptomatic and latent infec-
tions with polyomaviruses are common in the healthy human
population (16–18). Individuals with impaired immune re-
sponses due to organ transplantation, monoclonal antibody ther-
apy, hematological diseases, or human immunodeficiency virus
(HIV) infection are found to be especially susceptible to reactiva-
tion of polyomaviruses, which can lead to severe or fatal diseases
(reviewed in references 4 and 19).
Cutaneous human polyomavirus 6 (HPyV6) and HPyV7 (8)
are commonly shed from the skin together with the oncogenic
Merkel cell polyomavirus (MCPyV) (8, 20). Although no human
disease has been linked toHPyV6 andHPyV7 so far, initial studies
indicate that persistent infections with both viruses are very com-
mon, resulting in seropositivity rates of 35% to 90% by adulthood
(8, 17). Thus, an involvement of HPyV6 and/or HPyV7 in cuta-
neous tumors has to be considered (21–24).While the two viruses
have the same tropism asMCPyV, they are more closely related in
sequence to the Washington University and Karolinska Institute
polyomaviruses (WUPyV and KIPyV, respectively), which were
isolated from respiratory tract samples (5, 6). Hence, WUPyV,
KIPyV, HPyV6, andHPyV7 have been classified together as wuki-
polyomaviruses (15).
The polyomavirus major capsid protein VP1 determines anti-
genicity and mediates attachment to host-cell receptors. It is well
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established that VP1 possesses a jelly-roll topology and assembles
into 72 pentamers, which in turn form aT 7d icosahedral capsid
(25, 26). The VP1 pentamers associate withminor capsid proteins
VP2 and VP3, which are located inside the capsid. The presence
and roles of VP2 and VP3 seem to differ among polyomavirus
species (27). All known structures of polyomavirus VP1 show ex-
tended and structurally variable surface loops that emanate from a
conserved -sheet core structure formed by strands B, I, D, and G
and strands C, H, E, and F (25, 26, 28–35). These surface loops,
named BC-, DE-, HI-, and EF-loops after the-strands connected
by them, are chiefly responsible for viral antigenicity. For each
virus, they form a unique virus-host interaction platform that
determines host range, cell tropism, viral spread, and pathogenic-
ity. Engagement of sialylated glycanmotifs during cell attachment
and entry is a common feature of the better-studied orthopoly-
omaviruses (28–30, 32–36). In contrast, the routes of infection,
transmission, cell tropism, receptor specificity, and entry path-
ways of wukipolyomaviruses remain largely mysterious. To pro-
vide an initial framework for investigating themolecular determi-
nants of receptor specificity and tropism of HPyV6 and HPyV7,
we determined high-resolution crystal structures of their recom-
binantly expressed VP1 proteins. While the core structures are
highly conserved, the surface loops of HPyV6 and HPyV7 VP1
differ profoundly from those of related polyomavirus VP1 struc-
tures. Specific cell surface receptors remain to be unveiled for both
viruses, but, interestingly, our findings indicate that sialylated gly-
cans are likely not engaged during early infection steps. In support
of the crystallographic analyses, interactions of VP1 with either
2,3- or 2,6-linked sialic acids could not be detected by flow
cytometry cell binding studies and saturation transfer difference
(STD) nuclear magnetic resonance (NMR) spectroscopy.
MATERIALS AND METHODS
DNA cloning and protein expression. Following a strategy established
for the expression of soluble, assembly-incompetent VP1 pentamers (36),
DNAs coding for residues 20 to 291 of HPyV6 VP1 and residues 20 to 288
of HPyV7 VP1 (GenBank accession codes ADE45449 and ADE45474)
were cloned into pET15b vectors (Novagen). Soluble pentamers were ex-
pressed and purified as described earlier (30, 33). Four nonnative residues
(GSHM) are present at the N termini of both proteins after purification,
and a nonnative glutamine forms the C terminus of HPyV7 VP1. For cell
binding experiments, the JC polyomavirus (JCPyV) VP1 wild type and
L54F mutant (residues 22 to 289) and murine polyomavirus VP1 (RA
strain; residues 33 to 316) were expressed and purified accordingly
(30, 37).
Crystallization, data collection, and structure determination.
HPyV6VP1was concentrated to 6mg/ml in 20mMHEPES (pH 7.5)–150
mM NaCl–20 mM dithiothreitol (DTT), and crystals were obtained at
20°C using the sitting-drop vapor diffusion technique and a reservoir
containing 100 mM Tris (pH 8.5)–200 mM NaSCN (sodium thiocya-
nate)–13.3% (wt/vol) polyethylene glycol (PEG) 3350. HPyV7 VP1 was
crystallized using 7 mg/ml VP1–20 mM HEPES (pH 7.5)–150 mM NaCl
and a reservoir containing 100 mM Na malonate (pH 4.5)–15% (wt/vol)
PEG 3350 (hanging-drop vapor diffusion technique). Drops were set up
with 1l protein solution and 1l reservoir solution in each case. Crystals
were harvested into the respective reservoir solutions supplemented with
30% (vol/vol) glycerol prior to flash-freezing them in liquid nitrogen.
Diffraction data were collected at beamlines ID14-4 at ESRF (Grenoble,
France) (HPyV6) and X06DA at SLS (Villigen, Switzerland) (HPyV7).
Data sets were processed with XDS (38), and structures were solved by
molecular replacement with Phaser in CCP4 (39, 40). The WUPyV VP1
core structure (PDB accession no. 3S7X) (31) served as a search model to
solve the HPyV7 VP1 structure, and the refined HPyV7 VP1 coordinates
were then used to determine the structure of HPyV6VP1. Rigid-body and
simulated annealing refinement was in both cases carried out with Phenix
(41), followed by alternating rounds of model building in Coot (42) and
restrained refinement, including the translation-libration-screw method
(43) and 5-fold noncrystallographic symmetry restraints with Refmac5
(44). Structural superpositions were done using secondary-structure
matching (45) and the program Superpose in CCP4 (40). PyMOL (The
PyMOLMolecular Graphics System, Version 1.3; Schrödinger, LLC) and
the APBS tool plugin (46) were used to create structure figures.
Cell culture. HeLa S3 and 293TT (47) cells were maintained in a hu-
midified 37°C CO2 chamber in Dulbecco’s modified Eagle medium
(DMEM) supplemented with 1% penicillin-streptomycin, 6 mM L-glu-
tamine, 1 mM sodium pyruvate, and 10% heat-inactivated fetal bovine
serum (FBS). HeLa S3 cells were kindly provided by Katharina Rehn and
Dirk Schwarzer (IFIB, Tübingen, Germany) and 293TT cells by Christo-
pher C. Buck (National Cancer Institute, NIH).
Flow cytometry experiments.VP1pentamerswere labeledwithAlexa
Fluor 488 C5maleimide (Invitrogen). Proteins (1mg/ml) were incubated
in 20mMHEPES (pH 7.5)–150mMNaCl for 16 to 18 hwith 80mMDTT
at 4°C. Excess DTT was removed using two 5-ml HiTrap desalting col-
umns (GE Healthcare), and the dye (10 mM in 20 mM HEPES pH 7.0–
150 mM NaCl) was added dropwise by gently mixing it into the protein
solution (0.3 to 0.4 mg/ml in 20 mM HEPES pH 7.0–150 mM NaCl) to
give a 8-fold molar excess of the dye. The reaction mixture was incubated
for 18 h at 4°C. DTT (10 mM) was added, and the excess dye and DTT
were removed by desalting (two 5-ml HiTrap desalting columns). The
labeling efficiency was determined by UV light/visible light (UV/vis) ab-
sorption according to the manufacturer’s protocol.
Cells (80% to 90% confluent) were detached nonenzymatically from
flasks by incubation with Gibco enzyme-free cell dissociation buffer (Life
Technologies) for 30min at 37°C and were washed twice with phosphate-
buffered saline (PBS). A total of 5  106 cells were suspended in 100 l
PBS. Cells were mock treated or pretreated with 0.2 U/ml neuraminidase
(Clostridium perfringens neuraminidase type V; Sigma-Aldrich) at 37°C
for 30 min and then washed 3 times with 500 l PBS and pelleted after
each wash at 200  g (4 min; 4°C). Cells were incubated in 100 l of
labeled VP1 pentamer solution (50 g/ml in PBS) on ice for 2 h with
agitation every 15 to 20 min. HeLa S3 cells were washed twice in 500 l
PBS and fixed in 500 l PBS containing 1% formaldehyde for 30 min.
293TT cells were washed twice in PBS and then suspended in 500 l PBS
for the measurement. DAPI (4=,6-diamidino-2-phenylindole) was added
to 293TT cells to gate for live cells. Analysis was done using a BD FAC-
SCanto (Becton, Dickinson andCompany) flow cytometer equippedwith
a 488-nm excitation line. A total of 10,000 gated events weremeasured for
each sample. Data were analyzed using FlowJo software (Tree Star, Inc.).
Saturation transfer difference NMR spectroscopy. STD NMR spec-
tra were recorded at 283 K using 3-mm-inner-diameter Match tubes
(200-l sample volume) and a Bruker AVIII-600 spectrometer equipped
with a room temperature probe head and processed with TopSpin 3.0
(Bruker). Samples contained 1 mM 2,3-sialyllactose and 2,6-sialyllac-
tose (Carbosynth) (each) and a 50 M concentration of either HPyV6 or
HPyV7 VP1. Proteins were buffer exchanged prior to NMR experiments
in centrifugal concentrators to 20 mM potassium phosphate (pH 7.4)–
150 mM NaCl in D2O. Off- and on-resonance irradiation frequencies
were set to80 ppm and 7.0 ppm, respectively. The irradiation power of
the selective pulses was 57 Hz, the saturation time was 2 s, and the total
relaxation delay was 3 s. A 50-ms continuous-wave spin-lock pulse with a
strength of 3.2 kHz was employed to suppress residual protein signals. A
total of 512 scans were recorded. A total of 10,000 points were collected,
and spectra were multiplied with an exponential window function (line
broadening, 1 Hz) prior to Fourier transformation. Spectra were refer-
enced to 298 K using the-D-Glc anomeric proton as an internal standard
(48).
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Protein structure accession numbers.Coordinates and structure fac-
tor amplitudes have been deposited under accession numbers 4PCG
(HPyV6) and 4PCH (HPyV7) with the RCSB Protein Data Bank (www
.rcsb.org).
RESULTS
Overall structures of HPyV6 and HPyV7 VP1. The HPyV6 and
HPyV7 VP1 pentamer structures were solved at resolutions of 1.8
and 1.7 Å, respectively, and the refined structures have excellent
statistics (Table 1). The final coordinates include residues 22 to 87
and 94 to 290 in the case of HPyV6 and residues 23 to 47, 55 to 85,
and 96 to 286 of HPyV7 for all five VP1 chains in the asymmetric
units. Each VP1 monomer within the pentamer adopts the iconic
jelly-roll fold consisting of two apposed -sheets (Fig. 1). The
EF-loops fold into short three-stranded -sheets (E=, E, and E	)
and decorate the side of the pentamer. The I-strand is split into
two parts named I and I=. As is typical for polyomavirus VP1
structures, rather poor electron density was observed for the CD-
loops at the base of the HPyV6 and HPyV7 pentamers (25, 26,
28–32). This loop is flexible and assumes different conformations
even in the context of the intact virion (25, 26, 28). The long
BC-loop is divided for clarity into BC1- andBC2-loops that face in
different directions (Fig. 1C). The BC1-loops of the HPyV7 VP1
pentamer have elevated mobility, and they have continuous elec-
tron density only when contacting the neighboring protomer
within the crystal lattice. Thus, the final coordinates contain only
three ordered BC1-loops per pentamer. In contrast, the BC1-
loops of HPyV6 VP1 have good electron density and share similar
conformations that are independent of the presence of crystal
contacts. They could therefore be built for all five chains in the
asymmetric unit.
The C atoms of monomeric and pentameric HPyV6 and
HPyV7 VP1 structures superpose with very low root mean square
deviation (RMSD) values of 0.6 Å and 0.7 Å, respectively, reflect-
ing their high sequence identity of 68% (49). RMSD values for
individual residues exceed 1.5 Å only within the EF-loop, where
three additional residues elongate the HPyV6 VP1 EF-loop some-
what so that it projects further away from the 5-fold axis (Fig. 1C).
In order to quantify the level of structural diversity of VP1
structures within the members of the Polyomaviridae family, the
HPyV6 and HPyV7 VP1 coordinates were superposed with the
most closely related WUPyV (PDB accession no. 3S7X) and
KIPyV (PDB accession no. 3S7V) VP1 structures as well as the
evolutionarily more distant MCPyV (PDB accession no. 4FMG)
and simian virus 40 (SV40) (PDB accession no. 3BWQ) VP1
structures (15). Root mean square deviation (RMSD) values for
superpositions of VP1 monomers from HPyV6 or HPyV7 onto
their KIPyV and WUPyV counterparts are low (
1.2 Å), in line
with the classification of these four viruses into the wukipolyoma-
virus family. Superpositions of HPyV6 andHPyV7 VP1 onto VP1
monomers from the orthopolyomaviruses MCPyV and SV40
yield slightly higher RMSD values (1.4 to 1.7 Å). However, when
entire VP1 pentamers are superposed, the RMSDdifferences all lie
in a range from 1.3 Å (HPyV6-KIPyV) to 1.7 Å (HPyV6-SV40),
demonstrating that the pentameric VP1 arrangements are similar
across the wuki- and orthopolyomaviruses.
Organization of surface loops. The top surface of the VP1
pentamer, which corresponds to the accessible surface of the virus,
is almost entirely defined by theBC-,DE-, andHI-loops, and these
loops endow each polyomavirus with a unique platform for spe-
cific interactions with individual receptors (Fig. 1C). Typically,
this platform binds glycan receptors that terminate in sialic acid
(Neu5Ac), but sequences and linkages of the recognized oligosac-
charides differ among polyomaviruses, leading to specific interac-
tions with a small subset of sialylated glycans in each case (28–30,
32–36). However, despite these differences, the location of the
sialic acid binding site is conserved among the polyomaviruses for
which VP1 structures have been available to date. The sialic acid
binding site is typically located in a recessed area at the junction of
the BC1-, BC2-, DE-, and HI-loops of a VP1 monomer, and ad-
ditional contacts are contributed by the BC2- and DE-loops of
counterclockwise (ccw) and clockwise (cw) neighboring mono-
mers, respectively (28–30, 32–35). In order to assess the ability of
the HPyV6 and HPyV7 surface loops to form such a sialic acid
binding site, we compared the conformations and lengths of their
TABLE 1 Data collection and structural refinement statisticsa
Parameter HPyV6 VP1 HPyV7 VP1
Space group C2 C2
Unit cell dimensions
a, b, c (Å) 183.9, 89.4, 125.3 209.7, 86.4, 84.2
, ,  (°) 90.0, 131.3, 90.0 90.0, 92.1, 90.0
Data collection
Resolution (Å) 30.0–1.8 (1.85–1.80) 30.0–1.70 (1.75–1.70)
No. of unique reflections 140,450 (10,046) 161,009 (9,962)
Redundancy 4.1 (4.1) 3.9 (3.9)
Rmeas (%) 7.0 (56.8) 6.7 (55.9)
I/ 14.8 (2.8) 15.7 (2.4)
CC1/2 (%) 99.8 (84.7) 99.9 (75.4)
Completeness (%) 99.2 (96.4) 97.8 (82.1)
Wilson B-factor (Å2) 28.9 26.0
Refinement
Rwork/Rfree (%) 14.8/17.4 16.9/19.6
No. of atoms
Protein 10,171 9,856
Water 1,070 990
Average B-factor (Å2)
Protein 28.7 24.8
Water 34.2 29.0
RMSDs
Bond lengths (Å) 0.009 0.010
Bond angles (°) 1.381 1.391
Ramachandran plot (calculated
using MolProbity Server)
Favored (%) 95.9 97.5
Allowed (%) 4.1 2.4
Outliers (%) 0.0 0.1
a Values for the highest-resolution bin are given in parentheses. CC1/2, correlation
between intensities from random half-data sets.
Rmeas
hkl nn1 j1n | Ihkl,jIhkl,j|
hkl j
n Ihkl,j
, where n is the number of observations of
the reflection andIhkl,j the intensity of symmetry (or Friedel)-related observations.
Rwork
hkl|FobshklFcalchkl|
hkl Fobshkl
, where Fobs and Fcalc are the observed and calculated
structure factors, respectively. A total of 5% of the reflections were not used during
structure refinement to calculate Rfree.
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surface-exposed loops with the equivalent loops in WUPyV and
KIPyV, as well as in MCPyV and SV40. For clarity, only compar-
isons with the closely related KIPyV and the sialic acid-engaging
SV40 polyomavirus are shown in Fig. 2. As theHPyV6 andHPyV7
loop structures are very similar (Fig. 1C), only HPyV6 VP1 is
discussed and shown. The HI-loop of polyomavirus VP1 is only a
short hairpin in all structures crystallized to date, and it typically
forms a wall that closes the glycan-receptor binding site at one
end. Strikingly, this loop is extended by 14 residues in HPyV6
compared to KIPyV and WUPyV and by 9 residues compared to
SV40 and MCPyV (Fig. 2). Rather than projecting outward, the
HPyV6HI-loop folds on top of the pentamer and forms extensive
contacts within itself and with the DE-loop (not shown in detail).
To accommodate the extended HI-loop, the DE-loop of the ccw
monomer is displaced toward the 5-fold symmetry axis. The BC2-
loop of HPyV6 is severely truncated in comparison to other VP1
structures and lies flat on the VP1 surface (Fig. 2B). Taking these
data together, the elongated HI-loops and the truncated BC2-
loops of HPyV6 (and also HPyV7) lead to a profoundly altered
surface loop network.
TheHI-loop participates in the recognition of sialylated glycan
receptors in all sialic-acid binding polyomaviruses whose struc-
tures have been determined to date (28–30, 32–35), by contribut-
ing parts of the shallow receptor binding groove on the protein
FIG 1 Architecture of HPyV6 and HPyV7 VP1 pentamers. (A and B) Overall folds of HPyV6 (A) and HPyV7 (B) VP1 pentamers shown in a ribbon
representation, with VP1 monomers highlighted in magenta and gold, respectively. A dashed line represents the missing HPyV6 CD-loop residues, which are
defined only by rather poor electron density due to structural flexibility. (C)Closeup viewof the surface loop architectures ofHPyV6 andHPyV7VP1monomers.
The loops are colored as described for panels A and B, respectively. VP1 monomer structures were superposed using the secondary-structure-matching (SSM)
superposition tool (45) in the program Coot (42).
FIG 2 Architecture of VP1 surface loops. Superposition and comparison of VP1 surface loop structures are shown for wukipolyomaviruses HPyV6 and KIPyV
(PDB accession no. 3S7V) and orthopolyomavirus SV40 (PDB accession no. 3BWR). VP1monomers were superposed using the secondary-structure-matching
(SSM) superposition tool (45). (A) HI-, BC1-, and BC2-loops are highlighted in color in the overview. (B) Closeup view of the HI-loop receptor binding pocket.
The sialic acidmoiety (Neu5Ac) of theGM1glycan in the SV40VP1-GM1pentasaccharide complex structure (PDBaccession no. 3BWR) and theY256 side chain
of HPyV6 VP1 are shown in stick representation. The same view is taken for panels A and B. (C) Sequence alignment of the HI-loop region. Key residues
interacting with the sialic acid moiety in the SV40-GM1 glycan and MCPyV VP1–2,3-sialyllactosamine complex structures (PDB accession no. 4FMI) are
highlighted in blue and cyan, respectively. Regions in which all VP1 structures align with root mean square deviation (RMSD) values of1.0 Å (dark gray) and
1.5 Å (light gray) between C atoms are shaded.
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surface and providing direct or water-mediated contacts with gly-
can components. The extended HI-loop in HPyV6 and HPyV7
produces a prominent, elevated ridge on the virion surface that
partially covers the glycan binding site groove present in orthopo-
lyomaviruses (Fig. 3). Thus, the conformation of the HI-loop ap-
pears to hinder the binding of sialic acids to the HPyV6 and
HPyV7 capsids. In particular, HI-loop residues Y256 (HPyV6)
and L253 (HPyV7) (Fig. 2B and 3A) project into the groove and
would collide with a potential sialic acid ligand. The R154 side
chains in the cwHPyV6 andHPyV7EF-loops also help to close the
binding site (Fig. 3A). The uniquely elongatedHI-loops ofHPyV6
and HPyV7 are not conserved in either KIPyV or WUPyV (Fig.
3A). In fact, these two viruses have unusually short HI-loops (see
also Fig. 2C), and surface analysis shows that they possess a deep
groove leading toward the central pore (Fig. 3A). Thus, HPyV6
andHPyV7 feature a remodeled surface structure compared to all
other known VP1 structures, with likely consequences for recep-
tor binding. The HPyV6 and HPyV7 genomes sequenced so far
have revealed naturally occurring VP1 amino acid variations (8),
which are mostly buried in the assembled virus (not shown) and
thus are likely not critical for glycan receptor engagement. The
only exceptions areHPyV7 residues 63 (threonine or proline), 153
(asparagine or aspartate), and 167 (serine or threonine), which are
distributed across the BC2- and EF-loops and, therefore, could
theoretically account for modulated receptor interactions.
HPyV6 and HPyV7 VP1 do not bind sialic acids. Unas-
sembled recombinant VP1 pentamers are useful tools to study cell
attachment and entry and cellular trafficking of polyomaviruses
(30, 50). To investigate whether HPyV6 and HPyV7 engage sialic
acids on cell surfaces during early steps of infection, we analyzed
binding of their VP1 pentamers to two cultured human cell lines,
HeLa S3 and 293TT, by flow cytometry (Fig. 4). Prior to single-cell
binding experiments with Alexa Fluor 488-conjugated VP1 pen-
tamers, cells were mock treated or incubated with Clostridium
perfringensneuraminidase typeV to remove terminal2,3-,2,6-,
and 2,8-linked sialic acids from the cell surface. JCPyV and mu-
rine polyomavirus (RA strain) VP1 pentamers bind to both cell
lines in a neuraminidase-sensitive manner (30, 51) (Fig. 4B and
E), in line with their known use of sialylated receptors for attach-
ment. In contrast,HPyV6 andHPyV7VP1 attachment to both cell
lines is not affected by enzymatic removal of sialic acids (Fig. 4A
andD). Themeasured fluorescence signals forHPyV6 andHPyV7
VP1 pentamers are also similar to those seen with the control
representing neuraminidase-insensitive binding, the JCPyV VP1
L54F mutant (Fig. 4C and F). This mutant has a disrupted VP1
sialic acid binding site and no longer engages sialylated receptors
(37).
To probe for interactions in solution and to identify ligand
atoms in contact withVP1, we analyzed binding of theHPyV6 and
HPyV7 VP1 pentamers to the sialylated model compounds 2,3-
and 2,6-linked sialyllactose by STD NMR spectroscopy (52).
STD NMR spectroscopy has been successfully used to define, for
FIG3 Surface structures of VP1 pentamers. Closeup views of VP1 pentamer top-surface regions that are involved in sialic acid engagement in the case ofMCPyV
and SV40 are shown. Equivalent surface sections are shown in surface and cartoon representations for VP1 pentamers from HPyV6, HPyV7, and KIPyV (PDB
accession no. 3S7V) andWUPyV (PDB accession no. 3S7X) (A) and from SV40 (PDB accession no. 3BWR) andMCPyV (PDB accession no. 4FMI) (B). HI-loop
residues are highlighted on the surface representations according to the colors assigned to the respective viruses. Carbohydrates (Neu5Ac and Gal of 2,3-
sialyllactosamine andGM1 pentasaccharide) in panel B are shown in stick representations (colored by atom type; carbons in orange, oxygen in red, and nitrogen
in blue), and glycan-protein contacts (hydrogen bonding and salt bridges) are shown as dashed lines for MCPyV and SV40 VP1.
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example, the interactions ofMCPyVandBKPyVVP1with specific
glycan receptor motifs (32, 33). No significant magnetization
transfer was observedwith either type of sialyllactose fromHPyV6
orHPyV7VP1, suggesting that neither protein interacts with sim-
ple 2,3- or 2,6-linked sialylated oligosaccharides (Fig. 4G).
These findings are consistent with the crystal structure analysis,
and they are also in agreement with experiments employing
crystal soaking and glycan array screening, neither of which
FIG 4 HPyV6 and HPyV7 VP1 do not engage sialic acids. (A to F) Cell binding analysis. (G) Saturation transfer difference (STD) NMR spectroscopy of HPyV6 and
HPyV7VP1pentamerswith2,3- and2,8-sialyllactose. (A to F)HeLa S3 (A toC) and 293TT (D toF) cellswere subjected tomock treatment (PBS) orwere pretreated
with 0.2U/mlClostridium perfringens neuraminidase (NA), washed, and then incubatedwith Alexa Fluor 488-conjugatedVP1 pentamers. VP1 pentamer binding
was then analyzed by flow cytometry. Histograms represent the fluorescence intensity of Alexa Fluor 488 for 10,000 gated events in each case. Data for cells alone
are colored gray and black for mock- and NA-treated cells, respectively. Three independent experiments were performed, and results of a typical experiment are
presented. (B and E) JCPyV andmurine polyomavirus (RA strain) VP1 pentamers are included as positive controls for neuraminidase-sensitive attachment (30,
51). (C and F) JCPyV L54F is a VP1 mutant with an abolished sialic acid binding site (37) and was used to test for sialic acid-independent cell binding. FITC,
fluorescein isothiocyanate; max,maximum. (G) From top to bottom: 1H reference spectrum of 50MHPyV7VP1with 1mM2,3- and2,6-sialyllactose each;
STD NMR difference spectrum recorded with the same sample; STD NMR difference spectrum of 50 M HPyV6 VP1 with 1 mM (each) 2,3- and 2,8-
sialyllactose. No significant saturation transfer to either capsid protein was observed. HDO peaks were truncated for clarity.
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revealed interactions with tested sialylated compounds (data
not shown).
Unique features of the virion surface. In order to obtain some
initial clues about the molecular determinants of the receptor
specificities and antigenic properties of HPyV6 and HPyV7 VP1,
we examined their electrostatic surface potentials and compared
these with the electrostatic surface potentials of other polyomavi-
rus VP1 pentamers (Fig. 5). Consistent with their structural con-
servation, the electrostatic potentials for HPyV6 and HPyV7 VP1
are very similar (Fig. 5A). Both pentamers possess negatively
charged patches within the central pore, which are surrounded by
concentric positively and negatively charged rings around the
5-fold axis. The similarities in the distribution of surface charges
suggest that the two viruses pursue similar strategies for cell sur-
face attachment and perhaps also for viral entry.
The electrostatic surface potentials of the remaining wuki-
polyomavirus familymembers,WUPyV andKIPyV, differ and are
also distinct from those of HPyV6 and HPyV7 (Fig. 5A). Whereas
the WUPyV VP1 pentamer surface is mostly electropositive, the
corresponding KIPyV residues have a more negative potential.
Interestingly, the surface potentials ofHPyV6 andHPyV7VP1 are
more similar to that of MCPyV (compare Fig. 5A and B) and
feature a negatively charged area, a central pore around the 5-fold
axis, surrounded by positively and negatively charged patches
(Fig. 5A and B).
DISCUSSION
We have determined the high-resolution structures of VP1 pen-
tamers of the recently identified human polyomaviruses HPyV6
and HPyV7. Our structure analysis reveals essential features and
critical differences in surface morphology that are likely impor-
tant for antigenicity and receptor engagement of these two skin
viruses. The region that accommodates sialic acid receptors in
other polyomaviruses is obstructed, and consistent with this, cell
binding analysis and STD NMR spectroscopy (Fig. 4) as well as
experiments employing crystal soaking and glycan array screening
(data not shown) did not yield indications of binding of sialic acid
by HPyV6 or by HPyV7.
A new sialic acid binding site different in its overall location on
the VP1 pentamer from the polyomavirus sialic acid binding sites
structurally characterized so far (28–30, 32–35) is possible but, in
the light of our experiments, rather unlikely. The findings of our
structure-function analysis suggest instead that HPyV6 and
HPyV7 do not engage sialylated glycans on cell surfaces during
attachment and entry and likely recognize a different receptor
type. It is still possible, however, that HPyV6 and HPyV7 bind
sialic acids in a different location that is present only in the fully
assembled virus, such as in canyons between adjacent pentamers,
and not in the free VP1 pentamer.
The analysis of electrostatic surface potentials has in some cases
helped to identify potential receptor binding regions in viral pro-
teins, for example, in sialic acid binding adeno- and rotaviruses
(53, 54). We note that it is important to keep in mind that sialic
acid binding sites need not always display a positive electrostatic
potential, as hydrogen bonds rather than salt bridgesmediate con-
tacts with the sialic acid carboxylate in at least some polyomavi-
ruses (55) (see also Fig. 5B). As HPyV6, HPyV7, and MCPyV are
all shed from skin (8), this similarity might indicate a conserved
strategy for receptor engagement. MCPyV is unique among the
members of the polyomavirus family because of its sequential en-
gagement of negatively charged glycosaminoglycan (GAG) and
sialylated receptors (56). GAG binding sites on proteins are typi-
cally lysine/arginine-rich (57, 58); however, the binding site for
GAGs on MCPyV VP1 is not known. The electrostatic surface
potentials of HPyV6 and HPyV7 VP1 are indeed similar to that of
MCPyV, with potential consequences for receptor specificity, in-
cluding engagement of GAGs, but the typical shallow depression
that harbors sialic acid binding sites on MCPyV (32) and other
polyomavirus VP1s is clearly not evident in our HPyV6 and
HPyV7 VP1 structures. Thus, only a few conclusions concerning
specific receptor engagement for HPyV6 and HPyV7 are possible
until their receptor class has been identified.
Our analysis of the VP1 pentamer surface properties, such as
electrostatic distributions and loop morphology, suggests that a
structural-biology approach can improve the phylogenetic polyo-
mavirus classification that is based entirely on sequence similarity
FIG 5 Electrostatic surface potentials of VP1 pentamer from the wuki- and
orthopolyomavirus genera.Overall surface representations ofHPyV6,HPyV7,
and KIPyV (PDB accession no. 3S7V) andWUPyV (PDB accession no. 3S7X)
(A) and SV40 VP1 (PDB accession no. 3BWR) and MCPyV (PDB accession
no. 4FMI) (B) pentamers are colored according to electrostatic potential (cal-
culated using APBS tool 2.1; 46), with blue and red corresponding to 7 kT
and7 kT, respectively. Views are equivalent in panels A and B and are shown
from the top—the outer surface of the virion—along the 5-fold axis of the
pentamer. Carbohydrates (GM1 pentasaccharide and Neu5Ac and Gal of
2,3-sialyllactosamine) in panel B are shown in yellow stick representations,
and the glycan binding site is highlighted for clarity with a box.
Crystal Structures of HPyV6 and HPyV7 VP1 Pentamers
September 2014 Volume 88 Number 18 jvi.asm.org 10837
(15). In terms of surface loop length and structure, HPyV6 and
HPyV7 differ significantly from the other structurally character-
ized members of the wukipolyomavirus genus, WUPyV and
KIPyV. While the latter two viruses possess strongly charged VP1
pentamers, the electrostatic surfaces of the former two resemble
that of the orthopolyomavirusMCPyVmore closely. Our analysis
thus demonstrates the need for structure-based comparisons to
informunderstanding of potential receptor binding sites and con-
served regions of antigenicity, two characteristics that are largely
determined by the electrostatics and loop structure of VP1. It has
been shown that, in some cases, structural analysis even allows the
identification of evolutionary relationships that are not revealed
by sequence analysis (59–61).
Our comprehensive analysis and comparison of VP1 pentam-
ers fromdifferent polyomavirus genera lead us to propose that the
observed structural diversity explains differences and similarities
in the tissue tropism of wukipolyomaviruses comparedwith other
polyomaviruses. Cellular and tissue distributions of receptors and
coreceptors are important determinants of viral tropism. The es-
tablishment of experimental models and cell culture systems to
propagate HPyV6 and HPyV7 as well as other newly identified
polyomaviruses is clearly required. Such models should enable
functional studies of receptor engagement and cell entry mecha-
nisms of these viruses that arewidely circulatingwithin the human
population.
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Abstract
A large number of viruses, including many human pathogens, bind cell-
surface glycans during the initial steps of infection. Viral glycan receptors
such as glycosaminoglycans and sialic acid–containing carbohydrates are of-
ten negatively charged, but neutral glycans such as histo–blood group anti-
gens can also function as receptors. The engagement of glycans facilitates at-
tachment and entry and, consequently, is often a key determinant of the host
range, tissue tropism, pathogenicity, and transmissibility of viruses.Here, we
review current knowledge about virus-glycan interactions using representa-
tive crystal structures of viral attachment proteins in complex with glycans.
We illuminate the determinants of speciﬁcity utilized by different glycan-
binding viruses and explore the potential of these interactions for switching
receptor speciﬁcities within or even between glycan classes. A detailed un-
derstanding of these parameters is important for the prediction of binding
sites where structural information is not available, and is invaluable for the
development of antiviral therapeutics.
285
 
Click here for quick links to 
Annual Reviews content online, 
including:
• Other articles in this volume
• Top cited articles
• Top downloaded articles
• Our comprehensive search
FurtherANNUALREVIEWS
Glycan: generic term
for any free or
covalently attached
mono-, oligo-, or
polysaccharide and
carbohydrate
Sialic acids: α-acidic
keto sugars with a
9-carbon backbone
Glycan microarray:
high-throughput
screening tool to
analyze glycan-binding
speciﬁcities of viruses
and viral proteins
Glycosaminoglycans
(GAGs): linear
polysaccharides
composed of amino
sugars linked to uronic
acid or galactose
Histo–blood group
antigens (HBGAs):
noncharged glycans
present on red blood
cells, epithelial cells,
and mucosal secretions
INTRODUCTION
Of the four fundamental building blocks of life—proteins, carbohydrates, lipids, and nucleic
acids—carbohydrates (or glycans) arguably are the least well understood and the most under-
appreciated. Glycans append a wide variety of biological molecules and are found throughout the
kingdoms of life. They often contribute to physical and structural integrity, extracellular matrix
formation, signal transduction, protein folding, information exchange between cells, and pathogen
uptake. However, we know little about many of these functions because glycans are notoriously
difﬁcult to work with. Unlike nucleic acids and proteins, they cannot be cloned and sequenced,
and they cannot be studied with established molecular biology tools. They are usually difﬁcult
to synthesize, they are not always commercially available, and they often have unfamiliar names
that are only informative to a small group of scientists. Moreover, information about their three-
dimensional structures and conformational dynamics is still limited. All of these factors contribute
to the perception that glycans are less exciting than other biologically important molecules such
as nucleic acids and proteins.
The paucity of knowledge about glycan structure and function contrasts with the importance
of these molecules in many biological processes, and this contrast is particularly obvious when
investigating the life cycle of a virus. To gain entry into host cells and initiate an infectious cycle, a
virusmust ﬁrst attach to one or several receptors, or attachment factors, that are present on the host
cell surface. Engaging these receptors adheres the virus to its target cell and often determines host
range and tissue tropism.Many viruses use cell-surface glycans to facilitate attachment and entry. In
fact, carbohydrates such as sialic acids were among the ﬁrst virus receptors known (1–4). However,
despite an impressive number of virus-glycan complex structures that have been determined in
recent years, we are still largely ignorant of the rules that allow a virus to engage a speciﬁc glycan
sequence and enable it to switch to a different receptor with a limited change in amino acid
sequence. In the majority of cases, little is known about the afﬁnity between a virus and its cognate
glycan receptor, as current technologies are often not suitable for determining critical parameters
such as dissociation constants. Moreover, the densities and distribution patterns of glycans on cell
surfaces are not well understood. However, recent advances in studies of virus-glycan interactions
have made it possible to rapidly identify speciﬁc receptors by using glycan microarray screening
(5–9), to map glycan epitopes that bind to a virus in solution by using saturation transfer difference
NMR spectroscopy (10–14), to deﬁne the atomic level structure of the virus-glycan interaction by
using X-ray crystallography, and to rationalize mutations to determine the precise effect of glycan
binding in disease pathogenesis. These advances have contributed to a better understanding of
how viruses bind to glycans, and this knowledge will clearly be essential for combating infection
and designing improved therapeutic viral vectors.
In this review,we focus on viruses that exemplify different aspects of glycan receptor recognition
particularly well and for which structural data are available at near-atomic resolution. Using
these cases, we highlight general principles of virus-glycan receptor engagement, including the
recognition of sialic acids, glycosaminoglycans (GAGs), and noncharged oligosaccharides such as
histo–blood group antigens (HBGAs). Our objectives are to deﬁne themes and determinants of
glycan recognition and, in particular, to elucidate strategies that viruses use to switch receptor
speciﬁcities.
SIALIC ACID RECEPTORS
For many enveloped and nonenveloped viruses, cell-surface glycans featuring terminal sialic acids
have been identiﬁed as functional receptors (Figure 1). Sialic acids are ubiquitously expressed in
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Figure 1
Glycans as viral receptors. Host- and cell-speciﬁc variants of (a) sialic acids, (b) neutral oligosaccharides such as histo–blood group
antigens (HBGAs), and (c) glycosaminoglycans (GAGs) are used as receptors (or attachment factors) by many viruses. Examples of virus
families with members that are known to interact with one or more glycan types are indicated in the respective overlapping ellipses of
the Venn diagram. (a) The most common form of sialic acid in humans, N-acetylneuraminic acid, is shown in theα-conformation. This
monosaccharide often caps N- and O-glycans and glycolipids (R), which are attached via different glycosidic linkages to position C2.
Various modiﬁcations can occur at carbon positions C4, C5, and C7–9 (reviewed in 16). (b) Schematic representation of the type 2 core
antigen, which is part of the ABO blood group determinants on N- and O-glycans. R′ denotes a heterosaccharide core attached to a
glycoprotein. (c) Disaccharide units consisting of N-acetyl- or N-sulfohexosamine and either a uronic acid (glucuronic or iduronic acid)
or galactose form the long, unbranched GAG chains. As an example, heparan sulfate is shown in the schematic chair representation.
Heparan sulfate domains along the oligosaccharide chain usually vary in their modiﬁcation contents by N-sulfation or N-acetylation at
carbon position C2 of the hexosamine and sulfation at C2 of the uronic acid and at C6 of the hexosamine.
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-Asn-X-Ser/Thr-
higher vertebrates and are attached at terminal ends of N- and O-glycans as well as glycolipids
(15–17). The most common sialic acid in humans is α5-N-acetylneuraminic acid (Neu5Ac), but
various modiﬁcations (acetylation, methylation, and sulfation) at C4, C5, C7, C8, and C9 give rise
to more than 50 different sialic acid variants (Figure 1a) (18), not all of which occur in all species.
Sialic acids are usually connected via α2,3 or α2,6 glycosidic linkages to galactose (Gal) or
N-acetylgalactosamine (GalNAc) (19) such that protruding functional groups—carboxylate, glyc-
erol, N-acetyl, and hydroxyl groups in the case of Neu5Ac (Figure 1a)—are easily accessible for
engagement by viral attachment proteins (reviewed in 20). Furthermore, sialic acids can be con-
nected to one another with α2,8 or α2,9 linkages, and thus sialic acids can also occupy internal
positions within glycoconjugates (21–23). For example, di- and trisialic acid motifs are common in
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the context of human b- and c-series gangliosides (24). Even longer chains of sialic acids, so-called
polysialic acids, can modify proteins such as neural cell adhesion molecules and are aberrantly
expressed in tumors (23, 25–28). In addition to various sialic acid modiﬁcations, developmentally
regulated expression and distribution of different linkages can also strongly inﬂuence host range
and tissue tropism of sialic acid–engaging viruses. Classic examples are inﬂuenza viruses, which
infect different species depending on how the terminal Neu5Ac is linked to the underlying glycan
structure (reviewed in 29–33).
Structures of viral attachment proteins bound to sialylated glycans reveal that the terminal
Neu5Ac often serves as a hook during receptor engagement (reviewed in 20). In most cases, a
highly speciﬁc network of interactions fastens the Neu5Ac to the protein. The negatively charged
carboxylate at one end and the 5-N-acetyl group at the opposite end of Neu5Ac create a molecular
“ﬁngerprint” that appears to contribute toward selectivity over other glycans (20). However, ac-
cumulating structural data on virus-glycan interactions demonstrate that there are many strategies
by which a virus can engage Neu5Ac. Here, we review some of these strategies and discuss their
potential for speciﬁcity switching as well as their relevance for evolution and the emergence of
new virus strains.
A Conserved Binding Site for Sialic Acid in Some Polyomaviruses
Polyomaviruses are a rapidly expanding family of small, nonenveloped double-stranded DNA
viruses (34, 35). The major capsid protein of these viruses, VP1, is organized into 72 pentamers
on the virion surface and often engages sialic acid receptors of different types on host cells during
attachment, cell entry, or both. Due to the high similarity among VP1 sequences and the there-
fore largely conserved VP1 pentamer core structure, polyomaviruses represent an excellent model
system for correlating glycan receptor engagement and afﬁnity with virus uptake, tropism, and
pathogenesis. Crystal structures of VP1 in complex with sialylated glycans have been determined
for the human JC, BK, and Merkel cell polyomaviruses ( JCPyV, BKPyV, and MCPyV, respec-
tively) as well as human polyomavirus 9 (HPyV9); the murine polyomavirus (MPyV); and two
monkey polyomaviruses, simian virus 40 (SV40) and the B-lymphotropic polyomavirus (LPyV)
(Figure 2) (14, 36–43).
Phylogenetically, SV40, BKPyV, and JCPyV are especially closely related (44). Their VP1
sequences are >74% identical at the amino acid level, and all three viruses recognize glycans ter-
minating in Neu5Ac (45–48). SV40 engages the branched α2,3-linked GM1 ganglioside, BKPyV
binds toα2,8-α2,3-di-Neu5Ac b-series gangliosides, and JCPyV recognizes the linearα2,6-LSTc
pentasaccharide. The terminal Neu5Ac is engaged by all three viruses in a highly similar manner
within a binding groove formed by surface-exposed loops that emanate from the β-sheet frame-
work of each VP1 monomer (Figure 2a–c). Neighboring VP1 chains in a pentamer close the
groove at its ends and contribute contacts. There are conserved hydrogen bonds to the Neu5Ac
carboxylate and N-acetyl groups. Moreover, the glycerol chain is located in a shallow depression,
where it is recognized by van der Waals contacts and a backbone hydrogen bond. The methyl
group of the 5-N-acetyl chain projects into a hydrophobic cavity. This cavity is somewhat larger
and more polar in SV40 VP1, which likely explains why this virus is able to engage sialic acid
variants such as α5-N-glycolylneuraminic acid (Neu5Gc) (39, 49) that cannot be synthesized by
humans (50).
Despite the conserved contacts for terminal Neu5Ac, the SV40, BKPyV, and JCPyV VP1
proteins are highly speciﬁc for their respective glycan receptors. This speciﬁcity is achieved in
each case by an exceedingly small number of additional contacts outside the core Neu5Ac-binding
pocket. These limited auxiliary interactions are therefore attractive targets for switching receptor
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Figure 2
A highly plastic sialic acid–binding site on polyomavirus VP1. Panels a–f show views into the ligand-binding sites of six polyomaviruses
for which structural data are currently available. The views are similar in each case. The VP1 proteins are shown in surface
representation, with glycans and contacting protein represented with sticks. Hydrogen bonds and salt bridges between glycans and
proteins are indicated with black dashed lines. (a) Simian virus 40 (SV40) VP1–GM1 glycan complex (PDB ID 3BWR; 39), (b) BK
polyomavirus (BKPyV) VP1–GD3 glycan complex (PDB ID 4MJ0; 14), (c) JC polyomavirus ( JCPyV) VP1–LSTc pentasaccharide
complex (PDB ID 3NXD; 40), (d ) Merkel cell polyomavirus (MCPyV) VP1–GD1a glycan complex (PDB ID 4FMJ; 41), (e) murine
polyomavirus (MPyV) VP1 in complex with Neu5Ac–α2,3-Gal–β1,3-[α2,6-Neu5Ac]–GlcNAc–β1,3-Gal–β1,4-Glc (PDB ID 1VPS;
38), ( f ) B-lymphotropic polyomavirus (LPyV) VP1 in complex with α2,3-sialyllactose (PDB ID 4MBY; 42). A superposition of the six
terminal Neu5Ac residues from panels a–f is shown in the center. The colors of the monosaccharides correspond to the colors assigned
to the polyomaviruses in panels a–f. The loops surrounding the binding sites are labeled. The superposition highlights a conserved
location of the Neu5Ac-binding site, with distinct interaction networks within or adjacent to the core binding sites. Abbreviations:
GalNAc, N-acetylgalactosamine; GlcNAc, N-acetylglucosamine; Neu5Ac, 5-N-acetylneuraminic acid.
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speciﬁcities from one sialylated glycan to another. By comparing Figure 2a with Figure 2b, it is
readily apparent that residue 68 is the primary determinant of speciﬁcity for the glycans bound
by BKPyV and SV40. Lys68 in BKPyV VP1 forms a salt bridge with the carboxylate group of
the second Neu5Ac within the α2,8-α2,3-di-Neu5Ac sequence, whereas Ser68 at the equivalent
position in SV40 VP1 contacts the Gal at the nonreducing end of the longer branch of GM1.
Supporting a critical role of this residue in determining speciﬁcity, its mutation in BKPyV VP1
from Lys68 to Ser68 is sufﬁcient to retarget BKPyV from the α2,8-α2,3-di-Neu5Ac sequence
to GM1 in vitro and in cell culture (14). Remarkably, whereas SV40 and BKPyV enter cells via
caveolae-mediated endocytosis, JCPyV is internalized by clathrin-mediated endocytosis (51, 52).
Mutations in the VP1 proteins of SV40, BKPyV, and JCPyV might therefore be useful not only
for receptor-switching purposes but also for modulating entry pathways.
A number of studies have investigated similar relationships between VP1 mutations and
switches in glycan speciﬁcities for BKPyV, SV40, and JCPyV (53–59). It has also become clear
that some VP1 mutations in JCPyV are critical for JCPyV pathogenicity, probably by altering the
receptor-binding properties of this virus (53–56, 58).
Nonconserved Sialic Acid Binding in Other Polyomaviruses
The three polyomaviruses discussed in the above section all engageNeu5Ac by using highly similar
contacts and in a similar orientation. Therefore, it would seem reasonable to assume that other
sialic acid–binding polyomaviruses also engage Neu5Ac receptors in this manner. A conserved
strategy within a virus family for attachment to sialic acid makes sense from an evolutionary point
of view. For example, such a strategy is used by inﬂuenza viruses, which are perhaps the best-studied
viruses that engage sialic acid. All structures of the inﬂuenza virus hemagglutinin determined to
date engage the sialic acid portion of the glycan receptor in essentially the same orientation and
derive speciﬁcity by recognizing different glycosidic linkages.
Strikingly, however, MCPyV, MPyV, and LPyV, which complete the set of polyomavirus
VP1-ligand structures currently available, each engages Neu5Ac using a different strategy and in a
different orientation (Figure 2d–f ), although the three VP1 proteins are >50% identical in their
amino acid sequences (44). It is particularly noteworthy that Neu5Ac is bound in the same general
area of the protein, involving residues that are in some cases even conserved but nonetheless contact
different portions of Neu5Ac in each complex (38, 41, 42). Whereas MPyV and MCPyV have
a shallow, surface-exposed binding site that resembles those of SV40, JCPyV, and BKPyV, the
Neu5Ac-binding site on LPyV VP1 is much more recessed and essentially swallows the Neu5Ac
moiety (Figure 2f ). Thus, polyomaviruses have an unusually plastic binding site for Neu5Ac that
can engage the very same ligand in at least four different orientations and with different levels of
solvent accessibility. This degree of plasticity is to our knowledge unique to polyomaviruses.
Differential Recognition of Sialic Acid Variants by Coronaviruses
The structural diversity of sialic acids far exceeds that of other common monosaccharides due to
themany possible chemical modiﬁcations. Hence, it is not surprising that some viruses do not bind
indiscriminately to all surface-associated sialic acids but instead prefer speciﬁc variants (49, 60,
61). In some cases, glycan microarray screening has suggested, and X-ray crystallography studies
have conﬁrmed, that distinct Neu5Ac substitutions are essential for the observed interaction. Viral
receptor-binding proteins appear to favor particular sialic aid subtypes that carry additional acetyl
or hydroxyl groups (6, 49, 62, 63). For example, the Neu5Gc variant of Neu5Ac carries an extra
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hydroxyl group at the 5-N-acetyl moiety. Neu5Gc is not synthesized in humans (50) but can be
absorbed from dietary sources and is metabolically incorporated into certain cell types such as
intestinal endothelium and epithelium (64). Interestingly, Neu5Gc also accumulates in cancer
cells (65). An important role of Neu5Gc in viral attachment and in deﬁning species tropism has
been ﬁrmly established for several viruses (49, 62, 66), and these are not reviewed here. Instead,
we examine the implications of the engagement of O-acetylated sialic acids, which have recently
been investigated by structural analysis of coronaviruses (63, 67).
O-acetylation of sialic acid appears in host-, organ-, and cell-speciﬁc patterns (68). Somemem-
bers of the Coronaviridae family, including toroviruses and betacoronaviruses, possess hemag-
glutinin esterases (HEs) that allow reversible attachment to 5-N,9-O-diacetylneuraminic acid
(Neu5,9Ac2) or 4-O,5-N,9-O-triacetylneuraminic acid (Neu4,5,9Ac3) through the combined ac-
tion of two locally separated protein domains with either receptor-binding or receptor-destroying
function (sialate-O-acetylesterase) (69, 70). Whereas most HEs bind Neu5,9Ac2, some murine
coronaviruses can use 4-O-acetylatedNeu5Ac (Neu4,5Ac2) as a component of their receptors (69).
The crystal structure of bovine coronavirus (BCoV) HE was determined in complex with
Neu4,5,9Ac3 (67), and the murine coronavirus mouse hepatitis virus strain S (MHV-S) HE
protein was crystallized bound to Neu4,5Ac2 (63). The two proteins share an amino acid sequence
identity of approximately 60% and largely conserved overall structures. Comparison of the two
structures nicely illustrates the surprisingly modest structural changes underlying the difference
in speciﬁcity and demonstrates a strategy of subtly adjusting existing binding pockets to engage
different sialic acid functional groups (Figure 3). The two binding sites possess largely conserved
amino acids and reveal only minor changes in architecture in the receptor-binding region. Nev-
ertheless, comparatively minor differences in MHV-S HE result in a shift in receptor-binding
speciﬁcity toward 4-O- instead of 9-O-acetylated sialic acid (63). Interestingly, the hydrophobic
pocket that accommodates the 9-O-acetyl moiety in the BCoV complex (Leu161, Tyr184,
MHV-S 
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Figure 3
Engagement of differently O-acetylated 5-N-acetylneuraminic acid (Neu5Ac) by the hemagglutinin esterase (HE) proteins of bovine
coronavirus (BCoV) and mouse hepatitis virus strain S (MHV-S). (a) A view into the ligand-binding site of BCoV HE bound to
4-O,5-N,9-O-triacetylneuraminic acid (Neu4,5,9Ac3) (PDB ID 3CL5; 67). (b) MHV-S HE bound to 4-O,5-N-diacetylneuraminic acid
(Neu4,5Ac2) (PDB ID 4C7W; 63). The views are similar in each case. The HE proteins are shown in surface representation, with
glycans and contacting protein represented with sticks. Hydrogen bonds and salt bridges between glycans and proteins are indicated
with black dashed lines. A superposition of the two monosaccharides, shown in the middle, highlights minor structural changes within a
topologically conserved receptor-binding site on HE. These changes allow for an alternative engagement of methyl groups from
Neu4,5,9Ac3 and Neu4,5Ac2 in two conserved hydrophobic pockets. The colors of the monosaccharides correspond to the colors
assigned to the viruses in panels a and b.
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Leu266, and Leu267) (Figure 3a) is conserved in MHV-S HE (Ile166, Tyr189, Tyr281, and
Leu282) but in this case accommodates the 5-N-acetyl group (Figure 3b). Consequently, to
engage the 4-O-acetyl instead of 5-N-acetyl moiety in BCoV, a second hydrophobic pocket has
adapted in MHV-S. The R3 loop is extended to allow the backbone carbonyl group (Lys217) to
recognize the 5-N-acetyl group via hydrogen bonding, whereas the equivalent BCoV backbone
carbonyl group (Leu212) interacts with the 5-N-acetyl group in an altered loop conformation.
Hence, existing pockets engage topologically different acetyl groups in the two viruses, leading
to a rotation of the sialic acid in the binding site (Figure 3b). Due to this rotation, the glycerol
chain is solvent exposed in the MHV-S complex but recognized at the C8 hydroxyl group by a
backbone amide from the extended R3 loop. Thus, minor structural changes allow an alternative
docking of methyl groups from Neu5,9Ac2 and Neu4,5Ac2 into two conserved hydrophobic
pockets, with additional polar interactions assisting in speciﬁc recognition.
Not all coronaviruses haveHEs, and in fact coronaviruses such asBCoVandhuman coronavirus
OC43 (HCo-OC43) also rely mostly on the N-terminal domain (NTD) of their spike (S) proteins
for binding toNeu5,9Ac2 (71, 72).Despite signiﬁcant sequence similarity, theMHV-SNTDbinds
a protein receptor, and the virus exclusively uses HE for attachment to Neu4,5Ac2 (73). However,
structural details of the Neu5,9Ac2 engagement mode by S NTDs in comparison with that of
HEs remain to be elucidated (72, 74). It is not known whether severe acute respiratory syndrome
coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV), two
emerging pathogens, engage glycan-based receptors, although HE proteoglycans appear to be
involved in the attachment of SARS-CoV (75).
Physically Distinct Sialic Acid–Binding Sites in Reoviruses
The viruses discussed thus far use subtle modiﬁcations to modulate sialic acid binding speciﬁcities
in a conserved binding site. However, some viruses use entirely different locations and binding
modes on the same attachment proteins for glycan engagement. This strategy is exempliﬁed by
studies that provided a structural and functional basis for the interactions of two reovirus serotypes
with sialylated glycan receptors (76, 77).
The three major serotypes of mammalian orthoreoviruses (reoviruses) are represented by pro-
totype strains type 1 Lang (T1L), type 2 Jones (T2J), and type 3 Dearing (T3D). The well-studied
T1L and T3D reoviruses differ markedly in viral spread and cell tropism, and these differences
have been linked to sequence variations in the outer-capsid protein σ1 (78, 79). The ﬁber-like ho-
motrimericσ1 protein projects from the 12 vertices of the icosahedral reovirus virion andmediates
the attachment of the virus to target cells (78, 80). The σ1 protein can be partitioned into three
functionally and structurally distinct domains: the tail, body, and head. The N-terminal tail is
predicted to form an α-helical coiled coil (81, 82), the body primarily consists of β-spiral repeats
(76, 83), and the C-terminal head folds into a compact domain composed of eight antiparallel
β-strands (83). The head binds with high afﬁnity to the immunoglobulin superfamily member
JAM-A (junctional adhesion molecule A) (84). As all known reovirus serotypes bind JAM-A (83),
interactions with JAM-A are unlikely to dictate the serotype-speciﬁc differences in cell tropism.
Instead, these differences in tropism are likely a consequence of virus binding to serotype-speciﬁc,
sialylated glycan coreceptors.
Structure-function studies show that T3D σ1 engages terminal α2,3-, α2,6-, and α2,8-linked
sialic acids in a binding site in the β-spiral section, near the midpoint of the molecule (76).
Contacts are limited to theNeu5Acmoiety itself (Figure 4a). The coreceptor forT1L reoviruswas
identiﬁed by glycanmicroarray screening as theGM2glycan, a branched, sialylated tetrasaccharide
(77). Structural analyses of T1L σ1 bound to GM2 demonstrated that the protein, much like T3D
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Adaptation of a new glycan-binding site on reovirus σ1. Crystal structures of reovirus (a) type 3 Dearing (T3D) σ1 in complex with the
GM3 glycan (PDB ID 3S6X; 76) and (b) type 1 Lang (T1L) σ1 in complex with the GM2 glycan (PDB ID 4GU3; 77). In both panels,
σ1 is shown as a semitransparent surface. In the close-up views of the two binding sites, key contact residues and bound glycans are
represented with sticks. Black dashed lines display hydrogen bonds and salt bridges. Glycan moieties that are not involved in
interactions with the protein are shown in gray. Abbreviations: GalNAc, N-acetylgalactosamine; Neu5Ac, 5-N-acetylneuraminic acid.
σ1, also primarily engages Neu5Ac. Surprisingly, however, the Neu5Ac-binding site is located in
the head domain of σ1 (Figure 4b), and is thus approximately 150 A˚ distant from the Neu5Ac-
binding site of the homologous T3D σ1 protein. Both glycan-binding sites are distinct from the
respective JAM-A-binding sites and would allow sequential receptor engagement in a multistep
process. In addition to the overall location of the binding site, the strategy to engage Neu5Ac
also differs drastically between the two serotypes. In the case of T3D σ1, a bidentate salt bridge
with Arg202 anchors the Neu5Ac carboxylate, whereas this functional group is hydrogen bonded
to a noncharged residue (Gln371) in T1L σ1. The other functional groups of Neu5Ac are also
contacted in a different manner, although both proteins rely heavily on backbone interactions to
ligate the glycan.
Reovirus σ1 thus represents a rare example of a viral attachment protein for which different
strains have evolved physically distinct binding sites for essentially the same ligand, the Neu5Ac
compound.We do not know to which structures, such as a carrier protein, the glycans are attached
in each case, and the different locations of the two binding sites on σ1might thus be dictated by the
size and shape of that carrier. It is also possible that mechanisms of attachment are not conserved
between the reovirus serotypes, and this could contribute to the observed differences in viral
tropism and spread.
HISTO–BLOOD GROUP ANTIGEN RECEPTORS
In addition to sialic acids, some viruses also bind to neutral glycans such as HBGAs (Figure 1),
which are present on red blood cells as well as epithelial cells and mucosal secretions (85, 86).
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Well-studied examples for HBGA recognition are human noroviruses, which are members of the
Caliciviridae family and cause outbreaks of acute gastroenteritis worldwide (reviewed in 87, 88).
A human rotavirus also binds HBGAs, and this ﬁnding is of particular interest as most known
rotaviruses engage sialylated glycan receptors. Therefore, it appears that rotaviruses can switch
their speciﬁcity not only among sequences within a glycan family but also from one class of glycan
to another.
Switching Glycan Specificity from Sialic Acids to Histo–Blood
Group Antigens in a Rotavirus
Binding of rotaviruses to cells is mediated by outer-capsid protein VP4, a spike-like trimer that
projects from the virion surface and serves as a major target for neutralizing antibodies (89).
VP4 dictates the rotavirus classiﬁcation system into P[x] genotypes (90). Rotavirus infectivity
is enhanced by proteolytic cleavage of the VP4 trimer into N-terminal (VP8∗) and C-terminal
(VP5∗) subunits.TheVP8∗ subunit serves as the viral hemagglutinin andmediates interactionswith
glycan receptors (91), whereas the VP5∗ subunit facilitates membrane penetration (92). Animal
rotaviruses engage terminal sialic acid–containing receptors, and crystal structures in complexwith
sialic acid show VP8∗ assuming a galectin fold, with an interesting twist (62, 93–98). Galectins are
carbohydrate-binding proteins that typically engage galactose-terminating ligands via a conserved
binding site at the top of the molecule. However, this site is blocked in VP8∗, and the virus instead
engages its sialic acid receptor via a different interface that lies on the side of the spike-shaped
VP8∗ protein (99).
Rotaviruses are grouped historically into strains that are sensitive to treatment of cells with
neuraminidase (sialidase-sensitive strains) and those that are not (sialidase-insensitive strains).
Animal rotaviruses are usually sialidase sensitive, as they engage terminal sialic acid–containing
receptors (62, 93–98). The receptor speciﬁcities of human rotaviruses have been the subject of
considerable debate. Sialidase-insensitive strains can nevertheless engage and productively use
sialic acid–based receptors in which the sialic acid is attached to one branch of biantennary glycans
such as the GM1 and GD1a gangliosides (100). Because commonly used neuraminidases cannot
remove the sialic acid in these branched glycans, treatment with these enzymes has no effect on
infectivity.
A study combining glycan microarray screening and crystallographic analysis demonstrated
that VP8∗ from the human P[14] rotavirus strain HAL1166 speciﬁcally binds HBGAs at the
same site that binds sialic acid in other rotavirus strains (Figure 5) (101). Interestingly, the VP8∗
protein of HAL1166 rotavirus exhibits subtle modiﬁcations in its binding site that lead to its
inability to bind sialic acid and allow it to instead engage HBGAs (101). The change in speciﬁcity
is attributable to the insertion of a single amino acid in theHAL1166VP8∗ binding pocket (Ser187)
that reorients the neighboring residue Tyr188 such that its side chain clashes with sialic acid. At
the same time, the reoriented Tyr188 side chain can now participate in hydrophobic contacts with
the alternate receptor HBGA. As the remaining residues in the binding site are largely conserved
among rotaviruses that do and do not bind sialic acid, this analysis demonstrates the profound
effect on glycan speciﬁcity of an exceedingly subtle change in the receptor-binding pocket. It is
remarkable that rotaviruses can also switch between entirely different classes of glycans through
such modest changes in VP8∗.
Interestingly, the switch between glycan classes observed for rotaviruses resembles a charac-
teristic feature of caliciviruses. The protruding (P) domain of the major dimeric capsid protein
VP1 constitutes the bulk of the outer surface of the calicivirus capsid. Sequence alignments in
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Engagement of different classes of glycans in a conserved location on the rotavirus spike protein VP8∗. (a) A view into the
ligand-binding site of porcine rotavirus CRW-8 VP8∗ bound to the GM3 glycan (PDB ID 3SIT; 66). (b) The same view for human
rotavirus strain HAL1166 VP8∗ bound to a tetrasaccharide corresponding to the terminal structure of A-type histo–blood group
antigen (HBGA) (PDB ID 4DS0; 101). The VP8∗ structures are shown in semitransparent surface representation, and key contact
residues and bound glycans are depicted as sticks. Direct hydrogen bonds between VP8∗ and glycans are indicated by black dashed
lines. Carbon atoms of A-type HBGA residues are shown in yellow and carbons of GM3 residues in orange to indicate the different
classes of the two glycans. Glycan moieties that are not engaged by the protein are colored gray. A superposition of the two structures,
performed by using secondary structure matching, is shown in the middle. The close-up view shows that both glycans bind in the same
region of VP8∗. Subtle changes in architecture and sequence result in a switch between different classes of glycan receptors.
Abbreviations: GalNAc, N-acetylgalactosamine; GlcNAc, N-acetylglucosamine; Neu5Ac, 5-N-acetylneuraminic acid.
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combination with structural analysis revealed highly strain-speciﬁc HBGA-binding interfaces for
engagement of different ABH and Lewis epitopes by human noroviruses (87, 88, 102–104). In
contrast, the murine norovirus and the feline calicivirus engage sialic acids, possibly as parts
of gangliosides (105, 106). A region topologically similar to the HBGA-binding site of the hu-
man norovirus strain VA387 has been identiﬁed on the murine norovirus P domain as a poten-
tial sialic acid–binding site, but atomic-level structural data are not yet available (107). Hence,
functional and high-resolution structural studies are required to better understand glycan en-
gagement by caliciviruses, and in particular to examine the molecular aspects of the speciﬁcity
switch from HBGAs to Neu5Ac and how this switch is linked to possible adaptation to different
hosts.
GLYCOSAMINOGLYCAN RECEPTORS
The third class of glycan receptors or attachment factors used by viruses is formed by the polyan-
ionic GAGs. These linear glycans consist of β1,4-linked disaccharide blocks, which contain an
N-acetylated or N-sulfated amino sugar (GlcNAc or GalNAc) linked to either a uronic acid (glu-
curonic or iduronic acid) or galactose (Figure 1c) (108). Major GAG types are the nonsulfated
hyaluronan (HA) and the sulfated compounds heparan sulfate (HS), chondroitin sulfate (CS), der-
matan sulfate (DS), and keratan sulfate (KS). GAGs are components of proteoglycans and thus
are present in the extracellular matrix as well as on the cell surface of most eukaryotic tissues and
organs.
Given their prominent location at the surface of cells, it is not surprising that a large
number of viruses use GAGs as attachment or entry factors (see also 109–111). The list of
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viruses currently includes adenoviruses species B and C (112, 113), adeno-associated viruses
(AAVs) (114), herpes simplex virus types 1 and 2 (115–117), human cytomegalovirus (118, 119),
hepatitis viruses (120–123), dengue virus (124–126), papillomaviruses (127–131), MCPyV (132),
human immunodeﬁciency virus type 1 (133), foamy virus (134), norovirus genotype II (135),
respiratory syncytial virus (136), astroviruses (137), and members of the Togaviridae (138–140)
and Picornaviridae (141–147) families.
Despite this impressive list, our understanding of the rules underlying virus-GAG interac-
tions at the molecular and atomic levels is limited. Few reliable high-resolution structures of viral
receptor-binding proteins in complex with GAGs or GAG analogs exist, in contrast to the much
larger databases of viral proteins bound to HBGAs or sialic acid. In addition, chemical hetero-
geneity and modiﬁcations of GAGs have challenged the development of analytical techniques
to accurately deﬁne the GAG structures on target cells. Furthermore, observations that several
viruses, such as foot-and-mouth disease virus (FMDV), undergo cell culture adaptation resulting
in increased binding to HS without any selective pressure questioned the utilization of HS by
clinical, non-culture-adapted strains (143).
The picornavirus FMDV was one of the ﬁrst examples for which high-resolution studies of
GAG-virus interactions became available (141, 142). The FMDV particle engages heparin in a
shallow, surface-exposed groove, with contacts involving several heparin sulfate groups. Hep-
arin, a highly sulfated form of HS, is widely used for in vitro binding experiments. Structures of
human papillomavirus (HPV) capsid protein L1 from strains HPV-16 and HPV-18 in complex
with oligomeric heparin have more recently been reported (129). However, our inspection of the
available coordinates and electron densities (PDB IDs 3OAE and 3OFL) shows that the ligands
are not well deﬁned in the complexes and likely have low occupancies. The reported contacts
between the HPV L1 proteins and heparin must therefore be treated with caution. A number
of lower-resolution structures of complexes with GAGs or analogs have also been determined
for different AAVs (148–150). These viruses are promising vectors for gene therapy, and current
challenges lie in targeting AAVs to speciﬁc cells and enhancing cargo delivery while avoiding
neutralization by the immune system (151). GAGs, sialic acids, and Gal can serve as attachment
receptors for different AAV serotypes (114, 152–156). Crystal structures of human and simian
AAVs in combination with mutagenesis have identiﬁed GAG-binding sites with clusters of pos-
itively charged residues on the particle surfaces (154, 157–159). However, cocrystallization and
soaking experiments have not yielded high-resolution data that would allow for a detailed under-
standing of the interactions with GAGs. Cryo–electron microscopy (cryo-EM) has also shed some
light on AAV-GAG interactions, but the exact binding sites and conformational changes triggered
by GAG engagement remain controversial (148, 149), perhaps owing to the modest resolution
of the structures and the heterogeneous nature of the ligands used for complex formation. The
more homogeneous compound sucrose octasulfate (SOS) was used as a GAG analog in a cryo-EM
reconstruction of AAV-DJ particles to 4.8 A˚ (150). The structural analysis revealed only modest
local changes upon SOS complex formation relative to the crystal structure of the unliganded virus
(157). It furthermore showed that the ligand is primarily contacted by salt bridges with arginines
that were predicted earlier to be involved in GAG binding (157, 160). However, the short SOS
disaccharide has low occupancy and thus probably has lower afﬁnity for the virus capsid compared
with longer GAG chains. It is also conceivable that longer GAG chains achieve higher avidity by
bridging GAG-binding sites on the virion (161). Interestingly, a terminal Gal monosaccharide
is a cell-surface receptor for AAV serotype 9 (156, 162), providing support for a switch between
glycan receptor classes. AAV-9 is of particular relevance for gene delivery applications due to its
efﬁcient targeting and transduction of heart, liver, skeletal muscle, and alveolar epithelium. The
Gal-binding site has been mapped by modeling and mutagenesis onto the native AAV structure
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(162, 163), and moreover, initial studies report improved transduction efﬁciency by exploiting
both glycan receptors for cell entry after engraftment of the Gal receptor footprint onto the
GAG-binding serotype 2 virion (164). Interestingly, AAVs interact differentially with puriﬁed,
homogeneous heparin oligosaccharides (165). However, high-resolution structural information is
required to achieve a comprehensive understanding of diverse receptor recognition of AAVs and
facilitate strategies for retargeting this virus.
CONCLUSIONS
For many viruses, interactions with cell-surface glycans are the ﬁrst step in what can be a complex
attachment and entry process. This initial interaction is often of lower afﬁnity and, in some cases,
is followed by second binding event to a coreceptor that tethers the virus more ﬁrmly to the cell
surface. However, our understanding of how viruses engage glycans remains incomplete. The
vast majority of available atomic-resolution structures are of viruses (or viral proteins) bound to
either sialylated glycans or HBGAs, and these structures most often highlight a striking diver-
sity in receptor engagement rather than conserved strategies. Viruses have, for example, evolved
many different ways to engage sialic acid. Sometimes several binding modes can even be seen in
closely related viruses within the same family, as demonstrated by the polyomaviruses. Although
fascinating, this diversity in binding can clearly complicate efforts to predict interactions in even
closely related viruses.
Although the individual interactions differ from virus to virus, most viruses do seem to bind
glycan receptors in shallow, surface-exposed grooves that feature a limited number of contacts and
tend to have low afﬁnity for their ligand. A virus capsid protein that fully buries a portion of its
glycan receptor upon binding, as seen in complexes of LPyV with sialylated glycans (Figure 2f ),
is clearly the exception. Burying polar or charged compounds within a protein is obviously costly
in terms of energy. However, low afﬁnity and exposed binding surfaces may also offer important
advantages to viruses, as these features can modulate binding more easily and effect changes in
receptor binding with substitutions of few residues. Such changes could be required to allow a
virus to target new cell types, quickly adapt to a new host, or modulate its antigenicity in response
to immune surveillance. As demonstrated by the rotaviruses (Figure 5), switches between sialic
acid and HBGAs, which have quite different chemical structures, can also be achieved with a
surprisingly small set of substitutions in glycan-binding surfaces. We still lack detailed views of
GAG binding by viruses, which is particularly frustrating given the involvement of GAGs in
attachment by many viruses. For some viruses, GAGs are also predicted to induce conformational
changes in viral capsids during attachment and entry, but the nature and function of such changes
are unclear (166).
Coupled with tractable reverse genetics systems and high-resolution structural analyses, ad-
vances in glycan microarray screening now provide a powerful platform for the identiﬁcation and
characterization of glycan receptors and enable a thorough investigation of their interactions with
viruses. We expect that such studies will lead to new approaches for antiviral therapy and help to
establish a comprehensive toolbox for retargeting viruses fromone type of glycan to another, which
is of particular relevance for therapeutic viral vector development. An important remaining chal-
lenge lies in analyzing and quantifying the densities and developmentally regulated distribution
patterns of glycans on host- and tissue-speciﬁc cell surfaces. Moreover, an improved correlation
of afﬁnity measurements with structural studies is required for a more rigorous evaluation of the
determinants of speciﬁcity and for designing receptor switches. It is our hope that this review will
contribute to meeting these challenges by helping to stimulate interdisciplinary research in the
virus–glycan receptor ﬁeld.
www.annualreviews.org • Glycan Engagement by Viruses 297
 
SUMMARY POINTS
1. Many enveloped and nonenveloped viruses, including many human pathogens, engage
glycans such as sialic acids, sulfated glycosaminoglycans, and histo–blood group antigens
as receptors (or attachment factors).
2. The engagement of speciﬁc glycan receptors often determines host range and tissue
tropism and, ultimately, the outcome of the infection.
3. Glycan microarray screening has made it possible to rapidly identify speciﬁc virus glycan
receptors.
4. X-ray structures of viral attachment protein–glycan complexes deﬁne virus-glycan inter-
actions at the atomic level.
5. Conservations in sequence and three-dimensional structure as well as critical changes
between more homologous viral attachment proteins from different serotypes or closely
related viruses are often essential for glycan-binding speciﬁcities.
6. Switches of glycan receptor engagement can be due to limited changes within or approx-
imate to a conserved core binding site or may result in the adaptation of a completely
new binding site on the viral attachment protein.
7. Common interaction patterns and glycan binding modes on the molecular level have
been described in more detail for sialic acids and histo–blood group antigens, but high-
resolution complex structures of virus attachment proteins with glycosaminoglycans are
rare.
8. A detailed understanding of the glycan-binding speciﬁcity, interaction afﬁnity, and
receptor-switching potential of viruses provides a new way forward in the development
of antiviral strategies.
FUTURE ISSUES
1. Speciﬁc glycan receptors remain to be identiﬁed for many viruses.
2. Parameters that allow viruses to switch glycan receptors are still incompletely understood.
3. Modeling of glycan-virus interactions remains challenging due to the complexity and
often rather shallow nature of the glycan-binding sites.
4. A more rigorous correlation of structural data with afﬁnity measurements is required to
fully evaluate glycan-binding properties and receptor switches.
5. Densities and developmentally regulated distributions of glycans on host- and tissue-
speciﬁc cell surfaces need to be further analyzed and quantiﬁed.
6. Knowledge about virus-glycan interactions can provide a platform for the design of
antiviral compounds.
7. Knowledge about virus-glycan interactions facilitates the retargeting of viruses to alter-
nate receptors for gene delivery applications.
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Abstract
Viruses within a family often vary in their cellular tropism and pathogenicity. In many cases, these variations are due to
viruses switching their specificity from one cell surface receptor to another. The structural requirements that underlie such
receptor switching are not well understood especially for carbohydrate-binding viruses, as methods capable of structure-
specificity studies are only relatively recently being developed for carbohydrates. We have characterized the receptor
specificity, structure and infectivity of the human polyomavirus BKPyV, the causative agent of polyomavirus-associated
nephropathy, and uncover a molecular switch for binding different carbohydrate receptors. We show that the b-series
gangliosides GD3, GD2, GD1b and GT1b all can serve as receptors for BKPyV. The crystal structure of the BKPyV capsid
protein VP1 in complex with GD3 reveals contacts with two sialic acid moieties in the receptor, providing a basis for the
observed specificity. Comparison with the structure of simian virus 40 (SV40) VP1 bound to ganglioside GM1 identifies the
amino acid at position 68 as a determinant of specificity. Mutation of this residue from lysine in BKPyV to serine in SV40
switches the receptor specificity of BKPyV from GD3 to GM1 both in vitro and in cell culture. Our findings highlight the
plasticity of viral receptor binding sites and form a template to retarget viruses to different receptors and cell types.
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Introduction
Interactions of a virus with receptors on host cells are crucial for
viral entry and infection, and determine host range and tissue
tropism of the virus. As a result, receptor specificity and affinity are
tightly regulated, with changes in either producing a virus with
different spread and infectivity. Many zoonotic transmissions are
based on a virus acquiring binding capability for a new receptor.
Despite their importance, most viral specificity switches are poorly
characterized, especially for carbohydrate-binding viruses, as
methods capable of structure-specificity studies are only being
developed for carbohydrates. Here we characterize the receptor
specificity of the human BK Polyomavirus in depth, and retarget it
to use the Simian Virus 40 (SV40) receptor GM1.
The human polyomavirus BK Virus (BKPyV) is a non-
enveloped, double-stranded DNA (dsDNA) virus that belongs to
the family Polyomaviridae. Other members of the family include
Simian Virus 40 (SV40), the human JC Virus (JCPyV), Merkel
Cell Polyomavirus (MCPyV) and at least eight other recently
discovered human polyomaviruses [1]. BKPyV was first isolated
from a kidney transplant recipient in 1971 [2]. It establishes a
persistent asymptomatic infection in the genitourinary tract of
approximately 70% of the adult population [3,4,5]. A key
modulator of BKPyV reactivation is immunosuppression of the
host that leads to an increase in viral replication [3]. Complica-
tions of BKPyV reactivation include the development of poly-
omavirus-induced nephropathy (PVN) in kidney transplant
Figure 1. B-series gangliosides are receptors for BKPyV. (A) Schematic representation of structures of disialic acid-containing b-series
gangliosides GD3, GD2, GD1b, GT1b and of the monosialylated a-series ganglioside GM1 indicating the abbreviated designations used here for
individual residues in the gangliosides. (B) Ganglioside supplementation assays. Vero cells were incubated with gangliosides, challenged with BKPyV
and scored for infection. The average number of VP1 positive cells is plotted compared to controls. Error bars represent the standard deviation for 3
independent experiments. Asterisks indicate p-value (*p,0.05). (C) STD off-resonance (top) and difference (bottom) spectra of WT BKPyV VP1 in the
presence of 50-fold excess GD3 oligosaccharide. The off-resonance spectrum was scaled to 3%. GD3 resonances labeled in the difference spectrum
receive considerable saturation transfer from the protein. Regions with strong signal overlap are not labeled because saturation effects in this region
cannot be unambiguously assigned. Signals that were truncated are denoted by diagonal bars. (D) STD off-resonance (top) and difference spectrum
(bottom) of wild type BKPyV in the presence of 50-fold excess GD1b oligosaccharide. The spectrum is labeled as in C.
doi:10.1371/journal.ppat.1003688.g001
Author Summary
Viruses need to bind to receptors on host cells for viral
entry and infection, and the type of receptor bound
determines the range of hosts and tissues the virus can
infect. Viruses within a family often vary in their tissue
distribution and pathogenicity because changes in recep-
tor specificity can produce a virus with different spread
and infectivity. In fact, many transmissions between
species are based on a virus acquiring binding capability
for a new receptor. The structural changes that underlie
such receptor switching are not well understood. We have
analyzed the structural requirements for receptor binding
and switching of the human BK polyomavirus (BKPyV), the
causative agent of polyomavirus-associated nephropathy.
We show that BKPyV uses specific gangliosides that all
contain a common a2,8-disialic acid motif to infect cells,
and have characterized the interaction in atomic detail.
Our data explains the requirement for this disialic acid
motif and in particular highlights a single amino acid that
is central to determining specificity. Mutation of this
residue switches the receptor specificity, enabling BKPyV
to infect cells bearing a different class of gangliosides. Our
findings highlight the plasticity of viral receptor binding
sites and form a template to retarget viruses to different
receptors and cell types.
Switching Receptor Specificity of BK Polyomavirus
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recipients, and hemorrhagic cystitis in bone marrow transplant
recipients [3,6,7].
BKPyV attachment is mediated by cell-surface sialic acid [8].
The most common sialic acid type in humans is 5-N-acetyl
neuraminic acid (NeuNAc) [9]. Simians and most other mammals,
however, possess an enzyme that can attach an additional
hydroxyl group to NeuNAc, yielding 5-N-glycolyl neuraminic acid
(NeuNGc). In contrast to humans, these animals therefore carry
both NeuNAc and NeuNGc. Gangliosides were found to mediate
cell attachment of BKPyV [10], and gangliosides GD1b and
GT1b were later shown to function as specific receptors for
BKPyV [11] (Fig. 1). Gangliosides are ceramide-based glycolipids,
which are used as receptors for most of the well-characterized
polyomaviruses, for example GD1a and GT1b for Polyoma, or
GM1 for SV40 [12].
A polyomavirus capsid consists of 72 pentamers of the major
capsid protein VP1 [13,14]. Crystal structures of Polyoma, SV40,
MCPyV and JCPyV VP1 show that receptors are bound in
shallow grooves formed by VP1 loop structures on the outer
surface of the virus. These loops contribute to different receptor
specificities and are the only parts of VP1 that are not well
conserved [14,15,16,17,18].
In this study, we use viral infection assays to demonstrate that
the b-series gangliosides GD3, GD2, GD1b and GT1b enhance
BKPyV infection. We then define the common a2,8-disialic acid
motif on these gangliosides as the primary binding epitope for
BKPyV by NMR spectroscopy. In order to understand how the
disialic acid motif is recognized by the virus, we solved the
crystal structure of a BKPyV VP1 pentamer in complex with
GD3 and generated a model of the pentamer with the larger
GD1b oligosaccharide. Analysis of these complexes reveals
extensive interaction with the terminal sialic acid, specificity-
defining contacts with the internal sialic acid, thus explaining the
requirement for a disialic acid motif, and additional contacts
with the branched GD1b. Mutagenesis of residues contacting
the disialic acid motif abolishes infectivity and a comparison
with the SV40 VP1-GM1 complex attributes the different viral
receptor specificities to one point mutation. Introduction of this
mutation into BKPyV switches specificity, enabling BKPyV to
bind GM1 and abolishes binding to GD3, as shown by
saturation transfer difference (STD) NMR spectroscopy and
carbohydrate microarray analyses. The microarray analyses
moreover reveal that the mutant is specific for the ‘human’ sialic
acid NeuNAc. This contrasts with SV40 VP1, which has a
preference for the more prevalent NeuNGc found in simian
species and many other nonhuman mammals. The specificity of
the mutant thus sheds light on the influence of sialic acid on
species tropism.
Results
All b-series gangliosides support infection of BKPyV
To date, only four gangliosides had been tested to support
BKPyV infection, two of which, the b-series gangliosides GD1b
and GT1b, were confirmed as receptors [11]. The carbohydrate
moieties of gangliosides typically consist of two ‘‘arms’’ (Fig. 1A).
In this manuscript, we number the carbohydrates sequentially
(starting from the lipid anchor) and use ‘‘L’’ and ‘‘R’’ designations
to indicate whether a carbohydrate is part of the left or the right
arm, respectively. For example, NeuNAc 3R is the third
carbohydrate and located in the right arm (Fig. 1A, schematic
on the left hand side). The right arm consists of only sialic acids
and is used to classify gangliosides. The b-series gangliosides, e.g.
GD1b and GT1b, carry both NeuNAc 3R and NeuNAc 4R, while
a-series gangliosides such as GM1 carry only NeuNAc 3R
(Fig. 1A). We tested the effects of all common b-series gangliosides
on BKPyV infection by supplementing permissive Vero cells
with GD3, GD2, GD1b or GT1b (Fig. 1B). Consistent with
previous reports [11], gangliosides GD1b and GT1b enhanced
infectivity of Vero cells. However, gangliosides GD2 and GD3,
which had not been tested previously, also enhanced infection of
the cells (Fig. 1B). Incorporation of all b-series gangliosides into
the plasma membrane of Vero cells increased the binding of
labeled VP1 pentamers to cells (data not shown). In control
experiments, supplementing cells with the a-series ganglioside
GM1 had no effect on infection or binding (Fig. 1B, and data
not shown). The ability of b-series gangliosides to enhance
BKPyV infection was greater in the presence of the left arm,
with GD1b and GT1b supporting infection best (Fig. 1B). Taken
together, these data show that the a2,8-disialic acid motif in b-
series gangliosides is the minimal requirement for binding, with
the left arm of GD1b and GT1b contributing some additional
interactions.
BKPyV carbohydrate epitope mapping on b-series
gangliosides
We analyzed pentamer binding to GD3 and GD1b oligosac-
charides by STD NMR spectroscopy [19], which identifies ligand
atoms that contact a protein in solution. The strongest saturation
transfer from BKPyV VP1 to GD3 was observed for the methyl
group of the terminal NeuNAc 4R, followed by the methyl group
of the internal NeuNAc 3R (Fig. 1C). No significant transfer was
observed to any of the anomeric protons, or to the NeuNAc H3
protons. Interestingly, no transfer was observed for the Glc and
Gal residues of GD3 (Fig. 1C), suggesting that they may not
participate in binding.
We repeated the same experiment for GD1b oligosaccharide,
observing transfer to essentially the same set of protons from the
disialyl moiety plus additional transfer to Gal 4L and GalNAc 3L
in the GD1b left arm as well as the branching Gal 2 residue
(Fig. 1D). Resonances H4 and H1 from Gal 2 and H1 from
GalNAc 3L can be unambiguously assigned, but H3 from Gal 2
and H4 from GalNAc 3L overlap and cannot be distinguished.
From the Gal 4L ring, only the anomeric proton can be assigned
in the STD difference spectrum. The STD spectra thus show that
while the right arms of both GD3 and GD1b interact with BKPyV
VP1 in a similar way, additional contacts are provided by the left
arm of GD1b.
Structure of a BKPyV VP1-GD3 complex
To define the structural features underlying the receptor-
binding specificity of BKPyV, we solved the structure of the
BKPyV VP1 pentamer at 2.0 A˚ resolution (Table 1). The VP1
pentamer is a doughnut-shaped ring, with the five monomers
arranged around a central pore that aligns with the five-fold
symmetry axis (Fig. 2A). The monomers adopt a b-sandwich fold
with jelly-roll topology that is present in many viral capsid
proteins. The b-strands B, I, D, G and C, H, E, F (designated
alphabetically from the N-terminus of the full-length protein) are
linked by extensive loops that decorate the surface of the protein.
For clarity, the long BC-loop is subdivided into loops BC1 and
BC2, which face in different directions.
We incubated BKPyV VP1 crystals in 20 mM GD3 oligosac-
charide solution and solved the structure of the resulting complex
at 1.7 A˚ resolution (Table 1). Attempts to form a complex with
GD1b oligosaccharide by soaking or co-crystallization failed in
several crystal forms, likely because of the size of the GD1b
hexasaccharide. However, the GD3 structure encompasses the
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minimal motif required for binding and provides a template for
understanding interactions with the larger GD1b oligosaccharide.
The structures of unliganded and liganded BKPyV VP1 are
virtually identical (r.m.s.d. of 0.4 A˚ for all atoms of one
monomer), indicating that GD3 binding does not induce a
conformational change in the protein. GD3 engages BKPyV VP1
at the top of the pentamer, which corresponds to the outer
surface of the virion (Fig. 2A, B). Contacts involve residues in the
BC1-, HI- and DE-loops of one monomer, as well as the BC2-
loop of the clockwise neighboring VP1 monomer (BC2cw) and
the DE-loop of the counterclockwise neighbor (DEccw). Four of
the five binding sites within one pentamer are occupied by ligand,
while one is inaccessible due to crystal packing. Two of the four
occupied binding sites, however, participate in crystal contacts.
As their conformations are influenced by these non-physiologic
interactions, they will not be considered further. The two
remaining GD3 oligosaccharides do not participate in crystal
contacts and assume an identical conformation, which therefore
should represent a physiologically relevant complex. In both
cases, only the terminal NeuNAc-a2,8-NeuNAc motif interacts
with BKPyV VP1, while the Gal-Glc moiety projects into
solution. This is in agreement with the STD NMR data that
showed little saturation transfer between BKPyV VP1 and the
Gal-Glc portion of GD3.
Contacts between BKPyV VP1 and GD3
The terminal NeuNAc 4R is the main contact of GD3 with
BKPyV VP1. In all four occupied binding sites on the BKPyV
VP1 pentamer, NeuNAc 4R adopts the same conformation and
makes identical interactions with the protein. The sialic acid
Figure 2. Structure of a BKPyV VP1-GD3 oligosaccharide complex. (A) Structure of BKPyV VP1 pentamer in complex with GD3
oligosaccharide. One VP1 monomer is highlighted in green. Monosaccharides unbiased by crystal contacts are colored orange, while the ones
binding to crystal contacts are colored white. (B) Composite annealed difference electron density for the terminal disialic acid motif of GD3
oligosaccharide bound to BKPyV VP1 at a s level of 2.5. cw/ccw = belonging to the clockwise/counterclockwise neighboring VP1 monomer within the
pentamer. (C) Interactions of GD3 oligosaccharide with BKPyV VP1. The oligosaccharide is shown in orange. Side chains contacting the sugar are
colored as follows: those making hydrogen bonds are colored dark green, those making van der Waals interactions are light green, and those making
water-mediated hydrogen bonds are colored yellow. Atoms of the protein backbone are shown in gray, and water molecules are in cyan. Direct
hydrogen bonds are indicated as black dashed lines, water-mediated ones are grey. (D+E) Model of the interaction of BKPyV VP1 with GD1b
oligosaccharide. The left arm and the stem of GD1b are colored orange. Residues interacting with the left arm of GD1b are colored as in (C). The
disialic acid motif of GD1b and the protein residues contacting it are colored white.
doi:10.1371/journal.ppat.1003688.g002
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carboxylate group is recognized by two hydrogen bonds to the side
chains of S274 and T276 (Fig. 2C). Additional, water-mediated
hydrogen bonds are formed to the side chain of S273 and the
backbone of S274. The O4 hydroxyl group of NeuNAc 4R
interacts via water-mediated hydrogen bonds with the side chain
of N272, the backbone of G131, and the backbone nitrogen of
F75cw. The N-acetyl group makes a hydrogen bond to N272 and
a water-mediated hydrogen bond to R169cw. Its methyl group
inserts into a tight-fitting, hydrophobic pocket on BKPyV VP1
that is formed by four non-polar residues (L62, F65, F270 and
F75cw). Finally, the glycerol chain of NeuNAc lies in a shallow
groove and makes van der Waals contacts to the side chains of
P58, L62, L67, K68 and Q278. The glycerol chain also forms a
single hydrogen bond to the K68 backbone nitrogen. The
conformation of the NeuNAc 4R ring is stabilized by an
intramolecular hydrogen bond from the carboxylate group to
the O8 hydroxyl group.
The second sialic acid of GD3, NeuNAc 3R, has weaker
electron density and makes fewer contacts with the protein
(Fig. 2C). Its carboxylate group forms a salt bridge with the K68
side chain. The methyl group of its N-acetyl chain stacks against a
hydrophobic surface created by parts of the side chains of
H138ccw, S274 and T276. The prominent role of van der Waals
interactions with the methyl group mirrors the NMR results,
which feature prominent saturation transfer to the methyl groups
of both NeuNAcs (Fig. 1C).
Modelling of the BKPyV-GD1b interaction reveals
additional contacts
The BKV-GD3 complex structure enabled us to model the
interaction of BKV VP1 with the longer GD1b oligosaccharide,
using the tightly bound terminal NeuNAc 4R as an anchor. A
large number of possible GD1b oligosaccharide conformations
was calculated and superposed on the terminal NeuNAc 4R in the
BKV-GD3 complex structure. The oligosaccharide conformations
were filtered for presence of the specificity-defining contacts
between the protein and the internal NeuNAc 3R. The remaining
conformations could be classified into two groups: one in which
the left arm of GD1b pointed away from the protein, not engaging
in interactions, and one in which this arm made additional
contacts with BKV VP1. Some of the latter conformations were
then subjected to a final round of molecular dynamics (MD)
simulations in explicit water. We found that the ‘left’ arm is
involved in several weaker interactions with amino acids P58, D59,
L67, K68, E81, and K83. A snapshot of the complex is shown in
(Fig. 2D,E). According to this model, the Gal 4L residue of GD1b
can adopt a position enabling hydrogen bonds between its 2- and
3-hydroxyl groups and the side chain of E81, as well as hydrogen
bonds between its 6-hydroxyl group and the side chain of K83 and
the backbone carbonyl of P58. Moreover, the left arm of GD1b is
supported by van der Waals interactions with the side chain of
L67, and there is an intramolecular hydrogen bond between the
carboxylate group of the internal NeuNAc 3R and the N-acetyl
group of GalNAc 3L. The model is in accord with the observed
increase in BKV infection with increasing length of the left arm of
b-series gangliosides, and also with the STD NMR data that show
signals for some protons in the left arm.
Carbohydrate binding is crucial for BKPyV spread and
infectivity
To test the biological relevance of these interactions mutations
were introduced into an infectious clone of BKPyV. We first
probed the interaction with the tightly bound terminal NeuNAc
4R (Fig. 3A) with mutations designed to abolish carbohydrate
binding either by reducing the number of hydrogen bonds (S274A,
T276A, and S274A/T276A), eliminating van der Waals contacts
(F75V), or by introducing steric hindrance (L62W, F75W). Vero
cells were transfected with mutant or wild-type (WT) BKPyV
plasmid DNA. Viral gene expression was scored every 3 days over
a 22 day growth period. The first data point after transfection
indicated no difference between wild-type and the mutants in
terms of protein expression and localization (data not shown).
While WT BKPyV resulted in viral production that continued to
spread with time, all mutants that targeted the binding site for
terminal sialic acid did not propagate, highlighting the importance
of these interactions (Fig. 3B). We then targeted the binding site of
the internal NeuNAc 3R. Mutant H138A, in which a van der
Waals contact is removed from the second sialic acid, propagated
at a significantly reduced level compared to WT (Fig. 3B). We also
introduced the mutations in our recombinant pentamer construct.
Flow cytometry binding assays using WT and mutant pentamers
show that the mutants have greatly reduced cell binding (Fig. 3C),
suggesting that the loss of viral propagation is due to an
attachment defect. The structural integrity of mutant pentamers
was verified with circular dichroism spectroscopy, and their ability
to assemble into pentamers was confirmed with gel filtration (data
not shown). All the mutations were in the receptor binding site,
which is distant from the sites important for capsid assembly.
Thus, the mutations are very unlikely to cause defects in capsid
assembly.
Table 1. Crystallographic data collection and refinement
statistics.
BKPyV VP1 BKPyV VP1 - GD3 complex
Data collection
Space group P21212 P21212
Unit cell [A˚] 144.9, 152.3, 62.7 144.7, 152.6, 63.2
Resolution [A˚] 50 - 2.0 2.05 - 2.00 50 - 1.7 1.74 - 1.70
Total reflections 388,470 27,741 1,103,641 64,273
Unique reflections 94,342 6,826 154,169 11,266
Rmeas [%] 12.7 67.0 7.1 69.4
Completeness [%] 99.8 98.4 100.0 99.8
I/sI 11.01 2.40 19.44 2.66
Refinement
Rwork [%] 16.1 22.0 15.0 23.1
Rfree [%]* 19.0 25.1 17.7 24.9
Protein atoms 9,957 10,181
Average B-factor [A˚2] 23.1 21.5
Carbohydrate atoms - 197
Average B-factor [A˚2] - 33.1
Solvent atoms 899 1,327
Average B-factor [A˚2] 30.0 32.6
r.m.s.d.
Bond lengths [A˚] 0.010 0.010
Bond angles [u] 1.246 1.311
B-factor Wilson [A˚2] 27.1 26.4
r.m.s.d. = root-mean-square deviation.
*Rfree was calculated with 3.5% of the data.
doi:10.1371/journal.ppat.1003688.t001
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Finally, we mutated residues in the putative binding site for the
left arm of b-series gangliosides (Fig. 3D). Again, we designed
mutations to either introduce steric hindrance (D59Y and L67W)
or to remove contacts (D59A, L67A and K83A). The mutations
that created steric hindrance significantly reduced BKPyV spread
in culture. The D59A mutation had no significant effect, but L67A
and K83A both reduced BKPyV growth. In addition, the E81A
mutant, which also removes a contact from the second arm, was
described in an earlier paper to have slightly reduced growth [20].
The mutations likely did not abolish growth altogether because
they still permit interactions with the primary contact, terminal
sialic acid. While the D59Y and L67 mutations might in theory
also interfere with primary sialic acid binding due to the branched
nature of GD1b, the K83A and E81A mutations certainly only
target the second arm. Thus, mutagenesis confirms our structural
model and highlights the importance of specific contacts with the
second arm of GD1b. Taken together, our biological data confirm
that the binding site for terminal sialic acid is indispensable for
viral infection, while peripheral interactions further enhance
binding and infection.
Structural basis of specificity
BKPyV is most closely related to SV40 and JCPyV, with amino
acid identity among their VP1 proteins as high as 74%.
Nevertheless, the three viruses recognize different sialic acid
containing receptors. BKPyV interacts with a2,8-linked b-series
gangliosides, while SV40 binds the branched a2,3-linked GM1
ganglioside [12] and JCPyV attaches to the linear a2,6-linked
sequence in LSTc [17].
In receptor complexes of all three viruses, the terminal sialic
acid engages in critical and highly conserved interactions that
anchor the ligand to VP1 (Fig. 4) [16,17]. Specificity for the three
Figure 3. Mutation of residues that interact with the left and right branches of GD1b abolish or reduce growth. (A) Structural model of
the BKPyV-GD1b complex. Residues targeted for mutation are colored dark green for the disialic acid motif and light green for the left arm binding
sites, respectively. (B) Growth assay for the sialic acid binding site mutants. Vero cells were transfected with linearized WT or mutant BKPyV DNA. Cells
were fixed permeabilized and stained for VP1 at 3 day intervals for 22 days and analyzed by indirect immunofluorescence. Viral spread was quantified
by scoring for cells expressing VP1. The average number of VP1 positive cells is plotted from 3 independent experiments with each time point
representing the average number of infected cells per visual field for 8 fields. (C) Binding of the sialic acid binding site mutants to Vero cells. Cells
were incubated with purified His-tagged WT or mutant BKPyV pentamers and an Alexa Fluor 488 conjugated penta-His secondary antibody. Cells
were fixed and pentamer binding to cells assessed by flow cytometry. Histograms show the fluorescence intensity of the Alexa 488 antibody alone
(gray-filled), WT pentamer (black) and mutants (color) for 16104 events. (D) Growth assay for the left arm binding site mutants assessed as in B.
doi:10.1371/journal.ppat.1003688.g003
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different oligosaccharide receptor sequences arises in each case
from a small number of unique contacts outside the sialic acid
binding site. JCPyV recognizes an L-shaped conformation of the
LSTc oligosaccharide. The key residue that makes contacts to
both legs of this L-shaped glycan is N123 [17] (Fig.4C). BKPyV
(Fig. 4A) and SV40 (Fig. 4B) both have a glycine at the equivalent
position and thus cannot form similar contacts. BKPyV VP1
specificity for the a2,8-disialyl motif can be attributed to residues
K68 and H138, which form contacts with the internal NeuNAc
3R. These two residues are not conserved in SV40 or JCPyV, and
thus neither virus is able to specifically interact with a2,8-disialic
acid carrying glycans in the same manner [16,17]. Moreover,
none of the BKPyV residues contacting the left arm of gangliosides
are conserved in either SV40 or JCPyV. Although the SV40
receptor, GM1, resembles GD1b with an identical left arm,
BKPyV and SV40 VP1 bind the left arm at different sites on the
proteins (Fig. 4A,B). The two pockets recognize the left arm in
different ways. The GalNAc 3L methyl group of GM1 in the SV40
complex is bound at a similar position on VP1 as the NeuNAc 3R
methyl group in the BKPyV complex. BKPyV cannot bind the left
arm of GM1 in the orientation seen in the SV40 complex because
the binding site is blocked by the large side chain of K68, which
would lead to clashes with GalNAc (Fig. 4A,B). Apart from this
difference, BKPyV and SV40 VP1 share similar surface features at
the SV40 left arm binding site and display the same main chain
conformation in their surface loops. Thus, the inability of BKPyV
to bind to GM1 appears to be determined by the amino acid at
position 68.
A single point mutation enables BKPyV to recognize GM1
To validate the conclusions derived from the structural
comparisons, we introduced a K68S mutation into the BKPyV
VP1 pentamer expression construct. Purified K68S pentamers
were analyzed by STD NMR for binding to GD3 and GM1.
Unlike the WT BKPyV-GD3 pair, almost no saturation transfer
was observed for BKPyV K68S and GD3, indicating that the
mutation virtually abolished binding to the disialic acid motif of
GD3 (Fig. 5A). However, saturation transfer from BKPyV K68S
Figure 4. Carbohydrate binding sites of BKPyV, JCPyV and SV40. Recognition of carbohydrate receptors by BKPyV (A), SV40 (B), and JCPyV
(C). Only residues making direct hydrogen bonds or van der Waals interactions are shown. Residues that make conserved interactions are colored in
yellow, side chains whose positions are not conserved are shown in green (BKPyV), blue (SV40) and pink (JCPyV). (D) Comparison of carbohydrate
ligands of BKPyV, SV40 and JCPyV. The oligosaccharides are colored green, blue and pink for the BKPyV, SV40 and JCPyV ligands, respectively. The
structures were aligned using the protein main chain.
doi:10.1371/journal.ppat.1003688.g004
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Figure 5. The K68S mutation targets BKPyV to the SV40 receptor GM1. STD difference spectra of (A) BKPyV K68S with GD3, (B and C,
respectively) BKPyV K68S and SV40 with GM1. (D) SV40-GM1 off-resonance spectrum. A 50-fold excess of oligosaccharide was used for each spectrum.
The off-resonance spectrum was scaled to 3%. Resonances labeled in the difference spectra with GM1 (B and C) receive considerable saturation
transfer from BKPyV K68S and SV40. Regions with strong signal overlap are not labeled because they cannot be unambiguously assigned. Binding of
BKPyV K68S to GD3, previously seen for WT BKPyV (Fig. 1C), is abolished by the mutation (A). Carbohydrate microarray analyses of recombinant VP1
of (E) BKPyV, (F) BKPyV K68S and (G) SV40 using 21 ganglioside-related saccharide probes, which included the b-series gangliosides as well as GM1
variants NeuNAc-GM1 and NeuNGc-GM1. The doses of probes arrayed per spot are indicated. Numerical scores of the binding signals are means of
duplicate spots (with error bars). The complete list of probes and their sequences are in Supplemental Table S1.
doi:10.1371/journal.ppat.1003688.g005
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VP1 to GM1 was as efficient as for the SV40 VP1-GM1 pair,
which was included for comparison (Fig. 5B–D). This indicates
that the K68S mutation switches the binding preference of
BKPyV VP1 from GD3 to GM1. The STD NMR spectra of SV40
VP1 and BKPyV K68S VP1 with GM1 are almost indistinguish-
able, suggesting that GM1 engages in the same contacts with both
proteins. Saturation transfer is primarily observed to protons of the
NeuNAc 3R and Gal 4L rings. In addition, both the GalNAc and
the NeuNAc methyl groups in GM1 received considerable
saturation in the complexes, with the NeuNAc methyl group
being more affected. Our observations are in good agreement with
the crystal structure of the SV40 VP1-GM1 complex [16] and
demonstrate that a single amino acid mutation suffices for BKPyV
to adapt to the SV40 receptor.
BKPyV K68S mutant is specific for the human sialic acid
NeuNAc
BKPyV, JCPyV and SV40 differ in one aspect of their sialic
acid binding site. The cavity engaging the methyl group is tight-
fitting and lined with hydrophobic residues in BKPyV and JCPyV,
but significantly enlarged and partially hydrophilic in SV40
(Fig. 4A–C). This difference may reflect the different hosts of these
viruses, humans and simians, and the different types of sialic acids
characteristic for each host. While the most prominent sialic acid
in humans is NeuNAc, simians carry in addition to NeuNAc larger
amounts of N-glycolyl neuraminic acid (NeuNGc), in which the
methyl group is replaced by the bigger and more hydrophilic
glycolyl (CH2-OH) group [9,21]. SV40 preferentially binds to
NeuNGc-GM1, and the glycolyl group likely engages polar
residues in the cavity [16,22]. By contrast, the smaller and more
hydrophobic cavity of BKPyV and JCPyV cannot accommodate
the glycolyl group in a similar manner, thus making BKPyV and
JCPyV specific for NeuNAc.
To assess their specificity for human-type and simian-type sialic
acids, the VP1 proteins of WT BKPyV, mutant BKPyV K68S,
and SV40 were analyzed using a focused ganglioside microarray
comprised of 21 ganglioside-related saccharide probes, which
included the b-series gangliosides as well as GM1 variants
NeuNAc-GM1 and NeuNGc-GM1 (Supplemental Table S1).
Microarray analyses revealed differing binding specificities of the
three VP1 proteins (Fig. 5E–G). With the WT BKPyV, the only
detectable binding was to the b-series ganglioside GD1b (position
16) and the signal intensity was relatively low. No binding to any
other b-series gangliosides GD3, GD2, GT1b or GQ1b was
detected, possibly due the lower binding avidity to these probes
compared to GD1b in the array (Fig. 5E). The BKPyV K68S
mutant showed barely detectable binding to GD1b, but highly
specific and strong binding to the two NeuNAc-GM1 probes
(positions 10 and 11), which differed only in the composition of
their lipid moieties (Fig. 5F). Interestingly, there was no binding to
the simian-type NeuNGc-GM1 probes, in contrast to SV40 VP1,
which showed preferential binding to the two NeuNGc-GM1
probes (positions 12 and 13) (Fig. 5G). This finding is in accord
with earlier observations and consistent with our structural analysis
(Fig. 4).
BKPyV K68S uses NeuNAc-GM1 as a receptor on human
cells
We next tested whether BKPyV K68S was able to use human-
type NeuNAc-GM1 to attach to cells. Purified K68S or WT
BKPyV VP1 pentamers were incubated with simian (Vero) and
human (HEK) cells, and binding was detected by flow cytometry.
In both Vero and HEK cells, K68S mutant pentamers had
reduced binding compared to WT pentamers, reflecting either
lower affinity or a lower number of receptor molecules (Fig. 6A,C).
There was no significant change in the binding of K68S or WT
VP1 pentamers to Vero cells that were supplemented with 3 mM
NeuNAc-GM1 prior to incubation with the pentamers (Fig. 6A).
However, binding of K68S VP1 to HEK cells was increased upon
supplementation with GM1, whereas WT binding levels were
unchanged (Fig. 6C). This finding might be linked to the enzyme
CMP-sialic acid hydroxylase, which converts NeuNAc to NeuNGc
and is present on simian but not human cells [9]. We performed a
competitive binding assay with GM1 treated HEK cells in the
presence and absence of Cholera toxin subunit B (CTX), which
uses GM1 as a receptor [23]. CTX abolished binding of K68S
VP1, confirming that the K68S mutant is in fact retargeted to
GM1 (Fig. 6C). CTX had no effect on the binding of WT BKPyV
VP1 (Fig. 6C).
The K68S mutation was also assayed in long-term viral growth
assays. We found that while transfection of WT BKPyV plasmid
into Vero cells resulted in viral propagation and spread,
transfection with the K68S plasmid failed to propagate (Fig. 6B).
In human cells however the K68S mutant spread as efficiently as
WT regardless of supplementation with GM1 (Fig. 6D).
Discussion
In this structure-function study, we investigated the interaction
of BKPyV with its glycan receptors and identified key determi-
nants of specificity. We show that the conserved a2,8-disialic acid
motif on the right arm of b-series gangliosides is the minimal
binding epitope for BKPyV, with the variable left arm contrib-
uting some additional contacts. Point mutations in the receptor
binding site abolish viral spread and infectivity, demonstrating the
physiological relevance of the observed interactions.
Our data demonstrate that all of the b-series gangliosides tested
support BKPyV infection. As attachment likely requires multiple
interactions, the virus is predicted to engage a mixture of
gangliosides on the cell surface, depending on lipid composition.
While gangliosides are likely entry receptors for BKPyV, the main
binding epitope of BKPyV, a2,8-disialic acid, is not only present
on gangliosides, but also on glycoproteins. It has been shown for
another ganglioside-binding polyomavirus that such sialylated
glycoproteins act as decoy receptors [24]. The additional contacts
with the left arm of b-series gangliosides therefore may increase
BKPyV binding affinity for ganglioside ligands and distinguish
those from glycoproteins, which likely would lead the virus along
non-infectious entry pathways.
The importance of b-series gangliosides for BKPyV infection
may have implications for BKPyV tropism and pathogenesis.
Biochemical analyses indicate that the kidney, where BKPyV
persists, is rich in diverse sphingolipids and particularly gangli-
osides. The most abundant gangliosides in adult human kidney
are GM3 and GD3, but small amounts of more complex
gangliosides were also detected [25,26]. The relative abundance
of simple gangliosides differs between the kidney and the brain,
where complex gangliosides are most abundant in adults [27].
Therefore, the differences in affinity toward b-series gangliosides
are only one determinant of their usage as receptors in vivo, as a
lower affinity can be balanced by a greater abundance in the host
tissue. Moreover, gangliosides are differentially expressed in
cortical tubular, medullary and glomerular tissues of adult human
kidney and developmental changes in ganglioside expression
have been observed in bovine kidney [26]. Thus, our observation
of differing affinities toward b-series gangliosides raises the
question whether developmental or drug-induced changes in
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ganglioside distribution may play a role in BKPyV latency and
reactivation.
Structural comparison of BKPyV-GD3 with the closely related
SV40-GM1 complex suggested that a protruding lysine at position
68 may prevent BKPyV from binding GM1. To test this
hypothesis, we introduced the smaller SV40 residue S68 into
BKPyV VP1. This single mutation switched the oligosaccharide
specificity of BKPyV from b-series gangliosides to GM1, altering a
key attachment property of BKPyV. Known BKPyV VP1
sequences contain lysine, arginine or histidine at position 68. All
of these amino acids would block engagement of GM1 but
promote or at least tolerate binding of b-series gangliosides.
BKPyV strains do not carry a serine at position 68, and this may
indicate that recognition of GM1 instead of b-series gangliosides
may not be advantageous to the virus in the context of the host
organism. Possible explanations could be that GM1 is not very
abundant or is differentially localized in human kidneys [25,26].
There likely exists an evolutionary constraint on BKPyV to bind b-
series gangliosides, not GM1, especially as the remainder of the
SV40 GM1 binding site is mostly conserved in BKPyV.
We have shown that unlike SV40, the BKPyV K68S mutant is
specific for GM1 containing the human sialic acid NeuNAc, and
cannot engage its simian counterpart NeuNGc due to steric
hindrance. As the WT BKPyV and K68S binding sites for
terminal sialic acid are identical, WT BKPyV shares the same
sialic acid specificity. The inability of K68S to propagate in simian
Vero cells and its ability to attach to and propagate in human
HEK cells highlights the importance of sialic acid specificity for
viral species tropism. Collectively, our data on BKPyV, JCPyV
and SV40 suggest that each virus has adapted to the most
prominent sialic acid in its host.
SV40, JCPyV and BKPyV all feature a conserved platform of
core residues that allows them to efficiently engage terminal sialic
acid in a similar manner. These core residues mediate the vast
Figure 6. K68S BKPyV uses NeuAc-GM1 as a receptor for attachment and infection. (A) Binding of BKPyV K68S to Vero cells. Cells were
treated as in 3C fixed and pentamer binding to cells untreated (left) or treated with NeuNAc-GM1 (right) assessed by flow cytometry. Histograms
show the fluorescence intensity of the Alexa 488 antibody alone (gray-filled), WT pentamer (black) and K68S pentamer (green) for 16104 events. (B)
Growth assay for BKPyV K68S in Vero cells. Cells were transfected as previously described, treated with NeuNAc-GM1, fixed and stained over 23 days.
Viral spread was quantified by scoring for cells expressing T-Ag. The anti-V antigen monoclonal antibody 597 used in Figures 1 and 3 recognizes an
epitope that is disrupted by the K68S mutation, requiring the use of an mAb against T-Ag. The average number of T-Ag positive cells is plotted from 3
independent experiments. (C) Binding of BKPyV K68S to HEK cells. Cells were treated as previously described, fixed and pentamer binding to cells
untreated (left), or treated with NeuNAc-GM1 and CTX (right) assessed by flow cytometry. Histograms show the fluorescence intensity of the Alexa
488 antibody alone (gray-filled), K68S pentamer (green) WT pentamer (black), WT pentamer with CTX (orange) and K68S pentamer with CTX (blue) for
16104 events. (D) Growth assay for BKPyV K68S in HEK cells. Cells were transfected as previously described, treated with NeuNAc-GM1, fixed and
stained over 13 days. Viral spread was quantified as above. Gangliosides were added every 3 days.
doi:10.1371/journal.ppat.1003688.g006
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majority of interactions. However, each virus achieves its distinct
receptor specificity with a small number of strategically positioned
satellite residues, such as K68 in the case of BKPyV, that form
distinct contacts with additional carbohydrate moieties. Thus,
these satellite residues define the context in which a terminal sialic
acid can be bound, and as demonstrated here they present
attractive opportunities for switching receptor specificities.
It is tempting to speculate that at least some members of the
polyomavirus family have evolved from an initial sialic-acid
binding template through subtle modification of their satellite
residues, thereby expanding their host range and tropism. The
switching of specificity can occur naturally in viruses, and often
triggers altered pathogenicity and species tropism. In many
cases, switching is due to exceedingly small changes in the virus
capsid structure. Prominent examples include different serotypes
of adenoviruses, the canine and feline parvoviruses, as well as
avian, swine and human influenza viruses [28,29,30]. In many of
these cases, however, the molecular functions of these switches,
such as how specific mutations alter the interaction with
receptors, are not well understood at the atomic level. Switching
polyomavirus receptor specificities, as demonstrated here in a
first example, may therefore be a useful tool to study parameters
that define host receptor recognition, viral uptake, and entry
pathways.
Materials and Methods
Virus infection
Cells (ATCC, Manassas, VA) were maintained at 37uC in
Cellgro Minimum Essential Medium Eagle (MEM) supplemented
with 5% heat inactivated fetal bovine serum (Atlanta Biologicals)
and penicillin (10,000 U/ml) and streptomycin (10,000 mg/ml)
(Gibco). Cells seeded in 24-well dishes were pre-incubated with
media, dimethyl sulfoxide (DMSO) or gangliosides GM1, GD2,
GD3, GD1b, and GT1b (Matreya) at 0.3–30 mM for 17 h at
37uC. Prior to infection cells were chilled for 20 min at 4uC and
washed with 2% MEM. Cells were infected with 86105
Fluorescent Forming Units (FFU) per ml of BKPyV for 1 h at
37uC. The infectious media was then removed and replaced with
fresh growth media. Infection was scored 72 h post infection by
staining for VP1 and analyzed by indirect immunofluorescence.
Construction of the BKPyV pUC-19 expression plasmid was
previously described [20]. BKPyV VP1 mutants were generated
by site directed mutagenesis using QuickChange XL (Stratagene,
La Jolla, CA). Mutant and WT plasmids were digested with
BamHI (Promega). Vero or HEK cells were transfected with
(0.5 mg) of linearized mutant or WT BKPyV plasmid DNA using
Fugene 6 (Roche).
Indirect immunofluorescence
To detect expression of viral antigens cells were fixed with 2%
paraformaldehyde in phosphate buffered saline (PBS) for 20 min
at 25uC and permeabilized with 1% Triton-X 100 in PBS for
15 min at 37uC. Cells were incubated with the primary mouse
monoclonal antibody PAb597 (1:10 [20], or PAb416 (Ab-2)
(0.2 mg/ml) (Calbiochem), [31], used at 8 ng/ml to stain for
BKPyV T-Ag. After incubation cells were washed with PBS and
incubated with Alexa Fluor 488-labeled goat anti-mouse antibody
in PBS (Invitrogen).
Flow cytometry
Vero or HEK cells were incubated with media or 3 mM GM1
for 17–18 h. Cells were washed and suspended in 100 ml (10 mg/
mL) (Sigma) of CTX or PBS for 30 min on ice with 10 min
agitation. Cells were washed and then incubated with 100 ml of
purified wild type or mutant BKPyV VP1 pentamers (100 mg/mL)
in PBS on ice for 2 h with 30 min agitations or with PBS alone.
Cells were washed and suspended in 100 ml of Penta-His-
AlexaFlour 488 conjugated antibody (10 mg/mL) (Qiagen) in
PBS on ice for 1 h with 15 min agitations. Cells were washed and
fixed in 1% paraformaldehyde and binding analyzed using a BD
FACSCanto II flow cytometer (Benton, Dickinson, and Compa-
ny). Data were analyzed using Flow Jo (Tree Star Inc.) software.
Recombinant protein expression and purification
We expressed and purified a truncated form of BKPyV VP1
that assembles into pentamers but does not form capsids. DNA
coding for amino acids 30–300 of BKPyV VP1 was amplified by
PCR and cloned into the pET15b expression vector (Novagen) in
frame with an N-terminal hexahistidine tag (His-tag) and a
thrombin cleavage site. The protein was overexpressed in E. coli
BL21(DE3) and purified by nickel affinity chromatography and gel
filtration on Superdex-200. For crystallization, the tag was cleaved
with thrombin before gel filtration, leaving non-native amino acids
GSHM at the N-terminus.
STD NMR measurements
All NMR spectra were recorded using 3 mm tubes on a Bruker
DRX 500 MHz spectrometer fitted with a 5 mm cryogenic probe
at 283 K and processed with TOPSPIN 2.0 (Bruker). For all
proteins used for STD NMR, two NMR samples were prepared,
containing either 1 mM GM1 oligosaccharide (Alexis) or 1 mM
GD3 oligosaccharide (Sigma). Protein concentrations were
between 19 mM and 22 mM. An additional sample contained
20 mM WT BKPyV VP1 and 1 mM GD1b oligosaccharide
(Elicityl, F). Additional protein-free samples were prepared that
only contained 1 mM GM1, GD3 or GD1b oligosaccharide.
These samples were used to verify that no direct excitation of
ligand resonances occurred during STD NMR measurements, and
they served as samples for the spectral assignment. 0.1 mM
trimethylsilyl propionate was then added to the GD3 sample to
allow 1H referencing. The buffer used for all NMR measurements
contained 20 mM deutero-Tris pH 7.5, 150 mM NaCl, and
20 mM deutero-DTT. Samples were prepared in D2O and no
additional water suppression was used to avoid affecting the
anomeric proton signals. The off- and on-resonance frequencies
were set to 80 ppm and 7 ppm, respectively. The total relaxation
delay was 4 s. A cascade of 40 Gaussian-shaped pulses with 50 ms
duration each, corresponding to a strength of 65 Hz, and a
saturation time of 2 s was used for selective excitation. A 10 ms
continuous-wave spin lock filter with a strength of 3.7 kHz was
employed in order to suppress residual protein signals. 32 k points
were collected and zero filling to 64 k data points was employed.
Spectra were multiplied with an exponential line broadening
factor of 1 Hz prior to Fourier transformation.
To assign oligosaccharide proton resonances, series of 1D 1H-
TOCSY and COSY spectra as well as 1H, 13C-HSQC spectra
were acquired. Literature values for related oligosaccharides
served as additional assignment controls [32,33,34,35]. Assign-
ment of the acetate methyl groups was taken from [34] for GD3
and [32] for GM1.
Crystallization and structure determination
For crystallization, BKPyV VP1 was supplemented with 20 mM
DTT and concentrated to 6.6–7.0 mg/ml. The protein was
crystallized at 20uC by sitting drop vapor diffusion against a
reservoir of 16–18% PEG 3,350, 0.1 M HEPES pH 7.5 and 0.25
M LiCl (drop size 300 nl protein+300 nl reservoir). Crystals were
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harvested into reservoir solution containing 14–16% PEG 3,350
and cryoprotected by soaking in harvesting solution supplemented
with 30% (v/v) glycerol for 10 s before flash-freezing them in
liquid nitrogen. For oligosaccharide complex formation, crystals
were soaked in harvesting solution containing 20 mM GD3
oligosaccharide for 15 min before cryoprotection.
Diffraction data were collected at the SLS (Villigen, CH) and
processed with xds [36], and the structure was solved by molecular
replacement with Phaser [37] using the core of the SV40 VP1
pentamer (3BWQ) as the search model. After rigid body and
simulated annealing refinement in Phenix [38], missing parts of
the model were built in Coot [39]. Refinement proceeded by
alternating rounds of refinement in Refmac5 [40] and model
building in Coot. Fivefold non-crystallographic symmetry re-
straints were used throughout refinement. Oligosaccharide resi-
dues were located in weighted 2mFo-DFc and mFo-DFc electron
density maps and refined with restraints from the CCP4
monomers library; only the a2,3- and a2,8- glycosidic linkages
had to be user-defined. Data collection and refinement statistics
are given in Table 1. Coordinates and structure factor amplitudes
were deposited with the RCSB data bank (www.rcsb.org) with
entry codes 4MJ0 (BKPyV VP1 bound to GD3) and 4MJ1
(unliganded BKPyV VP1). Structure figures were prepared with
PyMol (Schro¨dinger Inc.).
Molecular modeling
To generate a model for the complex, we first explored the
conformational space of GD1b alone using high-temperature
molecular dynamics (MD) [41] and subsequently positioned the
individual sampled snapshots into the binding site using the a2,8-
disialic acid motif of crystal structure as an anchor point.
Molecular dynamics simulation of GD1b was performed at 700
K for 100 ns using the MM3 force field as implemented in the
TINKER software (http://dasher.wustl.edu/tinker/). Torsion
restraints were applied on the ring torsions to avoid inversion of
the carbohydrate rings during MD. Snapshots were recorded
every 0.5 ps resulting in a conformational ensemble consisting of
200000 frames. Further processing of the data was performed
using Conformational Analysis Tools (CAT) (http://www.md-
simulations.de/CAT/). Conformational maps were calculated as
described [41] in order to check that the accessible conformational
space of the glycosidic linkages was sufficiently explored
(Supplemental Fig. S1). All snapshots were positioned into the
crystal structure using three atoms of residue NeuNAc 4R as an
anchor and conformations that result in atom-overlaps with the
protein were removed. Additionally two filters were applied on the
remaining snapshots that control the position and orientation of
residue NeuNAc 3R: Only snapshots were allowed to pass that
have the center of the carboxylate and the N-acetyl group within
3 A˚ of the corresponding residue of the crystal structure. Several
conformations were manually selected and refined based on 5 ns
MD simulations at 300K in explicit water using YASARA [42].
Model coordinates are available from the authors upon request.
Carbohydrate microarray analyses
Microarrays comprised lipid-linked oligosaccharide probes,
neoglycolipids (NGLs) and glycolipids, robotically printed on
nitrocellulose-coated glass slides using a non-contact instrument
[43,44]. For the analyses, an array set of 21 ganglioside-related
probes (18 sialylated and 3 non-sialylated, in house designation
Ganglioside Dose Response Array set 1) was used, in which each
probe was arrayed at four levels: 0.3, 0.8, 1.7 and 5.0 fmol/spot.
The microarray analyses were performed essentially as described
[17]. In brief, microarrays were blocked in 5 mM HEPES
(pH 7.4), 150 mM NaCl, 0.3% (v/v) Blocker Casein (Pierce),
0.3% (w/v) bovine serum albumin (Sigma) and 5 mM CaCl2
(referred to as HBS-Casein/BSA). WT and mutant BKPyV VP1
were diluted in HBS-Casein/BSA and overlaid at 300 mg/ml and
150 mg/ml, respectively, followed by incubation with mouse
monoclonal anti-poly-histidine and biotinylated antimouse IgG
antibodies (both from Sigma). SV40 VP1 was tested as a protein-
antibody complex that was prepared by preincubating with mouse
monoclonal anti-poly-histidine and biotinylated anti-mouse IgG
antibodies at a ratio of 4:2:1 (by weight) and diluted in HBS-
Casein/BSA to provide a final SV40 VP1 concentration of
150 mg/ml. The SV40 and K68S protein samples had been
supplemented with DTT to prevent dimerization of pentamers,
while WT BKPyV VP1 was analysed without DTT. Binding was
detected with Alexa Fluor-647-labelled streptavidin (Molecular
Probes). Microarray data analyses were as described [45].
Supporting Information
Figure S1 Conformational energy maps for the GD1b
oligosaccharide. The maps show the accessible conformational
space of the glycosidic linkages and are calculated based on
200000 snapshots sampled from a 100 ns MD simulation at 700 K
using TINKER/MM3 as described in (Frank et al., 2007). Three
local energy minima are predicted for the internal NeuNAc-a2,3-
Gal linkage.
(PDF)
Figure S2 Growth of BKPyV K68S in the absence of
exogenous GM1. (A) Vero cells were transfected as previously
described, treated with media lacking GM1 ganglioside addition,
fixed and stained over 23 days. Viral spread was quantified by
scoring for cells expressing T-Ag. (B) HEK cells were transfected as
previously described, treated with media lacking GM1 ganglioside
addition, fixed and stained over 13 days. Viral spread was
quantified as above.
(TIF)
Table S1 Oligosaccharide probes. The table lists probes
with their sequences included in the ganglioside ‘dose- response’
set 1.
(DOC)
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Progressive Multifocal Leukoencephalopathy-Associated Mutations in
the JC Polyomavirus Capsid Disrupt Lactoseries Tetrasaccharide c
Binding
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ABSTRACT The human JC polyomavirus (JCPyV) is the causative agent of the fatal, demyelinating disease progressive multifocal
leukoencephalopathy (PML). TheMad-1 prototype strain of JCPyV uses the glycan lactoseries tetrasaccharide c (LSTc) and sero-
tonin receptor 5-HT2A to attach to and enter into host cells, respectively. Specific residues in the viral capsid protein VP1 are re-
sponsible for direct interactions with the 2,6-linked sialic acid of LSTc. Viral isolates from individuals with PML often contain
mutations in the sialic acid-binding pocket of VP1 that are hypothesized to arise from positive selection. We reconstituted these
mutations in theMad-1 strain of JCPyV and found that they were not capable of growth. The mutations were then introduced
into recombinant VP1 and reconstituted as pentamers in order to conduct binding studies and structural analyses. VP1 pentam-
ers carrying PML-associated mutations were not capable of binding to permissive cells. High-resolution structure determination
revealed that these pentamers are well folded but no longer bind to LSTc due to steric clashes in the sialic acid-binding site. Re-
constitution of the mutations into JCPyV pseudoviruses allowed us to directly quantify the infectivity of the mutants in several
cell lines. The JCPyV pseudoviruses with PML-associated mutations were not infectious, nor were they able to engage sialic acid
as measured by hemagglutination of human red blood cells. These results demonstrate that viruses from PML patients with sin-
gle point mutations in VP1 disrupt binding to sialic acid motifs and render these viruses noninfectious.
IMPORTANCE Infection with human JC polyomavirus (JCPyV) is common and asymptomatic in healthy individuals, but during
immunosuppression, JCPyV can spread from the kidney to the central nervous system (CNS) and cause a fatal, demyelinating
disease, progressive multifocal leukoencephalopathy (PML). Individuals infected with HIV, those who have AIDS, or those re-
ceiving immunomodulatory therapies for autoimmune diseases are at serious risk for PML. Recent reports have demonstrated
that viral isolates from PML patients often have distinct changes within the major capsid protein. Our structural-functional ap-
proach highlights that these mutations result in abolished engagement of the carbohydrate receptor motif LSTc that is necessary
for infection. Viruses with PML-associated mutations are not infectious in glial cells, suggesting that they may play an alterna-
tive role in PML pathogenesis.
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The human JC polyomavirus (JCPyV) is an icosahedral, nonen-veloped double-stranded DNA (dsDNA) virus and a member
of the Polyomaviridae family (1). JCPyV infects approximately
50% of the population, and the infection is asymptomatic in
healthy individuals (2, 3). Viral spread likely occurs via a fecal-oral
route, as JCPyV is shed in the urine of healthy individuals (4) and
can be detected in untreated wastewater (5–7). The site of initial
infection is thought to be the stromal cells of the tonsils (8), fol-
lowed by a persistent infection in the kidney (9) and in B lympho-
cytes of the bone marrow (10–12). In healthy individuals, JCPyV
remains in the kidney, but in immunosuppressed individuals,
JCPyV can spread to the central nervous system (CNS) (10, 13–
15) and infect astrocytes and oligodendrocytes (16, 17). Oligoden-
drocytes produce myelin, and astrocytes are critical to the process
of myelination in the CNS (18–20). JCPyV infection of astrocytes
and cytolytic destruction of the oligodendrocytes cause the fatal,
demyelinating disease progressive multifocal leukoencephalopa-
thy (PML) (21, 22). PML is a devastating disease that can result in
fatality within 3 months to 1 year of symptom onset if untreated
(23). PML affects approximately 3 to 5% of HIV-1-positive indi-
viduals, is considered an AIDS-defining illness, and is one of the
most common CNS-related diseases in AIDS (22). Since 2005, the
incidence of PML has risen in individuals receiving immuno-
modulatory therapies for autoimmune diseases (24). In particu-
lar, individuals with multiple sclerosis (MS) who are receiving the
biological therapy natalizumab have a 1:500 chance of developing
PML (25, 26). Natalizumab is an anti-VLA-4 (41 integrin) an-
tibody that blocks extravasation of VLA-4 T and B lymphocytes
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to the brain, where they normally bind to endothelial cells (27).
Therefore, while this treatment prevents the movement of lym-
phocytes to the brain, thus protecting the brain of an MS patient
from attack, the lack of immune surveillance can also result in
increased spread of JCPyV to the brain and thus increase the
chances of developing PML (25).
The mechanisms of JCPyV spread to the CNS and infection of
glial cells are not well understood, although spread is thought to
occur via a hematogenous route, possibly involving B lympho-
cytes (28–30). In addition, it is well documented that JCPyV un-
dergoes certain polymorphic changes within the host that render
it neurotropic. The nonpathogenic form of virus that resides in the
kidney is referred to as the archetype strain (Cy) and can be de-
tected in the urine of healthy individuals (4, 31–33). JCPyV un-
dergoes rearrangements in the noncoding control region
(NCCR), which contains the viral origin of replication and se-
quences that serve as binding sites for transcription factors neces-
sary for transcription of viral early and late genes (34–38). These
rearrangements include duplication of enhancer elements to con-
vert the virus to the neuropathogenic form (34, 39, 40). Viruses
found in the cerebral spinal fluid (CSF), brain tissue, and blood
but not in the urine contain NCCR rearrangements and are re-
ferred to as PML-type strains (22). Mad-1 is the laboratory proto-
type strain of the PML-type strain that was originally isolated from
the brain of a PML patient and contains a canonical 98-bp tandem
repeat in the NCCR (35). While NCCR rearrangements are nec-
essary for JCPyV growth in the CNS, the incidence of PML is
relatively low, given the rates of seropositivity (22). Thus, it is
likely that other viral, cellular, and individual host factors play a
role in PML pathogenesis.
Recently, a number of studies have reported that viral isolates
from PML patients also contain mutations in the viral capsid VP1
protein. VP1 is a pentameric protein that interacts with neighbor-
ing VP1 pentamers through C-terminal extensions linking to-
gether 72 pentamers to form the viral capsid. VP1 serves as the
viral attachment protein and mediates direct interactions with cell
surface receptors (41). Initial studies to define the receptors for
JCPyV infection revealed that JCPyV utilizes sialic acid (42, 43)
and the 5-HT2A receptor (44). The sialic acid component of the
receptor was thought to be an2,3- or2,6-linked sialic acid (45).
Our laboratory demonstrated that the presence of 2,6-linked
sialic acid correlates with JCPyV infection of cells and tissues in the
host, including B lymphocytes, kidney, and the glial cells astro-
cytes and oligodendrocytes (46). Moreover, JCPyV infection of B
lymphocytes, kidney, and glial cells is mediated by sialic acid (42,
45, 47, 48). We identified the specific sialic acid receptor motif for
the Mad-1 strain of JCPyV as lactoseries tetrasaccharide c (LSTc),
which terminates in 2,6-linked sialic acid (41). The high-
resolution crystal structure of JCPyV VP1 pentamers in complex
with LSTc revealed that the protein specifically binds to the termi-
nal 2,6-linked sialic acid and engages LSTc in a unique L-shaped
conformation. Mutation of VP1 residues that contact LSTc leads
to a severe defect in viral growth in glial cells (41). Interestingly,
viruses isolated from the blood and CSF of individuals with PML
exhibit mutations in these VP1 residues, including L54F, S266F,
and S268F/Y (49–53), which are located in the sialic acid-binding
pocket of VP1 (41). However, these mutations have never been
found in the urine of healthy individuals, nor are they present in
the urine of individuals with PML, in whom viral isolates with
PML-associated mutations are found in the CSF and blood. This
suggests that these mutations can arise within the JCPyV-infected
individual (50–53). Analysis of viral isolates from urine, blood,
and CSF from a single patient infected with a single JCPyV geno-
type supports this hypothesis. While virus isolated from the blood
and CSF of this individual carried PML-associated mutations in
VP1 (L54F, N264S, and S266F), these mutations were not present
in virus isolated from the urine (53). Mutations in VP1 sialic acid-
binding sites arise with high frequency, in as many as 80 to 90% of
the viral isolates, indicating that the majority of the isolates from
individuals with PML exhibit mutations in one or more of these
sites in VP1 (50, 52–55). The role of some of the PML-associated
mutations has been analyzed as virus-like particles (VLPs) in the
JCPyV genotype 3 background. VLPs with PML-associated muta-
tions have an altered capacity to engage sialic acid-containing re-
ceptors, as VLPs with PML-associated mutations bind to glial cells
in a neuraminidase-insensitive manner and bind to gangliosides
as measured by enzyme-linked immunosorbent assay (ELISA)
(50, 52). However, the role of these mutations in JCPyV infection
and spread in glial cells has not been addressed.
One hypothesis is that the mutations in VP1 sialic acid-binding
sites might render the virus more pathogenic in infected hosts by
allowing it to spread more readily to the brain due to reduced
nonspecific attachment to sialic acid pseudoreceptors. However, it
is also possible that viruses with PML-associated mutations are
defective particles produced due to high levels of viral replication
or that they are immune escape mutants. Thus, we questioned
whether these viruses represent the pathogenic form of the virus
that infects glial cells in the CNS. To this end, we utilized a
structure-function approach to define the role of these mutations
in JCPyV attachment to cellular receptors and infection of glial
cells by generating the PML-associated mutations in an infectious
viral clone, in pseudoviruses, and in purified VP1 pentamers using
the Mad-1 prototype PML strain as the backbone.
RESULTS
JC polyomaviruses with PML-associated mutations are not in-
fectious. Mutations in JCPyV VP1 arise in individuals with PML
at a very high frequency. In fact, 80 to 90% of viral isolates from
individuals with PML exhibit mutations in one or more of these
sites in VP1, and these mutations are never found in JCPyV iso-
lates from individuals without PML. Furthermore, these muta-
tions are found only in the blood and CSF, but not in the urine, of
individuals with PML, indicating that the mutations arise within
the host (50, 52–55). The most common PML-associated muta-
tions are L54F and S268F, accounting for approximately 50% of
PML-associated mutations, while the mutations S266F and S268Y
are less frequent but still common (Table 1) (50, 52). Surprisingly,
all four mutations target VP1 residues that form contacts with the
terminal sialic acid of the specific receptor motif LSTc (Fig. 1A)
(41). To define whether PML-associated VP1 mutations affected
JCPyV infectivity, we introduced the most common mutations
into the JCPyV infectious genomic clone with a Mad-1 VP1. Viral
DNA was transfected into the permissive glial SVG-A cell line and
analyzed for growth and spread over 22 days in culture. Infected
cells were analyzed by indirect immunofluorescence using an an-
tibody directed against the VP1 capsid protein. Throughout
22 days in culture, only the wild-type JCPyV with a Mad-1 VP1
was capable of growth and spread (Fig. 1B). On day 22, viral su-
pernatants were harvested from cells (in Fig. 1B) and used to infect
naive SVG-A cells. Wild-type JCPyV produced infectious viral
Maginnis et al.
2 ® mbio.asm.org May/June 2013 Volume 4 Issue 3 e00247-13
particles that were released into the supernatant, while viruses
with PML-associated mutations did not, indicating that the mu-
tant viruses could not propagate in glial cells (Fig. 1C).
VP1 pentamers with PML-associated mutations exhibit
abolished binding to glial cells. To determine whether the de-
creased levels of virus growth and infection in the PML-associated
mutants correlated with binding to cells, the mutations were in-
troduced into VP1 pentamers. The pentamers serve as a useful
tool for studies of JCPyV attachment, entry, and trafficking, as
they can bind to cells and traffic through the endosomal compart-
ment to the endoplasmic reticulum with kinetics similar to that of
virions (41, 56). Mutated VP1 pentamers were then purified and
used to assess binding to SVG-A cells by flow cytometry (Fig. 2).
JCPyV wild-type pentamers bind to SVG-A cells, while the VP1
pentamers with PML-associated mutations did not bind to cells,
indicating that residues in VP1 that mediate sialic acid binding to
the receptor motif LSTc are essential for VP1 engagement of
SVG-A cells.
VP1 pentamers with PML-associated mutations are not ca-
pable of binding to LSTc. To assess the structural effects of these
mutations, we solved crystal structures of three mutant VP1 pen-
tamers: L54F, S268F, and S268Y. In all cases, the crystal lattices are
identical to those of the wild-type JCPyV pentamers, with acces-
sible binding sites for LSTc in two of the five VP1 monomers in a
given pentamer. In order to analyze whether the mutants can still
engage LSTc, crystals of wild-type Mad-1 VP1 pentamers and the
L54F, S268F, and S268Y mutants were soaked in LSTc oligosac-
charide solution according to the exact procedure used for the
complex formation of wild-type VP1 (41), and structures were
determined to high resolution (see Table S1 in the supplemental
material). Crystal soaking experiments using 5 mM LSTc yielded
the JCPyV Mad-1 VP1-LSTc complex structure with two occu-
pied LSTc binding sites per VP1 pentamer (see Fig. S1B) but did
not result in additional electron density for carbohydrate moieties
in the case of any of the mutated VP1 pentamers. This demon-
strates that engagement of LSTc is severely compromised in all
three mutants.
We next investigated if any of the VP1 mutants are able to bind
LSTc at an increased concentration of 20 mM ligand and an ex-
tended soaking time of 2 h. While the L54F and S268Y mutants
still do not show any evidence for binding, weak interactions with
LSTc can be observed in the S268F mutant. The simulated an-
nealed omit electron density map for S268F clearly shows features
of the Neu5Ac-2,6-Gal-1,4-GlcNAc portion of LSTc in two
LSTc binding sites (see Fig. S1A in the supplemental material).
One of these trisaccharides could be built. The structural rear-
rangements in VP1 upon recognition of LSTc are similar to those
seen in the JCPyV Mad-1 VP1-LSTc complex, providing addi-
tional evidence for the presence of LSTc (41). N123 interacts via
hydrogen bonding with the terminal Neu5Ac and GlcNAc
N-acetyl group and is critical for the recognition of LSTc in the
L-shaped conformation (Fig. 3A). The N123 side chain is rear-
ranged in the S268F structure in order to accommodate the ter-
minal Neu5Ac (Fig. 3B). Consequently, residues 64 to 68 of the
clockwise BC2 loop move to prevent clashes with N123 in the new
position. Density for these induced-fit movements as well as par-
tially for the native conformation can be observed in the S268F
VP1-LSTc complex structures. These findings are consistent with
the occupancy of1.0 of the carbohydrate ligand within the final
complex structure. We conclude that the S268F mutant retains
some affinity for LSTc, whereas the other two mutants do not.
VP1 pentamers with PML-associated mutations clash with
LSTc. We next examined the effects of the three mutations L54F,
S268F, and S268Y on the VP1 structure. Residues L54, S266, and
S268 mediate direct contacts or are in close proximity to the ter-
minal Neu5Ac within the LSTc binding site of the wild-type
JCPyV VP1-LSTc complex (Protein Data Bank [PDB] accession
code 3NXD) (41) (Fig. 3). In order to compare the effects of the
mutations on the VP1 structure and its ligand binding properties,
the L54F, S268F, and S268Y VP1 structures were superposed onto
the JCPyV wild-type VP1-LSTc complex structure. In all three
VP1 mutant structures, well-defined electron density could be ob-
served for the respective mutated residue, confirming the presence
of the mutation.
Analysis of the S268F VP1 structure shows that the Neu5Ac
carboxyl group could still be recognized by S266 via a hydrogen
bond, but the hydrogen bond with the side chain of residue 268
within the HI loop would be lost. The side chain of F268 and the
2,6-linked Gal are 3.7 Å apart. Although this is a close contact, it
would still allow for engagement of LSTc without leading to severe
clashes. Consistent with this, interaction with LSTc was observed
with reduced affinity for S268F VP1 in the soaking experiment
with 20 mM LSTc (Fig. 3B). Based on B-factor analysis of the
bound LSTc and surrounding residues, we expect that the occu-
pancy of LSTc is about 0.6 to 0.8 in one accessible binding site
(chain C). The second binding site (chain B) has weaker electron
density for LSTc, indicating lower occupancy.
In the case of the L54F VP1 mutant structure, the phenyl side
chain of F54 points into the Neu5Ac binding pocket. With a dis-
tance of only 1.4 Å between the Neu5Ac moiety in the respective
location and the F54 side chain, LSTc binding would lead to severe
clashes (Fig. 3C). Finally, the S268Y VP1 structure shows that
introduction of the larger tyrosine side chain at position 268
would lead to a close contact of 2.9 Å between the Y268 hydroxyl
group and the 2,6-linked Gal. This steric interference likely
blocks recognition of the LSTc motif (Fig. 3D).
The S266F mutation also occurs frequently in PML patients.
We did not succeed in crystallizing the S266F VP1 pentamer, but
modeling suggests that replacement of S266 with a bulky phenyl-
alanine would abolish hydrogen bond formation with the Neu5Ac
carboxyl group. In addition, all allowed phenylalanine side chain
rotamer conformations would clash with the GlcNAc moiety of
TABLE 1 Frequency of JCPyV VP1 PML-associated mutations
Residuesa % frequency of VP1 mutations in PML patients Reference
L54F, K59N, D65H, N264T, S266F/L/T, S268F/Y/C 81 49
L54F, K59M/E/N, N264D/T, S266F/L, S268F/Y/C 52 50
L54F, K59E, D65H, N264D, S266F, S268F/Y, Q270H 90 52
L54F, S60P/T, D65H, N264S, S266F/L, S268F, Q270H 81 53
a Amino acid numbers are in accordance with the JCPyV Mad-1 strain (1), excluding the methionine at position 1.
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the long leg of the L-shaped LSTc motif. Therefore, binding of
LSTc is likely also abolished for S266F VP1. We therefore conclude
that the most frequently observed VP1 mutations in PML patients
directly alter contacts of VP1 with LSTc, with various effects on
binding ranging from substantially reduced interactions for the
S268F mutant to clashes for the L54F and S268Y (and likely also
the S266F) mutants.
JCPyV pseudoviruses with PML-associated mutations are
not infectious. The structural analyses demonstrate that JCPyV
pentamers expressing PML mutations are not capable of binding
to the functional receptor motif2,6-linked LSTc (Fig. 3), and the
functional data suggest that JCPyV PML mutants cannot bind to
or grow in SVG-A cells (Fig. 1 and 2). This led us to hypothesize
that JCPyV PML mutants may have low levels of binding and
growth that are not easily detected in our established culture
model of viral infection. While it is not possible to propagate vi-
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ruses with growth defects by standard methods, we have estab-
lished a JCPyV pseudovirus system to help determine the infectiv-
ity of mutant viruses. The pseudoviruses are generated by
transfecting the viral capsid proteins VP1, VP2, and VP3 into
HEK293FT cells together with a reporter plasmid that expresses
both green fluorescent protein (GFP) and a secreted form of lu-
ciferase (Gaussia luciferase). This assay is robust and provides a
sensitive method of detecting the infectivity of mutant viruses that
do not propagate under traditional culture methods. The PML-
associated mutations were introduced into the Mad-1 VP1 and
expressed in the pseudovirus system. Wild-type and mutant puri-
fied pseudoviruses were tested for infectivity in the human brain
cell types SVG-A (glial), SVG-R (glial variant resistant to JCPyV
infection), Poj19II (glial), and HFG-T (human fetal glial cells) or
the kidney cell line HEK293FT. Infectivity was measured at 72 h
postinfection by luciferase (Fig. 4). The JCPyV pseudoviruses with
PML-associated mutations were not infectious in any of the cell
types tested, including SVG-A cells, compared to the mock con-
trol and wild type (Mad-1) (Fig. 4). SVG-R cells are a variant of
SVG cells that are resistant to JCPyV infection despite levels of
virus binding equivalent to those of SVG-A cells (57). Thus, the
SVG-R cells serve as a useful control to demonstrate the level of
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background luciferase readings in this assay. Furthermore, the cell
lines used had variable levels of 5-HT2AR expression (data not
shown), indicating that the presence of 5-HT2AR does not influ-
ence infection of viruses with PML-associated mutations. These
data confirm that LSTc is a critical receptor motif for JCPyV in-
fection and suggest that 5-HT2AR is mediating a postattachment
step in the virus life cycle. However, the expression of T antigen
does influence infection by pseudoviruses, as the expression plas-
mid contains a simian virus 40 (SV40) origin of replication.
Therefore, HEK293FT cells which have high levels of T antigen
expression are readily infected by the pseudovirus, although kid-
ney cells are generally less susceptible to JCPyV infection in the
absence of T antigen in traditional culture models of JCPyV infec-
tion (48).
JCPyV pseudoviruses with PML-associated mutations do
nothemagglutinatehumanRBCs.The viruses and pseudoviruses
with PML-associated mutations were not infectious in a number
of cell lines tested. Further, purified pentamers do not bind to
SVG-A cells and have significantly reduced binding to LSTc as
analyzed by X-ray crystallography. In order to determine if the
PML-mutant pseudoviruses were capable of binding to other
sialic acid receptors, a hemagglutination assay was performed.
Wild-type JCPyV hemagglutinates human type O red blood cells
(RBCs) (42). Wild-type and PML-associated mutant JCPyV pseu-
doviruses of equal pseudovirus particle concentrations were tested
for the ability to agglutinate RBCs (Fig. 5). The PML mutant pseu-
doviruses were not capable of hemagglutination of red blood cells,
while the wild-type JCPyV pseudovirus resulted in agglutination
at a titer of 3.1 106 pseudovirus particles. These data suggest that
the viruses isolated from individuals with PML which have muta-
tions in VP1 that are critical for binding to LSTc no longer bind to
sialic acid.
DISCUSSION
Mutations in the JCPyV capsid protein VP1 frequently arise in
patients with PML. In this study, we examined the effect of three
frequently occurring mutations on key properties of the virus,
including growth, infectivity, capsid protein structure, and recep-
tor binding. We find that all mutations severely compromise the
interaction of the virus with its cognate receptor motif, the sialy-
lated LSTc glycan, due to steric interference. As a result, the mu-
tant viruses no longer hemagglutinate, and they no longer grow or
infect glial cells. Taken together, these data suggest that although
these viruses with PML-associated mutations are frequently found
in individuals with PML (52, 53), they are likely not infectious in
glial cells in the CNS due to reduced sialic acid binding.
Although viral isolates with VP1 mutations arise in individuals
with PML, it has not been demonstrated whether viruses with
PML-associated mutations are pathogenic in cells of the CNS.
Individuals with PML who develop viruses with PML-associated
mutations have higher levels of viral DNA in the CSF (52), yet it is
unclear if these viruses are actually capable of increased spread to
the brain or increased replication once they have reached the
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brain. Furthermore, these viruses have not been isolated from
JCPyV-infected cells of the brains of individuals with PML but
rather from the CSF. Given the avid interaction between JCPyV
and cell surface sialic acid, it is possible that the JCPyV isolates
with PML-associated mutations are found at a high frequency in
the CSF due to their loss of sialic acid binding. The wild-type
JCPyV, which retains the ability to bind to sialic acid, might re-
main cell associated, leading to lower levels of the wild-type virus
in the CSF (50, 52). Also, it is possible that PML-associated muta-
tions arise in the viral capsid as a mechanism of immune escape.
JCPyV establishes a persistent infection in the kidney of healthy
individuals with no significant complications, suggesting that the
virus is under immune surveillance. To spread hematogenously to
the CNS, the virus may undergo mutations in the viral capsid,
making these mutant viruses antigenically distinct and capable of
evading the host immune responses, resulting in increased spread.
VP1 is the most abundant capsid protein of the virus, and in-
creased antigenicity in the receptor-binding region may allow the
pathogenic forms of the virus to spread to the CNS, while the
immune system attacks the mutant viruses. Alternatively, muta-
tions in VP1 may arise in the CNS of infected individuals as a
mechanism of immune escape, resulting in increased spread and
infection of glial cells. Thus, it remains to be demonstrated if the
viruses with PML-associated mutations are pathogenic in the
brain. Our data demonstrate that JCPyV with PML-associated
mutations are not infectious in a panel of glial cell lines.
However, we also cannot exclude the hypothesis that JCPyVs
with PML-associated mutations are infectious in the brains of
individuals with PML. It is plausible that the loss of sialic acid
binding through mutation of specific residues in the viral capsid
may be necessary for increased spread to the brain and subsequent
infection of glial cells in a sialic acid-independent manner (58, 59).
It is reasonable to speculate that reduced binding to sialic acid
receptors in the periphery leads to increased spread of JCPyV to
the brain, as JCPyV binding to both red blood cells and B lympho-
cytes is mediated via interactions with sialic acid (Fig. 5) (47). This
hypothesis is similar to the scenario demonstrated for mouse
polyomavirus (MPyV) in which a mutation in the VP1 sialic acid-
binding pocket in a position orthologous to position S268 of
JCPyV leads to decreased MPyV binding to RBCs and increases
viral dissemination and pathogenicity of the virus, resulting in a
lethal outcome (58–61). JCPyV with PML-associated mutations
might then engage a non-sialic acid receptor on glial cells in the
CNS. It is also possible that the host cell factor necessary for infec-
tion by JCPyV with PML-associated mutations is not expressed
abundantly on the cell lines that we tested. The crystal structure of
JCPyV VP1 revealed a groove on the surface of the pentameric
capsid protein that is unique among all polyomaviruses crystal-
lized to date (41, 62, 63). This groove could well be involved in the
engagement of JCPyV with other receptor structures on the sur-
face of host cells, and such an interaction might be favored if
binding to LSTc is significantly reduced or blocked. There are
many differences between the in vitro infection model and a nat-
ural in vivo infection that we cannot fully account for in our cur-
rent tissue culture model of JCPyV infection. JCPyV infects ap-
proximately 50% of the population but rarely causes PML and
does so only in those who are immunocompromised by HIV in-
fection, AIDS, or immunomodulatory therapies. Therefore, the
development of PML must be multifactorial and involve host-
specific factors that are influenced in the disease states of HIV
infection or immune-mediated diseases such as MS. For instance,
the breakdown of the blood-brain barrier and/or use of antiretro-
viral therapies or natalizumab therapy may cause the upregulation
of alternate receptors or host cell factors that allow JCPyV to effi-
ciently attach and enter into glial cells in the CNS. Thus, the tissue
culture model of infection may not accurately demonstrate the
disease pathogenesis in vivo.
Gorelik and colleagues previously demonstrated that VLPs
with PML-associated mutations in the genetic background of the
JCPyV genotype 3 have reduced binding to kidney cells, red blood
cells, and lymphocytic cells but retain the ability to bind to the glial
cells SVG-A cells and astrocytes. Additionally, they demonstrated
that introduction of these mutations into a VLP leads to altered
receptor usage, consistent with an enhanced affinity for ganglio-
sides, including GM1, GM2, and GD3. However, the JCPyV type 3
VLP binds to asialo-GM1, GD1a, GD1b, GD2, and GT1b (52) and
has been reported to bind to GM1 and GM2 (Leonid Gorelik,
Consortium for Functional Glycomics [CFG], available online at
http://www.functionalglycomics.org, according to CFG policy).
This affinity of JCPyV type 3 for gangliosides may have influenced
the results of the PML-associated mutations in the type 3 VLPs.
Additionally, VLPs of JCPyV have been demonstrated to bind to a
panel of gangliosides in viral overlay assays, suggesting that VLPs
may nonspecifically engage sialic acid-containing gangliosides,
particularly those with 2,6-linkages (64). There are 7 known se-
rotypes of JCPyV and 13 distinct geographic subtypes that have
been determined (65). JCPyV isolates from genotypes 1 and 2 are
more frequently isolated from individuals than are other geno-
types, including type 3 (53, 54). In fact, type 3 strains are not
commonly isolated from the CSF of PML patients (50). We ana-
lyzed the effect of PML-associated mutations in the Mad-1 proto-
type strain, the prototype PML-type strain for genotype 1, for
which the receptors have been identified (41, 44). Additionally,
the amino acid sequences of VP1 of genotypes 1 and 3 differ in up
to eight residues (depending on the strain), and some of the mu-
tations are located close to the LSTc binding site. We previously
demonstrated that Mad-1 VP1 pentamers do not bind to any gan-
glioside structures in a glycan array screen (41), and we have not
been able to demonstrate that expression of gangliosides influ-
ences infection of JCPyV Mad-1 in glial cells (Atwood laboratory,
unpublished results). Thus, strain-specific differences in receptor
engagement could have influenced the results of the study pub-
lished by Gorelik et al. (52) when the JCPyV type 3 strain was
utilized to study the PML-associated mutations.
Structural analysis of Mad-1 and mutant VP1 pentamers re-
veals that steric hindrance introduced by PML-associated muta-
tions such as L54F or S268Y abolishes engagement of LSTc, and
these mutations would also block binding to other sialylated gly-
can motifs, independent of their location on gangliosides or gly-
coproteins or their linkage. Although some mutations, such as
S268F, lead to only minor clashes, these mutations would never-
theless drastically reduce the affinity of VP1 for LSTc due to re-
duced contacts and some steric interference. Consequently, such
interactions would likely not be functional for LSTc or any other
sialylated glycan whether they are in the genotype 1 or genotype 3
background.
Genotype 3 strains differ from Mad-1 in up to eight amino acid
positions. Five of these positions are included in our VP1 pen-
tamer construct (R74, S116, G133, L157, and K163). Residues
S116 and G133 are located near the LSTc binding pocket but do
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not make direct contacts with LSTc, while R74, L157, and K163 are
found outside the binding pocket. Additionally, V320, E331, and
K344 are found at the C terminus of the full-length VP1 protein
and far from the glycan receptor-binding site. Nevertheless,
amino acid differences in Mad-1 and genotype 3 that are near the
LSTc binding pocket would not change the drastic impact of the
mutation L54F or S268F/Y and likely S266F on the interaction
with sialylated glycan motifs, as these mutations are located di-
rectly in the binding pocket.
Interestingly, engagement of LSTc is likely preserved, perhaps
with only moderate decreases in affinity, for less frequently occur-
ring mutations. Reported PML-associated mutations K59M/E/N,
S60T, and D65H, which were not addressed in our study, are un-
likely to lead to structural changes and would still allow similar
contacts with LSTc. In the case of Q270H and N264D/S/T, the
hydrogen-bonding network in the Neu5Ac binding pocket would
be altered and, thus, these mutations would likely result in an
overall reduced affinity for sialylated motifs.
These findings highlight the importance of LSTc as a functional
receptor motif. Additionally, we demonstrated that viral isolates
with PML-associated mutations have reduced binding to LSTc
and other sialic acid motifs, and this reduced binding renders
these viruses noninfectious in both kidney and glial cells. Taken
together, this work illustrates that engagement of cell surface re-
ceptors is an important determinant of tissue tropism and viral
pathogenesis for JCPyV infection.
MATERIALS AND METHODS
Cells, viruses, and antibodies. SVG-A cells are a subclone of the human
glial cell line SVG transformed with an origin-defective SV40 mutant (66)
and were grown in minimum essential medium (MEM) supplemented to
contain 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin
(P/S) (Mediatech, Inc.) in a humidified incubator at 37°C. SVG-R cells are
resistant to JCPyV infection (57) and were grown in MEM supplemented
to contain 10% FBS. HEK293FT cells are derived from human embryonal
kidney cells transformed with the SV40 large T antigen (Invitrogen Life
Technologies) and were grown in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented to contain 10% FBS, 0.1 mM nonessential amino
acids (NEAA), 6 mM L-glutamine, 1 mM sodium pyruvate, and
500 mg/ml Geneticin. HFG-T cells are human fetal glial cells transformed
with an origin-defective SV40 T antigen (67) grown in modified Ea-
gle’s medium supplemented to contain 10% FBS. Poj19II cells are human
fetal glial cells transformed with a replication-defective JCPyV (68) grown
in DMEM supplemented to contain 10% FBS. Generation and propaga-
tion of the virus strain Mad-1/SVE were previously described (69).
JCPyV infection in SVG-A cells was assessed using PAB597, a hybridoma
supernatant that produces a monoclonal antibody against JCPyV VP1
(70) and was generously provided by Ed Harlow. Penta-His Alexa Fluor
488 was used at 20 g/ml (Qiagen).
Viral growth assay. VP1 mutations were generated in the genomic
JCPyV DNA of strain JC12 with a Mad-1 VP1 (68) and subcloned into
pUC19 (43). Mutations were introduced by site-directed mutagenesis us-
ing an Agilent QuikChange II site-directed mutagenesis kit (Qiagen) ac-
cording to the manufacturer’s instructions. Sequencing was performed at
Genewiz Inc. Primers used for mutagenesis were as follows (with mis-
matched nucleotides shown in boldface), 5=¡3=: L54F, GGTGACCCAG
ATGAGCATTTTAGGGGTTTTAGTAAGT and ACTTACTAAAACCC
CTAAAATGCTCATCTGGGTCACC; S266F, TGTGGCATGTTTACAA
ACAGGTTTGGTTCCCAGCAG and CTGCTGGGAACCAAACCTGTT
TGTAAACATGCCACA; S268F, TTTACAAACAGGTCTGGTTTCCAG
CAGTGGAGAGG and CCTCTCCACTGCTGGAAACCAGACCTGTTT
GTAAA; S268Y, GTTTACAAACAGGTCTGGTTATCAGCAGTGGAGA
GGACTC and GAGTCCTCTCCACTGCTGATAACCAGACCTGTTTG
TAAAC.
Ten micrograms of purified plasmid DNA was digested with BamHI
(Promega) at 37°C for 2 h to separate the JCPyV genomic DNA from the
pUC19 backbone plasmid. Digests were performed in triplicate for each
sample and verified by agarose gel electrophoresis. SVG-A cells were
plated to 40% confluence in 24-well plates (Corning). Cells in medium
without antibiotics were transfected with 1 g of digested DNA using
Fugene (Promega) at a 3:2 ratio (Fugene to DNA). Transfected cells were
incubated at 37°C overnight (O/N), and medium containing 5% FBS and
2% P/S was added to cells the next day. Cells were incubated at 37°C and
fed with 500 ml of medium containing 5% FBS, 1% P/S, and 1% ampho-
tericin B (Mediatech) or fixed for immunofluorescence staining at day 4
and at 3-day intervals thereafter for 22 days. For the infectivity assay,
supernatants were collected from the samples of the growth assay at
22 days posttransfection. SVG-A cells at 70% confluence in 24-well plates
(Corning) were infected with 150 l of virus supernatant at 37°C for 1 h;
then 1 ml of medium containing 5% FBS, 1% P/S, and 1% amphotericin
B was added to cells; and cells were incubated at 37°C for 72 h. Cells were
fixed and stained by indirect immunofluorescence.
Indirect immunofluorescence. Cells were washed in phosphate-
buffered saline (PBS), fixed in cold methanol (MeOH), and incubated at
20°C. Fixed cells were washed in PBS, permeabilized with 0.5% Triton
X-100 (TX-100; USB Corporation) at room temperature (RT) for 5 min,
incubated with VP1-specific antibody PAB597 (1:10) in PBS at 37°C for
1 h, washed with PBS, incubated with a goat anti-mouse Alexa Fluor 488
(1:1,000)-conjugated antibody in PBS at 37°C for 1 h, and then washed
with PBS. Cells were analyzed for nuclear VP1 staining under a 20 ob-
jective using an Eclipse TE2000-U microscope (Nikon).
JCPyV pseudovirus production. Codon optimization of the JCPyV
VP1, VP2, and VP3 genes was performed according to the National Can-
cer Institute Center for Cancer Research Lab of Cellular Oncology Tech-
nical Files (http://home.ccr.cancer.gov/LCO/production.asp) to achieve
optimal expression in the human-derived cell line 293FT. Genes were
synthesized by Blue Heron Biotech, LLC. The VP1 gene was subcloned
into the pwP vector in place of the murine polyomavirus (MPyV) VP1
gene. The JCPyV VP2 and VP3 genes were subcloned into the ph2p vec-
tors in place of the MPyV genes (71). The luciferase reporter vector phG-
luc (72) expresses a secreted form of Gaussia luciferase under the control
of the EF1 promoter. All plasmids were obtained from AddGene. Site-
specific mutations were made using the Agilent QuikChange II site-
directed mutagenesis kit prior to subcloning. Primers for generating
PML-associated mutations in VP1 (5=¡3=) were as follows, with mis-
matched nucleotides shown in boldface: L54F, TGGGCGACCCCGATG
AACATTTTCGCGGATTC and GAATCCGCGAAAATGTTCATCGGG
GTCGCCCA; S266F, GGCATGTTCACAAATCGCTTTGGCTCACAGC
AGTGGAGA and CTCCACTGCTGTGAGCCAAAGCGATTTGTGAAC
ATGCC; S268F, CACAAATCGCAGTGGCTTTCAGCAGTGGAGGG
GATT and AATCCCCTCCACTGCTGAAAGCCACTGCGATTTGTG;
S268Y, CACAAATCGCAGTGGCTACCAGCAGTGGAGGGGATT and
AATCCCCTCCACTGCTGGTAGCCACTGCGATTTGTG.
Pseudoviruses were produced by transfection of the VP1, VP2, VP3,
and phGluc plasmids into 293FT cells using Fugene 6 transfection reagent
(Promega) in a 5:1:1:1 ratio. Mock pseudovirus controls were generated
by transfecting HEK293FT cells with control plasmid and the phGluc
reporter plasmid in a 7:1 ratio. Cells were harvested 48 h posttransfection
by scraping and then pelleted and resuspended in buffer A (10 mM Tris,
pH 8, 50 mM NaCl, 0.1 mM CaCl2, 0.01% TX-100) with EDTA-free
protease inhibitors (Roche Applied Science). Cells were lysed by three
rounds of freezing and thawing, sonicated, and treated with 0.25% deoxy-
cholic acid at 37°C for 30 min. The pH was lowered to 6.0, and the lysates
were treated with type V neuraminidase (Sigma) at 37°C for 1 h. The pH
was then raised to 7.5, CaCl2 was added, and the lysate was treated with
DNase I (New England Biolabs). Pseudoviruses were then purified
through an iodixanol gradient by centrifugation at 234,000  g in an
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SW55 Ti rotor (Beckman) at 16°C for 3.5 h. The band containing pseu-
dovirus or corresponding control was extracted by syringe.
To determine the titers of pseudoviruses for properly encapsidated
genomes, they were again treated with DNase I and protected phGluc was
extracted using the DNeasy blood and tissue kit (Qiagen). The titer of the
packaged genome was determined using absolute quantification and Taq-
Man quantitative PCR (qPCR; Applied Biosystems) to create a standard
curve using serial dilutions of phGluc. The number of copies for the
known plasmid was plotted in a scatter plot against the threshold cycle
(CT) value determined for each dilution. A best-fit line was generated, and
the trend line equation from regression analysis was used to calculate the
relationship between the CT value of the unknown input template and
copies of the packaged pseudovirus plasmid. We determined the volume
of pseudovirus particles based on the encapsidated genomes to equal 107
viral particles/ml and diluted each sample to use equivalent amounts of
pseudovirus to perform experiments.
Pseudovirus luciferase infectivity assay.Cells were plated in a 96-well
plate to 70% confluency and infected with equal particle equivalents (1
107 particles/ml) of wild-type and mutant pseudovirus in incomplete me-
dium without phenol red, adjusted for equal volume equivalents with the
purification reagent Optiprep (33%). Infected cells were incubated at
37°C for 1 h and washed with PBS, complete medium without phenol red
was added, and cells were incubated at 37°C for 72 h. Secreted luciferase
was quantitated in 20 to 50 l of cellular supernatants using the BioLux
Gaussia luciferase assay (New England Biolabs) according to the manu-
facturer’s instructions using an opaque 96-well microplate in a GloMax
Multi-Detection System luminometer (Promega) equipped with an auto-
injector. Numbers of infected cells were also measured by quantifying
GFP-positive cells by fluorescence microscopy using an Eclipse TE2000-U
microscope (Nikon).
Generation of pentamers. cDNA coding for amino acids 22 to 289 of
the Mad-1 strain of JCPyV VP1 (UniProtKB entry code P03089) was
cloned into the pET15b expression vector (EMD Millipore) in frame with
an N-terminal hexahistidine tag (His tag) and a thrombin cleavage site as
described previously (41). Mutations were introduced by site-directed
mutagenesis with the Agilent QuikChange mutagenesis kit according to
the manufacturer’s instructions using primers listed for generation of
mutant viruses for viral growth assay. Sequences were verified by Ge-
newiz. VP1 pentamers were purified as described previously (56). Protein
concentrations were determined using a NanoDrop 2000c spectropho-
tometer (Thermo Fisher Scientific), and pentamers were concentrated to
~1 mg/ml.
Crystallization. JCPyV VP1 pentamers carrying mutation L54F,
S268F, or S268Y were concentrated to 4.5 mg/ml in 20 mM HEPES
(pH 7.5), 150 mM NaCl and crystallized at 20°C using the sitting drop
vapor diffusion technique and 100 mM HEPES (pH 7.5), 200 mM KSCN,
12% (wt/vol) polyethylene glycol 3350 (PEG 3350) as the reservoir solu-
tion. Drops were set up by mixing the protein solution 1:1 with the reser-
voir solution and cross-seeded by adding 0.2l of a microseeding solution
obtained from previous JCPyV VP1 crystals. In order to test for interac-
tion with LSTc oligosaccharide, crystals were soaked in the reservoir so-
lution complemented with 5 mM LSTc (Dextra, United Kingdom) for
3 min or with 20 mM LSTc for 2 h. Subsequently, crystals were transferred
for 2 s into a harvesting solution supplemented with 30% (vol/vol) glyc-
erol and 5 mM or 20 mM LSTc, respectively, and then flash-frozen in
liquid nitrogen.
Data collection and structure determination. Data sets were col-
lected at beamline X06DA at SLS (Villigen, Switzerland). Diffraction data
were processed with XDS (73), and structures were solved by molecular
replacement with Phaser in CCP4 (74, 75). The native JCPyV Mad-1 VP1
structure (PDB accession number 3NXG) lacking solvent molecules was
used as the search model. Rigid body and simulated annealing refinement
was carried out with Phenix (76) in order to remove model bias. Crystals
of L54F, S268F, and S268Y mutant pentamers have the same space group,
and similar unit cell parameters, as do wild-type JCPyV Mad-1 VP1 pen-
tamers, with a single VP1 pentamer forming the asymmetric unit in each
case. Mutations were introduced into the respective models, and water
molecules were added (excluding the LSTc binding site) using Coot (77).
Alternating rounds of model building in Coot and restrained refinement,
including 5-fold NCS restraints and the translation-libration-screw (TLS)
method (78), were performed with Refmac5 (79). In order to test for the
presence of LSTc, simulated annealing Fobs-Fcalc electron density maps in
the putative LSTc binding site of the mutated VP1 pentamers soaked with
LSTc were compared to the respective omit map of the Mad-1 VP1-LSTc
complex. In the case of S268F VP1, which showed some electron density
for LSTc, the ligand was built and refined using the CCP4 suite library and
user-defined restraints for the 2,6-glycosidic bond. Structure figures
were prepared with PyMOL (PyMOL Molecular Graphics System, version
1.3; Schrödinger, LLC).
Flow cytometry. Purified wild-type and mutant JCPyV VP1 pentam-
ers (100 g/ml) in a 100-l total volume of PBS were incubated with
SVG-A cells in suspension on ice for 2 h with occasional agitation. Cells
were washed, pelleted by centrifugation, and suspended in 75l of penta-
His Alexa Fluor 488 antibody (Qiagen) (20 g/ml) in PBS on ice for 1 h.
Cells were washed, pelleted, resuspended in PBS, and analyzed for pen-
tamer binding using a BD FACSCalibur (Becton, Dickinson and Com-
pany) flow cytometer equipped with a 488-nm excitation line. Data were
analyzed using BD CellQuestPro (Becton, Dickinson and Company) and
FlowJo software (Tree Star, Inc.).
Hemagglutination assay with JC pseudoviruses. Serial 2-fold dilu-
tions of 1  107 particles of wild-type or mutant JC pseudoviruses in a
volume of 99 l were prepared in PBS in a U-bottomed 96-well plate
(Corning) (dilution range, 1:2 to 1:4,096). A volume equivalent (99l) of
1 PBS was used as a negative control. Human type O negative red blood
cells (RBCs) that had been washed with Alsever’s buffer (0.1 M D-glucose,
0.027 M sodium citrate, 0.07 M NaCl, pH 6.5) were added to each well at
a volume equivalent of 99 l, and plates were gently agitated. Plates were
incubated at 4°C for 4 h and imaged using a ChemiDoc XRS imager
(Bio-Rad).
Protein structure accession numbers.Coordinates and structure fac-
tor amplitudes have been deposited with the RCSB Protein Data Bank
(http://www.pdb.org) under accession codes 4JCE (L54F), 4JCF (S268F),
and 4JCD (S268Y) of the structures obtained after crystal soaking in har-
vesting solution supplemented with 20 mM LSTc.
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The human JC polyomavirus (JCV) causes a fatal
demyelinating disease, progressive multifocal leu-
koencephalopathy (PML), in immunocompromised
individuals. Current treatment options for PML are
inadequate. Sialylated oligosaccharides and the
serotonin receptor are known to be necessary for
JCV entry, but the molecular interactions underlying
JCV attachment remain unknown. Using glycan array
screening and viral infectivity assays, we identify a
linear sialylated pentasaccharide with the sequence
NeuNAc-a2,6-Gal-b1,4-GlcNAc-b1,3-Gal-b1,4-Glc
(LSTc) present on host glycoproteins and glycolipids
as a specific JCV recognitionmotif. The crystal struc-
ture of the JCV capsid protein VP1 was solved alone
and in complex with LSTc. It reveals extensive inter-
actions with the terminal sialic acid of the LSTc motif
and specific recognition of an extended conforma-
tion of LSTc. Mutations in the JCV oligosaccharide-
binding sites abolish cell attachment, viral spread,
and infectivity, further validating the importance of
this interaction. Our findings provide a powerful plat-
form for the development of antiviral compounds.
INTRODUCTION
The human JC polyomavirus (JCV) is a member of the Polyoma-
viridae family, which also includes simian virus 40 (SV40), murine
polyomavirus (Polyoma), and the human BK virus (BKV). JCV is
a significant human pathogen for which approximately 50%–
80% of individuals are seropositive (Kean et al., 2009; Knowles
et al., 2003). JCV establishes a persistent, mostly asymptomatic
infection in the kidney (Dorries, 1998). However, the virus can
become reactivated in immunosuppressed hosts, leading to
enhanced viral replication and infection of glial cells, including
astrocytes and the myelin-producing oligodendrocytes, in the
central nervous system (CNS). JCV infection leads to cytolyticCell Hosdestruction of oligodendroglia and causes the fatal disease
progressive multifocal leukoencephalopathy (PML) (Khalili and
White, 2006; Seth et al., 2003; Silverman and Rubinstein, 1965;
Zurhein and Chou, 1965). PML is commonly associated with
human immunodeficiency virus (HIV) and acquired immunodefi-
ciency syndrome (AIDS) (Cinque et al., 2009). However, the
incidence of PML has increased recently in patients receiving
immunosuppressive therapies for autoimmune diseases (Carson
et al., 2009b; Major, 2009; Van Assche et al., 2005). The prog-
nosis of PML is bleak, as it usually proves fatal within 1 year of
symptom onset. Currently there are few treatments for PML
(Kishida, 2007).
JCV has a nonenveloped, icosahedral capsid that encloses
a circular double-stranded DNA genome (Shah et al., 1996).
Themajor component of the capsid is viral protein 1 (VP1). Struc-
tural studies of SV40 and Polyoma virions revealed that polyo-
mavirus capsids consist of 72 VP1 pentamers that are linked
via C-terminal extensions of VP1 (Liddington et al., 1991; Stehle
et al., 1994). VP1 attaches to receptors on host cells and thereby
initiates infection. In crystal structures of Polyoma and SV40
receptor complexes, the receptor binding site is formed by
VP1 loops at the outer surface of the capsid (Neu et al., 2008;
Stehle et al., 1994). JCV is internalized into cells via clathrin-
dependent endocytosis (Pho et al., 2000) and traffics through
endosomes and caveosomes (Querbes et al., 2006) to the
endoplasmic reticulum (ER). Viral uncoating is thought to begin
in the ER, followed by translocation to the cytosol and transport
of the genome to the nucleus for viral replication. Previous
studies have shown that sialylated oligosaccharides (Dugan
et al., 2008; Komagome et al., 2002; Liu et al., 1998b) and the
serotonin receptor 5-HT2AR (Elphick et al., 2004) are necessary
for JCV entry. The predominant sialic acid in humans is a-5-N-
acetyl neuraminic acid (NeuNAc), which caps many different
oligosaccharide structures (Varki, 2001).
In this study, we demonstrate that JCV binds specifically to the
oligosaccharide lactoseries tetrasaccharide c (LSTc), which
contains an a2,6-linked NeuNAc, using a glycan array screen.
The relevance of LSTc as a functional receptor for JCV is
confirmed through infectivity assays. We determined the crystal
structure of JCV VP1 in complex with LSTc, and based on the
structural analysis performed mutagenesis experiments thatt & Microbe 8, 309–319, October 21, 2010 ª2010 Elsevier Inc. 309
Figure 1. LSTc Is a Functional, Specific Receptor Motif for JCV
(A) Glycan microarray analysis of JCV VP1 showing highly selective binding to LSTc. Numerical scores for the binding intensity are shown as means of fluores-
cence intensities of duplicate spots at 2 (in blue) and 5 (in red) fmol/spot. Error bars represent half of the difference between the two values.
(B) Structures of selected glycans present on the glycan microarray. The oligosaccharide sequence of the LSTc probe is shown, as well as those of similar
compounds that were not bound.
(C) LSTc inhibits JCV Infection. JC virus was preincubated with LSTb or LSTc, and complexes were added to SVG-A cells for infection. Infected cells were quan-
tified based on nuclear VP1 staining. The data represent the average number of infected cells per visual field for eight fields of view from an experiment performed
in triplicate. Error bars indicate SD of triplicate samples. *p < 0.05.
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JCV Attachment to Its Glycan Receptor Motif LSTcprobe the specificity of JCVbinding to LSTc. Thesestudies estab-
lish the mechanism of JCV cell attachment and provide a founda-
tion for strategies to intervene in the attachment process.
RESULTS
JCV Specifically Engages the Oligosaccharide LSTc
Whereas it is clearly established that JCV infection depends on
interaction between VP1 and sialic acid, the nature of the oligo-
saccharide receptor has remained elusive. To approach this
problem, we expressed recombinant JCV VP1 pentamers
(Neu et al., 2008; Stehle and Harrison, 1997). The purified pen-
tamers were analyzed on glycan microarrays containing 81
lipid-linked sialylated oligosaccharides differing in the sialyl
linkage, backbone sequences, chain lengths, and branching
patterns. The microarrays represented carbohydrates found on
N- and O-linked glycoproteins as well as glycolipids (see Table
S1 available online). JCV VP1 bound specifically to a2,6-linked
LSTc (Figure 1A). LSTc is a linear pentasaccharide with the
sequence NeuNAc-a2,6-Gal-b1,4-GlcNAc-b1,3-Gal-b1,4-Glc.
This sequence represents the type that occurs in the peripheral
region of glycans of glycoproteins and glycolipids. The glycan
array contained several sequences that closely resembled
LSTc, but VP1 did not bind to these (Figures 1A and 1B).310 Cell Host & Microbe 8, 309–319, October 21, 2010 ª2010 ElsevieTo determine whether JCV engages LSTc to mediate infection
of host cells, JCV was preincubated with LSTc, and the mixture
was added to SVG-A cells, a glial cell line permissive for JCV.
The JCV/LSTc mixture significantly reduced JCV infection, while
incubation with JCV/LSTb had no effect on infection (Figure 1C).
LSTb is identical to LSTc in molecular weight and composition
but features a branching a2,6-linked sialic acid (Figure 1B).
Thus, the specific engagement of an LSTc-like sequence on
host cells is critical for JCV infection.
Overall Structure of the JCV VP1-LSTc Complex
We solved the crystal structure of a JCV VP1 pentamer in
complex with LSTc at 2.0 A˚ resolution (Figure 2A, Table 1). The
final structure contains amino acids 25–85 and 100–287 for all
five VP1 chains. Each VP1 monomer adopts the antiparallel
b sandwich fold iconic for viral capsid proteins. Two four-
stranded b sheets pack against each other. Their strands are
linked by loops in a way that gives rise to a jelly roll topology,
with the two b sheets consisting of strands B, I, D, G and C, H,
E, F, respectively.
LSTc binds on top of the JCV VP1 pentamer, on the outer
surface of the virion (Figures 2A and 2B). Two of the five possible
binding sites on VP1 contain LSTc, the other three are occluded
by crystal contacts. In the context of cell attachment by an entirer Inc.
Figure 2. Structure of JCV VP1 in Complex
with LSTc
(A) Structure of the JCV VP1 pentamer in complex
with LSTc. The protein is shown in cartoon repre-
sentation, with one VP1 monomer highlighted in
pink and the other monomers depicted in gray.
The LSTc oligosaccharide is drawn as a stick
model and colored according to atom type (nitro-
gens in blue, oxygens in red, and carbons in
orange).
(B) Close-up view of the LSTc binding site. JCV
VP1 and LSTc are drawn as in (A). A composite an-
nealed omit difference density map of LSTc is
shown contoured at 3.0 s for 2.0 A˚ around LSTc.
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JCV Attachment to Its Glycan Receptor Motif LSTcvirion, however, all five binding sites on a given pentamer could
be occupied by LSTc, which is not unlikely, given the relatively
low affinity of a single protein-carbohydrate interaction. The
binding site is formed by residues from the BC, DE, and HI loops
from one monomer as well as the BC loop from its clockwise
neighbor (Figure 2B). These loops also engage receptors in
SV40 and Polyoma VP1, and they are the only parts of VP1
that differ significantly among the three viruses (Neu et al.,
2008; Stehle and Harrison, 1997). The extensive BC loop can
be subdivided into two parts facing in different directions (BC1
and BC2). LSTc binds where the BC1 loop of one monomerTable 1. Crystallographic Statistics of JCV VP1 and JCV VP1-
LSTc Structures
JCV VP1-LSTc Complex JCV VP1
Data Collection
Unit cell (A˚) 149.7, 96.3, 128.2 149.6, 96.0, 128.6
Unit cell () 90, 110.3, 90 90, 110.4, 90
Space group C2 C2
Resolution (A˚) 35–2.0 2.05 –2.00 20–1.95 2.00–1.95
Total reflections 437,707 30,603 419,669 15,867
Unique reflections 114,938 8,302 119,853 8,429
I/sI 9.6 2.7 10.9 2.5
Rmerge (%) 11.7 48.3 9.3 32.4
Completeness (%) 99.5 97.5 96.5 91.7
Structure Refinement
Protein atoms 10,200 10,135
Average B factor (A˚2) 16.6 15.7
Carbohydrate atoms 136 -
Average B factor (A˚2) 24.3 -
Solvent atoms 980 1,054
Average B factor (A˚2) 25.4 26.4
Rwork (%) 18.9 18.0
Rfree (%) 21.2 20.8
Rmsd bond
lengths [A˚]
0.006 0.007
Rmsd bond
angles ()
0.9 1.0
Cell Hosapproaches the tip of the BC2 loop of its clockwise neighbor,
and it interacts with both. For reasons of clarity, residues and
loops of the main binding VP1 monomer will not be specifically
labeled, while those of its clockwise and counterclockwise
neighbors will be designated cw and ccw, respectively, herein.Interactions of JCV VP1 with LSTc
The bound LSTc molecule resembles the letter ‘‘L,’’ with the
shorter leg formed by NeuNAc and its a2,6-linkage to Gal, and
the longer leg consisting of the GlcNAc-b1,3-Gal-b1,4-Glc
trisaccharide (Figure 2B). In solution, the glycosidic bonds of
LSTc can rotate freely due to its unbranched sequence, and
the molecule can assume different conformations (Breg et al.,
1989). However, as the NeuNAc and GlcNAc moieties of LSTc
are attached to positions 6 and 1 of the same Gal residue, all
conformations feature a kink. JCV VP1 interacts selectively
with one of these conformations, contacting sugar moieties in
both legs of the L-shaped ligand. The observed conformation
of LSTc as well as its orientation with respect to the VP1 surface
differs from previously published homology models of JCV inter-
actions with oligosaccharides (Gee et al., 2004; Sunyaev et al.,
2009). These homology models were based on interactions
observed in the structure of Polyoma VP1 in complex with an
a2,3-sialylated oligosaccharide (Stehle and Harrison, 1997).
Although NeuNAc is bound in a similar location at the outer
surface of both proteins, the orientation of NeuNAc with respect
to the protein surface is different, and the interactions with the
oligosaccharide structures are not conserved.
Most of the interactions between JCV and LSTc involve the
three longer functional groups projecting from the terminal Neu-
NAc residue (Figures 3A and 3B). The NeuNAc carboxylate faces
toward the HI loop and is recognized by parallel hydrogen bonds
to the side chains of S266 and S268, as well as a water-mediated
hydrogen bond to S266. The extended NeuNAc glycerol chain
docks into a shallow depression on the protein surface that is
shaped by residues in the BC and HI loops. The bottom of the
depression is formed by the side chain of Q270. Hydrogen bonds
to the amide and hydroxyl groups of S60, located at the rim of the
depression, further anchor the glycerol chain. The methyl moiety
of the N-acetyl group inserts into a hydrophobic cavity at the
intersection between the HI, BC1, and BC2cw loops. Thet & Microbe 8, 309–319, October 21, 2010 ª2010 Elsevier Inc. 311
Figure 3. Interactions between JCV VP1 and LSTc
(A) Interactions between JCV VP1 and the terminal NeuNAc of LSTc. JCV VP1 is shown as a cartoon, with side chains interacting with LSTc in stick representation.
Waters are represented with spheres. Residues forming direct hydrogen bonds to NeuNAc are colored teal and residues forming van der Waals contacts or
water-mediated hydrogen bonds are colored pink. Direct hydrogen bonds between JCV VP1 and NeuNAc are shown as black dashed lines, and water-mediated
hydrogen bonds or bonds between protein atoms are colored gray. Intramolecular hydrogen bonds within the oligosaccharide are orange.
(B) Interactions between JCV VP1 and other parts of LSTc.
(C) The cartoon represents structural features of oligosaccharides that are required for JCV binding. These were extracted from our glycan microarray data.
Crossed-out sugar residues would produce steric clashes.
(D) Structural basis for JCV VP1 specificity for LSTc. JCV is shown in surface representation, with residues interacting with LSTc colored according to their change
in surface accessibility upon LSTc binding (gray <1 A˚2 change, light teal 1–10 A˚2 change, dark teal >10 A˚2 change). The branching substitutions at LSTc that
abolish binding are indicated as black hexagons, indicating where they would clash with protein or LSTc atoms.
(E) Structural changes in JCV VP1 upon LSTc binding. The structures of unliganded (gray) and liganded (pink) JCV VP1 were superposed using the b sandwich
core residues. Hydrogen bonds only present in unliganded VP1 are indicated with green dashes, and those only present in the complex are colored black.
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JCV Attachment to Its Glycan Receptor Motif LSTcN-acetyl group is hydrogen bonded to the side chain of N264.
Finally, the O4 hydroxyl group of NeuNAc forms a hydrogen
bond with the side chain of N123. The O4 hydroxyl group also
makes two water-mediated hydrogen bonds to N123 and
F67cw.
Specific contacts between JCV VP1 and the long leg of the
L-shaped LSTc mostly involve the GlcNAc residue. The side
chain of N123 forms hydrogen bonds to both the carbonyl of
the GlcNAc N-acetyl group and the side chain of R265. In turn,
the carbonyl group of the N-acetyl chain forms water-mediated
hydrogen bonds with S266 and the carboxyl group of the Neu-
NAc residue. The methyl group of the GlcNAc N-acetyl chain
makes van der Waals interactions with the methyl group of
T66cw. In addition, there is a hydrogen bond within LSTc linking
GlcNAc with the glycosidic oxygen of Gal.
Interestingly, 6-sialyl-lactosamine, which like LSTc has a Neu-
NAc-a2,6-Gal-b1,4-GlcNAc motif, was not recognized by JCV
VP1. Since the oligosaccharide is directly linked to a lipid tag312 Cell Host & Microbe 8, 309–319, October 21, 2010 ª2010 Elsevie(Table S1), productive engagement of this compound might be
prevented because the GlcNAc group, which contributes
contacts in the case of LSTc, is in close proximity to the lipid
here. Thus, for reasons of accessibility, JCV requires at least
the LSTc pentasaccharide as a binding motif (Figure 3C).
The glycan array tested the effect of additional, branching resi-
dues to this minimal binding motif. Attachment of a fucose to
O3 of GlcNAc and O3 of Glc, or attachment of a branching oligo-
saccharide chain to O6 of Gal (probe 64, Figure 1A, Table S1),
would lead to clasheswith either JCV VP1 or other LSTc residues
(Figure 3D). Attachment of a fucose to O2 of the first Gal does not
occur in parallel with sialylation of that group. However, the pres-
ence of a GlcNAc residue instead of the terminal Glc of LSTc, as
present in most glycans carrying LSTc-like sequences, is
unlikely to alter the conformation of the oligosaccharide.
There are no hydrogen bonds between JCV VP1 and the
remaining three sugar moieties in LSTc. However, the Glc and
two Gal residues contribute to the surface area buried uponr Inc.
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structure, indicating low flexibility due to van der Waals interac-
tions with VP1. These interactions are clearly relevant for affinity
and specific binding of JCV, as demonstrated by the glycan mi-
croarray.
JCV VP1 Undergoes Induced-Fit Movements
upon Binding LSTc
To determine whether JCV VP1 undergoes conformational
changes upon ligand binding, we solved the structure of unli-
ganded JCV VP1 at 1.95 A˚ resolution (Table 1). Comparison
with liganded VP1 shows that residues in the binding site rear-
range upon ligand binding (Figure 3E). In the unliganded struc-
ture, the N264 side chain is oriented toward the side chains of
S266 and S268 and forms hydrogen bonds with both residues.
Upon ligand binding, N264 swings around to interact with
Q270 and theN-acetyl chain of NeuNAc. In the unliganded struc-
ture, the ‘‘binding’’ conformation of N264 is already present as
a second conformation, suggesting a dynamic equilibrium
between two conformations that is shifted by ligand binding.
More drastic changes are seen at residue N123, whose
hydrogen bonds are critical for recognizing the L-shaped binding
conformation of LSTc. In the absence of LSTc, the N123 side
chain points closer toward the NeuNAc binding site, and would
clash with NeuNAc. To accommodate NeuNAc, the N123 side
chain moves. Its altered position leads to clashes with main-
chain atoms in the BC2cw loop, and so residues 64–68 of the
BC2cw loop move to accommodate the new conformation of
N123. Induced-fit movements were not observed in receptor
interactions of SV40 and Polyoma (Neu et al., 2008; Stehle and
Harrison, 1997). The induced fit of JCV VP1may facilitate binding
to LSTc in a specific conformation.
Carbohydrate Binding Sites in VP1 Are Necessary
for JCV Attachment, Infection, and Spread
The crystal structure of VP1 in complex with LSTc revealed
numerous contacts between the protein and LSTc. To test
whether binding of LSTc is required for JCV infection, we intro-
duced point mutations in the oligosaccharide-binding sites of
VP1 into an infectious JCV clone (highlighted in Figure 4A).
One set of mutants was designed to abolish the interaction
with NeuNAc, either by removal of hydrogen bonds (S266A/
S268A) or by steric hindrance (S266N/S268N and L54Y). We
also probed the importance of N123, which undergoes
induced-fit movements to specifically recognize the L-shaped
conformation of LSTc, by mutating it to alanine. In addition, we
mutated A126 and R265 in a unique groove on the VP1 surface
(Figure 4A), which is not present in Polyoma and SV40 (Neu
et al., 2008; Stehle et al., 1994) and may be relevant for interac-
tionswith JCV cell surface receptors. In addition, R265 forms van
der Waals contacts with the long leg of LSTc. Mutants were
analyzed for infectious spread in long-term growth assays
(Figures 4B and 4D). On the final day of the growth assay, super-
natants were harvested and used to inoculate SVG-A cells for an
infectivity assay (Figures 4C and 4E). Mutation of residues in the
NeuNAc binding site (L54Y, S266A/S268A, and S266N/S268N)
completely abolished JCV spread and infectivity (Figures 4B
and 4C). Interactions mediated by each of these residues must
therefore be required for a productive interaction with sialicCell Hosacid, which in turn is essential for JCV growth. N123A had
delayed viral spread in culture compared to wild-type
(Figure 4D) and exhibited a 50% reduction in infectivity (Fig-
ure 4E), demonstrating the important role of N123 in accommo-
dating LSTc. Mutation of R265, which forms van der Waals
contacts with LSTc, did not affect growth and infectvity but
resulted in reduced binding (Figure 4F). Virus with a mutation in
the groove (A126Q) was capable of infection, and grew to levels
equivalent to wild-type JCV. This indicates that, while the groove
is unique to JCV VP1, residue A126 likely does not contribute to
receptor binding. Virus carrying themore drastic A126Ymutation
was unable to grow. We envisage that this mutation introduces
local structural changes that affect residues critical for sialic
acid binding.
The residues targeted for mutation are far from the VP1
regions that mediate capsid assembly or interact with minor
capsid proteins. In order to verify that the mutants do not alter
or destablize the structure of VP1, we introduced the mutations
into the pentamer expression construct and expressed mutant
proteins in E. coli. Like wild-type, all mutant proteins were puri-
fied as pentamers, indicating that they are properly folded
(Figure S1A). Circular dichroism spectroscopy experiments
confirm that secondary structure compositions of wild-type
and mutant proteins are identical (Figure S1B).
To determine whether the decrease in viral growth and infec-
tivity exhibited by mutant viruses was attributable to virus
binding, we analyzed wild-type and mutant JCV VP1 pentamers
in a flow cytometry-based cell-binding assay (Figure 4F). Purified
pentamers were incubated with SVG-A cells, and binding was
detected using an antibody specific for their His tag. Flow cytom-
etry analysis revealed that mutants that do not support infection
(L54Y, A126Y, S266A/S268A and S266N/S268N) or do so at
reduced levels (N123A) also have reduced binding to cells in
comparison to wild-type VP1. Mutants with wild-type-like
growth properties (A126Q, R265A) were capable of binding to
host cells. While A126Q bound similar to wild-type, R265A
exhibits reduced binding. As the R265 side chain forms van
der Waals contacts with LSTc (Figures 3 and 4), its mutation
likely results in a modest reduction of affinity that can be
compensated by avidity in the context of the virion and thus
does not affect viral growth and infectivity. These data demon-
strate that the specific contacts between JCV VP1 and LSTc
observed in the crystal structure play a critical role in JCV attach-
ment and infection.
Structural Basis for the Binding Specificity of JCV
The crystal structure provides a platform for understanding the
binding properties of JCV VP1 to host cells. Comparison with
the structure of SV40 VP1 in complex with its receptor GM1,
which carries an a2,3-linked NeuNAc at a branching point
(Figure 1B), reveals that JCV and SV40 bind terminal NeuNAc
at the same location in the VP1 pentamer (Neu et al., 2008).
The specific interactions with the functional groups of NeuNAc
are conserved (Figure 5), highlighting their importance.
However, the JCV and SV40 VP1 proteins differ at the cavity
into which the methyl group of the terminal NeuNAc inserts.
In SV40 VP1, this cavity is quite large, polar at its rim, and likely
water filled, while the cavity is smaller and more hydrophobic in
JCV. This reflects the different host organisms of the two viruses.t & Microbe 8, 309–319, October 21, 2010 ª2010 Elsevier Inc. 313
Figure 4. Growth, Infectivity, and Binding of JCV VP1 Mutants
(A) Point mutations introduced into JCV VP1. LSTc is shown in stick representation.
(B) Growth of JCV VP1 wild-type and mutant viruses. SVG-A cells were transfected with linearized DNA from JCV VP1 wild-type and mutant constructs. Trans-
fected cells were fixed and stained at day 4 posttransfection, then at 3 day intervals for 22 days by indirect immunofluorescence. Transfected or infected cells
were quantified based on nuclear VP1 staining. Each data point represents the average number of infected cells per visual field for ten fields of view for three
independent experiments. Error bars indicate SD.
(C) Infectivity of supernatants from JCV VP1 wild-type andmutant viruses. SVG-A cells were inoculated with supernatants harvested from infected cells at day 22
from (B). Cells were fixed and stained by indirect immunofluorescence at 72 hr postinfection and quantified based on nuclear VP1 staining. The results are pre-
sented as the average number of infected cells per visual field for ten visual fields from three individual samples performed in triplicate. Error bars indicate SD.
(D) Growth of JCV VP1wild-type andN123A. N123Awas analyzed for viral growth as in (B). Each data point represents the average of number of infected cells per
visual field for ten fields of view for three independent experiments. Error bars indicate SD. *p < 0.05.
(E) Infectivity of supernatants from JCV VP1 wild-type and N123A. N123A was analyzed for infectivity as in (C). Error bars indicate SD. *p < 0.05.
(F) Cell-binding analysis of JCV wild-type and mutant pentamers. SVG-A cells were incubated with His-tagged wild-type or mutant pentamers and a Penta His
Alexa Fluor 488 antibody. Cells were fixed and pentamer binding was analyzed by flow cytometry. Histograms represent the fluorescence intensity of Alexa 488
for antibody alone (filled) and pentamer samples (open) for 10,000 gated events. Data are grouped into two histograms based onmutants that propagate (bottom)
or do not propagate (top) in SVG-A cells.
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Figure 5. Comparison of Oligosaccharide
Binding Sites of JCV and SV40 VP1
(A) JCV VP1 in complex with LSTc. (B) SV40 VP1 in
complex with GM1. The Glc in GM1 does not
contact the protein and was omitted for clarity.
The proteins are shown in surface representation,
with the BC and HI loops also indicated in cartoon
representation. Residues contributing to ligand
binding or specificity are shown in stick represen-
tation. They are colored gray when they are in the
same conformation in the two proteins. Residues
that are not conserved and assume different
conformations are colored pink for JCV and blue
for SV40. A blue sphere indicates the Ca position
of G131 in SV40. The carbohydrate ligands are
shown as orange sticks. Key hydrogen bonds
are shown as black dashes.
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is not NeuNAc but N-glycolyl neuraminic acid (NeuNGc), which
carries the larger and more polar CH2-OH group instead of the
methyl group of NeuNAc (Varki, 2001). SV40 binds to NeuNGc-
GM1 better than to NeuNAc-GM1 (Campanero-Rhodes et al.,
2007), which is consistent with its larger, more polar cavity.
However, NeuNAc is the most abundant sialic acid in humans,
and the smaller and more hydrophobic cavity of JCV is consis-
tent with its preference of NeuNAc-LSTc over NeuNGc-LSTc.
Thus, the structure of the oligosaccharide binding site has
consequences for the species specificity of the virus.
The position of NeuNAc in the larger context of an oligosac-
charide is clearly a major determinant of specificity (Figures 3C
and 3D). Amino acid N123 is key to recognizing the observed
L-shaped conformation of LSTc, since it makes hydrogen bonds
with both the GlcNAc and terminal NeuNAc sugar residues
(Figures 3A and 3B). Different linkages of NeuNAc, Gal, and
GlcNAc would not produce the precise arrangement of NeuNAc
and GlcNAc that is required for complex formation. As a result,
sialylparagloboside, which carries a2,3-linked NeuNAc but is
otherwise identical in sequence to LSTc, is not recognized
(Figure 1). The residue corresponding to N123 in SV40 is
a glycine, which would not be able to mediate these contacts
(Figure 5), explaining why SV40 does not attach to sequences
terminating in NeuNAc-a2,6-Gal-b1,4-GlcNAc (Campanero-
Rhodes et al., 2007; Neu et al., 2008).
Our data therefore provide strong support for a mode of
binding that requires both a terminal NeuNAc and the extended
L-shaped binding conformation of LSTc in the context of a long,
linear chain.
DISCUSSION
We demonstrate here by glycan array screening that recombi-
nant JCV VP1 pentamers selectively bind the LSTc oligosaccha-
ride. The observed interaction is of physiologic relevance, as
JCV infection can be blocked specifically by incubation with
soluble LSTc. In order to understand the molecular basis for
this recognition, we determined the structure of the JCV capsid
protein, VP1, in complex with LSTc at 2.0 A˚ resolution. The struc-
ture shows that JCV engages both the terminal sialic acid and
the unique L-shaped conformation of LSTc, which results in
additional contacts of the GlcNAc moiety with VP1 and likely isCell Hosa key determinant of its interaction with JCV VP1. Mutagenesis
of residues involved in sialic acid binding results in viruses that
are unable to grow and infect due to a binding defect.
Our finding that glycans terminating in the LSTc motif serve as
main receptors for JCV is consistent with biochemical assays
involving natively glycosylated cells (Liu et al., 1998b) (Figure 1B).
Homologs of LSTc, in which a GlcNAc replaces the terminal
Glc, are present in the human body as the termini of long oligo-
saccharide chains of the ‘‘i’’ antigen type (Feizi, 1985). All of the
glycans terminating in GlcNAc-LSTc contain repeating units of
[3-Gal-b1,4-GlcNAc-b1-]n (polyLacNAc repeats), and fulfill the
steric condition of a long carbohydrate that is unbranched at
its tip. These compounds should therefore bind JCV. The i
antigen is expressed on a high proportion of human peripheral
lymphocytes (Feizi et al., 1980). Glycan profiling by mass spec-
trometry has identified long glycans consistent with the LSTc
motif in theN-glycan fractions of several human tissues including
kidney, lung, and spleen (http://www.functionalglycomics.org/),
but tissues of the entire CNS were not analyzed. Lectin staining
of human tissues revealed that a2,6-linked NeuNAc is present on
the surface of B lymphocytes of the tonsils and spleen, on kidney
and lung cells, as well as on astrocytes and oligodendrocytes
(Eash et al., 2004). Only very low-level lectin staining was seen
for neurons and T lymphocytes. Notably, neurons, which
express the serotonin receptor, are not susceptible to infection
with JCV, most likely because they lack the oligosaccharide
receptor. As the expression pattern of LSTc-carrying glycans
corresponds to sites of JCV persistence (the kidney), and path-
ogenesis (the glial cells of the CNS), it is likely that the observed
specificity of JCV for LSTc contributes to targeting the virus to
these sites.
Previous studies report that JCV was also able to use a2,3-
linked sialic acids as receptors (Dugan et al., 2008). It is possible
that our glycan microarrays performed with pentamers failed
to detect low-affinity interactions of JCV with a2,3-linked
compounds because pentamers bind with much lower avidity
than virions. However, given the strong signal observed for
LSTc, such interactions would be very weak. Inspection of the
structure shows that linear a2,3-linked compounds would not
be able to interact favorably with JCV VP1. However, branched
compounds such as GM1 and GM2 would be able to bind, albeit
with significantly lower affinity compared to LSTc because of
their much smaller contact areas. Interestingly, unpublishedt & Microbe 8, 309–319, October 21, 2010 ª2010 Elsevier Inc. 315
Cell Host & Microbe
JCV Attachment to Its Glycan Receptor Motif LSTcresults by Leonid Gorelik and the Consortium for Functional
Glycomics (CFG), which are available online at http://www.
functionalglycomics.org/ according to CFGpolicy, confirm these
predictions. In glycan array screens of JCV VLPs of Mad-1
(which has the sameVP1 as the strain used in our studies), strong
binding was observed to LSTc-containing sequences, and weak
binding was observed for GM2, GM1, and similar short,
branched, a2,3-linked sequences. The weaker interactions
with GM1 and GM2 would not appear to be functional because
SV40, which does use GM1 as a receptor, does not compete
with JCV for binding sites (Liu et al., 1998a).
In contrast to the related polyomaviruses SV40, Polyoma, and
BKV, JCV does not enter cells by cholesterol-dependent endo-
cytosis but instead uses clathrin-mediated endocytosis. It is
enticing to speculate that this difference is reflected by their
carbohydrate receptor specificities. SV40, Polyoma, and BKV
all use gangliosides (Low et al., 2006; Tsai et al., 2003), which
in the case of SV40 initiate entry by inducing curvature of the
plasma membrane (Ewers et al., 2010). To induce curvature
upon binding, the oligosaccharide portion of the receptor must
be relatively rigid, which is the case for short, branched ganglio-
sides (Acquotti et al., 1991), but not for long, flexible polyLacNAc
extensions. Thus, the few amino acid changes between JCV and
related polyomaviruses might not only determine receptor spec-
ificity but also target the virus to a different entry pathway.
Statistical analyses of JCV sequences demonstrate that 52%
of PML patients carry JCV with one mutation in VP1 (L54F,
K59M/E/N, N264D/T, S266F/L, or S268F/Y/C) that likely arose
from positive selection (Sunyaev et al., 2009). Residues L54,
N264, S266, and S268 mediate direct contacts with NeuNAc.
Mutation of any of these four residues therefore adversely affects
sialic acid binding (Figures 3A and 4). Consistently, the L54F and
S268F mutants have reduced hemagglutination activity
(Sunyaev et al., 2009). Although residue K59 also contacts Neu-
NAc, its replacement with M, E, or N would still allow for similar
contacts. Not all of the mutations can therefore be attributed to
a selective pressure on the virus to alter its receptor binding site.
It is interesting to speculate about how mutations that should
block LSTc binding would be selected for in individuals with
PML. It is conceivable that JCV featuring amutated oligosaccha-
ride binding site can spread more rapidly to the CNS from its site
of persistence in the kidney because of diminished attachment
to carbohydrates. This scenario would be similar to a point muta-
tion in Polyoma VP1 that abolishes binding to nonfunctional
pseudoreceptors, thereby increasing viral spread and rendering
the virus more pathogenic (Freund et al., 1991). However,
a defect in sialic acid binding would abolish engagement of
both LSTc-carrying glycans and branched a2,3-linked
compounds. Unpublished glycan array screening data by
Leonid Gorelik and the CFG confirms this (http://www.
functionalglycomics.org/). One also cannot ascertain whether
JCV develops mutations in VP1 while replicating in remote sites
of infection such as the kidney or if they develop in the brain.
Moreover, it is not clear if patients carryingmutant JCV also carry
wild-type JCV. Finally, viruses with the mutations L54Y, S266A/
S268A, and S266N/S268N in the sialic acid binding site were
unable to infect cells and propagate in a long-term growth assay
because of a cell binding defect (Figure 4). Since wemutated the
residues identified in PML patients, albeit to different amino316 Cell Host & Microbe 8, 309–319, October 21, 2010 ª2010 Elsevieacids, we would predict that the mutations present in PML
patients would not propagate efficiently in glial cells.
In recent years, the incidence of PML has increased beyond
the HIV/AIDS population to include patients undergoing immu-
nosuppressive therapies for immunological disorders such as
multiple sclerosis (Linda et al., 2009; Wenning et al., 2009),
Crohn’s disease (Van Assche et al., 2005), rheumatoid arthritis,
and systemic lupus erythematosus (Carson et al., 2009a). Treat-
ment options for PML are currently inadequate (Kishida, 2007),
especially given the rapid devastation of this disease. We expect
that knowledge about the structure of JCV VP1 and its interac-
tion with receptors can serve as a platform from which such
treatment strategies can be developed.
EXPERIMENTAL PROCEDURES
Protein Expression and Purification
cDNA coding for amino acids 22–289 of the Mad-1 strain of JCV VP1 was
cloned into the pET15b expression vector (Novagen) in frame with an
N-terminal hexahistidine tag (His tag) and a thrombin cleavage site. The
N-terminal truncation was made because presence of these amino acids
had inhibited crystallization of the homologous Polyoma VP1, while the
C-terminal truncation was made to prevent capsid assembly in crystallization
setups (Stehle and Harrison, 1997). Mutations were introduced using Phusion
mutagenesis (NEB) according to the manufacturer’s instructions and
confirmed by sequencing (Table S2). Proteins were overexpressed in E. coli
BL21(DE3) and purified using nickel affinity chromatography. For glycan array
screening, flow cytometry, and circular dichroism, the proteins were addition-
ally purified by gel filtration. For crystallization, the His tag was removed by
incubation with thrombin prior to gel filtration. After cleavage, the nonnative
amino acid sequence GSHM remains at the N terminus of VP1.
Glycan Array Screening
The microarray was composed of 87 sequence-defined lipid-linked oligosac-
charide probes: 81 sialyl-terminating probes and six neutral probes as nega-
tive controls (Table S1). The probes were robotically printed in duplicate on
nitrocellulose-coated glass slides at 2 and 5 fmol per spot using a noncontact
instrument (Palma et al., 2006). The protein was precomplexed with mouse
monoclonal anti-poly-histidine (Ab1) and biotinylated anti-mouse IgG anti-
bodies (Ab2) (both from Sigma) in a ratio of 4:2:1 (by weight). In brief, the
JCV VP1-His tagged protein-antibody precomplexes were prepared by prein-
cubating Ab1 with Ab2 for 15min at ambient temperature, followed by addition
of VP1 and incubation for a further 15min on ice. The VP1-antibody complexes
were diluted in 5mMHEPES (pH 7.4), 150mMNaCl, 0.3% (v/v) Blocker Casein
(Pierce), 0.3% (w/v) bovine serum albumin (Sigma), 2.5 mM DTT, and 5 mM
CaCl2 to give a final VP1 concentration of 150 mg/ml, and overlaid onto the
arrays at 20C for 2 hr. Binding was detected with Alexa Fluor 647-labeled
streptavidin (Molecular Probes) and imaging (Palma et al., 2006), and data
analysis (Stoll and Feizi, 2009) was as described.
Crystallization and Data Collection
JCV VP1was concentrated to 4.5 mg/mL and crystallized by sitting drop vapor
diffusion at 20C. The reservoir solution contained 12% (w/v) PEG 3,350, 0.1M
HEPES (pH 7.5), and 0.2 M KSCN. Drops were set up by mixing 1 ml protein
solution with 1 ml reservoir solution and 0.2 ml microseeding stock from previ-
ously obtained crystals. Crystals were harvested into a solution containing
10% PEG 3,350, 0.1 M HEPES (pH 7.5), and 0.2 M KSCN and cryoprotected
by soaking for 10 s in harvesting solution containing 30% (v/v) glycerol and
flash freezing in liquid nitrogen. For complex formation, crystals were soaked
for 3 min in harvesting solution supplemented with 5 mM LSTc oligosaccha-
ride. The cryoprotecting solution also contained the same concentration of
LSTc oligosaccharide.
Structure Determination
Data reduction was performedwith XDS (Kabsch, 2010), and the structure was
solved bymolecular replacement in Phaser (McCoy et al., 2007) using a searchr Inc.
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was then performedwith Phenix and Refmac5 (Adams et al., 2010; Murshudov
et al., 1997), andmodel building was done in Coot (Emsley and Cowtan, 2004).
Five-fold noncrystallographic symmetry restraints were used throughout the
refinement for most of the protein. In data from crystals soaked in LSTc, the
ligand was located in 2Fo–Fc and Fo–Fc weighted electron density maps. The
ligand was refined using restraints from the CCP4 library, with the exception
of the a2,6-glycosidic bond, which had to be user defined. Waters were incor-
porated using Coot and ARP/wARP. The final models have good stereochem-
istry and agree very well with the experimental data (Table 1).
Cells, Viruses, and Antibodies
SVG-A cells are a subclone of the human glial cell line SVG transformedwith an
origin-defective SV40 mutant (Major et al., 1985). SVG-A cells were grown in
Minimum Essential Medium supplemented to contain 10% fetal bovine serum
(FBS) and penicillin/streptomycin (P/S) (Mediatech, Inc.) in a humidified incu-
bator at 37C. MAB597 is a hybridoma supernatant that produces a mono-
clonal antibody against JCV VP1 (Atwood et al., 1995) and was generously
provided by Ed Harlow. Penta His Alexa Fluor 488 was used at 10 mg/mL
(QIAGEN). Generation and propagation of the Mad-1/SVE strain of JCV were
performed as previously described (Vacante et al., 1989).
Viral Growth and Reinfection Assays
VP1 mutations were generated in the genomic JCV DNA of strain JC12 (Chen
and Atwood, 2002), subcloned in puc19 (Gee et al., 2004) with QuikChange
(Stratagene) according to the manufacturer’s instructions (Table S2), and
confirmed by sequencing. Of plasmid DNA, 10 mg was digested with BamHI
(Promega) for 2 hr at 37C to separate the JCV genomic DNA from the
puc19 backbone plasmid. Digests were performed in triplicate for each
sample. SVG-A cells were plated to 40% confluence on 18 mm round glass
coverslips (Thermo Scientific) in 12-well plates (Costar). Cells in medium
without antibiotics were transfected with 2 mg of digested DNA using Fugene
(Roche) at 3:2 ratio (Fugene:DNA). Transfected cells were incubated at 37C
O/N, and medium containing 5% FCS and 2% P/S was added to cells the
next day. Cells were incubated at 37C and fed with 500 ml of medium contain-
ing 5% FBS, 1% P/S, and 1% amphotericin B (Mediatech) or harvested for
immunofluorescence at day 4 and at 3 day intervals thereafter for 22 days.
For reinfection assays, supernatants were collected at 22 days posttransfec-
tion. SVG-A cells at 70%confluence on 22mm square glass coverslips (Fisher)
in 6-well plates (Costar) were infected with 150 ml of virus supernatant at 37C
for 1 hr, then medium containing 5% FBS, 1% P/S, 1% amphotericin B was
added to cells, and cells were incubated at 37C for 72 hr. Cells were fixed
and stained by indirect immunofluorescence.
Indirect Immunofluorescence
Cells were washed in PBS, fixed in cold MeOH, and incubated at20C. Cells
were washed in PBS, permeabilized with 0.5% TX-100 (USB Corporation) at
RT for 15 min, blocked with 10% goat serum (MP Biomedicals)/PBS at RT
for 30 min, incubated with VP1-specific antibody MAB597 (1:10) in PBS at
37C for 1 hr, washed with PBS, incubated with a goat-anti-mouse Alexa Fluor
488 (1:1000) in PBS at 37C for 1 hr, then washed with PBS. Cells were then
mounted on slides using VectaShield with Dapi (Vector Laboratories Inc.).
Cells were analyzed for nuclear VP1 staining under a 203 objective using an
Eclipse 800 or Eclipse TE2000-U microscope (Nikon) equipped with an
ORCA-ER digital camera (Hamamatsu).
LSTc Inhibition Assay
JCV (Mad-1/SVE) was pretreated with 5 mM of LSTb or LSTc (V Labs, Inc.)
(diluted in sterile diH2O) in media containing 2% FCS on ice for 1 hr. SVG-A
cells in 96-well plates were prechilled at 4C for 30 min. JCV-LST complexes
were added to cells and incubated at 4C for 1 hr. Cells were washed with PBS
twice; media containing 10% FCS, 1% P/S, and 1% amphotericin B was
added; and cells were incubated at 37C for 72 hr. Cells were fixed and stained
by indirect immunofluorescence as described above.
Flow Cytometry
Wild-type and mutant JCV VP1 pentamers (100 ml) in PBS were incubated with
SVG-A cells in suspension on ice for 2 hr with occasional agitation. Cells wereCell Hoswashed, pelleted by centrifugation, and suspended in 100 ml of Penta His Alexa
Fluor 488 antibody (QIAGEN) (10 mg/mL) in PBS on ice for 1 hr. Cells were
washed, pelleted, and fixed in 1% paraformaldehyde and analyzed for pen-
tamer binding using a BD FACSCaliber (Benton, Dickinson, and Company)
flow cytometer equipped with a 488 nm excitation line. Data were analyzed
using BD CellQuestPro (Benton, Dickinson, and Company) and FlowJo (Tree
Star, Inc) software.
Statistical Analysis
Means for triplicate sampleswere compared using an unpaired Student’s t test
(Microsoft Excel). P values <0.05 were considered statistically significant.
ACCESSION NUMBERS
Coordinates and structure factor amplitudes were deposited with the RCSB
data bank (http://www.rcsb.org/) under accession codes 3NXD and 3NXG.
Structure figures were prepared with PyMol (Schro¨dinger Inc.).
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Background: The AAA ATPases of the PAN/Rpt1–6 group regulate access of substrates to the 20S proteasome.
Results: Two groups of AAA proteins, CDC48 and AMA, function as novel proteasomal ATPases in archaea.
Conclusion: This network of regulatory ATPases increases the capacity of proteasomal protein degradation in archaea.
Significance:Diversification at the level of the regulatory ATPase provides a contrast to the fully differentiated 26S proteasome
of eukaryotes.
The proteasome is the central machinery for targeted protein
degradation in archaea, Actinobacteria, and eukaryotes. In its
basic form, it consists of a regulatory ATPase complex and a
proteolytic core particle. The interaction between the two is
governed by anHbYXmotif (whereHb is a hydrophobic residue,
Y is tyrosine, and X is any amino acid) at the C terminus of the
ATPase subunits, which stimulates gate opening of the protea-
somal-subunits. In archaea, the proteasome-interactingmotif
is not only found in canonical proteasome-activating nucleoti-
dases of the PAN/ARC/Rpt group, which are absent in major
archaeal lineages, but also in proteins of the CDC48/p97/VAT
and AMA groups, suggesting a regulatory network of protea-
somal ATPases. Indeed, Thermoplasma acidophilum, which
lacks PAN, encodes one CDC48 protein that interacts with the
20S proteasome and activates the degradation of model sub-
strates. In contrast,Methanosarcinamazei contains seven AAA
proteins, five of which, both PAN proteins, two out of three
CDC48proteins, and theAMAprotein, function as proteasomal
gatekeepers. The prevalent presence of multiple, distinct pro-
teasomal ATPases in archaea thus results in a network of regu-
latory ATPases that may widen the substrate spectrum of pro-
teasomal protein degradation.
Dynamic regulation of the proteome through protein degra-
dation is a central metabolic strategy for organisms in a chang-
ing environment. In archaea, Actinobacteria, and eukaryotes,
the proteasome plays a crucial role in protein degradation as
part of stress responses and for regulatory purposes (1).
Removal of misfolded proteins reduces the burden of poten-
tially toxic proteins (2), and targeted destruction by the protea-
some, especially in eukaryotes, is involved in processes such as
cell cycle progression (3) and the cellular immune response (4).
The proteasome is composed of a regulatory particle, which
binds to and unfolds substrate proteins, and a catalytic particle,
which fragments the substrates into peptides of 8–11 amino
acids in length (5). An additional layer of regulation is provided
by the covalent attachment of degradation tags to substrates,
SAMP4 in archaea (6), Pup in Actinobacteria (7), and ubiquitin
in eukaryotes (8), to direct them to the proteasome.
The catalytic 20S proteasome core particle (CP) forms a
cylindrical assembly consisting of four stacked heptameric
rings with an 7777 stoichiometry (9). This arrangement
sequesters the active sites to a central compartment formed by
the -subunits, limiting access to only those proteins that pres-
ent a degradation signal. The catalytic nucleophile, a threonine
residue (10), is the N-terminal residue of -subunits after auto-
processing of a leader peptide (11). The -subunits guide sub-
strates to the proteolytic chamber through a central channel,
which is occluded in the resting state by their flexible N-termi-
nal ends (12). The regulatory AAA ATPases Rpt1–6 (in
eukaryotes), PAN (in archaea), and ARC/Mpa (in Actinobacte-
ria) recognize, unfold, and translocate substrates into the CP
(13–15). Members of this orthologous group share a common
architecture, which consists of anN-terminal domain, involved
in substrate binding and interactionwith the degradation tag or
with subunits of the regulatory particle (16–18), and an AAA
unfoldasemodule. At their C terminus, the ATPases possess an
HbYXmotif (where Hb is a hydrophobic residue, Y is tyrosine,
and X is any amino acid) (19) that can penetrate into a binding
pocket of the -subunits, thereby stabilizing the open gate con-
formation of their N-terminal ends (20). The functional impor-
* This work was supported by institutional funds of the Max Planck Society.
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tance of the HbYXmotif is reflected by the ability of 7-residue
C-terminal peptides, isolated or fused to the 11S/PA26 non-
ATPase activator, to mimic the biochemical effects of full-
length PAN (19–22).
Although preparations of the 26S proteasome from
eukaryotes are routinely obtained via fractionation ofwhole cell
lysate, in archaea, the preparation of proteasome ATPase com-
plexes has been notoriously difficult. So far, there is no descrip-
tion of a fractionation approach, and the heterologous complex
consisting of PAN from Methanocaldococcus jannaschii and
the core particle from Thermoplasma acidophilum, an orga-
nism that lacks PAN (23), is the most widely studied archaeal
model system and the only one that could be imaged to date
(24).
Although the core particle degrades peptides and intrinsi-
cally disordered proteins in the absence of regulatory particles
(5, 25), the Rpt subunits are essential for Saccharomyces cerevi-
siae (26), andMpa is required byMycobacterium tuberculosis in
an infectious context (27), illustrating that the proteasomal
ATPases perform a crucial function, in particular for the
unfolding and degradation of (mis)-folded polypeptides under
stress conditions. Nonetheless, we find that PAN ATPases are
absent in a number of archaea (28), which raises the question of
how substrate proteins are made available to the proteasome in
these organisms.
Detecting a proteasome-interacting motif in the AAA
ATPase CDC48 of T. acidophilum prompted us to perform a
systematic analysis of archaeal AAAproteins, which uncovered
a network of ATPases with a common HbYX motif including
CDC48 and AMA proteins. For two model organisms, we pro-
vide evidence that these ATPases indeed physically interact
with their cognate core particle and show that they stimulate
proteasome activity in proteolytic assays, establishing CDC48
and AMA proteins as regulators of the proteasome in archaea.
EXPERIMENTAL PROCEDURES
Bioinformatics—Homologs of archaeal AAA proteins were
identified with HHsenser (29) searching the non-redundant
database of archaeal proteins (National Center for Biotechnol-
ogy Information (NCBI), nr_arc) with the AAA module
of AMA from Methanosarcina mazei (gi 21226406, Mm_
0304119–372). Assignment to orthologous groups of full-length
sequences was based on cluster analyses using CLANS (30). p
values for clustering were selected interactively to achieve for-
mation of orthologous groups. Groups of AAA proteins were
distinguished from other members of the AAA superfamily
using different p value cutoffs and relying on our classification
of AAA proteins (31). Members of orthologous groups were
verified by testing for concordant domain composition with
HHpred (32) and MUSCLE (33). The presence or absence of
genes was mapped onto the archaeal species tree with iToL
(34). C-terminal peptides comprising the last seven residues of
AAA proteins were extracted from full-length sequences.
Assignment of the HbYXmotif (19) was based on the presence
of a small or hydrophobic residue in third last and a Phe or Tyr
residue in penultimate position.
Cloning—Ta20S (Ta1288, gi 16081896), Ta20S (Ta0612,
gi 16081708), TaCDC48C (TaCDC481–733 lacking the last 12
residues), and TaCDC48-L745W (containing W466F, W541Y,
and L745W mutations) genes were synthesized by GenScript.
MmPAN-A (Mm1006, gi 20905437), MmPAN-B (Mm0789,
gi 20905207), Mm20S (Mm2620, gi 21228722), Mm20S
(Mm0694, gi 21226796), and TaCDC48 (Ta0840, gi 16081896)
were obtained as gifts from W. Baumeister and P. Zwickl.
MmCDC48-A (Mm0248, gi 20904601), MmCDC48-B (Mm0447,
gi 20904821), MmCDC48-C (Mm1256, gi 20905716), MmAMA
(Mm0304, gi 20904664), and Mm0854 (gi 20905268) ORFs
were amplified from genomic DNA ofM. mazei strain OCM88
(ATCC number: BAA159) by PCR. GFPssrA fragment was
PCR-amplified from pEGFP-N1 plasmid (Clontech) using a
reverse primer containing the ssrA tag (AANDENYALAA)
sequence. Proteasomal -subunit DNA fragments were cloned
into pET30b expression vector (Novagen); ATPases and
GFPssrA were cloned as N-terminally hexahistidine-tagged
proteins into pET28b; and proteasomal-subunits were cloned
as C-terminally hexahistidine-tagged proteins into pET22b.
Protein Production and Purification—Plasmids were trans-
formed into Escherichia coli C41(DE3) RIL expression strain.
Plasmids encoding the proteasomal - and -subunits were
co-transformed to assemble the CP proteasome directly inside
E. coli cells. Expressionwas achieved by growing single colonies
in LB medium, supplemented with the appropriate antibiotics
at 37 °C until an optical density of0.6was reached followed by
induction with 1 mM isopropyl-1-thio--D-galactopyranoside
and continued culturing overnight at 20 °C. Cell pellets were
resuspended in lysis buffer (50 mM Tris-HCl, pH 8.0, 500 mM
NaCl, 10 mM MgCl2, 5% glycerol, 10 mM imidazole, 5 mM
-mercaptoethanol, 0.4mg/ml lysozyme, 40g/ml DNase, and
except for the proteasome, EDTA-free protease inhibitor mix-
ture (Roche Applied Science)) and lysed by French press treat-
ment. After centrifugation, lysates were applied consecutively
to nickel-nitrilotriacetic acid metal affinity (50 mM Tris-HCl,
pH 8.0, 500 mM NaCl, 10 mM MgCl2, 5% glycerol, 10 mM-1 M
imidazole gradient, 5mM -mercaptoethanol), mono-Q anion-
exchange (50 mM Tris-HCl, pH 7.5, 50 mM-1MNaCl gradient,
10 mM MgCl2, 5% glycerol, 1 mM dithiothreitol (DTT)), and
Superose 6 gel filtration (50 mM Tris-HCl, pH 7.5, 100 mM
NaCl, and 1 mM DTT) chromatography columns (GE Health-
care). MmAMA accumulated in inclusion bodies and was puri-
fied under denaturing conditions using 4 M urea containing
buffers. In parallel, the quality of protein preparations was con-
trolled by electron microscopy, activity assays, and mass
spectrometry.
Peptidase and Protease Assays—Proteolytic assays made use
of three different fluorescent substrates, namely: quenched LFP
(24) (Mca-AKVYPYPME-Dpa(Dnp)-amide; GenScript; excita-
tion, 322 nm; emission, 398 nm) in the assays using 7-residue
peptides and quenched BODIPY-TR X casein (35) (Invitrogen;
excitation, 590 nm; emission, 645 nm) andGFPssrA (excitation,
488 nm; emission, 507 nm) in the assays using full-length
ATPases. Peptides were synthesized by GenScript. LFP assays
were performed with 0.6 nM CP, 250M 7-residue peptide, and
10M LFP in 50mMTris-HCl, pH 7.5, 100mMNaCl, and 1mM
DTT, for the duration of 120 min at 59 °C for T. acidophilum
proteins and 37 °C forM. mazeiones. Full-length protein assays
were done with 100 nM CP, 400 nM ATPase, 1 M substrate, 20
A Regulatory Network of Proteasomal ATPases
NOVEMBER 9, 2012•VOLUME 287•NUMBER 46 JOURNAL OF BIOLOGICAL CHEMISTRY 39255
mMATP, and 10 mMMgCl2. All measurements are the average
of three independent experiments and were carried out using a
Synergy H4 plate reader (BioTek). For the tryptophan fluores-
cence shift assay, proteinswere excited at 280 nm, and emission
spectra of the proteins with or without ATPS (Sigma-Aldrich)
were collected from 330 nm to 380 nm.
Surface Plasmon Resonance—Surface Plasmon Resonance
(SPR) experimentswere performed at 25 °Cwith a Biacore 2000
instrument (Biacore) and a data collection rate of 1 Hz. MmCP
was immobilized via amine coupling on a CM5 sensor chip (GE
Healthcare). The surface of the upstream flow cell was sub-
jected to the same coupling reaction in the absence of protein
and was used as a reference. MmPAN-A, MmCDC48-B, and
Mm0854 were supplemented with a 100-fold molar excess of
ATPS and then serially diluted into running buffer (10 mM
HEPES, pH 7.4, 150mMNaCl, and 0.005% (v/v) surfactant P20).
Analyte samples with five different concentrations (1000–62.5
nM) were injected over the control and experimental surfaces at
a flow rate of 10 l/min. A blank sample, containing only the
running buffer supplemented with ATPS in the respective
concentration, was injected under the same conditions to allow
for double referencing. Data analysis was carried out with the
BIAevaluation software (version 4.1.1).
Pulldowns—100 g of bait proteins (Ta20S, TaCDC48, and
TaCDC48C) were bound to cobalt-nitrilotriacetic acid
immobilized beads (GE Healthcare), mixed with T. acidophi-
lum cellular lysate, and incubated for 1 h at 59 °C. The samples
were then applied to Mobicol spin columns (MoBiTec) and
washed three times with washing buffer (50 mM Tris-HCl, pH
8.0, 250mMNaCl, 10mMMgCl2, 5% glycerol, 40mM imidazole,
5 mM -mercaptoethanol). Bound proteins were eluted with
elution buffer (50 mM Tris-HCl, pH 8.0, 250 mM NaCl, 10 mM
MgCl2, 5% glycerol, 500 mM imidazole, 5 mM -mercaptoetha-
nol), and captured binding partners were identified with mass
spectrometry.
Nano LC-MS/MSAnalysis—Tryptic digestion of the samples
and analyses of the peptides by LC-MS/MS and subsequent
data processing were done as described previously with slight
modifications (36). Analyses of the peptides were performed on
a Proxeon Easy-nLC system (Proxeon Biosystems) coupled to
an LTQ-Orbitrap-XL (Thermo Fisher Scientific) equipped
with a nanoelectrospray ion source (Proxeon Biosystems). The
injected peptide mixtures were subsequently eluted with a
47-min segmented gradient of 2–80% HPLC solvent B (80%
acetonitrile in 0.5% acetic acid) at a flow rate of 200 nl/min.
Mass spectra were analyzed using the software suite Max-
Quant, version 1.0.14.3 (37). The data were searched against a
target-decoy M. mazei database containing 5645 forward pro-
tein sequences and 262 frequently observed contaminants.
Trypsin was set as protease in which two missed cleavage sites
were allowed. Acetylation at the N terminus and oxidation of
methionine were set as variable modifications. Carbamidom-
ethylation of cysteine was set as fixed modification. Initial pre-
cursormass tolerance was set to 7 ppm at the precursor ion and
0.5Da at the fragment ion level. False discovery rateswere set to
1% at peptide and protein group level.
RESULTS
Prediction of Novel Proteasomal ATPases in the Archaeal
Kingdom—AAA proteins form a distinct group within the
AAA superfamily, whose unifying activity is the energy-de-
pendent remodeling of proteins and nucleic acids (31, 38). In a
cluster analysis of archaeal AAA proteins (supplemental Fig.
S1), we obtained separate clusters for Vps4 (39), membrane-
boundAAA (MBA) (40), an uncharacterized group exemplified
by open reading frame number 854 in the M. mazei genome
(Mm0854), AMA (41, 42), the proteasome-activating nucleo-
tidase PAN (14), and CDC48 (43). Comparative analysis across
81 sequenced archaeal genomes showed that CDC48 is the sole
subgroup found in all archaea and also has the highest degree of
paralogy (Fig. 1A). The proteasome-activating nucleotidase
PAN, however, is absent frommajor archaeal groups, including
all Thermoplasmata, Thermoproteales, and the deep-branch-
ing Thaumarchaeota and Korarchaeota (supplemental Fig. S2).
The C-terminal HbYX motif required for interaction with
the 20S proteasome is not only present in the known protea-
somal regulators of the PAN group, but also in all AMA pro-
teins and in many CDC48 proteins. All archaeal organisms
sequenced to date have at least one AAA protein with anHbYX
motif, supporting the notion that ATPase-mediated protea-
somal regulation is an essential function (supplemental Fig. S3).
Thus, organisms lacking PAN encode at least one CDC48 pro-
tein with a canonical HbYXmotif.
The number of putative proteasomal ATPases varies from
one inThermoplasmata to five in someMethanosarcinales (Fig.
1B). We therefore selected AAA proteins and cognate protea-
some core particles of T. acidophilum andM. mazei to explore
the idea that archaea employmultiple AAAproteins to regulate
proteasomal activity. T. acidophilum encodes only one CDC48
protein andnoPANortholog, and its proteasomal gatekeeper is
still elusive despite the fact that the core particle (TaCP) has
served as a long-standing model system together with the het-
erologous PAN protein of M. jannaschii (19–22, 24). In con-
trast,M. mazei contains sevenAAAproteins, five ofwhich have
the proteasome-interacting motif, including two CDC48 pro-
teins and a member of the AMA group (Fig. 1).
CDC48 Is the Proteasomal ATPase of T. acidophilum—Be-
cause the C-terminal peptides of PAN and Rpt ATPases have
been shown to mimic efficiently the activation of the protea-
some core particle by the full-length proteins (19), we used the
C-terminal peptide of TaCDC48, whose last three residues are
Leu-Tyr-Leu, to stimulate the hydrolysis of the fluorogenic nona-
peptide LFP by TaCP. Although the proteasome can degrade LFP
on its own, we observed a 2-fold higher fluorescence signal in the
presenceofC-terminalpeptideascomparedwithTaCPalone (Fig.
2A), providing initial support for ourhypothesis thatCDC48 is the
proteasomal gatekeeper in T. acidophilum.
In the next step, we tested the ability of full-length TaCDC48
to activate the T. acidophilum proteasome, using BODIPY-ca-
sein as a substrate. TaCP alone is able to degrade casein, and
TaCDC48 could stimulate this activity 2.5-fold, as judged by the
gain in fluorescence intensity of BODIPY fluorophores (Fig.
2B). This stimulation was entirely dependent on the HbYX
motif as a C-terminal deletion mutant of TaCDC48 lacking the
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last 12 residues (TaCDC48C) was unable to activate the pro-
teasome to any measurable extent (Fig. 2B).
Finally, we attempted to stimulate the degradation of
GFPssrA using full-length TaCDC48. GFPssrA is an estab-
lished model substrate for PAN and proteasome fromM. jann-
aschii, as well as for Mpa and proteasome from the actinobac-
teriumM. tuberculosis (44, 45). However, we did not detect its
degradation by the TaCDC48-TaCP system (Fig. 2C). It has
previously been reported that GFPssrA is unfolded by
TaCDC48 at high magnesium concentrations and can then be
degraded by a highly active, gateless proteasome mutant, in
which the 12 N-terminal residues of -subunits have been
removed (46). We attribute the need for a gateless proteasome in
that experiment to the fact that theTaCDC48construct contained
a C-terminal His tag and could not activate the proteasome via its
C-terminalHbYXmotif.Wepropose that this uncoupling and the
use of a constitutively active proteasome accounts for the different
outcome of the experiments. As we will show in the next section,
the ability to degradeGFPssrA appears to be limited to a subset of
active ATPase-proteasome tandems.
To probe the physical interaction of TaCDC48 andTaCP, we
changed the last residue of the ATPase from leucine to a tryp-
tophan in a tryptophan-free mutant background of TaCDC48,
TaCDC48-L745W, in analogy to an experiment conducted by
Goldberg and colleagues (19). In fluorescence emission spectra,
upon the addition of ATPS and in the presence of tryptophan-
free TaCP, the C-terminal tryptophan of TaCDC48-L745W
experiences a blue shift and a decrease in fluorescence intensity
(Fig. 2D). This is the expected outcome if binding of the
exposedC-terminal residues into the binding pocket of the pro-
teasomal -subunit moved the peptide tail from an aqueous to
a more hydrophobic environment. To collect further evidence
for an interaction of TaCDC48 and TaCP, we performed pull-
down experiments with either TaCDC48 or TaCP as bait in
cellular lysate ofT. acidophilum. BothCDC48 andTaCP return
each other as one of the most significant binding partners, but
the C-terminal deletionmutant TaCDC48C does not retrieve
TaCP (Table 1, supplemental Table 1). In summary, we find
that TaCDC48 directly interacts with and stimulates TaCP and
that its C-terminal residues are crucial for this activity.
A Network of Five AAA Proteins Regulates the Proteasome of
M. mazei—In contrast to T. acidophilum, M. mazei encodes
seven AAA proteins, of which we predict five to function as
proteasomal ATPases. This is the largest number of ATPases in
the putative regulatory network among sequenced archaea. To
collect evidence for such a network, we tested whether the
7-residue peptides corresponding to the C termini of the
ATPases could stimulate LFP peptidase activity of theM. mazei
20S proteasome (MmCP). In agreement with our prediction,
we found that peptides from the five AAA proteins that have
the HbYX motif increased the hydrolysis of the fluorogenic
LFP. These are the two PAN proteins (35), two out of three
CDC48 proteins, and the AMA protein (Fig. 3A). The C-termi-
nal peptides of CDC48-C and ofMm0854, which lack themotif,
FIGURE 1.Archaeal AAAproteins and thepredictionof novel proteasome regulators.A, the distribution of AAAATPases ismappedonto a tree of selected
archaeal species. Analysis of the C termini of archaeal AAA proteins indicates the presence of the HbYXmotif in CDC48 and AMA, as well as in PAN proteins.
CDC48 is ubiquitous and shows the highest degree of paralogy, whereas PAN is absent in Thermoproteales and Thermoplasmata and in deep-branching
Korarchaeota andThaumarchaeota, suggesting subgroup-specific loss rather than lateral gene transfer. AMAmost likely originated in the ancestor ofArchaeo-
globales and methanogens, and was lost in Halobacteria. For comparison, the occurrence of the 20S proteasome and SAMP proteins is shown. Panel A was
generated with iToL (34) (MBA,membrane-bound AAA). B, C-terminal sequences of PAN, CDC48, and AMA proteins. The species and sequences are shown in
the sameorder as inpanel A and illustrate thepresenceof theHbYXmotif (hydrophobic/small residue inblue, Tyr/Phe inmagenta). Species lackingPANcontain
at least one CDC48 ortholog with the HbYXmotif. All AMA proteins contain the HbYXmotif. The number of putative proteasomal ATPases ranges from one to
five, suggesting a regulatory network in many archaea. T. acidophilum andM. mazei, which were selected for experimental study, are highlighted.
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had no effect. The degree of stimulation ranged from 1.5-fold
forCDC48-B to9-fold forAMA.We also found that a PAN-A
variant, inwhich the naturally occurring Phe of theHbYXmotif
was mutated to Tyr, was a much stronger activator than wild
type, in line with results showing that the hydroxyl group of
Tyr, which is the most frequent residue in this position, stabi-
lizes the open gate conformation more efficiently (21).
Next, we extended our analysis to the seven full-length
ATPases, using BODIPY-casein as a substrate in protease
assays. The five ATPases with HbYXmotifs stimulated protea-
some activity from 2-fold for CDC48-A to 2.5-fold for PAN-A
(Fig. 3B). Again, CDC48-C andMm0854, which do not contain
the HbYXmotif, did not show any effect. Our results show that
full-length proteins stimulate the proteasome, albeit not as
strongly as isolated peptides. Although peptides are able to bind
independently and in maximal number, in full-length proteins,
only a subset of C-terminal tails can be expected to bind at a
given time due to steric constraints (symmetry mismatch).
Remarkably, of the five ATPases able to activate the protea-
some, only PAN-A was able to stimulate the degradation of
GFPssrA (Fig. 3C). This suggests that the ATPases may also
have differing substrate specificities in a cellular context, pos-
sibly mediated in part by their different N-terminal substrate
recognition domains. Nevertheless, it is worth noting that dif-
ferences are apparent even in orthologous ATPases with highly
similarN-domains, as seen by the inability of PAN-B tomediate
GFPssrA degradation.
To probe the physical interaction between the ATPases and
MmCP, we selected three for analysis by surface plasmon res-
onance (SPR), based on the degree of stimulation and ease of
handling (PAN-A, CDC48-B, and Mm0854). Mm0854 showed
only a background level of binding to MmCP, which correlates
with the absence of anHbYXmotif in this protein and its inabil-
ity to stimulate MmCP in degradation assays. PAN-A and
CDC48-B, in contrast, showed a clear concentration-depen-
dent response, providing evidence that a direct interaction of
ATPase and CP is responsible for their ability to activate the
proteasome (Fig. 3D).
DISCUSSION
We have defined a regulatory network of proteasomal
ATPases across the archaeal kingdom and validated their inter-
actions with the proteasome through in vitro studies with pro-
FIGURE 2.CDC48binds to and activates the proteasomeof T. acidophilum.A, the addition of the C-terminal peptide of TaCDC48 results in a 2-fold increase
in proteasomal degradation of the fluorogenic nonapeptide LFP, measured as gain in fluorescence intensity. Error bars indicate S.D. B, full-length TaCDC48
enhances the degradation of BODIPY-labeled casein by TaCP in the presence of ATP. A C-terminal deletion mutant of TaCDC48 (TaCDC48C) lacking the last
12 residues of TaCDC48 does not stimulate casein degradation in comparison with TaCP alone. C, eGFP-ssrA is not degraded by TaCP in the presence of
TaCDC48 and ATP. AU, absorbance units. D, in the presence of TaCP, the fluorescence emission spectrum of a C-terminal tryptophan variant of TaCDC48
(TaCDC48-L745W) moves from an aqueous to a more hydrophobic environment upon the addition of ATPS, indicated by a blue shift of the emission
maximum and a decreased intensity.
TABLE 1
TaCDC48 interacts with TaCP
Table 1 summarizes the identification of the - and -subunits of TaCP
and TaCDC48 in pulldown experiments using three different bait proteins (TaCP,
TaCDC48, TaCDC48C) in cellular lysate of T. acidophilum. The complete list of
identified proteins is shown in supplemental Table 1.
Bait proteinsa
Control TaCP TaCDC48 TaCDC48C
TaCDC48 0 13 117 120
-Subunit 10 46 17 8
-Subunit 2 20 8 2
aNumber represents the number of identified peptides.
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teins from two archaeal organisms that mark extremes in the
number of genomically encoded AAA ATPases. This network
features, in addition to known proteasome-activating nucleoti-
dases of the PAN type, two groups of AAA proteins, AMA and
CDC48, that hitherto have not been seen directly associated
with the 20S proteasome (Fig. 4).
Archaea-wide Significance of the NetworkModel—The inter-
action of AAA ATPases with the proteasome is determined by
the presence of HbYXmotifs at the very C terminus of ATPase
subunits. However, not only AAA ATPases contain this motif.
We find theHbYXmotif (pattern: [LVIMGAPFYW][FY]x) at
the C terminus of 63 proteins (of 1484 proteins coding genes) in
the T. acidophilum genome, one of which is CDC48. For
M. mazei, we detect this motif in 133 (of 3368) proteins, five of
which are the AAA proteins that are part of the regulatory net-
work we describe. We assume that only very few of these pro-
teins form ring-shaped complexes and offer this interaction
motif in a sufficiently high local concentration and extended
conformation to stimulate gate opening of the core particle.
Furthermore, there are other interaction partners of the pro-
teasome with this motif, for instance, the proteasome assembly
chaperones PbaA and PbaB, which are also conserved in
archaea (47), and there might be more remaining to be found.
Nevertheless, our analysis specifically and comprehensively
tracks this motif in ATP-dependent proteasome regulators of
the family of AAA unfoldases.
FIGURE 3. A network of AAA ATPases regulates the proteasome ofM. mazei. A, C-terminal peptides of AAA proteins fromM. mazei containing the HbYX
motif enhance LFP hydrolysis. The PAN-A F439Y mutant is a stronger activator of MmCP than PAN-A with the wild-type HbYX motif. Error bars indicate S.D.
B, full-length ATPases with the HbYXmotif stimulate degradation of BODIPY-labeled casein by MmCP. Error bars indicate S.D. AU, absorbance units. C, PAN-A
is the only AAA protein ofM. mazei that mediates degradation of eGFP-ssrA by MmCP. D, SPR sensorgrams show that MmPAN-A and MmCDC48-B physically
interact with MmCP in a concentration-dependent manner, whereas Mm0854 shows a much weaker interaction. RU, response units.
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The conservation of residues forming the binding pocket for
theHbYXmotif (invariant residues proline 17 and glycine 19) in
the proteasome -subunits indicate that all archaeal protea-
somes are most likely activated by the same mechanism.
Although we observe peculiar or highly divergent C termini
that do not allow an unambiguous decision regarding the pres-
ence of the motif, all archaea encode at least one AAA protein
that contains the HbYX motif in canonical form, emphasizing
the importance of proteasomal regulation by AAA proteins.
Even if PAN orthologs are absent in a genome, there is at least
one member of the CDC48 family with a clear HbYX motif,
defining thesemembers as proteasomal ATPases in the context
of our degradation and interaction assays. Likewise, as all mem-
bers of the AMA group contain the HbYX motif, we conclude
that gatekeeping of the proteasome is themain cellular function
of this group, thereby increasing the repertoire of proteasome
regulators.
Functional Implications—Components of the archaeal pro-
teasomemachinery generally improve survival rate under stress
conditions (48) and are essential for growth (49). Functional
diversification of the core particle through gene duplication is
known forHaloferax volcanii, in which a second type of -sub-
unit (and PAN-B) is up-regulated during starvation (50), and
for Pyrococcus furiosus, where the 1-subunit is up-regulated
under heat stress, resulting in more thermostable PfCP parti-
cles (51). Accordingly, for the dynamic proteome of a cell living
in changing environments, an adaptable network of regulators
of the central protein destruction machinery conceivably con-
fers advantages. The general capabilities of the proteasomal
system for targeted degradation would be increased through
the participation of different N-terminal substrate recognition
domains of the regulatoryATPases. As a consequence, a greater
variety of substrates could be recognized with higher affinity
and specificity. In addition to amore sophisticated regulation of
proteolysis, the presence ofmultiple proteasomal ATPasesmay
also generate some redundancy.H. volcanii, for example, toler-
ates a gene knock-out of both of its PANproteins under normal
growth conditions (6), potentially because it still has two
CDC48 proteins with an HbYXmotif.
Currently, it is unclear how this regulatory network of
ATPases is integrated with the SAMP-based tagging system,
whose conjugates are increased (SAMP1) or decreased
(SAMP2) in a genetic background depleted of the PANproteins
(6). It remains to be studied whether motif-containing CDC48
proteins participate in the SAMPylation system and whether
they are able to compensate for a deletion of PAN proteins.
Importantly, there is no correlation between the presence of the
SAMP proteins and specific proteasomal ATPases (Fig. 1A).
Evolutionary Implications—Comparative analysis of the con-
tent of putative proteasomal ATPases in archaeal genomes sug-
gests a complex ancestral state, which is likely to include two
CDC48 proteins and one PAN protein. The pattern of conser-
vation suggests that PANhas been lost in certain lineages rather
than laterally transferred (23), whereas AMAmost likely origi-
nated in a common ancestor of methanogens and Archaeoglo-
bales. The number of putative proteasomal ATPases varies in
extant archaea between one and five, pointing to clade-specific
solutions for the functional task of targeted protein degrada-
tion. Nevertheless, the approximate number of three protea-
somal ATPases in the ancestor of all archaea (one PAN, two
CDC48 proteins) suggests that it would have already relied on a
network of AAA proteins to regulate its central proteolytic
machinery.
The employment of different AAA proteins as regulators of
the proteasome in the majority of archaea contrasts with the
situation in eukaryotes, where the heterooligomeric PAN
orthologs Rpt1–6 act exclusively asATPase regulators (the reg-
ulators Blm10 and 11S are not ATPases). Although AMA pro-
teins are not found in eukaryotes, CDC48 (p97) is conserved
and fulfills functions in a plethora of pathways. However, there
is only evidence for a direct interaction of CDC48 with the 19S
regulatory particle, rather than the 20S core particle (52), serv-
ing as a gearbox that segregates ubiquitylated from unmodified
substrate proteins (53). Therefore, the fully differentiated 26S
proteasome is, with the notable exception of immunological
responses in vertebrates, basically fixed in its composition.
Diversity in the ubiquitin-proteasome system of eukaryotes
mainly takes place at the level of E3 ligases, which confer spec-
ificity in the tagging of substrates. Their radiating number,
ranging from 80 in yeast to 600 in humans (54), enables
specific involvement of the proteasome in the regulation of
numerous cellular processes. Despite the fact that E3-like
FIGURE 4.Thenetworkof proteasomalAAAATPases.A, in archaea, PAN, CDC48, andAMAproteins constitute a regulatory network of proteasomal ATPases.
Interaction is governed by the C-terminal HbYX motif; different N-domain folds in the ATPases are denoted. 2xpsi, double-psi barrel; CC/OB, coiled-coil and
oligosaccaride-binding domain. B, in eukaryotes, the heterooligomeric PAN-like Rpt1–6 subunits function within the 19S particle as the regulatory ATPase of
the proteasome. The HbYXmotifs of Rpt2 and Rpt5 are important for gate opening.
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ligases for SAMPylation in archaea have not been discovered
yet, a network of regulatory ATPases constitutes an additional
strategy to expand the capacity of proteasomal protein
degradation.
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